

I. EDITORIAL POLICY

The Journal of Nuclear Medicine (JNM) publishes material of interest to the practitioners and scientists in the broad field of nuclear medicine. Proffered articles describing original laboratory or clinical investigations, brief communications, technical notes and letters to the editor will be considered for publication. Case Reports and First Impressions are no longer being accepted. Occasionally, invited articles, editorials and reviews of selected topics will be published. Manuscripts, including illustrations and tables, must be original and not under consideration by another publication.

JNM has agreed to receive manuscripts in accordance with the *Uniform Requirements for Manuscripts Submitted to Biomedical Journals* as cited in the following sources: *Ann Intern Med.* 1997;126:36-47, and *JAMA*. 1997;277:927-934. In preparing manuscripts, authors should follow the *Uniform Requirements for Manuscripts Submitted to Biomedical Journals* and the specific author instructions detailed below. Also, helpful guidance in conforming to the *Uniform Requirements* may be found in *Huth E J. Medical Style & Format: An International Manual for Authors, Editors, and Publishers*. Philadelphia, PA: ISI Press; 1987.

II. MANUSCRIPT SUBMISSION

Submit four copies of the manuscript and figures to the following address:

Martin P. Sandler, MD

The Journal of Nuclear Medicine
Society of Nuclear Medicine
1850 Samuel Morse Drive
Reston, VA 20190-5316
Phone: (615) 322-3761
Fax: (615) 343-2504
E-mail: tom.ebers@mcmail.vanderbilt.edu

Manuscripts will not be accepted by facsimile.

All manuscripts should be accompanied by a cover letter from the author responsible for correspondence regarding the manuscript. The cover letter should contain the following copyright disclosure statement in compliance with the Copyright Revision Act of 1976, effective January 1, 1978.

Upon acceptance by The Journal of Nuclear Medicine, all copyright ownership for the article _____ is transferred to The Society of Nuclear Medicine. We, the undersigned coauthors of this article, have contributed significantly to and share in the responsibility for the release of any part or all of the material contained within the article noted above. The undersigned stipulate that the material submitted to The Journal of Nuclear Medicine is new, original and has not been submitted to another publication for concurrent consideration.

We also attest that any human and/or animal studies undertaken as part of the research from which this manuscript was derived are in compliance with regulations of our institution(s) and with generally accepted guidelines governing such work.

We further attest that we have herein disclosed any and all financial or other relationships that could be construed as a conflict of interest and that all sources of financial support for this study have been disclosed and are indicated in the acknowledgments.

This statement must be signed by all of the listed coauthors. Designate "first author" and "corresponding author" in parentheses by their signatures.

This copyright transfer requirement does not apply to work pre-

pared by U.S. government employees as part of their official duties.

The cover letter should also contain a statement that the manuscript has been seen and approved by all authors and should give any additional information that may be helpful to the Editor. If there has been any prior publication of any part of the work, this should be acknowledged and appropriate written permission included. If color illustrations are included, a statement that the author(s) is (are) willing to assume the cost of color separations and reproduction is requested.

Authors may suggest individuals who could serve as reviewers for their manuscripts.

III. REVIEW PROCEDURE

Submitted manuscripts are reviewed for originality, significance, adequacy of documentation, reader interest, composition and adherence to the guidelines contained herein. Manuscripts not submitted in accordance with these instructions will be returned to the author for correction before beginning the peer review process.

All manuscripts considered suitable for review are evaluated by a minimum of two reviewers. Reviewers receive manuscripts with abbreviated title pages (no author names listed) to ensure unbiased review. It is unusual for a manuscript to be accepted for publication without first undergoing a process of revision. Revised manuscripts are judged on the adequacy of responses to suggestions and criticisms made during the initial review. Two copies of the revised manuscript should be sent with a diskette (3.5- or 5.25-in.) containing the word processing file of the manuscript. The disk should be labeled with the name of the file, word processing software, operating environment (i.e., DOS, Windows) and platform (i.e., IBM, Macintosh). A diskette need not be sent before a revision is requested. *JNM* reviewers may seek assistance from sources within their institution when reviewing manuscripts, but the data reported in submitted manuscripts must be kept confidential at all times.

All accepted manuscripts are subject to editing for scientific accuracy, clarity and style. Authors of accepted manuscripts may also incur printing charges (\$80 per page) for articles exceeding eight printed pages.

IV. FORMAT REQUIREMENTS

A. General Requirements

Manuscripts must be written in English. When necessary, authors should seek the assistance of experienced, English-speaking medical editors. A medical editor should review the final draft of the original and any revisions of the manuscript. Articles written in substandard English will be returned before review or production, as applicable.

Type the manuscript on white bond paper, 8½ × 11 in. (21.6 × 27.9 cm), with margins of at least 1½ in. (4 cm). Type size should be at least 10 pt. Type on one side of the paper only, double spacing every page. Begin each of the following sections on separate pages and in the following order: title page, abbreviated title page, abstract, text (see Text Presentation below), acknowledgments, references, tables (each on a separate page) and figure legends. Number pages consecutively, beginning with the abstract. The use of automated word processing functions (such as auto numbering, footnotes or endnotes, or formatted tables) should be avoided. To ensure anonymity in the review process, authors' names should appear on the full title page only. Names of authors or institutions should not be given in the text or on illustrations.

B. Title Page

The title page of the manuscript should include the following: (1) concise and informative title (fewer than 200 characters); (2) short running headline or footline of no more than 40 characters (letters and spaces) placed at the bottom of the title page and identified; (3) complete byline, with first name, middle initial and last name of each author and highest academic degree(s) (up to 10 authors may be cited); (4) complete affiliation for each author, with the name of department(s) and institution(s) to which the work should be attributed; (5) disclaimer, if any; (6) name, address, telephone number, fax number and e-mail address of one author responsible for correspondence about the manuscript; (7) name, address, telephone number, fax number and e-mail address of the first author, specifying whether this person is currently in training (e.g., fellow, resident or student); (8) name, address and e-mail address of author to whom reprint requests should be directed, or statement that reprints are not available. Financial support for the work should be noted in a statement on this page as well as in the acknowledgments.

C. Abbreviated Title Page

An abbreviated title page, giving only the title, should be included in each copy of the manuscript. This allows for anonymity during the review process.

D. Abstract

A structured abstract must be included with each original scientific manuscript submitted to *JNM*. The abstract should contain a maximum of 350 words and include four clearly identifiable elements of content: rationale (goals of the investigation), methods (description of study subjects or experiments, animals and observational and analytical techniques), results (major findings) and principal conclusions. Except for the rationale, which should state the goals of the investigation, these sections should be preceded by headings (i.e., **Methods, Results and Conclusion**). Three to five key words should also be submitted with the abstract.

E. Text

1. Presentation

Generic names should be used throughout the text. Identify instruments and radiopharmaceuticals by manufacturer name and address in parentheses and describe procedures in sufficient detail to allow other investigators to reproduce the results.

The text of **original scientific and methodology articles** is usually divided into the following sections: **Introduction, Materials and Methods, Results, Discussion and Conclusion**. The text of original scientific papers, exclusive of the abstract, legends, tables and references, should not exceed 5000 words.

Brief Communications should contain a concise description of no more than 1250 words, 2 illustrations, 2 tables and a maximum of 5 references. Abstracts for this type of article should contain a maximum of 150 words.

Letters should concern previously published material or matters of general interest and should be brief and to the point. A diskette (3.5- or 5.25-in.) containing a copy of the word processing file of the letter should accompany a hard-copy version of the manuscript. The disk should be labeled as described above in Review Procedure. Letters should also be accompanied by a copyright disclosure statement as specified above in Manuscript Submission. All material is subject to editing. Letters commenting on previously published articles should be received within 1 year of the date of the referenced article's publication. Letters should contain no images or tables and no more than 5 references.

JNM policy prohibits the use of hyperbolic terms or phrases in the title, abstract or body of the text of submitted manuscripts. Qualitative claims as to the superiority (superior, best), primacy (first, novel, unique) or performance of an idea or instrument should be omitted.

2. References

References (not to exceed 40) should be cited in consecutive numerical order at first mention in the text and designated by reference number underlined and in parentheses. References appearing in a table or figure should be numbered sequentially with those in the text.

The reference list must be typed, double-spaced and numbered consecutively as in the text. When listing references, follow American Medical Association style (*American Medical Association Manual of Style*, 9th ed. Baltimore, MD: Williams & Wilkins; 1998). Abbreviate journal names according to the *List of Journals Indexed in Index Medicus*. "Unpublished observations" and "personal communications" should not be used as references, although written—not verbal—communications may be noted as such in the text. References cited as "in press" must have been accepted for publication and not merely in preparation or submitted. The author is responsible for the accuracy of all references and must verify them against the original document.

List all authors when six or fewer; for seven or more, list the first three followed by et al.

For journal articles:

Alavi A, Clark C, Fazekas F. Cerebral ischemia and Alzheimer's disease: critical role of PET and implications for therapeutic intervention. *J Nucl Med*. 1998;39:1363–1365.

Goris ML, Strauss HW. Predictions for nuclear medicine in the next decade. *Radiology*. 1998;208:3–5.

Leskinen S, Pulkki K, Knuuti J, et al. Transport of carbon-11-methionine is enhanced by insulin. *J Nucl Med*. 1997;38:1967–1970.

Licho R, Soares E, Feinbloom D, Weaver JP. Comparison of bone SPECT with structural imaging modalities in directing the management of back pain [abstract]. *J Nucl Med*. 1998;39(suppl): 29P.

For books and book chapters:

Sherlock S, Dooley J. *Diseases of the Liver and Biliary System*. 9th ed. Oxford, England: Blackwell Scientific Publications; 1993.

Wootton R. Measurement of bone blood flow in humans. In: Schoutens A, Arlet J, Gardeniers J, Hughes S, eds. *Bone Circulation and Vascularization in Normal and Pathological Conditions*. New York, NY: Plenum Press; 1993:85–94.

3. Units of Measurement

All measurements should be listed in Système Internationale (SI) units. Older conventions may be used after the SI units but should be placed in parentheses.

4. Abbreviations and Symbols

With the exception of units of measurement, *JNM* discourages the use of abbreviations. For additional information on proper medical abbreviations, consult *Scientific Style and Format: The CBE Manual for Authors, Editors, and Publishers*. Chicago, IL: Council of Biology Editors; 1994. The first time an abbreviation is used, it should be preceded by the full word or name of the item being abbreviated.

5. Tables

Type each table double-spaced on a separate page. Do not submit tables as photographs. The number of tables should be limited to seven, except in the case of dosimetry articles, which may exceed that number in lieu of illustrations.

Tables should be self-explanatory and should supplement, not duplicate, the text. Each table must be cited in consecutive numerical order in the text. Number the tables consecutively with an arabic number following the word "TABLE." Titles should be descriptive and brief and typed centered in upper- and lowercase letters. Horizontal rules should be placed below the title and column headings and at the end of the table. Do not use vertical lines. Give each column a short or abbreviated heading.

Place explanatory matter in footnotes, not in the heading. Use the following symbols in this sequence: *, †, ‡, §, ¶, **. Expand in the footnote all nonstandard abbreviations used in each table in the order in which they appear in the table. For footnotes, identify statistical measures of variations, such as standard deviation and standard error of the mean. If data from another published source are used, obtain written permission from the publisher of the original source and acknowledge fully. If data from an unpublished source are used, obtain permission from the principal investigator and acknowledge fully.

6. Illustrations

Illustrations should clarify and augment the text. Because imaging is a major aspect of nuclear medicine, the selection of sharp, high-quality illustrations is of paramount importance. Figures of inferior quality will be returned to the author for correction or replacement. Additionally, because of space limitations, illustrations are frequently reduced in size. Each submitted illustration should clearly identify areas of interest with only enough surrounding area necessary for orientation.

The number of illustrations submitted should not be excessive for the length of the manuscript and in no case should the total number of illustrations exceed seven. These seven illustrations may consist of up to 14 separate glossy figure parts.

Submit four complete sets of glossy illustrations, no smaller than $3\frac{1}{2} \times 5$ in. nor larger than 8×10 in. Do not send original artwork. Glossy photographs of line drawings rendered professionally on white drawing paper in black India ink, with template or typeset lettering, should be submitted. No hand-drawn or typewritten art will be accepted. Letters, numbers and symbols (typeset or template) must be clear and of sufficient size to retain legibility after reduction. Avoid dotted or lined shadings.

Each illustration must be numbered and cited in consecutive order in the text. Illustrations should be identified on a gummed label affixed to the back of each illustration and contain the following information: figure number, part of figure (if more than one, i.e., A, B or C), short running headline (from the title page) and designation of "top."

Color illustrations will be considered for publication, but the author is responsible for all charges relating to separations and printing. An estimate of these charges will be sent to the author at the time of revision. Author approval of charges is required before production will begin. Additionally, authors may incur charges for corrections to black and white images (e.g., resetting labels and symbols, ganging multipart images as one image). Four complete sets

of glossy color photographs (not transparencies) must be submitted for review. Polaroid prints are not acceptable. All submitted illustrations become the property of The Society of Nuclear Medicine and will not be returned unless the manuscript is rejected. Only two sets of illustrations are returned with rejected manuscripts.

7. Legends for Illustrations

Legends for illustrations should be concise and should not repeat the text. Legends should be typed double-spaced on a separate page. Each figure should be cited in consecutive numerical order in the text. Number the figures with an arabic number following the word "FIGURE." Use letters to designate parts of illustrations (e.g., A, B or C) and describe each part clearly in the legend. Any letter designations or arrows appearing on the illustration should be identified and described fully. Nonstandard abbreviations used in each figure should be expanded in the legend in the order in which they appear in the illustration.

Original (not previously published) illustrations are preferred for publication in *JNM*; however, if illustrations have been published previously, authors are responsible for obtaining written permission from the publisher to reprint. The source of the original material must be cited in the references and the following credit line in parentheses included in the legend: "Reprinted with permission of Ref. X." All permission releases must be submitted to the Editor at the time of manuscript submission.

F. Acknowledgments

Acknowledge persons or agencies contributing substantially to the work, including any grant support.

V. MANUSCRIPT CHECKLIST

- Four double-spaced, typed copies of the manuscript.
- 3.5- or 5.25-in. diskette containing only final, revised, accepted version of the manuscript.
- Four sets of unmounted glossy figures (no smaller than $3\frac{1}{2} \times 5$ in. nor larger than 8×10 in.).
- Copyright transfer.
- Title page with title, authors' names and complete affiliations; complete address, telephone number, fax number and e-mail address for corresponding author and first author, if different; and complete address and e-mail address of author for reprint requests.
- Abbreviated title page with only title of manuscript.
- Structured abstract (maximum 350 words) and key words.
- References in consecutive numerical order. Reference list typed double-spaced. References in correct style.
- Figures and tables in consecutive numerical order.
- Legends for all figures, typed double-spaced.
- Consent forms for patient photographs.
- Written permission from the publisher to reprint previously published figures and tables.

- Äärimaa, T. 12
 Aarsvold, JN, 929(ab)
 Abós, MD, 296
 Abdel-Dayem, HM, 84(ab), 574,
 889(ab)
 Abdel-Nabi, HH, 94(ab), 1233
 Abe, H, 1465(ab)
 Abe, Y, 1179(ab)
 Abella-Columna, E, 255(ab)
 Abenhardt, W, 1133(ab)
 Abi-Dargham, A, 114(ab), 122(ab),
 121(ab), 435(ab), 581(ab), 1162(ab)
 Abitbol, C, 204(ab)
 Abou-Zied, MM, 1069(ab)
 Abrahamian, H, 1368(ab)
 Abram, U, 1913
 Abrams, MJ, 184
 Abrams, PG, 75(ab)
 Abumrad, N, 406(ab)
 Abunku, O, 53(ab)
 Aburano, T, 1644
 Aburano, T, 211(ab), 212(ab), 216(ab),
 569(ab), 747(ab), 855(ab), 1173(ab)
 Acampa, W, 194(ab), 338(ab), 725(ab),
 777(ab), 1683
 Acar, P, 910(ab)
 Acharya, SA, 1404(ab)
 Achilefu, SI, 996(ab)
 Acosta, E, 73(ab)
 Acton, PD, 108(ab), 583(ab), 1200(ab),
 1345(ab), 1812
 Adachi, I, 748(ab), 798(ab), 807(ab),
 1204(ab), 1319(ab)
 Adachi, Y, 514(ab)
 Adam, C, 433(ab)
 Adam, LE, 308(ab), 1239(ab)
 Adam, M, 283
 Adams, BK, 861(ab)
 Adams, S, 282(ab), 1152(ab)
 Adams, WD, 1298(ab)
 Adamson, KL, 541(ab), 1246(ab)
 Adelstein, SJ, 986(ab), 1377(ab)
 Adem, A, 174(ab)
 Adema, GJ, 1028(ab)
 Adler, LP, 118
 Afriyie, MO, 57(ab), 201(ab), 478(ab),
 930(ab)
 Agafitei, D, 28(ab)
 Agafitei, R, 170(ab)
 Aggarwal, K, 174(ab)
 Agnese, G, 1123(ab)
 Agostini, D, 8(ab), 175(ab), 901(ab),
 905(ab)
 Agresti, R, 1114(ab)
 Agu, R, 610(ab)
 Aguade, S, 315(ab)
 Aharon, S, 1098
 Ahdoot, R, 1080(ab), 1363(ab)
 Ahlberg, AW, 517(ab), 518(ab), 711(ab)
 Ahlman, H, 2094
 Ahmed, S, 1079(ab)
 Ahn, IM, 529(ab)
 Ahn, JY, 309(ab)
 Ahn, SH, 1394(ab)
 Ah-See, AK, 552(ab)
 Aihara, Y, 217
 Aisa, F, 296
 Aitken, CL, 1281(ab)
 Ajzenberg, C, 1252
 Akabani, G, 631, 1197
 Akagi, N, 1035(ab), 1084(ab), 1101(ab),
 1189(ab)
 Akaki, S, 394, 1971
 Akamune, A, 1271(ab)
 Akashi, K, 814(ab)
 Akashi, Y, 1595
 Akhurst, T, 912(ab), 1042(ab)
 Akinboboye, O, 29(ab)
 Akincioglu, C, 39(ab)
- Akino, H, 1137(ab)
 Akioka, K, 1492
 Aktas, A, 849(ab)
 Aktay, R, 1434
 Al Haider, ZY, 861(ab)
 Al Sakhi, HA, 764(ab)
 Al Yasi, AR, 764(ab), 1108(ab)
 Alam, F, 940(ab)
 Alauddin, MM, 103(ab), 334(ab),
 1361(ab), 1368(ab)
 Alavi, AA, 61(ab), 108(ab), 118(ab),
 199(ab), 274(ab), 276(ab), 333(ab),
 387(ab), 401(ab), 453(ab), 520(ab),
 521(ab), 526(ab), 562(ab), 625,
 868(ab), 888(ab), 995, 1054(ab),
 1070(ab), 1117(ab), 1143, 1200(ab),
 1240(ab), 1241, 1257, 1286(ab),
 1812, 2107
 Alazraki, NP, 209(ab), 234(ab), 238(ab),
 929(ab)
 Albayrak, S, 864(ab)
 Albelda, SM, 1241
 Albers, P, 1133(ab)
 Alberto, R, 1913
 Alboni, P, 778(ab)
 Alderson, PO, 228(ab), 412(ab)
 Alenius, ST, 862, 1326(ab), 1330(ab)
 Alexoff, DL, 1301(ab)
 Alfano, B, 442
 Alhaddad, IA, 788(ab)
 Ali, H, 1728
 Alkan, E, 429
 Allen, LW, 579
 Allen-Auerbach, M, 184(ab), 186(ab),
 189(ab)
 Allidina, Y, 769(ab)
 Aloj, L, 385(ab), 1547
 Alonso, C, 60(ab)
 Alperson, M, 45(ab)
 Alpert, NM, 391(ab), 579(ab), 1266(ab),
 1269(ab)
 Al-Sugair, AS, 81(ab)
 Al-Tikriti, MS, 154(ab)
 Altmann, A, 1011(ab)
 Altorki, N, 1303(ab)
 Alyafei, S, 1018(ab)
 Al-Za'abi, K, 879(ab)
 Amano, S, 399
 Amanullah, AM, 738(ab)
 Amar, MH, 175(ab)
 Amaral, H, 59(ab), 904(ab)
 Ambrose, KR, 1484
 Amici, LA, 1208(ab)
 Amin, KC, 236(ab)
 Amoachi, GS, 43(ab)
 Amthauer, H, 387
 An, R, 988(ab)
 Anand, A, 580(ab)
 Andersen, TT, 1030(ab)
 Anderson, A-L, 323(ab)
 Anderson, BO, 557(ab)
 Anderson, CJ, 997(ab)
 Anderson, JH, 1180
 Anderson, S, 9(ab)
 Ando, A, 728(ab)
 Andrade, MA, 11(ab)
 Andreas, J, 125(ab), 925(ab)
 Andreeff, M, 1385(ab)
 Angel, J, 315(ab)
 Angelberger, P, 74(ab), 395(ab),
 1081(ab)
 Angeletti, S, 843(ab)
 Angerstein, C, 420(ab), 428(ab),
 429(ab), 1029, 1374(ab), 1380(ab)
 Anidjar, R, 1459(ab), 1464(ab)
 Anjilvel, S, 1211(ab)
 Annala, AJ, 20(ab), 826(ab)
 Anstett, F, 359(ab)
 Anthonio, RL, 507
- Antin, JH, 1031(ab)
 Antonietti, T, 910(ab)
 Antonini, A, 271(ab), 914(ab), 1264
 Antonucci, D, 363
 Anwar, K, 970(ab)
 Aoki, J, 390(ab), 399
 Aoki, S, 574(ab), 1300(ab)
 Aomi, S, 744(ab)
 Aoyagi, K, 399, 878(ab), 1018(ab)
 Aoyagi, T, 1116
 Aoyama, T, 191(ab)
 Apice, G, 1142(ab)
 Apicella, A, 66(ab)
 Apostolidis, C, 166, 433(ab), 1375(ab),
 1380(ab)
 Appelbaum, JW, 75(ab)
 Aqel, R, 174(ab)
 Arahata, Y, 1179(ab)
 Arai, H, 207(ab), 527(ab)
 Arai, T, 574(ab), 835(ab)
 Araki, T, 574(ab), 835(ab)
 Aranda, R, 1083(ab)
 Arano, Y, 479, 1371(ab), 1406(ab)
 Arap, W, 883
 Araujo, WM, 1040(ab)
 Arbab, AS, 574(ab), 835(ab)
 Arbizu, J, 424(ab), 555(ab)
 Arends, AJ, 1257(ab)
 Arevalo, A, 1209(ab)
 Arianejad, M, 1468(ab)
 Arienz, S, 1142(ab)
 Arisaka, Y, 86(ab), 1095(ab)
 Arlauskas, P, 1079(ab)
 Armijo, I, 516(ab)
 Arnello, F, 52
 Arnold, E, 177(ab)
 Arnold, J, 238(ab)
 Arnold, S, 737
 Arora, R, 350(ab)
 Arouca, PT, 746(ab)
 Ar'Rajab, A, 237(ab)
 Arrighi, JA, 21(ab), 346(ab)
 Asada, T, 1192(ab)
 Asai, S, 793
 Asano, T, 1188(ab)
 Aseno, MJ, 296
 Asero, S, 1114(ab)
 Ashare, AB, 760(ab)
 Ashburn, W, 750(ab), 1121(ab),
 1225(ab), 1256(ab)
 Aslan, S, 1046(ab)
 Asselin, M-C, 1666
 Astrom, K, 224(ab)
 Atcher, RW, 322(ab)
 Atkins, HL, 264(ab), 490(ab)
 Atochina, O, 888(ab)
 Atsma, DE, 740(ab)
 Atthey, M, 161(ab)
 Aubert, B, 157(ab), 1517
 Aubier, M, 962(ab)
 Aubriot, JH, 901(ab), 905(ab)
 Auer, C, 290(ab)
 Augeri, C, 926(ab)
 Augustijns, P, 610(ab)
 Aula, P, 12
 Aung, M, 732(ab)
 Austin-Seymour, MM, 69(ab)
 Avery, RA, 275(ab), 1199(ab), 1270(ab)
 Aviner, S, 522(ab)
 Avril, N, 104(ab), 550(ab), 593(ab),
 1311(ab)
 Awata, S, 244
 Axworthy, DB, 75(ab)
 Ayabe, K, 86(ab), 1095(ab)
 Ayaz, M, 429
 Aziz, A, 1098(ab)
 Aznar, M, 542(ab)
 Azuma, A, 514(ab)
 Azuma, H, 1132
- Azuma, M, 859(ab)
 Azure, MT, 994(ab)
 Baba, K, 936(ab)
 Babich, JW, 894(ab)
 Baccarne, V, 473(ab)
 Bacharach, SL, 385(ab), 464(ab),
 472(ab), 565(ab), 1029(ab), 1297(ab)
 Badawi, RD, 1236(ab)
 Badimon, JJ, 355(ab)
 Bading, JR, 1361(ab)
 Bae, SK, 1045(ab)
 Baer, FM, 791(ab)
 Baetens, J, 610(ab)
 Bagatella, F, 1053(ab)
 Bagella, C, 1105(ab)
 Baghaci, H, 307(ab), 598(ab), 1233(ab)
 Bagni, B, 538(ab)
 Bagni, I, 538(ab)
 Bahk, YW, 217(ab), 376(ab)
 Bähre, M, 540(ab), 605(ab), 730(ab),
 921(ab), 944(ab)
 Bai, C, 462(ab)
 Baidoo, KE, 318(ab), 492(ab)
 Bailey, KM, 9N(9), 15N(11)
 Bakan, A, 864(ab)
 Baker, K, 306(ab)
 Baker, LH, 1456
 Bakker, J, 58(ab)
 Bakker, P, 1107(ab)
 Bakker, WH, 320(ab), 414(ab), 416(ab),
 762, 2081
 Bakker-Woudenberg, IAJM, 2066
 Bal, CS, 927(ab), 934(ab)
 Bal, G, 1255(ab)
 Balan, KK, 249(ab), 1093(ab)
 Balatoni, J, 105(ab), 1012(ab)
 Balbastro, E, 553(ab)
 Baldassari, AR, 1630
 Baldessarini, RJ, 148(ab)
 Baldwin, RM, 124(ab), 143(ab),
 148(ab), 154(ab), 270(ab), 444(ab),
 607(ab), 1208(ab), 1902
 Ballangrud, ÅM, 164(ab), 1935
 Ballester, M, 911, 5(ab)
 Ballinger, J, 1201(ab)
 Ballinger, JR, 530, 273(ab), 331(ab),
 614(ab), 1019(ab), 1025(ab)
 Ballkissoon, AA, 1455(ab)
 Ballok, ZE, 381(ab)
 Balm, AJM, 1414
 Balon, H, 287(ab)
 Baltauss, T, 1127(ab)
 Baltuch, G, 276(ab)
 Balza, E, 434(ab)
 Bamder, NH, 1008(ab)
 Bander, NH, 1001(ab)
 Bandy, D, 717(ab), 1304(ab)
 Banerjee, S, 1015(ab), 1402(ab)
 Bang, BK, 376(ab)
 Banzo, J, 296
 Barber, HB, 601(ab)
 Barber, RW, 135(ab), 494(ab)
 Barbet, J, 198, 1002(ab), 1216
 Bareille, R, 1756
 Barendswaard, EC, 431(ab), 1764
 Bares, R, 245(ab), 247(ab), 460(ab),
 871(ab), 933(ab), 946(ab), 956(ab),
 957(ab), 1133(ab), 1289(ab)
 Bar-Meir, E, 45(ab)
 Barnett, CA, 712(ab)
 Baron, J-C, 25, 749(ab)
 Baron, JM, 480(ab)
 Barr, LL, 53(ab)
 Barré, L, 25
 Barracough, ED, 625, 108(ab),
 1200(ab), 1812, 2107
 Barrett, CL, 77(ab)

- Barrett, HH, 601(ab)
 Barrett, JA, 892(ab)
 Barrio, JR, 102(ab), 142(ab), 284(ab), 332(ab), 585(ab), 587(ab)
 Barritault, L, 910(ab)
 Barron, BJ, 902(ab), 1459(ab), 1462(ab), 1463(ab), 1464(ab)
 Barrow, SA, 1161(ab)
 Bar-Sever, Z, 51(ab), 522(ab), 880(ab)
 Bartenstein, P, 290(ab), 291(ab), 397(ab), 448(ab), 451(ab), 737
 Barthe, N, 868
 Barthel, H, 570(ab)
 Barthel, P, 904
 Bartholomeusz, D, 277
 Bartlett, ML, 758(ab)
 Bartold, SP, 1226
 Bartolomei, M, 72(ab), 235(ab), 266(ab), 1125(ab)
 Basik, M, 1124(ab)
 Basoglu, T, 864(ab)
 Basse-Cathalinet, B, 412, 868, 1756
 Bastidas, D, 1001(ab), 1008(ab)
 Bastien, SA, 615(ab)
 Bateman, JE, 1224(ab)
 Bateman, TM, 27(ab), 710(ab), 724(ab), 1291(ab)
 Batra, SK, 1536
 Battelli, LA, 379(ab)
 Battisti, P, 1716
 Battle, XL, 298(ab), 473(ab)
 Baudoux, A, 882(ab)
 Baudouy, M, 1301
 Baudrexel, S, 881(ab)
 Bauer, E, 102(ab)
 Baulac, M, 935
 Baulieu, JL, 1393(ab)
 Baum, M, 560(ab), 1116(ab)
 Baum, RP, 1152(ab)
 Bauman, BD, 360(ab)
 Baumann, G, 195(ab)
 Bausart, R, 1109(ab)
 Bautovich, G, 218(ab)
 Bavaria, G, 1244(ab)
 Bax, JJ, 1(ab), 180(ab), 190(ab), 192(ab), 731(ab), 765(ab), 831(ab), 1204, 1866, 1893
 Bayhan, HF, 404(ab)
 Baza, S, 1524
 Beanlands, RS, 732(ab)
 Beauchamp, RD, 1784
 Becherer, A, 362(ab), 1049(ab), 1347(ab)
 Beck, M, 1081(ab)
 Becker, K, 433(ab), 550(ab)
 Becker, LC, 359(ab), 1263(ab)
 Becker, MD, 228(ab), 412(ab)
 Becker, MJ, 2066
 Becker, W, 48(ab), 396(ab), 420(ab), 428(ab), 429(ab), 537(ab), 907(ab), 992(ab), 1029, 1374(ab), 1375(ab), 1380(ab)
 Beck-Peccoz, P, 922(ab)
 Bedard, MA, 267(ab)
 Bedrosian, I, 1117(ab), 1143
 Beets, AL, 1918
 Begent, RH, 541(ab), 1246(ab)
 Beger, HG, 250, 422(ab)
 Béhé, M, 396(ab), 420(ab), 428(ab), 429(ab), 907(ab), 1029, 1374(ab), 1375(ab), 1380(ab)
 Behloul, F, 821(ab)
 Behnke, A, 1246
 Behr, TM, 48(ab), 396(ab), 420(ab), 428(ab), 429(ab), 907(ab), 992(ab), 1029, 1374(ab), 1375(ab), 1380(ab)
 Beitzel, MP, 329(ab)
 Beju, D, 815(ab)
 Belanger, M, 1280(ab)
 Belasco, J, 521(ab)
 Belezzuoli, E, 750(ab), 1121(ab), 1256(ab)
 Belin, A, 8(ab), 175(ab)
 Bell, RA, 504(ab)
- Bellemann, ME, 1016(ab), 1032(ab), 1251(ab)
 Bellen, JC, 277
 Beller, GA, 142, 821
 Bellina, CR, 926(ab)
 Benada, A, 173(ab), 743(ab)
 Benali, H, 16(ab), 140(ab), 471(ab), 595(ab), 1314(ab)
 Bénard, F, 526(ab), 562(ab), 832(ab), 1241, 1257
 Bencherif, B, 446(ab), 447(ab), 1207(ab)
 Bender, H, 974(ab), 988(ab), 1133(ab), 1384(ab)
 Bender, LW, 967(ab)
 Benelhadj, S, 1252
 Bengel, FM, 30(ab), 33(ab), 34(ab), 35(ab), 183(ab), 188(ab), 904
 Ben-Haim, S, 741(ab), 811(ab)
 Benjegård, SA, 2094
 Benkelfat, C, 577(ab)
 Bennett, JA, 319(ab), 1030(ab)
 Bennett, S, 504(ab)
 Bennink, RJ, 1107(ab), 1451
 Bentl, R, 271(ab), 914(ab), 1630
 Bentourquia, M, 832(ab)
 Benvenuti, C, 917
 Benz, P, 125(ab), 1222(ab)
 Berberoglu, S, 524(ab), 919(ab)
 Beresford, GW, 1536
 Bergert, B, 117(ab)
 Bergman, J, 12
 Bergmann, L, 262(ab)
 Bergmann, R, 293(ab)
 Bergmann, SR, 29(ab), 182(ab), 310(ab), 720(ab), 911(ab), 1882
 Bergmans, P, 106(ab), 111(ab)
 Bergner, U, 1154(ab)
 Bergsneider, M, 146(ab), 147(ab)
 Beric, A, 1184(ab)
 Berk, AJ, 102(ab)
 Berman, DS, 6(ab), 9(ab), 22(ab), 25(ab), 27(ab), 28(ab), 170(ab), 710(ab), 722(ab), 810
 Berman, RM, 576(ab)
 Berna, LL, 3(ab), 5(ab), 734(ab), 786(ab)
 Bernà, L, 19, 911
 Bernard, BF, 2081
 Bernard, HF, 317(ab), 320(ab), 414(ab), 418(ab)
 Bernardo, M, 123(ab)
 Bernardo-Filho, M, 1379(ab)
 Bernatz, S, 1702
 Bernay, I, 864(ab)
 Berndorff, D, 434(ab)
 Bernecker, P, 1277
 Bernhardt, P, 2094
 Berridge, MS, 383(ab), 886(ab)
 Berrouschot, J, 570(ab)
 Berry, G, 38(ab)
 Besnard, JC, 1343(ab), 1393(ab)
 Bestetti, A, 77
 Betman, L, 265(ab)
 Betteridge, J, 737(ab)
 Bettinardi, V, 302(ab), 459(ab)
 Bettinsoli, G, 375(ab)
 Beu, M, 977, 575(ab)
 Beuthien-Baumann, B, 543(ab)
 Beyer, T, 597(ab), 1134(ab)
 Beyer, W, 1041(ab)
 Bezante, GP, 1832
 Bezerra, RJ, 1379(ab)
 Bhargava, KK, 57(ab), 961(ab), 1404(ab)
 Bhatnagar, A, 562(ab), 904(ab)
 Bhosale, P, 902(ab)
 Bianchi, C, 1556
 Bianchi, J, 1104(ab)
 Bianchi, PA, 1123(ab), 1630
 Bianchi, R, 926(ab)
 Bianco, J, 723(ab)
 Bidani, N, 1334(ab)
 Biedenstein, S, 185(ab)
- Bier, D, 1342
 Biersack, HJ, 78(ab), 974(ab), 988(ab), 1133(ab), 1384(ab)
 Bigner, DD, 631
 Bihl, H, 248(ab), 254(ab), 1059(ab), 1068(ab), 1149(ab)
 Bilger, K, 460(ab), 1289(ab)
 Bilkay, UY, 753(ab)
 Binkert, BL, 1024
 Bird, NJ, 135(ab)
 Bird, V, 206(ab)
 Birnbaumer, L, 1083(ab)
 Birell, A, 144(ab)
 Bishayee, A, 978(ab)
 Bishop, HA, 229(ab), 230(ab), 379(ab), 468(ab), 548(ab), 1320(ab)
 Bishop, MC, 399(ab)
 Bissoli, S, 1053(ab)
 Bizais, YJ, 298(ab), 473(ab)
 Black, K, 1182(ab)
 Black, SE, 1193(ab)
 Blais, M, 753(ab), 1262(ab)
 Blanco, P, 1524
 Blankenberg, FG, 38(ab), 184, 846(ab)
 Blanksma, PK, 507, 351(ab), 717(ab), 755(ab)
 Blasberg, RG, 1012(ab)
 Blatt, SA, 225(ab), 226(ab), 408(ab)
 Blatter, J, 1011(ab)
 Blaufox, MD, 1352
 Bleckmann, C, 941(ab), 2021
 Blend, MJ, 347, 394(ab), 1138(ab), 1276(ab)
 Bleiza, M, 83(ab)
 Blier, P, 577(ab)
 Blijham, GH, 639
 Blocklet, DC, 1333(ab), 1978
 Blockmans, D, 899(ab)
 Blondet, C, 585
 Blood, CH, 485(ab)
 Blood, DK, 182(ab)
 Bloodworth, GA, 1454(ab)
 Blum, J, 231(ab)
 Blum, JE, 36(ab)
 Blum, S, 788(ab)
 Blumenthal, RD, 428(ab), 429(ab), 981(ab), 1380(ab), 1609
 Blundell, P, 153(ab)
 Bobbaers, H, 899(ab)
 Boccio, JR, 1080
 Bocciolone, L, 235(ab)
 Bocher, M, 545(ab), 1037(ab)
 Bockisch, A, 475(ab), 923(ab), 1918
 Boellaard, R, 1235(ab), 1313(ab)
 Boer, G, 1107(ab)
 Boerman, OC, 58(ab), 192, 432(ab), 829, 892(ab), 1028(ab), 2066
 Boersma, E, 731(ab), 1866
 Bofiliais, I, 931(ab)
 Bohdiewicz, P, 83(ab)
 Bohnen, NI, 850(ab)
 Bohuslavizki, KH, 46(ab), 71(ab), 257(ab), 776, 941(ab), 1041(ab), 1033(ab), 1150(ab), 1246, 1657, 2021
 Bokemeyer, C, 1133(ab)
 Bokhari, S, 182(ab)
 Bolch, WE, 978(ab), 1327, 1947, 2115
 Boldrini, E, 1148(ab)
 Bolinger, B, 427(ab)
 Bolognese, L, 363
 Bolzati, C, 1382(ab)
 Bom, HS, 286(ab), 549(ab), 1202(ab), 1378(ab)
 Bomanji, J, 737(ab)
 Bombardieri, E, 251(ab), 1114(ab)
 Bonab, AA, 579(ab), 1161(ab), 1266(ab)
 Bonaduce, D, 194(ab), 1683
 Bonapace, ES, 366(ab)
 Boni, G, 926(ab)
 Böni, R, 79(ab)
 Böning, G, 1234(ab)
 Bönisch, H, 1342
 Bonow, RO, 342(ab)
 Bonte, FJ, 896(ab)
- Bontemps, L, 1466(ab)
 Booij, J, 106(ab), 111(ab), 113(ab), 272(ab), 753, 1091, 1216(ab)
 Bookheimer, SY, 283(ab)
 Boon, P, 277(ab)
 Boonstra, H, 432(ab), 1132(ab)
 Booth, BJM, 1536
 Borbath, I, 1013(ab), 1109(ab)
 Bordenave, L, 1756
 Borgers, M, 19(ab), 822(ab)
 Borges, AC, 195(ab)
 Borges-Neto, S, 26(ab), 477(ab)
 Borggrefe, M, 1, 834(ab)
 Bormans, G, 19(ab), 98(ab), 822(ab), 899(ab)
 Bormans, GM, 288(ab), 610(ab), 898(ab), 1353(ab)
 Börner, AR, 566(ab)
 Bornstein, A, 171(ab), 176(ab)
 Borrón, M, 768
 Borsi, L, 434(ab)
 Boschi, A, 1382(ab)
 Bossle, F, 1342
 Bossuyt, A, 256(ab), 413(ab), 488(ab), 703(ab), 709(ab), 872(ab)
 Böttcher, HE, 1186, 1292
 Böttcher, M, 1292
 Botti, C, 46
 Bottlaender, M, 1374
 Bouchareb, Y, 31(ab)
 Boucher, L, 41(ab)
 Bouchet, LG, 978(ab), 1327, 1524, 1947, 2115
 Boudraa, A, 821(ab)
 Bouhnik, JP, 136(ab)
 Bourguet, P, 140(ab), 1314(ab)
 Bourque, CR, 1369(ab)
 Bousson, V, 1092(ab)
 Bouvard, G, 8(ab), 175(ab), 901(ab), 905(ab)
 Bouwens, L, 1250(ab)
 Bowen, WD, 486(ab)
 Bowsher, JE, 139(ab), 1260(ab)
 Brag, JM, 729(ab)
 Braga, HM, 1148(ab)
 Brambs, H, 422(ab)
 Brandalise, S, 1148(ab)
 Brandalise, SR, 958(ab)
 Brandt-Mainz, K, 923(ab)
 Brans, B, 277(ab)
 Brasseur, N, 876
 Braunstein, RH, 206(ab)
 Bray, M, 1370(ab)
 Breaud, JL, 1092(ab)
 Brechbiel, MW, 166, 268, 322(ab), 327(ab), 329(ab), 415(ab), 431(ab)
 Brecht-Krauss, D, 1637
 Bredow, J, 543(ab)
 Breeman, WA, 317(ab), 320(ab), 414(ab), 418(ab)
 Breider-Backes, I, 1152(ab)
 Breithardt, G, 1, 834(ab)
 Breitz, HB, 75(ab), 1355(ab)
 Bremner, JD, 578(ab), 1220(ab)
 Brenner, W, 46(ab), 47(ab), 71(ab), 776, 1033(ab), 1246
 Breuning, A, 254(ab)
 Bricker, JA, 613(ab)
 Brigger, P, 1297(ab)
 Brill, AB, 590(ab), 1364(ab), 1524
 Brink, I, 340(ab)
 Brinkbarumer, K, 1243(ab)
 Brinkbaumer, K, 1048(ab)
 Brinkmann, BH, 677, 1098
 Brinkschmidt, C, 388(ab)
 Briscoe, E, 553(ab)
 Britten, AE, 161(ab)
 Britton, A, 984(ab)
 Britton, KA, 60(ab)
 Britton, KE, 467(ab), 764(ab), 904(ab), 1108(ab)
 Britz-Cunningham, SH, 714(ab)
 Brix, G, 1016(ab), 1032(ab)
 Brockmann, H, 830(ab)

- Broder, JD, 206(ab)
 Brotherton, JH, 347(ab)
 Brouillaud, B, 1756
 Brouwers, AH, 892(ab)
 Brown, BM, 1383(ab)
 Brown, CA, 9(ab)
 Brown, KL, 492(ab)
 Brown, RP, 373(ab)
 Brown, RS, 88(ab), 89(ab), 87(ab), 556
 Brownell, A, 582(ab)
 Brücher, BL, 550(ab)
 Bruckbauer, T, 1316(ab)
 Bruland, ØS, 1197
 Brun, T, 597(ab)
 Brunelli, C, 1832
 Brunetti, A, 442
 Brunken, R, 773(ab)
 Brunner, C, 395(ab)
 Bruno, A, 338(ab), 725(ab), 777(ab), 914(ab), 1630
 Brust, JC, 1205(ab)
 Brust, P, 293(ab), 584(ab)
 Bruyant, PP, 1676
 Buchert, R, 257(ab), 1150(ab), 1657, 2021
 Buchmann, I, 247(ab), 945(ab)
 Buchpiguel, CA, 870(ab), 916(ab)
 Buchsbaum, MS, 355(ab)
 Buck, A, 1158(ab)
 Buck, AK, 368(ab)
 Buckley, KS, 1453(ab)
 Bucky, LP, 1143
 Budinger, T, 352(ab)
 Budinger, TF, 311(ab)
 Buell, U, 450(ab)
 Buffoni, F, 1123(ab)
 Bugaj, J, 320(ab)
 Bugaj, JE, 993(ab), 996(ab)
 Bugeon, S, 1393(ab)
 Büll, U, 1133(ab)
 Bunjes, D, 262(ab)
 Buonomici, P, 363
 Buranapong, P, 131
 Burchert, W, 543(ab), 719(ab), 1272(ab)
 Burckhardt, D, 359(ab)
 Burckhardt, DD, 1244(ab)
 Burg, M, 346(ab)
 Burger, A, 1342
 Burger, C, 1288(ab)
 Burke, G, 377(ab)
 Burke, R, 776(ab)
 Burke, RJ, 771(ab)
 Burkhardt, H, 537(ab)
 Burnham, CA, 1258(ab)
 Burns, HD, 400(ab), 1014(ab)
 Burns, RJ, 721(ab), 771(ab), 776(ab)
 Burrascano, JJ, 1197(ab)
 Buscombe, JR, 68(ab), 536(ab), 541(ab), 1038(ab)
 Busemann Sokole, E, 1091
 Bush, LR, 994(ab)
 Bush, V, 218(ab)
 Buskens, E, 311
 Bussière, F, 1301
 Butterworth, EA, 1279(ab)
 Buvat, I, 16(ab), 140(ab), 471(ab), 595(ab), 1301, 1314(ab)
 Byars, LG, 597(ab)
 Bybel, B, 707(ab)
 Byrd, DR, 557(ab)
 Byrne, CL, 1312(ab)
 Byrne, FR, 1083(ab)
 Cabral-Neto, JB, 1379(ab)
 Cabrejas, RC, 60(ab)
 Cabrera, A, 555(ab)
 Cacavio, A, 84(ab)
 Cadiot, G, 1602
 Cadorette, J, 832(ab), 876
 Cai, H, 485(ab)
 Caillat-Vigneron, N, 40, 960(ab)
 Caló, G, 1168(ab), 1556
 Calame, W, 2073
 Calcagno, ML, 1080
 Caldeira-de-Araujo, A, 1379(ab)
 Caldwell, CB, 1193(ab)
 Caldwell, JH, 339(ab), 1279(ab), 1400(ab)
 Calegaro/Manzini, JU, 11(ab)
 Callahan, MJ, 913(ab)
 Callahan, RJ, 1161(ab)
 Callans, LS, 1143
 Callen, DJ, 1193(ab)
 Calmanovici, GP, 1080
 Calne, DB, 283
 Calnon, DA, 821
 Calvo, R, 555(ab), 1096(ab), 1145(ab)
 Camargo, EE, 746(ab), 848(ab), 958(ab), 1148(ab)
 Cameron, R, 1370(ab)
 Camici, PG, 507, 834(ab), 1848
 Camp, V, 1344(ab)
 Camp, VM, 331
 Campbell, C, 1211(ab)
 Campion, L, 198
 Campisi, R, 32(ab)
 Campos, LP, 165(ab)
 Campos, R, 1040(ab)
 Campreciós, M, 911
 Camprecios, M, 5(ab)
 Canavese, G, 1123(ab)
 Candell-Riera, J, 315(ab)
 Caner, B, 849(ab)
 Canesi, M, 271(ab)
 Cannas, P, 843(ab)
 Cantin, J, 1124(ab)
 Cantwell, MN, 2053
 Canzi, C, 914(ab), 1928
 Caporali, C, 538(ab)
 Caputo, G, 574
 Capuzzi, DM, 1458(ab)
 Caracó, C, 1547
 Carbon, C, 893(ab)
 Carey, J, 990(ab)
 Cargnel, S, 1053(ab)
 Carhart, C, 1245(ab)
 Carli, F, 1123(ab)
 Carlisle, M, 545(ab)
 Carlson, KA, 846, 495(ab)
 Carlson, SM, 554(ab), 1099(ab), 1130(ab)
 Caro, RA, 1080
 Carola, F, 77
 Carpenter, R, 1108(ab)
 Carr, CE, 2014
 Carrasquillo, JA, 268, 327(ab), 385(ab), 464(ab), 565(ab), 837, 1006(ab), 1027(ab), 1029(ab), 1391
 Carretta, RF, 21N(9)
 Carrio, I, 3(ab), 5(ab), 734(ab), 786(ab), 1212(ab)
 Carrió, I, 19, 911
 Carroll, MJ, 467(ab), 1108(ab)
 Carson, RE, 119(ab), 168(ab), 464(ab), 472(ab), 1321(ab)
 Carter, EA, 370(ab), 391(ab), 894(ab), 895(ab)
 Carter, PC, 324(ab)
 Casas, M, 19
 Casati, R, 251(ab)
 Case, JA, 27(ab), 604, 724(ab), 1291(ab)
 Casey, ME, 306(ab), 1316(ab)
 Caskey, C, 1463(ab)
 Casolo, GC, 196(ab)
 Castaigne, A, 224, 917
 Castellani, M, 251(ab), 338(ab), 1085(ab), 1928
 Castellari, M, 725(ab), 777(ab)
 Castellucci, P, 387(ab)
 Castle, VP, 519(ab)
 Castronovo, F, 1031(ab)
 Catafau, A, 5(ab)
 Catafau, AM, 3(ab), 19, 123(ab), 734(ab), 786(ab), 911, 1212(ab)
 Catsafados, E, 522
 Cavalieri, V, 488(ab), 872(ab)
 Cayre, A, 672
 Ceccarelli, C, 1716
 Celerier, C, 1756
 Cengiz, K, 864(ab)
 Centi Colella, A, 556(ab)
 Cerisano, G, 363
 Cesani, F, 553(ab), 906(ab)
 Cessna, JT, 1508
 Chae, SC, 735(ab)
 Chakder, S, 352
 Chakrabarty, S, 737(ab)
 Chaljub, G, 906(ab)
 Chalon, S, 1343(ab)
 Chaly, TC, 1339(ab)
 Champailleur, A, 733(ab)
 Champlin, RE, 160(ab)
 Chan, GL, 283
 Chan, H, 382(ab)
 Chan, T, 297(ab)
 Chandra, P, 507(ab)
 Chandra, S, 279(ab)
 Chang, CP, 1065(ab), 1186(ab)
 Chang, C-S, 1106
 Chang, CW, 244(ab), 1365(ab)
 Chang, CY, 285(ab)
 Chang, L, 443(ab)
 Chang, SM, 349(ab)
 Chang, W, 896(ab)
 Chang, Y, 402(ab)
 Chang, YS, 1275(ab), 1350(ab)
 Changlai, S, 225(ab), 226(ab), 408(ab)
 ChangLai, S-P, 1446
 Channing, MA, 464(ab)
 Chapman, JT, 1245(ab)
 Chapman, WC, 1784
 Charache, P, 454(ab)
 Charbonnier, B, 223(ab)
 Charles, ND, 1313
 Charlop, A, 69(ab), 551(ab)
 Charney, DS, 124(ab), 143(ab), 576(ab), 578(ab), 580(ab), 1208(ab), 1220(ab), 1902
 Charon, Y, 602(ab)
 Charpak, G, 868
 Charron, M, 50(ab), 597(ab), 850(ab), 1134(ab)
 Chatal, J-F, 198, 1216
 Chatterton, BE, 277
 Chatzioannou, AF, 303(ab), 1164
 Chatzioannou, SN, 17(ab), 348(ab)
 Chatzimavroudis, G, 753(ab)
 Chaudhuri, G, 32(ab)
 Chaudhuri, TR, 994(ab)
 Chauvet, P, 585
 Chechik, A, 63(ab)
 Chefer, S, 1349(ab)
 Chen, CC, 539
 Chen, C-H, 118
 Chen, FD, 1365(ab)
 Chen, G-H, 1106
 Chen, HJ, 1365(ab)
 Chen, JQ, 484(ab)
 Chen, K, 717(ab), 1045, 1304(ab)
 Chen, L, 494(ab)
 Chen, M, 1391(ab)
 Chen, P, 1344(ab)
 Chen, SH, 1012(ab)
 Chen, T, 846, 1091(ab), 1111(ab)
 Chen, W, 1315(ab)
 Chen, WS, 1024(ab)
 Chen, Y, 1373(ab), 1395(ab)
 Chen, Y-C, 582(ab)
 Chen, Z, 1370(ab)
 Cheng, KT, 1383(ab), 1390(ab)
 Cheng, SH, 1052(ab)

- Chun, KJ, 810(ab)
 Chun, KS, 1394(ab)
 Chung, CK, 1195(ab)
 Chung, J, 2(ab), 23(ab), 309(ab), 358(ab), 386(ab), 452(ab), 476(ab), 529(ab), 742(ab), 789(ab), 790(ab), 819(ab), 938(ab), 998(ab), 999(ab), 1143(ab), 1171(ab), 1195(ab), 1196(ab), 1198(ab), 1214(ab), 1221(ab), 1275(ab), 1350(ab), 1387(ab), 1392(ab)
 Chung, J-K, 339, 986
 Chung, SK, 217(ab), 376(ab)
 Chung, WS, 1358(ab)
 Chung, YA, 376(ab)
 Ciancio, G, 377(ab)
 Ciarmiello, A, 442
 Cieuta, C, 786
 Ciftci, I, 849(ab)
 Cila, A, 524(ab)
 Cirignano, L, 304(ab)
 Cittanti, C, 167(ab), 778(ab), 1168(ab), 1556
 Civelek, AC, 454(ab), 940(ab)
 Clackdoyle, R, 1255(ab)
 Clairand, I, 157(ab), 1517
 Clausen, M, 46(ab), 71(ab), 257(ab), 776, 941(ab), 1033(ab), 1041(ab), 1133(ab), 1150(ab), 1246, 1657, 2021
 Cleveland, W, 799
 Clinthorne, NH, 133(ab)
 Clorius, JH, 372(ab)
 Cloutier, S, 1100(ab)
 Clulow, J, 1263(ab)
 Cnaan, A, 520(ab)
 Coco-Graham, WA, 894(ab)
 Cody, K, 983(ab)
 Coelho, OR, 746(ab)
 Coenen, HH, 501(ab), 575(ab)
 Cohen, A, 539(ab)
 Cohen, C, 238(ab)
 Cohen, I, 6(ab), 28(ab), 170(ab), 346(ab), 378(ab)
 Cohen, RM, 119(ab)
 Cohen, W, 572(ab)
 Cokgor, I, 631
 Colacci, C, 843(ab)
 Colamussi, P, 167(ab), 778(ab), 1168(ab), 1556
 Colcher, D, 1536
 Cole, C, 204(ab)
 Cole, GM, 284(ab)
 Cole, WC, 1165(ab)
 Coleman, RE, 26(ab), 81(ab), 136(ab), 339(ab), 477(ab), 631, 814, 1241(ab), 1176
 Colin, P, 743(ab)
 Collart, JP, 219(ab)
 Collier, BD, 1369(ab)
 Collins, P, 1232(ab)
 Colnot, DR, 263(ab)
 Colombo, F, 914(ab)
 Comans, EF, 407(ab), 827(ab)
 Comans, EFI, 1204
 Comtat, C, 2053
 Conant, R, 1138(ab)
 Conciato, L, 77
 Condos, S, 21(ab)
 Connell, EJ, 20N(3)
 Connelly, K, 119(ab)
 Connolly, LP, 51(ab), 52(ab), 56(ab), 908(ab), 1896
 Connors, JM, 1031(ab)
 Conrad, B, 290(ab)
 Consigny, PM, 491(ab)
 Constable, C, 144(ab), 382(ab)
 Constantine, E, 377(ab)
 Conti, PS, 103(ab), 334(ab), 465(ab), 1361(ab), 1368(ab)
 Contoreggi, C, 441(ab)
 Conwell, R, 1225(ab)
 Cook, C, 513(ab), 517(ab)
 Cooke, CD, 508(ab), 511(ab), 650, 787(ab), 1290(ab)
 Cooper, MS, 615(ab)
 Copello, F, 522
 Coppola, RC, 1348(ab)
 Corazzari, T, 538(ab)
 Corbett, JR, 15(ab), 232, 361(ab), 506(ab), 817(ab)
 Cordero, M, 768
 Corleto, VD, 843(ab)
 Corne, R, 707(ab)
 Cornel, JH, 1(ab), 190(ab), 192(ab), 731(ab), 1866
 Cornelius, EA, 73(ab), 987(ab)
 Corone, C, 546(ab)
 Cörper, S, 871(ab)
 Correia, JA, 1258(ab)
 Corsi, M, 275(ab), 730, 1199(ab), 1270(ab)
 Corstens, FH, 58(ab), 432(ab), 192, 829, 892(ab), 1028(ab), 2066
 Cortelazzi, D, 922(ab)
 Cortino, GR, 66(ab)
 Costa, DC, 737(ab)
 Costa, PL, 916(ab)
 Cottu, P, 1105(ab)
 Coulden, R, 1093(ab)
 Coulon, C, 1374
 Coulon, MA, 1092(ab)
 Coulon, P, 868
 Counsell, RE, 155(ab)
 Couturier, O, 1286(ab)
 Covelli, EM, 442
 Crandell, PS, 459(ab)
 Crane, PD, 1369(ab)
 Cremerius, U, 1133(ab)
 Cremieux, AC, 893(ab)
 Cremonesi, M, 72(ab), 266(ab)
 Crepin, M, 1127(ab)
 Crespo-Jara, AA, 424(ab), 555(ab), 1096(ab), 1145(ab)
 Crestani, B, 962(ab)
 Cribier, A, 179(ab), 513, 805
 Crijns, HJ, 507
 Criss, JS, 1144(ab)
 Croisille, P, 821(ab)
 Croon, CD, 740(ab)
 Cross, DJ, 294(ab)
 Crouzel, C, 1374
 Crow, J, 68(ab)
 Crow, W, 906(ab)
 Cullom, SJ, 724(ab), 1262(ab), 1291(ab)
 Cummings, JL, 283(ab), 285(ab)
 Cunha, ML, 1040(ab)
 Cuocolo, A, 194(ab), 338(ab), 725(ab), 777(ab), 1683
 Cupps, B, 4(ab)
 Curcio, MJ, 166, 431(ab)
 Curran, KM, 409(ab)
 Curtis, JL, 1205(ab)
 Curtis, KS, 771(ab)
 Cutler, DP, 1304(ab)
 Cwajg, E, 1857
 Cwajg, J, 1857
 Cwikla, JB, 68(ab), 536(ab), 1038(ab)
 Cyr, JE, 321(ab), 887(ab)
 Czech, N, 47(ab)
 Czech, NJ, 730(ab)
 Czerniecki, BJ, 1117(ab), 1143
 Czernin, J, 130(ab), 184(ab), 186(ab), 189(ab), 225(ab), 226(ab), 227(ab), 285(ab), 408(ab), 1083(ab), 1293(ab), 1468(ab), 2043
 Czuczman, M, 949(ab)
 Da Silva, AJ, 596(ab), 820(ab), 1248(ab)
 Dachille, MA, 597(ab), 1134(ab)
 Dadparvar, S, 856(ab)
 Dae, M, 352(ab)
 Dae, MW, 820(ab), 1249(ab)
 Dafermou, A, 778(ab), 1168(ab)
 Daffin, FC, 479(ab)
 D'Agnolet, A, 246(ab), 280(ab), 378(ab), 883(ab), 959(ab)
 Dahl, JR, 1339(ab)
 Dahlberg, ST, 456(ab)
 Dahlbom, M, 131(ab), 225(ab), 226(ab), 303(ab), 1083(ab), 1231(ab), 1468(ab)
 Dahlheimer, JL, 316(ab), 1024(ab)
 Dahman, BA, 986(ab)
 Dai, D, 775(ab)
 D'Aiuto, G, 66(ab)
 Daldrup, H, 392(ab)
 Daley, L, 480(ab)
 Dalipaj, M, 732(ab)
 Damien, J, 1466(ab)
 Dams, ET, 58(ab), 192, 2066
 Daneker, GW, 92(ab)
 Dangas, G, 1322(ab)
 Danias, PG, 711(ab)
 Danielli, R, 556(ab), 843(ab)
 Dannals, RF, 115(ab), 373(ab), 446(ab), 447(ab), 454(ab), 1014(ab), 1164(ab), 1180, 1207(ab), 1349(ab)
 Dansereau, RN, 616(ab), 1030(ab), 1399(ab)
 Dantas, FJ, 1379(ab)
 Daou, D, 173(ab), 369(ab), 411(ab), 701(ab), 794(ab), 743(ab), 809(ab), 1602
 Darabaneanu, A, 429(ab)
 Darcourt, J, 1301
 Darlas, Y, 8(ab), 175(ab), 901(ab), 905(ab)
 Darling, J, 1293(ab)
 Darsow, U, 451(ab)
 Darteville, P, 173(ab)
 Das, SS, 904(ab)
 Dasgupta, B, 464
 Dass, C, 889
 D'Asseler, Y, 1250(ab)
 Daube-Witherspoon, ME, 472(ab), 1321(ab)
 Davidoff, S, 366(ab)
 Davids, E, 125(ab)
 Davidson, T, 560(ab), 1116(ab)
 Davies, G, 343(ab), 344(ab)
 Davies, HM, 1346(ab)
 Davila-Roman, VG, 4(ab)
 Davis, RE, 184
 Davis, RT, 1896
 Daviskas, E, 382(ab)
 Dawant, BM, 1364(ab)
 Dawson, S, 738(ab)
 d'Azemar, P, 223(ab)
 De Beco, V, 1092(ab)
 De Bree, R, 263(ab)
 de Bruin, K, 753
 De Caestecker, J, 899(ab)
 De Cesare, A, 31(ab)
 De Coster, P, 219(ab), 766(ab), 792(ab)
 De Cristofaro, M, 573(ab)
 de Groot, T, 19(ab), 822(ab)
 de Groot, TJ, 288(ab), 898(ab), 1353(ab)
 de Herder, WW, 416(ab)
 de Jong, M, 317(ab), 320(ab), 322(ab), 414(ab), 415(ab), 418(ab), 1389(ab), 2081
 de Jong, R, 507
 de Klerk, JM, 311, 639
 De La Pena, RC, 1180(ab)
 De Leyn, P, 98(ab)
 de los Cobos, JP, 19
 de Marie, S, 2066
 de Mattos, JC, 1379(ab)
 de Notaristefani, F, 46
 De Paoli, T, 1080
 de Rooij, L, 667
 De Rosch, MA, 321(ab), 887(ab), 950(ab), 954(ab)
 De Sadeleer, C, 210(ab)
 De Scheerder, I, 822(ab)
 de Silva, R, 747
 De Toffol, B, 1393(ab)
 de Voigt, M, 1257(ab)
 De Vos, F, 1354(ab)
 de Vries, DJ, 1011
 de Vries, E, 890(ab)
 de Vries, EG, 393(ab), 1159(ab)

- Diefenbach, B, 1061
 Diegeler, A, 337(ab)
 Diemling, M, 1049(ab), 1347(ab)
 Dierckx, RA, 269(ab), 277(ab), 783,
 1250(ab), 1354(ab)
 Dierickx, L, 703(ab), 709(ab)
 Dierickx, LO, 256(ab), 413(ab)
 Dietlein, M, 202(ab), 973(ab)
 Diggles, L, 1080(ab), 1363(ab)
 Diggle, LE, 1233
 Diksic, M, 577(ab)
 Dimattia, DG, 350(ab)
 DiMatta, DG, 810(ab)
 Dimitrakopoulou-Strauss, A, 1061(ab),
 1288(ab), 1323(ab)
 Din, SU, 711(ab)
 Dinanian, S, 743(ab)
 Ding, H-J, 1446
 Ding, Y, 1377(ab)
 Ding, Y-S, 1154
 Ding, YS, 406(ab), 439(ab), 442(ab),
 1218(ab)
 Dinkelborg, L, 434(ab)
 Dinkelborg, LM, 837(ab)
 Dione, DP, 21(ab)
 Dionne, G, 1100(ab)
 Dirschinger, J, 24(ab)
 Dispersyn, GD, 19(ab)
 Dittmann, H, 946(ab), 957(ab)
 Djokich, D, 1716
 Dobbeleir, AA, 706(ab), 707, 1468
 Dobko, T, 283
 Dobrzeniecki, AB, 1280(ab)
 Dodig, D, 531(ab), 937(ab)
 Doenst, T, 1186
 Doerr, RJ, 1069(ab)
 Dogan, S, 441(ab)
 Dohmen, BM, 245(ab), 460(ab),
 933(ab), 946(ab), 956(ab), 957(ab),
 1133(ab)
 Dohr, D, 262(ab)
 Doi, K, 1160(ab)
 Dolbier, WR, 401(ab)
 Dolin, RJ, 562(ab)
 Dollé, F, 1374
 Dom, RJ, 288(ab)
 Domingo, P, 3(ab)
 Donnetti, M, 556(ab)
 Donohoe, KJ, 1236
 Dopichaj-Meuge, U, 920(ab)
 Dopichj-Menge, U, 948(ab)
 Doppman, JL, 539
 Dorbala, S, 924, 507(ab), 716(ab)
 Dormeier, A, 540(ab)
 Dörner, J, 48(ab)
 Dose, J, 2021
 Doshi, NK, 1223(ab)
 Doting, MH, 70(ab), 1119(ab)
 Dou, Y, 856(ab)
 Doudet, DJ, 283
 Dougherty, DD, 579(ab)
 Downs, H, 942
 Dowrkin, H, 83(ab)
 Doze, P, 292(ab), 351(ab), 496(ab),
 1167(ab), 1177(ab)
 Drane, WE, 371(ab), 406
 Dresel, S, 150, 1048(ab), 1243(ab)
 Dresel, SH, 625, 660
 Dresser, T, 174(ab)
 Driedger, A, 41(ab)
 Drum, D, 837
 Drzezga, A, 451(ab), 737
 Duarte, P, 61(ab), 387(ab), 453(ab),
 868(ab), 1286(ab)
 Duatti, A, 1168(ab), 1382(ab)
 Dubois, EA, 22(ab), 25(ab)
 Dubois Rande, JL, 31(ab)
 Dubois-Randé, J-L, 224, 917
 Dubovsky, EV, 1122
 Dubrovnik, M, 105(ab)
 Ducassou, D, 412, 868
 Duchesne, N, 267(ab), 1100(ab)
 Duda, S, 837(ab)
- Dudczak, R, 74(ab), 362(ab), 1049(ab),
 1081(ab)
 Dudczak, R, 395(ab)
 Duet, M, 1252
 Dufour, M, 1100(ab)
 Duhamel, A, 956
 Dulac, O, 786
 Dummer, R, 79(ab)
 Dumont, F, 1354(ab)
 Dumont, M, 1103(ab)
 Dumont, MJ, 1100(ab)
 Duncan, BH, 711(ab)
 Duncan, JS, 1220(ab)
 Duncan, R, 747
 Duncker, C, 262(ab)
 Dunkelmann, S, 528(ab), 558(ab)
 Dunn-Dufault, R, 614(ab)
 Dunnwald, LK, 551(ab), 557(ab)
 Dupont, JO, 422
 Dupont, P, 98(ab)
 Dupont, S, 935
 Durband, M, 79(ab)
 Durie, B, 246(ab), 959(ab)
 Durigon, M, 157(ab)
 Dutschka, K, 1342
 Duval, A-M, 917
 Duverney, C, 18(ab)
 Duxbury, DM, 1224(ab)
 Dwivedi, SN, 927(ab)
 Dworkin, H, 287(ab)
 Dworkin, HJ, 993
 Dyer, SM, 1263(ab)
 Dymond, DS, 764(ab)
 Early, ML, 107(ab)
 Early, JF, 557(ab), 614, 1237(ab)
 Easton, EJ, 42(ab)
 Eberl, S, 144(ab), 312(ab), 382(ab)
 Ebner, SA, 1453(ab)
 Echt, EA, 236(ab)
 Eck, SL, 333(ab), 995
 Eckelman, WC, 119(ab), 149(ab),
 150(ab), 168(ab), 329(ab), 472(ab),
 1547
 Edell, SL, 613(ab)
 Edelstein, Y, 1144(ab)
 Edenbrandt, L, 96, 224(ab)
 Edlin, J, 73(ab)
 Edmondson, SJ, 764(ab)
 Edwards, C, 1184(ab)
 Edwards, DS, 892(ab), 1369(ab)
 Edwards, GK, 1112(ab)
 Eersels, J, 765(ab)
 Efange, SM, 1356(ab)
 Efsen, F, 290
 Egawa, S, 859(ab)
 Egert, S, 828(ab)
 Eggert, AA, 1028(ab)
 Egli, A, 1913
 Ehrenkaufer, RL, 1356(ab)
 Ehrt-Braun, C, 423(ab)
 Eichstaedt, H, 387
 Eidelberg, D, 1178(ab), 1184(ab), 1264,
 1339(ab)
 Eidson, M, 799
 Eigler, N, 356(ab)
 Eigstved, A, 1136(ab)
 Eilles, C, 1154(ab)
 Eisbruch, A, 1125, 1130(ab)
 Eisenberg, DA, 1457(ab)
 Eisenhut, M, 1011(ab), 487(ab), 1484
 Eisensohn, I, 112(ab)
 Ejiri, K, 847(ab)
 Eke, S, 524(ab)
 El Fakhri, G, 16(ab), 595(ab)
 El Gohary, MA, 861(ab)
 El Mallah, M, 942
 El Tom, F, 861(ab)
 Eldeiry, S, 446(ab)
 Elder, DE, 1143
 El-Desouki, M, 928(ab)
 El-Doza, B, 879(ab)
 Eldridge, KR, 963(ab)
 Elgamel, AA, 1138(ab)
 Elgazzar, AH, 785(ab), 879(ab)
- Elhendy, A, 1(ab), 731(ab), 1866
 Eliashiv, DS, 280(ab)
 Ell, PJ, 343(ab), 344(ab), 560(ab),
 737(ab), 1113(ab), 1115(ab), 1116(ab)
 Elliott, DG, 967(ab)
 Elliott, MD, 509(ab), 513(ab), 517(ab)
 Ellis, GK, 69(ab), 551(ab)
 Ellison, D, 1108(ab)
 Elmaleh, DR, 1340(ab), 1341(ab)
 Elsinga, PH, 116(ab), 292(ab), 351(ab),
 1167(ab), 1270
 Elsner, K, 1623
 Elstodt, J, 373(ab)
 Ely, T, 1344(ab)
 El-Zeftawy, H, 889(ab)
 El-Zeftawy, HA, 84(ab)
 Emmanouilides, C, 260(ab)
 Emmett, L, 869(ab)
 Emmi, L, 573(ab)
 Emond, P, 1343(ab)
 Ende, JF, 406
 Enderle, M, 871(ab)
 Endo, K, 217, 336(ab), 390(ab), 399,
 878(ab), 1003(ab), 1005(ab),
 1018(ab)
 Endres, CJ, 1169(ab)
 Eng, W, 400(ab), 1014(ab)
 Ensing, K, 1270
 Enterottacher, A, 1311(ab)
 Enterottacher, A, 1243(ab)
 Epelman, S, 1148(ab)
 Epstein, S, 29(ab), 911(ab)
 Erami, SS, 530
 Ercakmak, N, 919(ab), 1046(ab)
 Ercoli, LM, 281(ab), 283(ab)
 Erdi, AK, 466(ab)
 Erdi, YE, 466(ab), 1238(ab), 1935
 Erdman, WA, 237(ab), 896(ab)
 Eremi, O, 552(ab)
 Eriksson, L, 306(ab)
 Erion, J, 320(ab)
 Erion, JL, 993(ab), 996(ab)
 Erlandsson, K, 1224(ab), 1232(ab)
 Ernst, N, 840(ab)
 Erwin, WD, 712(ab), 1278(ab),
 1327(ab)
 Escher, P, 1243(ab)
 Eschmann, SM, 871(ab), 933(ab)
 Eschner, W, 202(ab)
 Eshima, D, 331, 419(ab), 497(ab),
 504(ab), 995(ab)
 Eshima, L, 331
 Estes, JM, 76(ab)
 Estorch, M, 3(ab), 5(ab), 19, 734(ab),
 786(ab), 911
 Etchebehere, EC, 746(ab), 848(ab),
 958(ab), 1148(ab)
 Etcheberrigaray, A, 19
 Eubank, WB, 69(ab)
 Eubanks, S, 1329(ab)
 Euhus, DM, 237(ab)
 Evander, E, 224(ab)
 Evans, D, 1121(ab)
 Evans, DG, 62(ab)
 Evans, SM, 401(ab)
 Evenepoel, P, 1451
 Everaert, H, 256(ab), 488(ab), 703(ab),
 709(ab)
 Everett, JR, 168(ab), 472(ab)
 Ezquerro, NF, 508(ab), 1290(ab)
 Ezuddin, SH, 799, 768(ab)
 Faber, TL, 315(ab), 650, 753(ab)
 Fagundes, JJ, 848(ab)
 Fahey, FH, 1356(ab)
 Fain, R, 495(ab)
 Fain, RL, 846
 Faivre-Chauvet, A, 198, 1216
 Falchi, A, 1105(ab)
 Fallon, BA, 1197(ab)
 Fan, C, 1373(ab), 1395(ab)
 Fang, B, 1459(ab), 1464(ab)
 Fantuzzi, E, 1716
 Faraggi, M, 701(ab), 794(ab), 805,
 809(ab), 893(ab), 903(ab), 1602
 Farahani, K, 142(ab)
 Farahati, J, 1342
 Farde, L, 102, 120(ab), 151(ab),
 436(ab), 1343(ab)
 Faries, MB, 1117(ab)
 Farnsworth, RH, 54(ab), 55(ab), 1805
 Farquhar, TH, 130(ab), 1164, 2043
 Farrell, R, 304(ab)
 Fauconnier, TK, 504(ab), 995(ab)
 Fava, M, 579(ab)
 Fawwaz, RA, 90(ab), 228(ab), 611(ab)
 Fawwaz, RJ, 412(ab)
 Fazio, F, 302(ab), 1617
 Fazzini, PF, 363
 Felder, CA, 715, 1217(ab), 1301(ab)
 Feldmann, HJ, 397(ab)
 Felecan, RC, 1466(ab)
 Felix, R, 387
 Felix, SB, 795(ab)
 Feng, B, 816(ab), 829(ab)
 Feng, D, 717(ab)
 Ferdegħini, M, 926(ab)
 Ferlin, G, 1053(ab)
 Fernandez, P, 412, 1756
 Ferrari, C, 1928
 Ferraro-Borgida, M, 518(ab)
 Ferretti, JA, 825(ab)
 Fessler, JA, 15(ab)
 Fevravi, M, 72(ab)
 Feyerabend, B, 1033(ab)
 Ficaro, EF, 817(ab)
 Ficaro, EP, 15(ab), 361(ab), 506(ab)
 Fiche, M, 198
 Fieber, S, 337(ab)
 Fields, L, 1383(ab)
 Fig, LM, 1292(ab)
 Figdor, CG, 1028(ab)
 Fikrle, A, 752(ab)
 Filmont, JE, 8(ab), 175(ab), 901(ab),
 905(ab)
 Finat-Duclos, F, 672
 Finestone, H, 1144(ab)
 Fini, A, 1053(ab)
 Fink, U, 550(ab)
 Fink-Bennett, DM, 287(ab), 1226
 Finke, J, 247(ab)
 Finkelman, C, 625
 Finlay, WH, 383(ab)
 Finn, R, 105(ab), 1012(ab), 1042(ab)
 Finn, RD, 95(ab), 166, 328(ab), 431(ab),
 1238(ab), 1722, 1764, 1935
 Finzi, A, 338(ab)
 Fioravanti, C, 400(ab), 1014(ab)
 Fiorenza, M, 72(ab), 266(ab)
 Fioretti, PM, 1(ab), 190(ab), 192(ab),
 731(ab), 1866
 Fiorenza, M, 1125(ab)
 Fischer, K, 433(ab)
 Fischer, KC, 525(ab)
 Fischer, S, 840(ab), 1227(ab)
 Fischer, T, 403(ab), 1036(ab), 1372(ab)
 Fischman, AJ, 153(ab), 193(ab),
 370(ab), 391(ab), 421(ab), 547(ab),
 579(ab), 729(ab), 783(ab), 894(ab),
 895(ab), 908(ab), 1090(ab), 1161(ab),
 1258(ab), 1266(ab), 1269(ab),
 1340(ab), 1341(ab)
 Fisher, A, 177(ab)
 Fisher, AD, 169(ab)
 Fisher, DA, 922(ab)
 Fisher, DR, 75(ab)
 Fisher, RS, 366(ab), 854(ab)
 Fisher, SJ, 76(ab), 88(ab), 89(ab),
 155(ab), 405(ab), 612(ab), 991(ab)
 Fissekis, JD, 334(ab), 1361(ab),
 1368(ab)
 Fitzgerald, J, 614(ab), 995(ab)
 Flamen, P, 98(ab), 899(ab)
 Flameng, W, 19(ab)
 Fleckenstein, J, 896(ab)
 Fleming, D, 553(ab)

- Fleming, JS, 1503
 Fletcher, JW, 15N(4)
 Flint, A, 556
 Flores, J, 74(ab), 395(ab)
 Flores, LG, 1057(ab)
 Florimonte, L, 725(ab)
 Flotats, A, 3(ab), 5(ab), 19, 734(ab), 786(ab), 911
 Flower, MA, 161(ab), 983(ab), 1224(ab), 1232(ab)
 Flugelman, MY, 741(ab), 811(ab)
 Flux, GD, 983(ab)
 Foa, P, 1085(ab)
 Foder, B, 1136(ab)
 Foetzschi, R, 268(ab)
 Fogarasi, M, 484
 Foged, C, 435(ab)
 Fogelman, I, 409(ab), 410(ab)
 Folks, RD, 315(ab), 508(ab), 511(ab), 650, 787(ab), 1290(ab)
 Fong, W, 758(ab)
 Foody, JM, 773(ab)
 Forastiere, A, 594(ab)
 Ford, C, 1083(ab)
 Ford, PV, 17(ab), 348(ab), 1226
 Forman, J, 1079(ab)
 Formiconi, AR, 1310(ab)
 Forssell-Aronsson, E, 2094
 Forster, GJ, 925(ab)
 Forster, J, 144(ab)
 Fourme, T, 173(ab), 743(ab)
 Fournier, RS, 1070(ab)
 Fowler, JS, 145(ab), 406(ab), 439(ab), 440(ab), 442(ab), 443(ab), 588(ab), 715, 1154, 1176(ab), 1215(ab), 1217(ab), 1218(ab), 1285, 1301(ab)
 Fox, PT, 942
 Fraker, DF, 1143
 Franceschi, D, 145(ab), 442(ab), 443(ab), 588(ab), 1215(ab), 1217(ab), 1218(ab), 1176(ab)
 Franceschini, R, 1382(ab)
 Francis, B, 400(ab)
 Francis, IR, 77(ab)
 Frank, JW, 455(ab)
 Frank, TL, 1263(ab)
 Franke, W-G, 1484
 Franke, WG, 268(ab), 374(ab), 543(ab), 975(ab), 1385(ab)
 Franken, PR, 256(ab), 707, 703(ab), 706(ab), 709(ab), 1468
 Frantzis, A, 976(ab)
 Franzius, C, 388(ab), 392(ab)
 Frater, C, 869(ab)
 Fratkin, MJ, 1455(ab)
 Freedman, M, 1183(ab)
 Freeman, LM, 810(ab)
 French, J, 276(ab)
 Frenkel, A, 265(ab)
 Frey, EC, 134(ab), 470(ab), 1252(ab)
 Frey, M, 340(ab)
 Frezza, F, 46
 Friberg, L, 1136(ab)
 Friebel, M, 487(ab)
 Friedl, M, 1277
 Friedman, AH, 631
 Friedman, HS, 631
 Friedman, JD, 6(ab), 9(ab), 22(ab), 25(ab), 28(ab), 170(ab)
 Frier, M, 365(ab), 399(ab)
 Frisch, M, 451(ab)
 Fröhlich, A, 250
 Froles, LG, 1047(ab)
 Fröhlich, L, 282(ab)
 Front, A, 741(ab), 811(ab)
 Front, D, 265(ab)
 Frost, J, 1304(ab)
 Frost, JJ, 446(ab), 447(ab), 1207(ab)
 Frouin, F, 31(ab)
 Frouin, V, 31(ab)
 Fryer, TD, 135(ab)
 Fu, FH, 909(ab)
 Fu, JJC, 1106
 Fu, X, 148(ab), 498(ab)
 Fujibayashi, Y, 91(ab), 177, 330(ab), 471, 493(ab), 704(ab), 1000(ab), 1034(ab), 1085, 1174(ab), 1332(ab)
 Fujii, H, 563(ab), 1026(ab), 1155(ab)
 Fujii, K, 240(ab), 767(ab)
 Fujii, R, 1590
 Fujimori, K, 713(ab)
 Fujimoto, T, 70
 Fujino, K, 1884
 Fujino, S, 191(ab), 512(ab), 812(ab)
 Fujioka, H, 1271(ab)
 Fujita, K, 713(ab)
 Fujita, M, 124(ab), 143(ab), 270(ab), 471, 781(ab), 1902
 Fujita, T, 1273(ab)
 Fujiwara, H, 2036
 Fujiwara, M, 1091(ab), 1203(ab)
 Fujiwara, S, 1999
 Fujiwara, T, 70
 Fukuchi, K, 239, 796(ab), 799(ab), 800(ab), 801(ab), 854, 1187(ab)
 Fukuchi, M, 780(ab)
 Fukuda, H, 244, 317, 567(ab), 1022(ab)
 Fukui, M, 1203(ab)
 Fukumitsu, N, 874(ab)
 Fukumoto, M, 1035(ab), 1084(ab), 1101(ab), 1189(ab)
 Fukumura, T, 1111(ab)
 Fukushi, K, 289(ab)
 Fukushima, K, 426(ab), 796(ab), 799(ab), 800(ab), 801(ab), 1072(ab), 1187(ab)
 Fukuyama, H, 1992
 Fukuzawa, S, 13(ab), 745(ab)
 Fulham, MJ, 144(ab)
 Fumey, R, 224
 Furhang, EE, 131
 Furman, V, 1197(ab), 1205(ab)
 Fuseau, C, 1374
 Fussell, BA, 107(ab)
 Fuster, D, 123(ab)
 Fuster, V, 355(ab)
 Futami, S, 1047(ab)
 Futatsubashi, M, 1088(ab), 1282(ab)
 Gabriel, JL, 492(ab)
 Gabruk-Szostak, B, 1036(ab), 1372(ab)
 Gabrys, J, 769(ab)
 Gadsbøll, N, 290
 Gaebel, W, 575(ab)
 Gaffney, R, 277
 Gagnon, A, 1244(ab)
 Gagnon, D, 137(ab)
 Gagnon, JH, 542(ab)
 Gaines, T, 96(ab)
 Gainey, W, 27(ab)
 Gainey, WE, 1291(ab)
 Gal, R, 376
 Galelli, M, 1928
 Galley, N, 268(ab)
 Galt, JR, 753(ab), 1262(ab)
 Galynker, B, 1144(ab)
 Gambhir, SS, 102(ab), 130(ab), 131(ab), 225(ab), 226(ab), 227(ab), 231(ab), 285(ab), 295(ab), 323(ab), 332(ab), 408(ab), 1468(ab), 1507, 2043
 Gameren, A, 414(ab)
 Gamez, C, 1145(ab)
 Ganes, J, 984(ab)
 Gänzbacher, B, 104(ab)
 Gansow, OA, 166, 268, 329(ab)
 Gao, DW, 352(ab), 1249(ab)
 Garcez, AT, 870(ab)
 Garcia, EV, 92(ab), 315(ab), 508(ab), 511(ab), 650, 753(ab), 787(ab), 1262(ab), 1290(ab)
 Garcia, M, 773(ab)
 Garcia, MJ, 424(ab), 1096(ab), 1145(ab)
 Garcia, N, 845(ab), 1401(ab)
 García-López, F, 296
 Gardin, I, 786
 Garfinkle, WB, 1457(ab)
 Garg, PK, 1208(ab), 1362(ab)
 Garmestani, K, 166, 322(ab), 329(ab), 415(ab)
 Garreau, L, 1343(ab)
 Garty, B, 51(ab)
 Garza, V, 439(ab)
 Gaskill, M, 287(ab)
 Gasparini, M, 251(ab), 1085(ab)
 Gasperi, M, 1716
 Gates, M, 574
 Gatley, SJ, 438(ab), 440(ab), 442(ab), 443(ab), 586(ab), 1218(ab)
 Gatti, S, 914(ab)
 Gautherot, E, 198, 1002(ab), 1216
 Gauthier, H, 37(ab), 223(ab), 1147(ab)
 Gayed, I, 1463(ab)
 Geerlings, MW, Jr., 166
 Geerlings, MW, Sr., 166
 Geibel, A, 220(ab)
 Geldof, AA, 667
 Gelfand, MJ, 53(ab)
 Genereau, T, 962(ab)
 Genin, R, 701(ab), 794(ab), 809(ab), 1602
 Gennari, R, 1125(ab)
 Gentili, A, 1456(ab)
 George, J, 766(ab), 792(ab)
 George, M, 258(ab)
 Georges, B, 210(ab)
 Georgi, P, 570(ab)
 Georgiou, MF, 204(ab), 208(ab), 377(ab)
 Geraghty, S, 44(ab)
 Gerali, A, 1114(ab)
 Gerber, B, 558(ab)
 Gerdsen, I, 268(ab)
 Gerhard, A, 571(ab)
 Gerlach, L, 1016(ab), 1032(ab)
 Germano, G, 6(ab), 22(ab), 25(ab), 28(ab), 170(ab), 710(ab), 722(ab), 810, 839(ab)
 Gerson, MC, 360(ab)
 Gerundini, P, 251(ab), 271(ab), 338(ab), 914(ab), 1085(ab), 1630, 1928
 Gewirtz, H, 757(ab)
 Geworski, L, 920(ab)
 Geyer, BC, 486(ab)
 Geypens, B, 1451
 Ghesani, M, 215(ab), 891(ab)
 Ghesani, NV, 856(ab)
 Ghez, C, 1178(ab)
 Ghilardi, MF, 1178(ab)
 Ghoos, Y, 1451
 Giamarile, F, 585
 Gianelli, MV, 522
 Gianoli, L, 1617
 Gibril, F, 539
 Gibson, R, 1014(ab)
 Gibson, RE, 400(ab)
 Gietzen, F, 185(ab)
 Gifford, AN, 438(ab), 440(ab), 586(ab)
 Gifford, HC, 590(ab)
 Giganti, M, 167(ab), 302(ab), 778(ab), 1168(ab), 1382(ab), 1556
 Giger, S, 495(ab)
 Gil, R, 121(ab)
 Gilardi, MC, 302(ab), 1617
 Gilbert, F, 552(ab)
 Gilbert, HM, 889(ab)
 Gilbert, K, 278(ab)
 Gildehaus, M, 1311(ab)
 Gildersleeve, DL, 232
 Gilissen, CM, 1353(ab)
 Gilland, DR, 1260(ab)
 Gillet, JB, 219(ab)
 Gillham, R, 747
 Gilligan, D, 1093(ab)
 Gillin, A, 144(ab)
 Gilsbach, J, 450(ab)
 Gimenez, M, 555(ab), 1145(ab)
 Gindi, GR, 299(ab), 301(ab)
 Giovannazzi, R, 1114(ab)
 Gipponi, M, 1123(ab)
 Gips, S, 741(ab), 811(ab)
 Girard, P, 701(ab)
 Gironell, A, 1212(ab)
 Giubbini, R, 375(ab)
 Giubbini, RM, 172(ab), 178(ab)
 Giuliano, AE, 203(ab), 1112(ab), 1120(ab)
 Giunta, S, 46
 Gjedde, A, 125(ab), 441(ab), 1186, 1292
 Glasbrenner, B, 422(ab)
 Glaser, C, 985(ab)
 Glass, D, 1463(ab)
 Glass, EC, 203(ab), 1112(ab), 1120(ab)
 Glatting, G, 82(ab), 247(ab), 262(ab), 422(ab), 571(ab), 1272(ab), 1623
 Glatz, G, 593(ab)
 Glees, J, 984(ab)
 Glees, JP, 161(ab)
 Glick, SJ, 456
 Glover, DK, 142, 821
 Gnechi-Ruscone, T, 1848
 Go, RT, 279(ab)
 Goddard, S, 96(ab)
 Godley, ML, 643
 Goebel, SU, 539
 Goedemans, W, 1389(ab)
 Goes, JR, 848(ab)
 Goethals, P, 491
 Gold, HK, 193(ab)
 Goldberg, M, 917(ab)
 Goldenberg, DM, 67(ab), 261(ab), 428(ab), 429(ab), 500(ab), 603(ab), 968(ab), 972(ab), 981(ab), 992(ab), 1002(ab), 1392, 1375(ab), 1380(ab), 1392, 1609
 Goldfarb, CR, 1144(ab)
 Goldman, D, 445(ab)
 Goldman, ME, 1322(ab)
 Goldman, MS, 1457(ab)
 Goldner, K, 1303(ab)
 Goldschmidt, H, 1061(ab)
 Goldsmith, SJ, 1001(ab), 1008(ab), 1024, 1303(ab)
 Goldstein, CI, 301(ab)
 Goldstein, DS, 302, 963(ab), 965(ab), 969(ab), 2014
 Golish, SR, 295(ab)
 Gomes, EF, 11(ab)
 Gomez, D, 1008(ab)
 Gomez-Marin, O, 377(ab)
 Gona, JM, 94(ab)
 Goncalves, JC, 1148(ab)
 González, J, 768
 González, V, 164(ab)
 Gonzalez, N, 768
 Gonzalez, P, 516(ab)
 Gonzalez, R, 208(ab)
 Gonzalez, RS, 970(ab)
 Gonzalez Trotter, DE, 139(ab)
 Goodbody, AE, 872(ab)
 Goodman, MM, 331, 1344(ab)
 Goodman, T, 87(ab)
 Goodpaster, B, 1798
 Goodwin, DA, 1138
 Goodwin, GW, 1186
 Gordon, EM, 103(ab)
 Gordon, I, 643
 Gordon, L, 260(ab), 971(ab), 1383(ab), 1390(ab), 1454(ab)
 Gorenberg, M, 45(ab), 56
 Gorey, JG, 1348(ab)
 Görges, R, 923(ab)
 Goris, ML, 252(ab)
 Gorman, J, 121(ab)
 Gormley, J, 1225(ab)
 Gosalbez, R, 204(ab)
 Goshen, E, 63(ab), 1213(ab)
 Gössweiner, S, 1049(ab)
 Goswami, RK, 934(ab)
 Gotou, E, 874(ab)
 Gottschild, D, 1251(ab)
 Gould, T, 357(ab), 402(ab)
 Gouriou, J, 1517
 Govindan, SV, 603(ab), 968(ab)
 Goydos, J, 232(ab)

- Graeber, GM, 229(ab), 230(ab), 548(ab)
 Graefe, K-H, 1342
 Graef, D, 1077(ab)
 Graf, S, 362(ab)
 Graham, LS, 482(ab)
 Graham, MM, 614, 784(ab), 1074(ab)
 Gralow, JR, 69(ab), 551(ab)
 Gramatzki, M, 992(ab)
 Grana, C, 72(ab), 1125(ab)
 Granowska, M, 764(ab), 1108(ab)
 Granowski, A, 1108(ab)
 Grant, S, 209(ab), 238(ab)
 Grattan, L, 454(ab)
 Gratz, S, 48(ab), 396(ab), 420(ab), 1029
 Grazioso, R, 304(ab)
 Greco, M, 1114(ab)
 Green, AJ, 541(ab), 1246(ab)
 Green, LA, 102(ab)
 Green, MA, 775(ab)
 Green, MV, 1321(ab)
 Green, SL, 472(ab)
 Greenberg, ID, 707(ab)
 Greenberg, JH, 118(ab)
 Greenspan, B, 174(ab)
 Greer, PJ, 2053
 Gregoire, V, 1013(ab)
 Gregor, RT, 1414
 Gregoric, E, 1067(ab)
 Gremillet, E, 80(ab), 733(ab)
 Gridelli, B, 914(ab)
 Grierson, JR, 100(ab), 101(ab), 245(ab), 335(ab)
 Grieser, A, 571(ab)
 Griesinger, F, 992(ab)
 Griffith, IJ, 963(ab), 969(ab)
 Griffith, R, 1180(ab)
 Griffiths, GL, 500(ab), 603(ab), 968(ab), 1002(ab)
 Grigsby, PW, 1129(ab)
 Grilley, K, 902(ab)
 Groch, MW, 509(ab), 712(ab), 1278(ab), 1327(ab)
 Groch, PJ, 712(ab), 1278(ab), 1327(ab)
 Groen, HJ, 561(ab)
 Groisselle, C, 1305(ab)
 Grollier, G, 8(ab), 175(ab)
 Gropler, RJ, 4(ab), 824(ab), 836(ab), 842(ab)
 Grosev, D, 937(ab)
 Grosner, D, 45(ab), 56, 968, 1111
 Gross, MD, 554, 1292(ab)
 Gross, P, 374(ab)
 Grosser, O, 754(ab)
 Grossman, Z, 949(ab)
 Grosu, A, 397(ab)
 Groth, P, 528(ab), 558(ab)
 Gruender, W, 537(ab)
 Gruenwald, F, 974(ab)
 Gründler, G, 125(ab), 1222(ab)
 Gualdi, G, 843(ab)
 Gualdrini, G, 1716
 Guan, CT, 498(ab)
 Guana, C, 235(ab), 266(ab)
 Guaraldi, MS, 954(ab)
 Guardia, J, 19
 Guarnero, R, 870(ab)
 Gubernick, JA, 1457(ab)
 Guelfguat, M, 1144(ab)
 Guendish, D, 1349(ab)
 Guenther, I, 1374
 Guerrero, JL, 391(ab)
 Guhlke, S, 974(ab), 988(ab), 1384(ab)
 Guhlmann, A, 1623, 1637
 Guhlmann, CA, 82(ab), 93(ab), 422(ab)
 Guillauseau, P-J, 1252
 Guillio, P, 738(ab)
 Guilloteau, D, 1343(ab), 1393(ab)
 Guirgues, AF, 1457(ab)
 Gullberg, GT, 128(ab), 137(ab), 313(ab), 462(ab), 589(ab), 816(ab), 829(ab), 1254(ab), 1296(ab)
 Gundry, S, 339(ab)
 Gunel, E, 548(ab)
 Gunning, WB, 113(ab)
 Guo, J, 854(ab)
 Guo, NN, 114(ab), 117(ab), 435(ab), 1162(ab)
 Guo, W, 1563
 Gupta, NC, 229(ab), 230(ab), 379(ab), 548(ab), 1320(ab)
 Gupta, P, 280(ab), 1182(ab)
 Gupta, PK, 9(ab)
 Gur, RC, 108(ab), 1200(ab), 1218(ab), 1812
 Gurli, N, 1434
 Gutierrez, F, 123(ab)
 Guy, MJ, 983(ab)
 Gvirtz, G, 860(ab)
 Ha, CS, 955(ab)
 Ha, JW, 833(ab)
 Haaparanta, M, 12, 1163(ab)
 Haas, F, 18(ab), 1824
 Haase, A, 540(ab), 921(ab), 944(ab)
 Haataja, L, 12
 Haberkorn, U, 487(ab), 1010(ab), 1011(ab), 1016(ab), 1032(ab), 1261(ab)
 Habraken, JBA, 1091
 Hachamovitch, R, 710(ab), 722(ab)
 Hadjipavlou, A, 906(ab)
 Hadley, D, 747
 Hagen, R, 254(ab)
 Hager, A, 1080
 Hagg, B, 1457(ab)
 Haggé, RJ, 477(ab)
 Hahn, J, 973(ab)
 Hahn, K, 112(ab), 126(ab), 389(ab), 853(ab), 1048(ab), 1243(ab)
 Hahn, LJ, 448
 Haigh, PI, 203(ab), 1112(ab), 1120(ab)
 Hain, SF, 409(ab), 425(ab), 1135(ab)
 Hajjar, G, 1609
 Hakimi, M, 719(ab)
 Halaç, M, 429
 Halfter, H, 1017(ab)
 Halkar, R, 209(ab)
 Halkar, RK, 929(ab)
 Hall, H, 151(ab), 1157(ab)
 Halldin, C, 102, 120(ab), 151(ab), 435(ab), 436(ab), 1157(ab), 1343(ab)
 Hallkar, RK, 92(ab)
 Halon, DA, 741(ab), 811(ab)
 Ham, H, 972
 Ham, HR, 52, 210(ab)
 Hamacher, K, 575(ab)
 Hamacher, KA, 162(ab), 158(ab)
 Hamamoto, K, 1071(ab)
 Hambye, A-S, 706(ab)
 Hamberg, L, 547(ab)
 Hamblen, SM, 1241(ab)
 Hambye, AE, 707
 Hambye, A-S E, 1468
 Hamill, JJ, 1316(ab)
 Hamill, T, 400(ab), 1014(ab)
 Hamilton, RJ, 347
 Hamkens, W, 1222(ab)
 Hammersley, PA, 99(ab)
 Hamon, M, 8(ab), 175(ab)
 Hamper, U, 373(ab)
 Han, G, 866(ab), 1277(ab), 1317(ab), 1325(ab)
 Han, JH, 1076(ab)
 Han, MH, 1094(ab)
 Han, SH, 639
 Hanaoka, NH, 1040(ab)
 Hanauske, A-R, 1771
 Hander, TA, 942
 Handmaker, H, 36(ab), 231(ab)
 Handschuh, G, 433(ab)
 Hanelin, L, 359(ab)
 Hanke, H, 837(ab)
 Hannequin, PP, 839(ab), 1336(ab)
 Hanrahan, S, 352(ab)
 Hansen, HJ, 500(ab), 603(ab), 968(ab), 1002(ab)
 Hansen, L, 1403(ab)
 Hansen, N, 1112(ab)
 Hansen, NM, 203(ab), 1120(ab)
 Hanson, DP, 1098
 Hanson, E, 995(ab)
 Hanson, JM, 1180(ab)
 Hanson, MW, 477(ab)
 Hantzopoulos, PA, 104(ab)
 Hanzawa, S, 1088(ab)
 Hao, X, 1277(ab)
 Hapdey, S, 471(ab)
 Hara, T, 239(ab), 240(ab), 241(ab)
 Harada, J, 874(ab)
 Haradahira, T, 1342(ab), 1351(ab)
 Haraden, BM, 824(ab), 836(ab), 842(ab)
 Harden, G, 1295(ab)
 Hardoff, R, 51(ab), 522(ab), 880(ab)
 Hareyama, M, 713(ab)
 Harkness, BA, 1356(ab)
 Harmen, MC, 890(ab)
 Harper Mozley, LM, 1200(ab)
 Harper, PG, 425(ab)
 Harris, TD, 892(ab)
 Harrison, RL, 459(ab), 1236(ab)
 Harron, AW, 1140(ab)
 Harshbarger, T, 1181(ab)
 Hart, R, 732(ab)
 Hartman, NG, 267(ab)
 Hartsough, N, 1121(ab), 1225(ab)
 Hartung, D, 754(ab)
 Hartung, WM, 754(ab)
 Hartwig, E, 1637
 Hasebe, N, 747(ab)
 Hasegawa, A, 217
 Hasegawa, BH, 127(ab), 458(ab), 596(ab), 820(ab), 1248(ab), 1249(ab)
 Hasegawa, K, 728(ab)
 Hasegawa, R, 718(ab), 767(ab)
 Hasegawa, S, 239, 708(ab), 803(ab), 804(ab), 805(ab), 806(ab), 823(ab), 1693, 1884
 Haseley, DR, 572(ab), 784(ab)
 Hashemzadeh-Gargari, H, 318(ab)
 Hashikawa, K, 1160(ab), 1175(ab), 1190(ab), 1302(ab)
 Hashimoto, A, 193(ab), 783(ab)
 Hashimoto, T, 1328(ab), 1337(ab)
 Hashizume, I, 1088(ab)
 Hashmi, R, 1098(ab)
 Hatano, K, 1179(ab)
 Hatano, T, 874(ab)
 Hatch, S, 553(ab)
 Hattori, N, 34(ab), 35(ab), 183(ab), 782(ab), 1840
 Hatushiba, K, 943(ab)
 Haubner, R, 1061, 104(ab)
 Haufe, S, 372(ab)
 Hausleiter, J, 356(ab)
 Hausmann, D, 719(ab)
 Havlik, E, 74(ab), 395(ab), 1081(ab)
 Hawkins, RA, 458(ab), 1045, 1248(ab)
 Hawman, PC, 15(ab), 361(ab)
 Hayase, M, 814(ab)
 Hayase, N, 1035(ab), 1084(ab), 1101(ab), 1189(ab)
 Hayashi, N, 1441
 Hayashi, Y, 426(ab), 1072(ab)
 Hayashida, K, 796(ab), 801(ab), 1187(ab)
 Hayashida, N, 779(ab)
 Haynes, NG, 775(ab)
 Hays, MT, 1358
 Hayward, RM, 1074(ab)
 He, Z-X, 1857
 Heald, DL, 383(ab), 886(ab)
 Heath, E, 594(ab)
 Heeney, T, 721(ab)
 Heiba, SI, 785(ab), 879(ab)
 Heinz, A, 445(ab), 1219(ab)
 Heiss, P, 205, 1367
 Heiss, WD, 306(ab)
 Helal, BO, 173(ab), 411(ab), 701(ab), 743(ab)
 Helfenbein, J, 1343(ab)
 Helft, G, 355(ab)
 Heller, EN, 788(ab)
 Heller, GV, 517(ab), 518(ab), 702(ab), 711(ab)
 Hellman, RS, 1369(ab)
 Helmholz, T, 754(ab)
 Helsabeck, C, 1143
 Helvie, MA, 1099(ab)
 Hemelaar, JT, 753
 Hendel, RC, 342(ab), 509(ab), 513(ab), 517(ab)
 Hendler, A, 769(ab), 1370(ab)
 Hendler, T, 1213(ab)
 Hendrikse, HN, 116(ab)
 Hendrikse, NH, 292(ab), 1159(ab)
 Henke, K, 1158(ab)
 Hennion, C, 868
 Henry, H, 912(ab)
 Henry, TD, 342(ab)
 Henze, E, 46(ab), 47(ab), 71(ab), 776, 1033(ab), 1246
 Henze, M, 1011(ab)
 Henzlova, MJ, 363(ab), 759(ab), 1322(ab)
 Heo, J, 738(ab)
 Herriot, AG, 984(ab)
 Hermann, BP, 1180(ab)
 Hermann, GA, 857(ab)
 Hermans, C, 882(ab)
 Herment, A, 31(ab)
 Hernandez Pampaloni, M, 32(ab)
 Hernekamp, C, 47(ab)
 Herranz, R, 123(ab)
 Herrero, P, 4(ab), 824(ab), 836(ab), 842(ab)
 Herrington, B, 1230(ab)
 Herscovitch, P, 119(ab), 168(ab)
 Hershkop, MS, 769(ab)
 Hertel, A, 282(ab), 1152(ab)
 Herz, M, 205, 1367
 Herzog, H, 977
 Herzog, HR, 575(ab), 501(ab), 566(ab)
 Hesse, B, 290
 Hewitt, T, 732(ab)
 Heydari, N, 125(ab)
 Heyden, A, 224(ab)
 Heys, SD, 552(ab)
 Hicke, BJ, 402(ab)
 Hidai, H, 1792
 Hiddemann, W, 992(ab)
 Hiele, M, 98(ab)
 Hiemke, C, 1222(ab)
 Hiemstra, PS, 2073
 Higa, T, 1063(ab)
 Higashi, K, 86(ab), 1095(ab)
 Higashi, T, 88(ab), 479, 1097(ab), 1424, 1463
 Higashino, H, 1071(ab)
 Higazy, E, 785(ab)
 Higginbotham, C, 419(ab)
 Higuchi, T, 727(ab), 761(ab), 915(ab), 1366(ab), 1367(ab)
 Hilgers, FJM, 1414
 Hill, TC, 714(ab)
 Hillier, DA, 510(ab)
 Hillier, S, 153(ab), 1161(ab)
 Hilson, A, 541(ab)
 Hilson, AJ, 68(ab), 536(ab), 1038(ab)
 Hilton, J, 373(ab), 1164(ab), 1207(ab)
 Hibert, M, 173(ab)
 Himeno, S, 1078(ab)
 Hines, H, 574, 481(ab)
 Hinkle, GH, 1563
 Hirai, J, 191(ab)
 Hirai, M, 728(ab)
 Hirai, T, 471
 Hiraki, Y, 394, 1971
 Hiramatsu, T, 430(ab), 1020(ab)
 Hiraoka, M, 1424
 Hirasawa, T, 1131(ab)
 Hirata, K, 1492
 Hirayama, H, 728(ab)
 Hiroto, N, 1185(ab)
 Hirota, S, 426(ab), 1072(ab)
 Hirsch, WS, 1457(ab)
 Hirschmann, M, 853(ab)

- Hitzel, A, 179(ab), 513
 Hitzemann, RJ, 442(ab), 443(ab), 715,
 1217(ab), 1285
 Hliscs, R, 975(ab)
 Hnatowich, DJ, 484, 693, 900(ab),
 1397(ab)
 Ho, Y-J, 1446
 Hode, F, 1301(ab)
 Hoefnagel, CA, 70(ab), 1119(ab), 1414
 Hoefs, JC, 1745
 Hoejgaard, L, 1136(ab)
 Hoekstra, CJ, 463(ab), 564(ab)
 Hoekstra, HJ, 262, 381, 398(ab),
 1146(ab)
 Hoekstra, OS, 407(ab), 463(ab),
 564(ab), 953(ab)
 Hoenl, K, 754(ab)
 Hoff, P, 1197
 Hoffman, A, 427(ab)
 Hoffman, EJ, 130(ab), 599(ab), 2043
 Hoffman, JM, 92(ab), 331, 1344(ab)
 Hoffman, TJ, 419(ab)
 Hoffmann, K-T, 387
 Hofstrand, PD, 1072
 Höft, S, 776
 Högerle, S, 340(ab), 423(ab)
 Hoh, C, 408(ab)
 Hoh, CK, 130(ab), 225(ab), 285(ab),
 1045, 1293(ab), 2043
 Hoher, M, 341(ab)
 Hohn, A, 501(ab)
 Hojo, S, 65(ab)
 Hol, CK, 226(ab)
 Holden, JE, 187(ab), 283, 354(ab),
 1169(ab), 1186
 Hollema, H, 1132(ab)
 Holló, A, 786
 Holloway, B, 68(ab)
 Holly, TA, 513(ab), 517(ab)
 Holm, S, 1136(ab)
 Holopainen, I, 12
 Holst, H, 224(ab)
 Hombach, V, 341(ab)
 Homma, N, 512(ab)
 Hommer, D, 445(ab), 1219(ab)
 Homs, C, 844(ab)
 Honda, N, 802(ab), 877(ab), 885(ab),
 1188(ab)
 Hong, KP, 736(ab)
 Hong, MK, 166(ab), 1359(ab), 1387(ab)
 Hong, SJ, 529(ab)
 Hong, SW, 986, 1043(ab), 1051(ab),
 1058(ab), 1066(ab), 1073(ab),
 1075(ab), 1128(ab), 1151(ab)
 Hong, T, 1468(ab)
 Hör, G, 282(ab), 1152(ab)
 Hordijk, GJ, 259(ab), 1056(ab)
 Hor, M, 803(ab), 804(ab), 1190(ab),
 1302(ab), 1693, 1884
 Horibe, K, 1179(ab)
 Horikawa, E, 70
 Horiuchi, KS, 330(ab), 493(ab)
 Horowitz, S, 63(ab)
 Horti, AG, 1349(ab)
 Hosea, S, 9(ab)
 Hoshizaki, H, 217
 Hosokawa, R, 471
 Hosono, M, 802(ab), 877(ab), 885(ab),
 1188(ab), 1216
 Hospers, G, 890(ab)
 Hossfeld, DK, 941(ab)
 Hosten, N, 387
 Hou, C, 660, 1345(ab)
 Houry, S, 1077(ab)
 Houston, T, 377(ab)
 Hove, J, 295(ab)
 Hovey-Andersen, R, 1230(ab)
 Hoving, B, 1313(ab)
 How, MS, 935(ab)
 Howard Jones, E, 560(ab)
 Howarth, DM, 64(ab), 579
 Howell, RW, 978(ab)
 Hrastnik, D, 1067(ab)
 Hsiao, I, 299(ab)
 Hsiao, JY, 244(ab)
 Hsieh, J-F, 1446
 Hsu, C, 130(ab), 1299(ab), 2043
 Hsu, HB, 1269(ab)
 Hsu, L, 947(ab)
 Hsu, PI, 367(ab)
 Hu, G, 863(ab), 866(ab), 1087(ab)
 Hu, J, 21(ab)
 Hua, C, 133(ab)
 Huang, CC, 465(ab)
 Huang, MT, 1065(ab)
 Huang, S, 142(ab), 147(ab), 297(ab)
 Huang, SC, 146(ab), 281(ab), 283(ab),
 284(ab), 585(ab), 587(ab), 717(ab)
 Huang, WS, 1170(ab)
 Huang, X-F, 660
 Hubb, AH, 379(ab)
 Huber, JS, 305(ab)
 Huberty, JP, 1248(ab)
 Hübinger, A, 977
 Hubner, KF, 96(ab), 469(ab)
 Huddart, RA, 425(ab)
 Hudson, W, 350(ab)
 Huesman, RH, 457(ab)
 Hüfner, M, 396(ab)
 Hughes, OD, 399(ab)
 Huglo, D, 33
 Huguier, M, 1077(ab)
 Huic, D, 952(ab)
 Huijgens, PC, 953(ab)
 Huiskes, AW, 311
 Hültenschmidt, B, 248(ab)
 Humm, JL, 131, 156(ab), 328(ab),
 1238(ab), 1764, 1935
 Humphries, J, 1383(ab)
 Hung, JC, 1391(ab)
 Hunter, A, 277
 Hunter, CJ, 1008(ab)
 Hunter, G, 547(ab)
 Hunter, J, 520(ab)
 Hunter, KM, 96(ab)
 Hupp, BD, 1264(ab)
 Husain, SS, 94(ab)
 Hustinx, R, 333(ab), 401(ab), 453(ab),
 562(ab), 995, 1054(ab), 1239(ab),
 1257, 1286(ab)
 Hutchison, AW, 552(ab)
 Hutchins, GD, 846, 495(ab)
 Hutchinson, RJ, 519(ab)
 Hutton, I, 364(ab)
 Huynh, P, 1463(ab)
 Hwang, BT, 909(ab)
 Hwang, DR, 114(ab), 117(ab), 435(ab),
 609(ab), 1162(ab), 1209(ab)
 Hwang, E, 915(ab)
 Hwang, E-H, 1644
 Hwang, EH, 216(ab), 727(ab), 761(ab)
 Hwang, JH, 49(ab)
 Hwang, SB, 994(ab)
 Hwang, WS, 1857
 Hyun, IY, 505(ab), 918(ab)
 Hyun, MC, 883(ab)
 Iacopi, F, 46
 Iannettoni, MD, 1089(ab)
 Ibbotson, ME, 764(ab)
 Ichihara, T, 12(ab), 895, 1300(ab),
 1331(ab)
 Ichise, M, 143(ab), 273(ab), 530,
 1183(ab), 1201(ab), 1902
 Ichiya, Y, 1091(ab), 1595, 1778
 Ida, I, 399
 Ide, C, 253(ab)
 Ide, M, 563(ab), 1078(ab), 1155(ab)
 Ido, A, 352(ab), 747(ab), 1249(ab)
 Ido, T, 70
 Igarashi, H, 874(ab)
 Ihling, C, 423(ab)
 Iida, H, 312(ab), 841(ab), 862
 Iida, Y, 685, 1003(ab)
 Ikeda, DM, 1122(ab)
 Ikeda, E, 1818
 Ikegami, H, 744(ab)
 Ikezoe, J, 1071(ab), 1271(ab), 1287(ab)
 Ilgan, S, 404(ab), 1366(ab), 1367(ab)
 Ilgin, N, 446(ab), 447(ab)
 Ilhan, I, 524(ab)
 Im, KC, 1226(ab)
 Imahashi, K, 823(ab)
 Imahori, Y, 1590
 Imamura, M, 1097(ab), 1424
 Imamura, T, 1185(ab)
 Imon, Y, 1583
 Imran, MB, 244
 Inagaki, K, 240(ab)
 Inagaki, M, 13(ab), 745(ab)
 Inagaki, T, 569(ab)
 Ingram, L, 1463(ab)
 Innis, RB, 107(ab), 124(ab), 143(ab),
 148(ab), 154(ab), 270(ab), 444(ab),
 576(ab), 578(ab), 580(ab), 607(ab),
 1208(ab), 1902
 Inoshiro, N, 78(ab)
 Inoue, M, 943(ab)
 Inoue, T, 336(ab), 390(ab), 399,
 404(ab), 878(ab), 1005(ab), 1018(ab),
 1271(ab)
 Inoue, Y, 418, 793, 862(ab), 867(ab)
 Irie, S, 569(ab)
 Irie, T, 289(ab)
 Irlgartinger, G, 1061(ab)
 Irwin, I, 587(ab)
 Isaka, N, 895
 Isaki, K, 1174(ab)
 Ishibashi, K, 859(ab)
 Ishida, Y, 796(ab), 799(ab), 800(ab),
 801(ab), 1187(ab)
 Ishigaki, T, 1179(ab)
 Ishii, K, 426(ab), 1072(ab), 1185(ab)
 Ishii, Y, 243(ab), 704(ab), 1085, 1132,
 1441
 Ishikawa, Y, 211(ab), 212(ab), 747(ab),
 855(ab), 1173(ab)
 Ishimaru, Y, 1271(ab)
 Ishiwata, S, 705(ab), 808(ab)
 Ishizaki, A, 211(ab), 212(ab), 855(ab)
 Ishizuka, K, 243(ab), 1282(ab), 1332(ab)
 Iskandrian, AE, 339(ab), 738(ab)
 Islam, QT, 533(ab)
 Isner, JM, 760(ab)
 Isobe, S, 728(ab)
 Israel, O, 265(ab)
 Issa, M, 209(ab)
 Issaq, E, 968, 1111
 Iterbeke, K, 1913
 Ito, H, 102, 841(ab)
 Ito, K, 1179(ab)
 Ito, T, 728(ab)
 Ito, Y, 859(ab)
 Itoh, M, 70, 567(ab)
 Itoh, N, 713(ab)
 Itoh, Y, 748(ab), 798(ab), 807(ab)
 Itti, R, 1466(ab)
 Ivancovic, V, 897(ab), 952(ab), 1227(ab)
 Ivanovic, M, 1264(ab)
 Iversen, P, 1136(ab)
 Iwaki, T, 1160(ab)
 Iwanaga, K, 371
 Iwanczyk, JS, 599(ab)
 Iwanochko, RM, 721(ab), 771(ab),
 776(ab)
 Iwasaki, T, 217, 780(ab)
 Iwata, K, 127(ab)
 Iwata, M, 530(ab)
 Iwata, Y, 1652
 Iyer, M, 102(ab)
 Iyo, M, 289(ab)
 Izak, M, 810(ab)
 Iznaga-Escobar, N, 768
 Jääskeläinen, S, 12
 Jacobson, AF, 784(ab), 410(ab)
 Jacobson, D, 990(ab)
 Jadvar, H, 255(ab), 421(ab), 908(ab),
 1122(ab), 1451(ab)
 Jaeckle, KA, 1206(ab)
 Jaenicke, L, 1033(ab)
 Jaffe, R, 741(ab), 811(ab)
 Jager, PL, 70(ab), 393(ab), 398(ab),
 1119(ab), 1146(ab)
 Jagoda, E, 149(ab), 150(ab), 1547
 Jakse, G, 1133(ab)
 Jamart, J, 219(ab)
 James, JL, 490(ab)
 Jamil, G, 517(ab), 711(ab)
 Jan, HA, 764(ab), 1108(ab)
 Jana, S, 84(ab), 889(ab)
 Janakiraman, N, 260(ab)
 Jang, J-J, 339
 Jang, JS, 1066(ab)
 Jang, MJ, 1171(ab), 1195(ab), 1196(ab)
 Jang, S, 274(ab), 562(ab)
 Jänicke, F, 2021
 Janier, MF, 821(ab)
 Jank, J, 1049(ab)
 Janowitz, WR, 347(ab)
 Jansen, HM, 1354(ab)
 Jansen, L, 70(ab), 1119(ab)
 Janssen, AG, 106(ab), 753, 1107(ab)
 Janssen, ML, 432(ab)
 Jao, G-H, 60
 Jarritt, PH, 343(ab), 344(ab)
 Jaszczałk, RJ, 138(ab), 139(ab), 1176,
 1260(ab)
 Jeandot, R, 412
 Jeannin, L, 1913
 Jeffrey, SS, 559(ab), 1122(ab)
 Jenison, JD, 357(ab)
 Jenkin, B, 381(ab)
 Jenkins, BG, 582(ab)
 Jenkins, WT, 401(ab)
 Jenner, N, 420(ab), 1029
 Jensen, M, 1136(ab)
 Jensen, RT, 539
 Jeon, TJ, 833(ab)
 Jeong, H, 327(ab), 1006(ab)
 Jeong, HJ, 286(ab), 549(ab), 1202(ab),
 1378(ab)
 Jeong, JM, 339, 309(ab), 529(ab),
 938(ab), 998(ab), 999(ab), 1143(ab),
 1275(ab), 1350(ab), 1387(ab),
 1392(ab)
 Jerin, J, 597(ab)
 Jermann, E, 72(ab)
 Jian, JJ, 1052(ab)
 Jiang, S, 1010(ab), 1011(ab)
 Jinnouchi, S, 1047(ab), 1057(ab)
 Johannsen, B, 584(ab)
 Johkoh, T, 566
 John, CS, 405(ab), 486(ab), 488(ab)
 Johnson, CA, 1321(ab)
 Johnson, G, 813(ab), 815(ab)
 Johnson, LL, 350(ab)
 Johnson, LS, 1197(ab)
 Joja, I, 1971
 Jokisch, DW, 1947
 Jolles, PR, 1455(ab), 1226
 Jomura, H, 858(ab)
 Jonas, SP, 1205(ab)
 Jones, AG, 1031(ab)
 Jones, AL, 1038(ab)
 Jones, DW, 445(ab), 1348(ab)
 Jones, JC, 1180(ab)
 Jones, T, 592(ab)
 Jones, WF, 305(ab), 306(ab)
 Jonkhoff, AR, 953(ab)
 Joo, KS, 1226(ab)
 Joshi, R, 1012(ab)
 Joshi, V, 489(ab)
 Jansson, E, 297(ab)
 Jousse, F, 385(ab), 464(ab), 565(ab)
 Judy, PF, 590(ab)
 Juengling, FD, 220(ab)
 Jung, DJ, 205(ab)
 Jung, HY, 918(ab)
 Jungbluth, A, 328(ab)

- Junghans, U, 337(ab)
 Jungkind, D, 1398(ab)
 Juni, JE, 287(ab)
 Jurcic, JG, 163(ab), 1935
 Jürgens, H, 388(ab), 392(ab)
 Jurisson, SS, 484(ab)
 Juweid, ME, 261(ab), 972(ab), 1609
 Kabasakal, L, 429, 1369(ab)
 Kachi, T, 1179(ab)
 Kachur, AV, 401(ab)
 Kadrimas, DJ, 132(ab), 589(ab), 1298(ab)
 Kaeplinger, S, 1251(ab)
 Kage, R, 385(ab)
 Kagetsu, NJ, 891(ab)
 Kageyama, M, 1138
 Kahaly, GJ, 925(ab)
 Kahl, F, 224(ab)
 Kaiser, LR, 1241
 Kaji, T, 207(ab)
 Kajihara, M, 563(ab)
 Kakuda, K, 865(ab)
 Kakuma, K, 865(ab)
 Kalden, JR, 537(ab)
 Kalender, B, 429
 Kalff, V, 381(ab)
 Kalinowski, EA, 1080(ab), 1363(ab)
 Kamano, T, 802(ab), 885(ab)
 Kameyama, S, 418
 Kaminska, A, 786
 Kaminski, MS, 76(ab), 77(ab), 990(ab), 991(ab)
 Kamoto, Y, 1273(ab)
 Kampen, WU, 46(ab), 47(ab)
 Kamran, M, 716(ab)
 Kanamaru, H, 1137(ab)
 Kanamori, S, 1424
 Kanaya, K, 818(ab)
 Kanayama, S, 812(ab)
 Kanazawa, S, 394
 Kanegae, K, 963
 Kaneko, N, 818(ab)
 Kanel, G, 1745
 Kanemitsu, S, 812(ab)
 Kanetsuki, I, 222(ab)
 Kang, DY, 213(ab), 515(ab), 735(ab), 1023(ab), 1086(ab)
 Kang, H, 1394(ab)
 Kang, WJ, 23(ab)
 Kang, X, 22(ab), 25(ab), 170(ab)
 Kanjiram, J, 810(ab)
 Kanmaz, B, 429
 Kanno, I, 317
 Kanno, T, 1282(ab)
 Kantlehner, R, 1243(ab)
 Kanz, L, 946(ab), 957(ab)
 Kao, A, 378(ab)
 Kao, AH, 346(ab)
 Kao, C, 1334(ab)
 Kao, C-H, 327(ab), 1006(ab), 1106, 1446
 Kao, PF, 109(ab)
 Kao, P-F, 1180
 Kao, T, 1452(ab)
 Kapczinski, F, 577(ab)
 Kaplinsky, E, 749(ab)
 Kapucu, N, 524(ab), 919(ab)
 Kapur, A, 343(ab), 344(ab)
 Karacay, H, 500(ab), 1002(ab)
 Karak, P, 987(ab)
 Karak, PI, 1228(ab)
 Karamychev, VN, 1405(ab)
 Karanikas, G, 74(ab)
 Karkabi, B, 741(ab), 811(ab)
 Karlsson, P, 120(ab), 1343(ab)
 Karner, I, 739(ab)
 Karp, J, 481(ab)
 Karp, JS, 308(ab), 401(ab), 1239(ab), 1257
 Kartamihardja, H, 904(ab)
 Karvelis, KC, 1140(ab)
 Kasagi, K, 530(ab)
 Kasai, S, 211(ab), 212(ab), 855(ab)
 Kasai, T, 779(ab)
- Kasamatsu, N, 1088(ab)
 Kasanuki, H, 744(ab)
 Kasegai, A, 1465(ab)
 Kashimada, A, 802(ab), 877(ab), 885(ab), 1188(ab)
 Kashiwagi, T, 859(ab)
 Kassiu, M, 144(ab), 1164(ab)
 Kassis, AI, 986(ab), 1377(ab)
 Kastin, A, 968
 Kastrati, A, 24(ab)
 Katafuchi, T, 801(ab)
 Katayama, K, 859(ab)
 Katayama, N, 867(ab)
 Kates, AM, 4(ab)
 Kato, H, 91(ab), 1000(ab)
 Kato, T, 1179(ab)
 Katoh, C, 527(ab), 862, 963, 1204(ab), 1247(ab), 1319(ab)
 Katoh, K, 770(ab)
 Katon, D, 518(ab), 702(ab)
 Katsifis, A, 144(ab)
 Katsikis, PD, 184
 Katsuda, N, 1331(ab)
 Katsuura, H, 207(ab)
 Katz, J, 10N(1), 9N(4), 22N(7)
 Katzir, Z, 860(ab)
 Kaufman, D, 1258(ab)
 Kaufman, G, 759(ab)
 Kaufmann, PA, 1848
 Kauppinen, TA, 1326(ab)
 Kawabe, J, 858(ab), 1652
 Kawabe, K, 418, 1342(ab), 1351(ab)
 Kawaguchi, T, 1332(ab)
 Kawai, Y, 14(ab)
 Kawakami, T, 943(ab)
 Kawamura, M, 770(ab)
 Kawashima, R, 244, 317
 Kawasumi, M, 761(ab)
 Kawasumi, Y, 1179(ab)
 Kawata, K, 514(ab)
 Kazzimudin, M, 788(ab)
 Keane, MJ, 379(ab)
 Keeble, W, 364(ab)
 Kegeles, LS, 114(ab), 117(ab), 121(ab), 122(ab), 1210(ab), 1211(ab)
 Keidar, Z, 265(ab)
 Keller, S, 1144(ab)
 Kelley, DE, 1798
 Kelly, MJ, 381(ab)
 Kema, IP, 393(ab)
 Kemp, BJ, 1306(ab)
 Kemp, G, 1532
 Kemp, PM, 1503
 Kempf, JS, 232(ab)
 Kenemans, P, 966(ab)
 Keng, F, 349(ab), 1857
 Kengen, RA, 1118(ab)
 Keppeler, P, 1637
 Kerenyi, L, 373(ab), 594(ab)
 Kerenyi, LL, 115(ab)
 Kerich, M, 1219(ab)
 Kerner, M, 126(ab)
 Kerr, KR, 412(ab)
 Kerrou, K, 1077(ab)
 Kertesz, A, 1306(ab)
 Keshigar, M, 560(ab), 1113(ab), 1115(ab)
 Keshigar, MR, 1116(ab)
 Kessler, H, 1061
 Ketchum, LE, 9N(3)
 Kettner, B, 936(ab)
 Kettner, BI, 795(ab)
 Keyeux, A, 882(ab)
 Khalkhali, I, 1233, 1256(ab)
 Khandekar, S, 773(ab)
 Khandekar, SP, 236(ab)
 Khanvali, B, 574
 Khatri, A, 1468(ab)
 Khaw, BA, 815(ab), 838(ab), 1832
 Khazaeli, MB, 967(ab)
 Khedkar, NY, 1126(ab)
 Khorsand, A, 362(ab)
 Kida, T, 1342(ab), 1351(ab)
 Kiernan, FJ, 711(ab)
- Kiesewetter, DO, 119(ab)
 Kijewski, MF, 475(ab)
 Kikuchi, K, 747(ab)
 Kikuchi, T, 1071(ab), 1287(ab)
 Kilcoyne, R, 44(ab)
 Kilroy, K, 1070(ab)
 Kilts, C, 1344(ab)
 Kim, B, 49(ab), 380(ab), 736(ab), 751(ab), 851(ab), 884(ab), 1076(ab), 1102(ab), 1141(ab), 1194(ab)
 Kim, BG, 1128(ab)
 Kim, BI, 1051(ab), 1058(ab), 1066(ab), 1073(ab), 1151(ab)
 Kim, BK, 999(ab), 1387(ab)
 Kim, BN, 1214(ab)
 Kim, B-T, 1045
 Kim, BT, 386(ab), 1226(ab)
 Kim, C, 339
 Kim, CK, 213(ab), 515(ab), 735(ab), 1023(ab), 1086(ab), 1322(ab)
 Kim, CS, 452(ab)
 Kim, D, 49(ab), 751(ab)
 Kim, DY, 852(ab)
 Kim, E, 1462(ab)
 Kim, EE, 404(ab), 955(ab), 1005(ab), 1206(ab), 1366(ab), 1367(ab), 1467(ab)
 Kim, EH, 166(ab), 1359(ab), 1358(ab), 1360(ab)
 Kim, ES, 534(ab)
 Kim, GS, 205(ab)
 Kim, GY, 1086(ab)
 Kim, H, 751(ab)
 Kim, IS, 1006(ab)
 Kim, I-S, 837
 Kim, J, 452(ab)
 Kim, JH, 10(ab), 1128(ab), 1226(ab)
 Kim, JS, 214(ab), 534(ab), 568(ab), 955(ab)
 Kim, JY, 286(ab), 549(ab), 1045, 1076(ab), 1202(ab), 1226(ab), 1378(ab)
 Kim, KB, 2(ab), 742(ab)
 Kim, KE, 568(ab)
 Kim, KM, 529(ab), 1221(ab), 1275(ab)
 Kim, KW, 1128(ab)
 Kim, M, 327(ab), 339, 1006(ab)
 Kim, M-K, 837, 1381
 Kim, MK, 286(ab), 1202(ab)
 Kim, S, 773(ab), 1094(ab), 1458(ab)
 Kim, SE, 49(ab), 380(ab), 736(ab), 751(ab), 851(ab), 884(ab), 1076(ab), 1102(ab), 1141(ab), 1194(ab), 1226(ab)
 Kim, SH, 217(ab), 376(ab)
 Kim, SK, 452(ab), 476(ab), 529(ab), 742(ab), 938(ab), 1171(ab)
 Kim, SM, 534(ab)
 Kim, WB, 1350(ab)
 Kim, YC, 549(ab)
 Kim, YJ, 273(ab), 530, 1201(ab), 1392(ab)
 Kim, YK, 2(ab), 386(ab), 1143(ab)
 Kimble, LP, 753(ab)
 Kimura, Y, 1269(ab)
 Kinahan, PE, 597(ab), 1134(ab), 2053
 King, D, 276(ab)
 King, MA, 456, 456(ab), 590(ab), 604, 1011, 1312(ab)
 King, P, 439(ab)
 Kinget, R, 610(ab)
 Kinne, RW, 537(ab)
 Kino, S, 211(ab), 212(ab), 855(ab)
 Kinomura, S, 244
 Kinoshita, N, 514(ab)
 Kinoshita, T, 841(ab)
 Kinser, JA, 752(ab)
 Kinuya, S, 430(ab), 761(ab), 855(ab), 1020(ab), 1138, 1644, 1874
 Kipper, M, 1256(ab)
 Kipper, S, 1121(ab)
 Kipper, SL, 62(ab)
 Kira, T, 1331(ab)
 Kirchner, PT, 1434
- Kirihara, Y, 239(ab)
 Kirk, GA, 339(ab)
 Kirkman, E, 1361(ab)
 Kishi, H, 241(ab)
 Kison, PV, 76(ab), 87(ab), 556, 1130(ab), 1125, 1456
 Kitabatake, A, 748(ab), 807(ab)
 Kitagaki, H, 1185(ab)
 Kitagawa, Y, 1132
 Kitamura, K, 1302(ab)
 Kiuchi, T, 1463
 Klauber, GT, 913(ab)
 Klein, A, 571(ab)
 Klein, GJ, 457(ab)
 Klein, JL, 315(ab)
 Kleinz, R, 1222(ab)
 Kletter, K, 362(ab), 1049(ab), 1347(ab)
 Klimke, A, 575(ab)
 Klippenstein, D, 949(ab)
 Kloiber, R, 448
 Kloos, RT, 532(ab)
 Klose, E, 1261(ab)
 Klosterman, L, 469(ab)
 Kluge, R, 337(ab)
 Klumpp, H, 444(ab)
 Klutmann, S, 46(ab), 71(ab), 257(ab), 776, 1033(ab), 1041(ab), 1150(ab), 1246, 2021
 Knapp, FF Jr, 356(ab), 608(ab), 765(ab), 827(ab), 831(ab), 974(ab), 975(ab), 1204, 1384(ab), 1385(ab), 1484, 1508, 1918
 Knapp, WH, 719(ab)
 Knesaurek, K, 1322(ab), 1324(ab)
 Knickmeier, M, 834(ab)
 Knight, LC, 492(ab)
 Knight, M, 984(ab)
 Knockaert, D, 899(ab)
 Knuuti, J, 862
 Ko, YH, 1102(ab)
 Kobayakawa, N, 1116
 Kobayashi, H, 327(ab), 744(ab), 818(ab), 837, 1027(ab), 1381
 Kobayashi, J, 1204(ab)
 Kobayashi, K, 865(ab)
 Kobayashi, T, 239
 Kobayashi, Y, 1063(ab)
 Kober, B, 220(ab)
 Kobori, O, 239(ab)
 Koch, CJ, 401(ab)
 Koch, L, 1375(ab), 1380(ab)
 Köchl, H, 1376(ab)
 Kochs, E, 291(ab)
 Kochunov, PV, 942
 Kocjan, G, 1115(ab)
 Koenders, EB, 192
 Koeppe, RA, 1265(ab)
 Koga, S, 847(ab), 1172(ab), 1335(ab)
 Kogure, D, 1192(ab), 1583
 Koh, JW, 1055(ab)
 Koh, KK, 10(ab)
 Kohelet, D, 860(ab)
 Kohlmyer, SG, 459(ab), 1236(ab), 1237(ab)
 Kohsaka, T, 867(ab)
 Kohya, T, 748(ab), 798(ab), 807(ab)
 Koivunen, E, 883
 Koizumi, K, 835(ab)
 Koizumi, M, 137
 Kojima, A, 1331(ab)
 Kokochis, SA, 50(ab)
 Kokudo, N, 137
 Kolansinka, AD, 68(ab)
 Kolasinka, AD, 536(ab)
 Kolasinska, AD, 1038(ab)
 Kolb, HJ, 992(ab)
 Kolbert, KS, 163(ab)
 Kole, AC, 262, 381
 Kolesnikov-Gauthier, H, 33
 Kolsky, KL, 489(ab)

- Komai, K, 727(ab)
 Komatsu, M, 1971
 Komeda, M, 1840
 Komiyama, N, 705(ab)
 Komo, S, 281(ab), 283(ab)
 Kondas, D, 287(ab)
 Kondo, F, 779(ab)
 Konings, R, 179(ab), 513
 Konings, IR, 322(ab), 415(ab)
 Konishi, J, 7(ab), 471, 479, 530(ab),
 685, 782(ab), 1003(ab), 1097(ab),
 1273(ab), 1371(ab), 1406(ab), 1424,
 1463, 1840, 1992
 Konishi, S, 430(ab), 1020(ab), 1644
 Konishi, T, 895
 Konno, M, 748(ab), 798(ab), 807(ab)
 Konstantinides, S, 220(ab)
 Kontaxakis, G, 1288(ab), 1323(ab)
 Kooij, PP, 762
 Koole, M, 1250(ab)
 Koops, HS, 262
 Koops, W, 1414
 Kopiwoda, S, 184, 814(ab)
 Kopiwoda, SK, 846(ab)
 Kopka, K, 1017(ab), 1064(ab)
 Koplan, BA, 142
 Kopp, AF, 871(ab)
 Koral, KF, 77(ab)
 Koren, AO, 1349(ab)
 Koren, R, 376
 Korenreich, L, 51(ab), 522(ab)
 Korf, J, 1354(ab)
 Kosaka, N, 239(ab), 240(ab), 241(ab)
 Koshiji, T, 1840
 Koskinen, MO, 1326(ab)
 Kostakoglu, L, 1303(ab)
 Kosten, TR, 444(ab)
 Kosuda, S, 1125
 Kotani, J, 781(ab)
 Kothari, KK, 1015(ab), 1402(ab)
 Kotler, MN, 1457(ab)
 Kotz, D, 13N(5), 16N(5), 13N(7),
 9N(12)
 Kotzerke, J, 82(ab), 262(ab), 341(ab),
 368(ab), 1272(ab), 1407, 1623, 1637
 Kouji, T, 12(ab)
 Kouyoumdjian, JC, 1127(ab)
 Kovacs, M, 41(ab)
 Kowell, AP, 285(ab)
 Koyama, K, 858(ab)
 Koyama, T, 1204(ab)
 Kozak, RW, 166
 Kraan, J, 1270
 Kraeber-Bodré, F, 198, 1216
 Kragh, TJ, 133(ab)
 Kramer, EL, 62(ab), 1281(ab)
 Kramer, MR, 880(ab)
 Krams, S, 846(ab)
 Kranenborg, MH, 829
 Kranert, WT, 1152(ab)
 Krasnow, AZ, 1369(ab)
 Krause, TM, 220(ab)
 Krausz, Y, 252(ab), 880(ab), 1122(ab)
 Krawczynska, EG, 508(ab), 511(ab),
 787(ab), 1290(ab)
 Krch, D, 1184(ab)
 Krenning, BJ, 322(ab), 415(ab)
 Krenning, EP, 317(ab), 320(ab),
 414(ab), 416(ab), 418(ab), 762, 2081
 Krevsky, B, 366(ab)
 Krijanovski, OI, 1031(ab)
 Krishnamurthy, GT, 264(ab)
 Kritz, F, 13N(11)
 Kritz, H, 1277
 Kritzman, JN, 15(ab), 361(ab), 506(ab),
 817(ab)
 Kroger, LA, 302, 324(ab), 1381(ab)
 Kröger, S, 46(ab), 257(ab), 776,
 1150(ab), 1246
 Krohn, KA, 614
 Kroll, DJ, 350(ab)
 Kroll, S, 76(ab), 990(ab), 991(ab)
 Kronauge, JF, 1031(ab)
 Kronenberg, MW, 1699
- Kroon, B, 70(ab), 1119(ab)
 Kropp, J, 374(ab), 543(ab), 975(ab),
 1385(ab), 1484, 1918
 Kross, B, 468(ab)
 Krumm, RP, 857(ab)
 Kuan, P, 825(ab)
 Kuang, A, 1373(ab), 1395(ab)
 Kubo, A, 1021(ab), 1026(ab)
 Kubo, H, 1300(ab)
 Kubo, N, 798(ab), 807(ab), 1247(ab),
 1319(ab)
 Kubo, S, 7(ab), 1840
 Kubo, T, 779(ab), 1160(ab), 1175(ab)
 Kubota, K, 70, 567(ab), 1022(ab)
 Kubota, T, 1085
 Kudo, T, 20(ab), 826(ab)
 Kudoh, T, 7(ab), 782(ab), 1840
 Kuehne, A, 975(ab)
 Kuhar, M, 441(ab)
 Kuhl, DC, 1306(ab)
 Kuhl, DE, 294(ab)
 Kuhn, HH, 185(ab)
 Kuhne, A, 543(ab)
 Kuikka, JT, 1326(ab)
 Kuji, I, 1818
 Kukis, DL, 302, 965(ab), 969(ab),
 980(ab), 1381(ab), 2014
 Kula, NS, 148(ab)
 Kumagai, H, 574(ab)
 Kumakura, Y, 1284(ab)
 Kumar, A, 927(ab), 934(ab)
 Kumar, VV, 1268(ab)
 Kundley, K, 1191(ab)
 Kundu, NG, 1361(ab)
 Kung, HF, 108(ab), 150, 152(ab),
 583(ab), 660, 1200(ab), 1345(ab),
 1352(ab), 1812
 Kung, M-P, 150, 660
 Kung, MP, 152(ab), 583(ab), 1345(ab),
 1352(ab)
 Kuniyasu, Y, 1318(ab), 1328(ab),
 1337(ab)
 Kuntzsch, M, 245(ab)
 Kupferschläger, J, 460(ab)
 Kurata, C, 6, 2088
 Kurdziel, KA, 1455(ab), 1456(ab)
 Kurian, V, 1349(ab)
 Kurabayashi, T, 2007
 Kuroda, M, 1971
 Kuroda, T, 718(ab), 767(ab)
 Kuroki, M, 685, 1003(ab), 1005(ab)
 Kuroki, T, 858(ab), 1652
 Kurtaran, A, 74(ab), 395(ab), 1081(ab),
 1082(ab)
 Kusakabe, K, 744(ab), 818(ab)
 Kushner, SA, 150, 583(ab)
 Kusuoka, H, 566, 708(ab), 823(ab), 854,
 1003, 1166(ab), 1884
 Kuten, A, 265(ab)
 Kuwabar, H, 293(ab), 584(ab)
 Kuwabara, Y, 718(ab), 767(ab),
 1091(ab), 1111(ab), 1203(ab), 1595,
 1778
 Kuwert, T, 1, 185(ab), 1017(ab)
 Kuzuya, T, 803(ab), 804(ab)
 Kvols, LK, 322(ab), 415(ab)
 Kwan, YC, 1052(ab)
 Kwekkeboom, DJ, 416(ab), 762, 2081
 Kweon, J, 505(ab)
 Kwok, CG, 60
 La Madeleine, C, 876
 Laatsch, H, 907(ab)
 Labbie, AS, 204(ab)
 Lacaine, F, 1077(ab)
 Lacan, G, 1156(ab)
 Lacroix, M, 219(ab)
 Lacy, J, 723(ab)
 Lacy, JL, 775(ab)
 Laffin, SP, 52(ab), 56(ab)
 Laffont, S, 140(ab), 1314(ab)
 Lage, C, 1379(ab)
 Lahdenranta, J, 883
 Lahiri, A, 345(ab), 464
 Lahorte, P, 269(ab)
- Lai, KH, 367(ab)
 Lai, L, 431(ab)
 Lai, S, 6(ab), 22(ab), 25(ab), 170(ab),
 710(ab)
 Laine, AF, 310(ab), 720(ab)
 Laine, H, 862
 Lajeunie, E, 1252
 Lakhani, SR, 1115(ab)
 Lalush, DS, 134(ab), 461(ab), 1252(ab),
 1253(ab)
 Lamb, HJ, 180(ab)
 Lambert, C, 1396(ab)
 Lambert, R, 41(ab), 1124(ab), 2029
 Lamborn, KR, 963(ab), 1317, 2014
 Lamki, L, 1462(ab)
 Lamki, LM, 902(ab), 1459(ab),
 1463(ab), 1464(ab)
 Lammonica, D, 949(ab)
 Lamy-Lhullier, C, 956
 Lan, J-L, 1446
 Lan, L, 579, 64(ab)
 Lancaster, JL, 942
 Landau, B, 25
 Landoni, C, 1617
 Landsman, D, 62(ab)
 Landsnes, DG, 232(ab)
 Lang, AE, 273(ab), 530, 1201(ab)
 Lang, L, 149(ab), 150(ab), 168(ab),
 1547
 Lang, O, 248(ab), 254(ab), 1059(ab),
 1068(ab), 1149(ab)
 Lang, S, 985(ab), 1277
 Lange, D, 1261(ab)
 Langleben, D, 1122(ab)
 Langston, JW, 587(ab)
 Laniece, P, 602(ab)
 Lanke, J, 96
 Lapointe, D, 832(ab), 876
 Larena-Avellaneda, A, 202(ab)
 Larger, E, 903(ab)
 Larisch, R, 575(ab)
 Larobina, M, 442
 Larsen, P, 1136(ab)
 Larsen, RH, 1197
 Larsen, T, 238(ab), 929(ab)
 Larson, SM, 95(ab), 131, 156(ab),
 163(ab), 328(ab), 912(ab), 970(ab),
 1007(ab), 1012(ab), 1039(ab),
 1042(ab), 1044(ab), 1238(ab), 1722,
 1764, 1935
 Laruelle, M, 114(ab), 117(ab), 121(ab),
 122(ab), 141(ab), 435(ab), 474(ab),
 581(ab), 606(ab), 609(ab), 1162(ab),
 1209(ab), 1210(ab), 1211(ab),
 1242(ab)
 Lasic, M, 1017(ab)
 Lastoria, S, 66(ab), 1142(ab)
 Laterza, C, 123(ab)
 Latus, KA, 343(ab), 344(ab)
 Lauer, B, 337(ab)
 Lauer, I, 540(ab), 730(ab), 944(ab)
 Laufer, J, 1103(ab)
 Laver, O, 376
 Laverman, P, 58(ab), 192, 892(ab), 2066
 Lawhorn-Crews, HM, 101(ab)
 Lawhorn-Crews, JM, 1079(ab)
 Lawrence, B, 497(ab), 995(ab)
 Lawson, G, 253(ab)
 Lawson, M, 717(ab), 1304(ab)
 Lawton, T, 1117(ab)
 Laymon, CM, 136(ab)
 Le Boterff, J, 198
 Le Cloirec, J, 140(ab), 369(ab),
 1314(ab)
 Le Guludec, D, 369(ab), 701(ab),
 794(ab), 805, 809(ab), 893(ab),
 903(ab), 962(ab), 1602
 Le, N, 268, 327(ab), 837, 1381
 Le Rest, C, 298(ab), 473(ab)
 Le Roux, G, 40
 Leach, SD, 1784
- Leahy, RM, 129(ab), 130(ab)
 Lear, JL, 44(ab), 200(ab), 221(ab),
 296(ab), 314(ab), 797(ab), 1165(ab)
 Learoyd, DL, 924(ab)
 LeBlanc, JW, 133(ab)
 Lebtahi, R, 369(ab), 701(ab), 794(ab),
 805, 809(ab), 893(ab), 903(ab),
 962(ab), 1602
 Leclercq, S, 905(ab)
 Lecomte, R, 876, 832(ab)
 Lecouffe, P, 956
 Ledges, M, 169(ab)
 Leduc, V, 956
 Lee, B, 49(ab), 751(ab)
 Lee, BH, 1023(ab)
 Lee, BY, 1359(ab)
 Lee, CJ, 1094(ab)
 Lee, CK, 1182(ab)
 Lee, DS, 2(ab), 23(ab), 309(ab), 339,
 358(ab), 386(ab), 452(ab), 476(ab),
 529(ab), 742(ab), 789(ab), 790(ab),
 819(ab), 938(ab), 986, 998(ab),
 999(ab), 1143(ab), 1171(ab),
 1195(ab), 1196(ab), 1198(ab),
 1214(ab), 1221(ab), 1275(ab),
 1350(ab), 1387(ab), 1392(ab)
 Lee, DW, 1221(ab)
 Lee, E, 221(ab)
 Lee, ED, 1128(ab)
 Lee, EJ, 529(ab)
 Lee, FT, 328(ab)
 Lee, HB, 1352
 Lee, HG, 217(ab)
 Lee, HK, 166(ab), 205(ab), 214(ab),
 534(ab), 568(ab), 1359(ab)
 Lee, J, 213(ab), 515(ab), 735(ab),
 819(ab), 1023(ab), 1086(ab)
 Lee, JD, 704(ab), 833(ab)
 Lee, JH, 888(ab), 1301(ab)
 Lee, JI, 1073(ab)
 Lee, J-K, 1446
 Lee, JS, 309(ab), 386(ab), 452(ab),
 476(ab), 986, 1043(ab), 1051(ab),
 1058(ab), 1066(ab), 1073(ab),
 1075(ab), 1151(ab), 1171(ab),
 1196(ab), 1198(ab), 1214(ab),
 1221(ab)
 Lee, K, 339, 1194(ab)
 Lee, KB, 213(ab), 515(ab), 735(ab),
 1023(ab), 1086(ab)
 Lee, KH, 49(ab), 380(ab), 736(ab),
 751(ab), 851(ab), 884(ab), 1076(ab),
 1102(ab), 1128(ab), 1141(ab),
 1194(ab), 1226(ab)
 Lee, KS, 955(ab), 1348(ab)
 Lee, KU, 1198(ab)
 Lee, LS, 1065(ab)
 Lee, MC, 2(ab), 23(ab), 339, 309(ab),
 358(ab), 386(ab), 452(ab), 476(ab),
 529(ab), 742(ab), 789(ab), 790(ab),
 819(ab), 938(ab), 986, 998(ab),
 999(ab), 1143(ab), 1171(ab),
 1195(ab), 1196(ab), 1198(ab),
 1214(ab), 1221(ab), 1275(ab),
 1350(ab), 1387(ab), 1392(ab)
 Lee, MM, 2(ab), 23(ab), 358(ab),
 789(ab), 790(ab), 819(ab)
 Lee, MY, 1226(ab)
 Lee, RJ, 1563
 Lee, S, 476(ab), 1045(ab), 1171(ab),
 1194(ab)
 Lee, SC, 367(ab), 1460(ab)
 Lee, SG, 214(ab)
 Lee, SH, 736(ab), 1066(ab), 1143(ab)
 Lee, SK, 1195(ab), 1196(ab)
 Lee, SW, 213(ab), 515(ab), 735(ab),
 1023(ab), 1086(ab)
 Lee, SY, 205(ab), 376(ab), 217(ab)
 Lee, TW, 1058(ab)
 Lee, WH, 505(ab)
 Lee, WR, 736(ab)

- Lee, YJ, 23(ab), 214(ab), 339, 938(ab),
 998(ab), 999(ab), 1392(ab)
 Lee, YS, 1051(ab), 1151(ab)
 Lee, Z, 383(ab), 886(ab)
 Leenders, KL, 1264
 Lefebvre, B, 1728
 Leimer, M, 395(ab), 1081(ab), 1082(ab)
 Leitao, AC, 1379(ab)
 Leitha, T, 881(ab), 985(ab), 1376(ab),
 1477
 Leitinger, I, 362(ab)
 Leitman, N, 169(ab), 177(ab)
 Lele, RD, 1191(ab)
 Lele, VR, 1191(ab)
 Lemahieu, I, 491
 Lenox, M, 306(ab)
 Leonard, SM, 342(ab), 509(ab),
 513(ab), 1327(ab)
 Leppo, JA, 456(ab)
 Lerch, H, 1, 185(ab)
 Lerut, A, 98(ab)
 Leslie, MD, 425(ab), 1135(ab)
 Leslie, WD, 422
 Leta, R, 3(ab)
 Leung, AN, 574
 Leung, C, 1370(ab)
 Leung, JY, 556
 Levame, M, 37(ab)
 Léveillé, J, 1124(ab)
 Leveillee, RJ, 204(ab), 206(ab)
 Leveque, FC, 930(ab)
 Levine, RA, 193(ab)
 Levy, AV, 145(ab), 715, 1176(ab),
 1301(ab)
 Levy, E, 1147(ab)
 Lew, W, 981(ab)
 Lewellen, TK, 459(ab), 1236(ab),
 1237(ab)
 Lewin, HC, 6(ab), 9(ab), 22(ab), 25(ab),
 28(ab), 170(ab), 710(ab), 722(ab)
 Lewis, BS, 741(ab), 811(ab)
 Lewis, DH, 572(ab)
 Lewis, JS, 177, 997(ab)
 Lewis, LD, 763(ab)
 Lewis, MR, 997(ab)
 Lewis, PJ, 278(ab), 763(ab)
 Lewkowicz, LA, 177(ab)
 Lexow, N, 150
 Leyton, M, 577(ab)
 Li, AN, 356(ab), 1508
 Li, B, 1004(ab)
 Li, H, 307(ab), 598(ab), 1233(ab)
 Li, J, 77(ab), 1373(ab)
 Li, JM, 97(ab)
 Li, L, 1386(ab)
 Li, P, 2107
 Li, SR, 1081(ab)
 Li, WI, 383(ab)
 Li, YC, 498(ab)
 Liang, JZ, 1317(ab)
 Liang, Z, 1277(ab), 1325(ab)
 Liang, ZL, 498(ab)
 Liani, M, 880(ab)
 Liao, SQ, 909(ab), 1062(ab), 1065(ab),
 1186(ab)
 Liberson, A, 45(ab)
 Libutti, SK, 385(ab), 464(ab), 565(ab),
 1029(ab), 1297(ab)
 Licho, R, 258(ab), 456, 590(ab), 604
 Liebenhoff, S, 1036(ab)
 Lieberman, G, 541(ab)
 Liebig, JR, 574
 Liebowitz, M, 581(ab)
 Liechty, D, 200(ab)
 Liem, IH, 1414
 Lien, H-C, 1106
 Liepe, K, 374(ab), 975(ab)
 Lietzenmayer, R, 946(ab), 956(ab),
 957(ab)
 Lignelli, A, 228(ab)
 Lilien, DL, 1745
 Lim, BB, 405(ab), 486(ab)
 Lim, HG, 742(ab)
 Lim, JI, 1350(ab)
- Lim, SC, 549(ab)
 Lim, SM, 986, 166(ab), 1051(ab),
 1058(ab), 1066(ab), 1073(ab),
 1075(ab), 1128(ab), 1151(ab),
 1358(ab), 1359(ab), 1360(ab),
 1394(ab), 1043(ab)
 Lim, ST, 358(ab), 790(ab)
 Lima, MC, 746(ab), 848(ab)
 Limouris, GS, 976(ab)
 Lin, BH, 1087(ab)
 Lin, CH, 1365(ab)
 Lin, CK, 1052(ab)
 Lin, E, 52(ab), 56(ab)
 Lin, HD, 1307(ab)
 Lin, HM, 1365(ab)
 Lin, JW, 310(ab), 720(ab)
 Lin, KP, 1307(ab)
 Lin, KQ, 1268(ab)
 Lin, KS, 318(ab)
 Lin, MP, 2053
 Lin, P, 1153(ab)
 Lin, PC, 250(ab), 544(ab)
 Lin, Q, 1918
 Lin, S, 77(ab)
 Lin, SH, 581(ab)
 Lin, SZ, 1170(ab)
 Lincke, T, 570(ab)
 Lindahl, D, 96
 Lindner, DJ, 1369(ab)
 Lindsley, KL, 69(ab)
 Line, BR, 319(ab), 1030(ab), 1399(ab)
 Link, JM, 614, 1279(ab)
 Linker, R, 110(ab), 112(ab), 126(ab),
 853(ab)
 Links, J, 359(ab)
 Links, JM, 38N(8), 1349(ab)
 Linnoila, M, 445(ab)
 Liow, J, 1304(ab)
 Lipszyc, H, 355(ab)
 Lisbona, R, 542(ab)
 Lisciandriano, D, 1630
 Lister-James, J, 36(ab), 40(ab), 57(ab),
 321(ab), 417(ab), 887(ab), 950(ab),
 954(ab), 1081(ab), 1082(ab)
 Litofsky, NS, 258(ab)
 Liu, A, 1151
 Liu, H, 1008(ab), 1181(ab)
 Liu, JC, 1170(ab)
 Liu, JZ, 866(ab), 1087(ab)
 Liu, M, 94(ab)
 Liu, P, 769(ab)
 Liu, Q, 438(ab)
 Liu, RS, 244(ab), 367(ab), 909(ab),
 1050(ab), 1062(ab), 1065(ab),
 1170(ab), 1186(ab), 1307(ab),
 1365(ab), 1452(ab), 1460(ab)
 Liu, WS, 1050(ab)
 Liu, XS, 822(ab)
 Liu, Y, 21(ab), 339(ab), 1369(ab)
 Liu, YH, 817(ab)
 Liu, Z, 815(ab), 813(ab)
 Liuand, R-S, 60
 Livingston, RB, 69(ab), 551(ab)
 Livni, E, 582(ab)
 Livshitz, S, 749(ab)
 Ljungberg, M, 1524
 Llacer, J, 130(ab), 2043
 Lihani, I, 919(ab)
 Loc'h, C, 935
 Lockman, J, 539(ab)
 Locko, RC, 1205(ab)
 Lodge, MA, 1029(ab)
 Loehr, H, 403(ab), 1036(ab)
 Loftus, BM, 1414
 Logan, J, 439(ab), 442(ab), 588(ab),
 1176(ab), 1215(ab), 1218(ab), 1285,
 1301(ab)
 Löhr, M, 1374(ab)
 Loisance, D, 917
 Lombardo, I, 435(ab)
 Lomena, F, 123(ab)
 Loncaric, S, 937(ab)
 London, ED, 1349(ab)
 Long, R, 287(ab)
- Longari, V, 251(ab), 338(ab), 725(ab),
 777(ab), 1085(ab)
 Longino, MA, 155(ab)
 Lonneux, M, 253(ab), 1109(ab)
 Lonneux, MG, 1316(ab)
 Loogemann, J, 247(ab)
 Lopatin, G, 1151
 López, G, 424(ab)
 Lopez, MA, 1229(ab)
 Lopez, R, 427(ab)
 Lopez-Carrero, C, 123(ab)
 Lorberboym, M, 539(ab), 860(ab)
 Lord, EM, 401(ab)
 Lorenz, E, 1234(ab)
 Lormeau, B, 1252
 Losman, MJ, 500(ab)
 Losordo, DW, 760(ab)
 Lötter, MG, 1532
 Lottgen, J, 1064(ab)
 Loutfi, A, 542(ab)
 Loutfi, I, 879(ab)
 Lovqvist, A, 328(ab), 1007(ab)
 Lowe, J, 339(ab)
 Lu, JG, 909(ab)
 Lu, L, 497(ab), 504(ab), 995(ab),
 1346(ab)
 Lubberink, M, 982(ab)
 Luciani, A, 1716
 Lucignani, G, 1617
 Luddens, H, 1222(ab)
 Luder, H, 279(ab)
 Ludolph, AC, 571(ab)
 Ludwig, W-D, 387
 Luescher, D, 752(ab)
 Lugo, D, 427(ab)
 Lukasiewicz, RL, 1030(ab), 1399(ab)
 Lukes, J, 360(ab)
 Lull, RJ, 935(ab), 1226
 Lundin, A, 96
 Lundqvist, H, 982(ab)
 Luo, H, 1918
 Luo, SZ, 1386(ab)
 Lustig, M, 1213(ab)
 Lutter, G, 340(ab)
 Lüttges, J, 1033(ab)
 Lutropp, CA, 159
 Luu, AN, 1009(ab)
 Luurtsema, G, 393(ab)
 Lysionek, AE, 1080
 Ma, D, 431(ab), 1722
 Ma, KH, 1170(ab)
 Macapinlac, H, 1042(ab), 1044(ab)
 Macapinlac, HA, 95(ab), 912(ab),
 1039(ab)
 MacDonald, LA, 509(ab)
 MacDonald, LR, 599(ab)
 Macey, DJ, 160(ab), 967(ab), 979(ab),
 1317
 Mach, RH, 1356(ab)
 Machac, J, 355(ab), 363(ab), 759(ab),
 1322(ab), 1324(ab)
 Machida, K, 802(ab), 877(ab), 885(ab),
 1188(ab)
 Machulla, H, 245(ab)
 Machulla, HJ, 933(ab)
 Macke, H, 72(ab)
 Macke, HR, 762
 Mackey, D, 218(ab)
 Mackey, DW, 85
 McLaren, D, 102(ab)
 MacLean, AB, 541(ab)
 MacMullan, J, 730
 Madar, I, 1180
 Maddahi, J, 1(ab)
 Madeddu, G, 1105(ab)
 Madras, BK, 153(ab), 1161(ab)
 Madsen, MT, 1315(ab)
 Maeda, H, 12(ab), 847(ab), 1131(ab),
 1335(ab)
 Maeda, J, 1342(ab), 1351(ab)
 Maeda, M, 289(ab)
 Maehara, Y, 1778
 Maekawa, M, 1137(ab)
 Maes, A, 19(ab), 822(ab), 899(ab)
- Maes, B, 1451
 Maetani, S, 1063(ab)
 Maeyama, S, 859(ab)
 Maffioli, L, 251(ab), 1114(ab)
 Magata, Y, 7(ab), 150(ab), 1406(ab)
 Magee, M, 869(ab)
 Maggioni, A, 235(ab)
 Magnani, P, 1617
 Magnussen, J, 218(ab), 869(ab)
 Magnussen, JS, 85
 Magri, GC, 178(ab), 375(ab)
 Maguire, GQ, 1281(ab)
 Mahowald, JL, 1259(ab)
 Mainenti, P, 338(ab)
 Maini, CL, 46
 Mainolfi, C, 442
 Maisey, MN, 409(ab), 410(ab)
 Majd, M, 523(ab)
 Majewski, S, 468(ab), 600(ab)
 Majstorov, V, 1036(ab)
 Makino, K, 12(ab)
 Makino, T, 1131(ab)
 Makriyannis, A, 438(ab)
 Makuuchi, H, 1078(ab)
 Malamitsi, J, 904(ab)
 Malatesta, T, 46
 Male, TA, 873(ab)
 Malguria, N, 1138(ab)
 Malison, RT, 444(ab), 576(ab)
 Mallet, J-J, 1676
 Malloch, C, 364(ab)
 Malmin, RE, 482(ab), 1245(ab)
 Malone, KM, 1211(ab)
 Maltz, JS, 311(ab)
 Manchanda, R, 321(ab), 950(ab),
 954(ab)
 Manco-Johnson, M, 44(ab)
 Mancuso, NS, 371(ab)
 Mandel, S, 526(ab)
 Manders, JM, 829
 Maneke, E, 828(ab)
 Manetou, A, 976(ab)
 Mangin, JF, 786
 Mangioni, C, 235(ab)
 Mangner, TJ, 101(ab)
 Mangold, D, 446(ab)
 Mankoff, DA, 69(ab), 551(ab), 557(ab),
 614
 Mann, A, 518(ab)
 Mann, JJ, 114(ab), 117(ab), 121(ab),
 122(ab), 609(ab), 1162(ab), 1210(ab),
 1211(ab)
 Mann, K, 923(ab)
 Manner, T, 12
 Mannting, F, 772(ab), 889, 1031(ab)
 Mannting, MG, 772(ab)
 Manoj, C, 412(ab)
 Manrique, A, 179(ab), 513, 805
 Manthey, N, 389(ab)
 Marais, J, 1532
 Marasini, B, 77
 Marchandise, B, 766(ab), 792(ab)
 Marchandise, X, 33
 Marchione, T, 573(ab)
 Marcus, CS, 1080(ab), 1363(ab)
 Marcus, RE, 249(ab)
 Mardirossian, G, 972(ab), 1524
 Marek, K, 107(ab)
 Margouleff, C, 1178(ab)
 Mari, C, 3(ab), 5(ab), 19, 734(ab),
 786(ab), 911
 Mariani, G, 522, 926(ab), 1123(ab),
 1832
 Marini, C, 363
 Marion, C, 402(ab)
 Marois, M, 1100(ab)
 Marsden, PK, 763(ab)
 Marshall, RC, 712(ab), 1278(ab)
 Marti, JM, 424(ab), 845(ab), 1096(ab),
 1401(ab)
 Martin, A, 40
 Martin, CS, 775(ab)
 Martin, G, 1124(ab)

- Martin, JC, 3(ab), 5(ab), 786(ab), 1212(ab)
 Martin, JM, 734(ab)
 Martin, W, 364(ab)
 Martin, WH, 110
 Martinez, CJ, 1126(ab)
 Martinez, D, 435(ab), 1209(ab)
 Martinoff, S, 24(ab)
 Maruno, H, 705(ab), 808(ab)
 Maruyama, A, 708(ab), 803(ab), 804(ab), 805(ab), 806(ab), 823(ab), 1693
 Maruyama, I, 1085
 Marwin, SE, 43(ab)
 Marzilli, LG, 1403(ab)
 Mas, JF, 839(ab), 1336(ab)
 Masai, M, 780(ab)
 Masaki, K, 858(ab)
 Mason, JC, 821(ab)
 Masoomi, M, 984(ab)
 Massardo, T, 516(ab)
 Masson, H, 267(ab)
 Masson, LF, 432(ab)
 Mastin, ST, 371(ab)
 Mastripolito, R, 602(ab)
 Masuda, I, 782(ab)
 Masuda, K, 1091(ab), 1111(ab), 1203(ab), 1595, 1778
 Masuda, S, 1465(ab)
 Masuda, Y, 718(ab), 767(ab)
 Masuyama, K, 512(ab), 812(ab)
 Matacchieri, RA, 1339(ab)
 Mathai, M, 1367(ab)
 Matheja, P, 1, 1064(ab)
 Matheoud, R, 338(ab), 1928
 Mather, JF, 711(ab)
 Mather, SJ, 1108(ab)
 Matherson, KJ, 601(ab)
 Mathew, T, 1368(ab)
 Mathews, D, 237(ab), 896(ab)
 Mathews, WB, 115(ab), 373(ab), 446(ab), 447(ab), 1014(ab), 1164(ab), 1207(ab)
 Mathur, A, 108(ab), 625, 1200(ab), 1812, 2107
 Matsubara, S, 1792
 Matsuda, H, 1192(ab), 1583
 Matsui, S, 512(ab), 812(ab)
 Matsui, T, 1188(ab)
 Matsumori, A, 7(ab)
 Matsumoto, K, 1590
 Matsumoto, M, 1190(ab), 1302(ab), 1331(ab)
 Matsumura, K, 1172(ab)
 Matsunari, I, 191(ab), 512(ab), 761(ab), 904, 1824, 1874
 Matsuno, K, 718(ab), 767(ab)
 Matsuoka, M, 1318(ab), 1328(ab), 1337(ab)
 Matsuoka, Y, 685, 1005(ab)
 Matsushima, T, 1203(ab)
 Matsushita, T, 1332(ab)
 Matsuta, Y, 1137(ab)
 Matsuzawa, Y, 239
 Mattes, MJ, 1392
 Mattfeldt, T, 368(ab)
 Matthay, KK, 1248(ab)
 Matusi, P, 1184(ab)
 Mattner, F, 144(ab)
 Matunari, I, 727(ab)
 Matzen, K, 550(ab)
 Maublant, J, 672
 Maounoury, C, 910(ab)
 Maurer, AH, 366(ab), 492(ab), 854(ab), 1226, 1236, 1313
 Maurer, G, 362(ab)
 Maurer, K, 282(ab)
 Mausner, LF, 302, 489(ab), 490(ab)
 Mawlawi, O, 114(ab), 117(ab), 435(ab), 474(ab), 1162(ab), 1209(ab), 1242(ab)
 Mayer, S, 1367
 Mayrin, V, 857(ab)
 Maysky, M, 760(ab)
 Mazière, B, 935
 Maziere, B, 411(ab)
 Mazumdar, M, 95(ab)
 Mazza, SM, 379(ab)
 Mazzadi, A, 821(ab)
 Mazzanti, C, 445(ab)
 Mazzanti, JC, 283(ab)
 McAfee, JG, 1396(ab)
 McAlpine, B, 234(ab)
 McBride, BC, 357(ab)
 McBride, J, 844(ab)
 McBride, W, 1002(ab)
 McBride, WJ, 500(ab)
 McCarthy, DW, 177
 McCarthy, G, 1220(ab)
 McCarthy, TJ, 177
 McCluskey, ER, 342(ab)
 McCready, VR, 161(ab), 984(ab)
 McCullough, NT, 989(ab)
 McCullough, SP, 160(ab)
 McDade, M, 364(ab)
 McDermott, MR, 166, 431(ab), 1722, 1935
 McDonald, KL, 197(ab), 876(ab)
 McElgin, WT, 150
 McFalls, EO, 1304(ab)
 McGagh, DA, 970(ab)
 McGhie, AI, 27(ab), 724(ab), 1291(ab)
 McGill, CC, 517(ab), 518(ab), 702(ab)
 McGillicuddy, JE, 554(ab)
 McGuinness, G, 1281(ab)
 McIntyre, R, 200(ab)
 McCloud, T, 547(ab)
 McPherson, DW, 608(ab), 1918
 McSherry, BA, 456(ab)
 Meadors, K, 1164
 Meares, CF, 302
 Mease, RC, 1396(ab)
 Mechanic, KY, 444(ab)
 Medeiros, FB, 11(ab)
 Medeiros, M, 11(ab)
 Medina, JF, 845(ab), 1401(ab)
 Medvedec, M, 531(ab), 937(ab)
 Meegalla, SK, 150, 152(ab), 660
 Mega, MS, 283(ab)
 Mehanny, S, 507(ab)
 Mehilli, J, 24(ab)
 Mehta, BM, 1935
 Mehta, L, 236(ab)
 Meignan, M, 37(ab), 223(ab), 1147(ab)
 Meijer, WG, 393(ab)
 Meikle, SR, 144(ab)
 Meinken, GE, 489(ab), 490(ab)
 Meisami, T, 408(ab)
 Meisetschläger, G, 593(ab)
 Meissner, C, 871(ab)
 Meldolesi, U, 573(ab)
 Mele, D, 778(ab)
 Melega, WP, 1156(ab)
 Melin, J, 792(ab)
 Meller, B, 540(ab), 605(ab), 921(ab), 944(ab), 1372(ab)
 Meller, J, 48(ab)
 Mellouli, M, 376
 Melo, T, 1019(ab)
 Meltzer, CC, 2053
 Meltzer, CC, 597(ab), 1134(ab)
 Meltzer, P, 153(ab), 1161(ab)
 Menard, L, 602(ab)
 Mendieta, C, 1142(ab)
 Mentis, M, 1178(ab), 1184(ab)
 Mentis, MJ, 119(ab), 1264
 Menzel, C, 78(ab)
 Merced, M, 715(ab)
 Merdler, A, 741(ab), 811(ab)
 Meredith, RF, 967(ab), 979(ab)
 Merkle, P, 1068(ab)
 Merlet, P, 31(ab), 224, 411(ab), 917, 1147(ab)
 Mertens, IJ, 311
 Mesotten, LV, 19(ab), 822(ab)
 Mester, J, 46(ab), 71(ab), 257(ab), 1033(ab), 1041(ab), 1150(ab), 1246, 1657, 2021
 Methé, BM, 616(ab)
 Metsähönen, L, 12
 Metz, CE, 1011
 Meyer, GJ, 719(ab)
 Meyer, MA, 951(ab), 1274(ab)
 Meyer, P, 450(ab), 537(ab)
 Meyers, FI, 963(ab)
 Michalevich, D, 376
 Michel, CI, 1316(ab)
 Michigishi, M, 761(ab)
 Michigishi, T, 216(ab), 430(ab), 1020(ab), 1644
 Mick, R, 1143
 Mier, W, 487(ab)
 Migneco, O, 1301
 Mignon, M, 369(ab), 1602
 Mikami, T, 2088
 Mikami, Y, 718(ab), 767(ab)
 Mikolajczyk, K, 1288(ab)
 Mikuni, M, 399
 Milan, E, 172(ab), 178(ab)
 Miller, I, 552(ab)
 Miller, J, 208(ab), 377(ab)
 Miller, SD, 306(ab)
 Miller, TR, 1129(ab)
 Milesi, W, 985(ab)
 Milliken, BD, 347
 Min, JJ, 286(ab), 549(ab), 1202(ab), 1378(ab)
 Minami, C, 1080(ab), 1363(ab)
 Mineura, K, 1590
 Minguez, J, 424(ab)
 Minoshima, S, 294(ab), 737
 Miranda, R, 170(ab)
 Mirick, GR, 302, 1317, 2014
 Misaki, T, 530(ab), 865(ab)
 Mishkin, FS, 917(ab), 977(ab)
 Missimer, J, 268(ab), 1264
 Mitchell, K, 52(ab), 56(ab)
 Mitchell, T, 1462(ab)
 Mitsumori, A, 394
 Miura, S, 812(ab)
 Mix, M, 340(ab), 423(ab), 591(ab), 1308(ab), 1309(ab)
 Mixon, L, 359(ab)
 Miyahara, M, 12(ab)
 Miyake, M, 70
 Miyamoto, T, 1131(ab)
 Miyaoka, RS, 1237(ab)
 Miyatake, K, 799(ab), 800(ab)
 Miyazaki, Y, 1874
 Miyazono, N, 222(ab)
 Miyoshi, S, 566
 Mizziara, H, 11(ab)
 Mo, T, 1373(ab), 1395(ab)
 Mochiduki, T, 527(ab)
 Mochizuki, S, 779(ab)
 Mochizuki, T, 207(ab), 798(ab), 807(ab), 963, 1071(ab), 1271(ab), 1287(ab)
 Mock, BH, 495(ab), 846
 Modlin, I, 73(ab)
 Moe, RE, 557(ab)
 Moeller, JR, 1178(ab), 1184(ab), 1264
 Mognetti, T, 585
 Mohammed, A, 487(ab)
 Moins, N, 672
 Moisan, C, 1100(ab)
 Moka, D, 403(ab), 1036(ab)
 Moka, DC, 202(ab), 791(ab), 830(ab), 932(ab), 973(ab)
 Mokler, FT, 1918
 Molenaar, WM, 262, 381
 Molinari, E, 926(ab)
 Molinet, R, 166, 1375(ab), 1380(ab)
 Moller, P, 422(ab)
 Molloy, PT, 520(ab), 521(ab)
 Molls, M, 397(ab)
 Molthoff, CF, 966(ab)
 Momen, A, 413(ab)
 Momiki, S, 1088(ab)
 Momomura, S-i, 1116
 Momose, M, 744(ab), 818(ab)
 Momose, T, 1284(ab)
- Moncayo, R, 74(ab)
 Monsieurs, M, 1250(ab)
 Montanaro, D, 84(ab)
 Montane, BS, 204(ab)
 Monteleone, F, 556(ab), 843(ab)
 Montenegro, NB, 870(ab)
 Montoya, J, 117(ab)
 Montravers, F, 1077(ab)
 Moog, F, 1407
 Moon, DH, 166(ab), 205(ab), 214(ab), 529(ab), 534(ab), 568(ab), 1359(ab)
 Moore, A, 131(ab)
 Moore, MJ, 1025(ab)
 Moore, SC, 475(ab), 482(ab), 483(ab)
 Moore, WH, 17(ab), 348(ab)
 Morales, A, 768
 Morales, B, 59(ab)
 Moran, JK, 1352
 Morano, GN, 1199(ab), 1270(ab)
 Morel, D, 412
 Moresco, RM, 302(ab)
 Moretti, J, 960(ab), 962(ab), 1092(ab), 1127(ab), 1305(ab)
 Moretti, J-L, 40
 Moretti, R, 172(ab)
 Mori, E, 1185(ab)
 Mori, K, 705(ab)
 Mori, Y, 779(ab), 874(ab)
 Morin, J, 1100(ab)
 Morita, DM, 1040(ab)
 Morita, K, 527(ab), 748(ab), 798(ab), 807(ab), 963, 1204(ab), 1319(ab)
 Morita, T, 240(ab)
 Morita, Y, 1319(ab)
 Moriwaki, H, 1187(ab)
 Moroi, M, 193(ab)
 Morozumi, T, 781(ab)
 Morpurgo, PS, 922(ab)
 Morr, I, 1010(ab), 1011(ab)
 Morris, HH, 279(ab)
 Morris, JG, 454(ab)
 Morris, MM, 997(ab)
 Morrison, KS, 283
 Mortelmans, L, 19(ab), 98(ab), 610(ab), 822(ab), 1451
 Mortelmans, LA, 899(ab)
 Morton, KA, 159
 Mosada, R, 94(ab)
 Moser, AJ, 856(ab)
 Moser, E, 220(ab), 247(ab), 423(ab)
 Moser, EA, 340(ab), 1308(ab)
 Moses, WW, 305(ab)
 Moskovitz, B, 968, 1111
 Motomura, N, 895, 1300(ab), 1331(ab)
 Motzer, RJ, 970(ab)
 Mountz, JM, 994(ab), 1181(ab)
 Moustafa, H, 904(ab)
 Moustakidis, P, 4(ab)
 Moutray, K, 27(ab)
 Moutray, KL, 724(ab), 1291(ab)
 Movahed, A, 1329(ab)
 Moyer, BR, 321(ab), 417(ab), 950(ab), 954(ab)
 Moyer, C, 950(ab)
 Moyna, N, 702(ab)
 Moyse, D, 917
 Mozley, PD, 108(ab), 150, 199(ab), 583(ab), 625, 1200(ab)
 Mozley, PD, 1812, 2107
 Mu, M, 150, 152(ab), 660, 1345(ab)
 Mueller-Berg, M, 946(ab), 957(ab), 1289(ab)
 Muffoletto, A, 906(ab)
 Mukherjee, J, 437(ab), 1267(ab), 1338(ab)
 Mukhin, AG, 1349(ab)
 Mukhopadhyay, SK, 232
 Mukovitzky, J, 558(ab)
 Mulholland, GK, 495(ab)
 Mullan, BP, 677, 1098
 Mullani, N, 1462(ab)
 Müller, SP, 475(ab), 483(ab), 923(ab)
 Müller-Gärtner, HW, 566(ab), 575(ab), 977

- Müller-Schauenburg, W, 460(ab)
 Mundler, O, 1252
 Municino, A, 810(ab)
 Munro, SM, 169(ab)
 Munz, DL, 195(ab), 795(ab), 840(ab), 897(ab), 920(ab), 936(ab), 948(ab), 952(ab), 1227(ab)
 Munz, F, 448(ab), 593(ab)
 Murakami, M, 1131(ab)
 Muramatsu, T, 1131(ab)
 Muramori, A, 1874
 Muranoto, S, 243(ab)
 Murase, K, 1071(ab), 1271(ab), 1287(ab)
 Murata, H, 705(ab), 808(ab), 1005(ab)
 Murata, T, 1174(ab)
 Murata, Y, 64, 1101(ab), 1874
 Murayama, S, 1595
 Murguia, JS, 613(ab)
 Murphy, GP, 1138(ab)
 Murphy, J, 44(ab)
 Murray, P, 869(ab)
 Murren, J, 73(ab)
 Murthy, DR, 518(ab), 702(ab), 711(ab)
 Murthy, K, 542(ab)
 Murud, KM, 1197
 Musachio, J, 1164(ab)
 Musachio, JL, 446(ab), 447(ab), 1014(ab), 1207(ab)
 Muto, P, 66(ab), 1142(ab)
 Muzi, M, 614
 Muzic, RF, Jr, 118
 Muzik, O, 101(ab), 592(ab), 1079(ab), 1985
 Muzzammil, T, 1025(ab)
 Myrick, S, 209(ab)
 Mzengeza, S, 577(ab)
 Nabatame, H, 1992
 Nabeshima, S, 1063(ab)
 Nabi, H, 949(ab)
 Nabi, HA, 67(ab), 1069(ab)
 Nachar, O, 1728
 Naddaf, S, 84(ab), 889(ab)
 Nader, K, 741(ab), 811(ab)
 Nader, S, 773(ab)
 Nagahama, Y, 1992
 Nagai, R, 217
 Nagamachi, S, 1047(ab), 1057(ab)
 Nagamatsu, H, 744(ab), 818(ab)
 Nagano, AS, 1179(ab)
 Nagao, M, 1287(ab)
 Nagasaki, T, 865(ab)
 Nagasawa, M, 859(ab)
 Nagata, M, 779(ab)
 Nagata, S, 781(ab)
 Nagatani, Y, 1792
 Nagatsuka, S, 289(ab)
 Nagaya, N, 800(ab)
 Nagueh, SF, 1857
 Nahmias, C, 604(ab), 1666
 Nahum, AE, 161(ab)
 Naiman, JT, 228(ab), 412(ab)
 Nair, N, 256, 1366(ab)
 Naito, A, 847(ab)
 Naito, M, 859(ab)
 Nakabeppe, Y, 222(ab), 726(ab)
 Nakada, K, 88(ab), 89(ab), 527(ab), 963
 Nakagawa, M, 514(ab), 1091(ab), 1111(ab), 1203(ab), 1595, 1778, 2007
 Nakagawa, T, 239, 1971
 Nakahara, H, 1047(ab)
 Nakai, H, 1173(ab)
 Nakai, M, 1137(ab)
 Nakajima, K, 216(ab), 727(ab), 761(ab), 855(ab), 915(ab), 1644, 1874
 Nakajo, M, 222(ab), 726(ab)
 Nakamoto, Y, 479, 685, 1003(ab), 1097(ab), 1424, 1463
 Nakamura, A, 1179(ab)
 Nakamura, F, 1204(ab)
 Nakamura, H, 566, 942(ab), 1166(ab)
 Nakamura, K, 1021(ab), 1026(ab)
 Nakamura, M, 895
 Nakamura, S, 243(ab), 704(ab), 1441
 Nakamura, T, 514(ab), 713(ab), 1264
 Nakano, A, 704(ab)
 Nakano, T, 12(ab), 895, 1166(ab)
 Nakao, K, 782(ab)
 Nakashima, S, 865(ab)
 Nakata, J, 874(ab)
 Nakata, S, 1071(ab)
 Nakaya, J, 718(ab), 767(ab)
 Nakayama, H, 781(ab)
 Nakamura, T, 1178(ab), 1184(ab)
 Nam, SJ, 1102(ab)
 Namavarri, M, 102(ab), 585(ab)
 Namba, H, 289(ab)
 Nanasato, M, 728(ab)
 Nanto, S, 781(ab)
 Narayanan, MV, 456(ab), 1312(ab)
 Narayanan, TK, 1267(ab), 1338(ab)
 Narita, Y, 312(ab)
 Narula, J, 3(ab), 5(ab), 738(ab), 786(ab), 838(ab), 911
 Naruse, A, 1201(ab)
 Naruse, H, 780(ab)
 Natale, D, 339(ab)
 Natali, PG, 46
 Nathan, L, 32(ab)
 Nativ, O, 968, 1111
 Naumovski, L, 184
 Navarro, V, 1001(ab), 1008(ab)
 Nayak, N, 775(ab)
 Neal, VJ, 1293(ab)
 Nejmeddine, F, 40, 960(ab)
 Nekolla, S, 24(ab), 30(ab), 33(ab), 34(ab), 35(ab), 183(ab), 188(ab), 1824
 Nekolla, SG, 18(ab)
 Nel, MG, 1532
 Nelson, AD, 118, 886(ab)
 Nelson, CA, 321(ab), 417(ab), 887(ab), 950(ab), 954(ab)
 Nelson, DL, 268
 Neri, D, 434(ab)
 Netusil, N, 588(ab), 1285
 Neuhoff, AW, 1099(ab)
 Neumaier, B, 262(ab), 571(ab), 1388(ab), 1623
 Neumann, DR, 236(ab)
 Neumann, FJ, 24(ab)
 Neumann, RD, 565(ab), 1009(ab), 1547
 Nevere, J, 24(ab), 1311(ab), 1824
 Newling, DW, 667
 Newman, RD, 1405(ab)
 Ng, C, 1208(ab)
 Ng, CK, 353(ab)
 Ng, CS, 249(ab)
 Ngo, HK, 521(ab)
 Nguyen, C, 794(ab)
 Nguyen, K, 102(ab), 323(ab)
 Nguyen, KN, 131(ab)
 Nguyen, N, 34(ab), 828(ab)
 N'Guyen, T, 1305(ab)
 Nguyen, TV, 582(ab)
 Ngyuen, HQ, 1117(ab)
 Nibbering, PH, 2073
 Nichols, D, 22N(1), 25N(2), 28N(5)
 Nichols, K, 171(ab), 176(ab), 181(ab), 507(ab), 716(ab), 715(ab), 924, 1882
 Nichols, KJ, 650
 Nichols, TE, 2053
 Nicholson, RL, 1306(ab)
 Nickel, O, 925(ab)
 Nickerson, DS, 942
 Nickles, RJ, 187(ab), 437(ab), 503(ab), 1163(ab), 1169(ab)
 Nicodemus, CF, 40(ab), 57(ab)
 Nicolai, E, 194(ab), 1683
 Nicolini, J, 1080
 Nicolo, G, 1123(ab)
 Nielsen, TT, 1292
 Niesen, A, 1152(ab)
 Nieweg, OE, 70(ab), 262, 1119(ab)
 Niida, Y, 1818
 Niimura, K, 1985
 Niiro, Y, 1318(ab), 1328(ab), 1337(ab)
 Nikolov, G, 539(ab), 860(ab)
- Nikula, T, 433(ab)
 Nikula, TK, 166
 Nilsson, F, 434(ab)
 Nishiguchi, S, 1652
 Nishii, R, 1047(ab), 1057(ab)
 Nishikawa, J, 418
 Nishikawa, T, 1095(ab)
 Nishimura, H, 1160(ab), 1175(ab), 1190(ab)
 Nishimura, K, 1840
 Nishimura, S, 294(ab), 770(ab)
 Nishimura, T, 65(ab), 239, 384(ab), 566, 708(ab), 803(ab), 804(ab), 805(ab), 806(ab), 823(ab), 854, 1003, 1160(ab), 1166(ab), 1175(ab), 1190(ab), 1302(ab), 1693, 1884
 Nishimura, Y, 1424
 Nishio, M, 781(ab)
 Nishioka, A, 1101(ab)
 Nishiyama, Y, 198(ab), 875(ab)
 Nishizawa, S, 1273(ab), 1463, 1992
 Nitobe, J, 1999
 Nitzsche, EU, 340(ab), 423(ab), 1308(ab), 1309(ab)
 Noachtar, S, 737
 Noack, D, 936(ab)
 Nobezawa, S, 1088(ab), 1282(ab)
 Nobili, F, 522
 Nocaudie, M, 33
 Noda, A, 294(ab)
 Noël, M-H, 25
 Noelpp, UB, 1261(ab)
 Noguchi, J, 1342(ab), 1351(ab)
 Noguchi, S, 65(ab)
 Nohara, R, 7(ab), 471
 Nomura, Y, 12(ab), 895
 Nonokawa, M, 728(ab)
 Nonomura, A, 535(ab)
 Noorden, PJ, 272(ab)
 Noorduy, L, 1107(ab)
 Norenberg, JP, 322(ab), 415(ab)
 Nørgaard, MA, 290
 Normolle, DN, 77(ab)
 Nosotti, M, 1085(ab)
 Novak-Hofer, I, 326(ab)
 Novikov, I, 749(ab)
 Noz, ME, 1281(ab)
 Nozaki, S, 239
 Nozaki, Y, 14(ab)
 Nukata, M, 1190(ab)
 Numminen, P, 1330(ab)
 Núñez, RF, 912(ab), 1039(ab), 1044(ab)
 Nuss, R, 44(ab)
 Nüssle, K, 1623
 Nüsslin, F, 460(ab)
 Nutt, R, 306(ab), 597(ab)
 Nuutila, P, 862
 Nuvoli, S, 1105(ab)
 Nyuts, J, 19(ab), 822(ab), 899(ab)
 Oates, E, 913(ab)
 Oberdorfer, F, 1016(ab), 1032(ab)
 Obradovich, JE, 101(ab)
 O'Brien, TJ, 677, 1098
 Ochi, H, 858(ab), 1492, 1652
 O'Connell, JW, 1249(ab)
 O'Connor, MK, 677, 1098, 1259(ab)
 Oda, K, 317
 Odaka, K, 34 (ab), 35(ab), 183(ab)
 Odano, I, 1737
 O'Doherty, MJ, 425(ab), 1135(ab)
 O'Donnell, JK, 1138(ab)
 O'Donnell, RT, 159(ab), 963(ab), 965(ab), 969(ab), 980(ab), 1381(ab), 2014, 2102
 O'Donoghue, JA, 156(ab), 970(ab), 1337, 1764
 Oehme, L, 268(ab)
 Oehr, P, 78(ab)
 Oellerich, WE, 4(ab)
 Oelling, J, 387
 Oestmann, J, 48(ab)
 Ofiuoglu, S, 395(ab), 1081(ab)
 Ogasawara, T, 1132
 Ogawa, M, 1583
- Ogawa, Y, 1101(ab)
 Ogino, M, 471
 Oguchi, M, 86(ab), 1095(ab)
 Ogura, Y, 846(ab)
 Oh, CS, 1366(ab)
 Oh, JH, 852(ab)
 Oh, SH, 452(ab)
 Oh, SJ, 10(ab), 166(ab), 1359(ab)
 Ohana, G, 376
 Ohara, T, 781(ab)
 Ohira, H, 567(ab), 1022(ab)
 Ohkawa, M, 198(ab), 875(ab)
 Ohkubo, M, 1737
 Ohkubo, S, 812(ab)
 Ohmori, Y, 1590
 Ohno, M, 330(ab)
 Ohshima, H, 14(ab)
 Ohta, Y, 770(ab)
 Ohtake, H, 878(ab)
 Ohtake, T, 418, 793, 862(ab), 867(ab), 939(ab), 1116, 1284(ab)
 Ohtomo, K, 793, 862(ab), 867(ab), 939(ab), 1116, 1284(ab)
 Ohtsuki, K, 184, 814(ab), 2007
 Ohyama, N, 243(ab)
 Ohyanagi, M, 780(ab)
 Oka, H, 801(ab)
 Okada, H, 1088(ab), 1282(ab)
 Okada, K, 243(ab), 1137(ab)
 Okada, N, 64
 Okada, RD, 813(ab), 815(ab)
 Okada, T, 7(ab)
 Okada, Y, 713(ab)
 Okamoto, MY, 870(ab)
 Okamoto, S, 12(ab)
 Okauchi, T, 1342(ab), 1351(ab)
 Okawa, T, 744(ab), 818(ab)
 Okay, Y, 916(ab)
 Okazaki, A, 705(ab), 808(ab)
 Okazawa, H, 577(ab)
 Okeepe, JH, 1291(ab)
 O'Keefe, JH, 724(ab)
 Okpaku, AS, 274(ab), 453(ab)
 Oksman, Y, 63(ab)
 Oku, N, 1175(ab), 1190(ab), 1302(ab)
 Oku, S, 1284(ab)
 Okuda, K, 471
 Okumura, Y, 1971
 Okuyama, T, 569(ab)
 Olatidoye, AG, 702(ab)
 Old, LJ, 970(ab)
 Old, SE, 1093(ab)
 Oliner, CM, 1457(ab)
 Oliva, JP, 768
 Oliver, J, 971(ab)
 Ollinger, JM, 1236(ab)
 Olschewski, M, 220(ab)
 Olson, J, 331
 Olsson, H, 436(ab)
 Omata, M, 1116
 Omata, N, 1174(ab)
 Omiecinski, E, 1290(ab)
 Omote, H, 207(ab), 527(ab)
 Onder, M, 39(ab)
 Onfroy, M-C, 25
 Ong, GL, 1392
 Ongseng, F, 1144(ab)
 Onishi, T, 1192(ab)
 Ono, S, 244, 1057(ab)
 Ono, Y, 198(ab), 312(ab)
 Onoguchi, M, 705(ab)
 Önsel, Ç, 429
 Oomichi, M, 802(ab), 885(ab)
 Oosterwijk, E, 829
 Opitz, M, 48(ab)
 Oppermann, HC, 47(ab)
 Oquendo, M, 1210(ab), 1211(ab)
 Ordóñez, C, 1290(ab)
 Oriuchi, N, 399, 878(ab), 1005(ab), 1018(ab)
 Orringer, MB, 1089(ab)
 Osada, H, 802(ab), 877(ab), 885(ab), 1188(ab)

- Osaki, S, 825(ab)
 Osende, JI, 355(ab)
 Oshima, S, 217
 Osorio, L, 981(ab)
 Oster, ZH, 825(ab)
 Ota, K, 942(ab)
 Ota, T, 747(ab)
 Otsubo, H, 1183(ab)
 Otsuki, K, 514(ab)
 Ott, K, 550(ab)
 Ott, RJ, 1224(ab), 1232(ab)
 Ottaviani, M, 1374
 Otto, AC, 1532
 Otto, HJ, 754(ab)
 Ouchi, N, 1022(ab)
 Ouchi, Y, 1088(ab), 1282(ab)
 Ouellet, R, 832(ab), 1728
 Owen, AN, 1457(ab)
 Owens, R, 1329(ab)
 Oya, S, 1345(ab)
 Oyama, N, 1137(ab)
 Oyen, WJ, 58(ab), 192, 432(ab), 892(ab), 1028(ab), 2066
 Oz, OK, 896(ab)
 Ozaki, T, 289(ab)
 Ozalp, E, 524(ab), 919(ab), 1046(ab)
 Ozawa, S, 13(ab), 745(ab)
 Ozker, KS, 1369(ab)
 Paans, AM, 300(ab), 755(ab)
 Pace, WM, 559(ab)
 Pacini, F, 1716
 Padhy, AK, 904(ab)
 Paganelli, G, 72(ab), 235(ab), 266(ab), 1125(ab)
 Pagini, E, 459(ab)
 Pahl, MM, 916(ab)
 Pai, MS, 756(ab), 1055(ab), 1094(ab)
 Paik, CH, 268, 327(ab), 837, 1006(ab), 1027(ab), 1381
 Paik, DS, 327(ab), 837
 Pak, I, 524(ab), 919(ab)
 Pak, KY, 815(ab), 838(ab), 1832
 Palestro, CJ, 43(ab), 57(ab), 201(ab), 478(ab), 930(ab), 961(ab), 1404(ab)
 Pallela, V, 485(ab), 1080(ab)
 Pallela, VR, 352, 491(ab), 1398(ab)
 Palmas, W, 181(ab)
 Palmedo, H, 974(ab), 988(ab)
 Palmer, AW, 85
 Palmer, J, 96, 224(ab)
 Palombo-Kinne, E, 537(ab)
 Pan, D, 332(ab)
 Pan, S, 427(ab)
 Pan, T-S, 456
 Pan, X, 1334(ab)
 Panet, R, 1037(ab)
 Panin, VY, 1296(ab)
 Pansini, F, 538(ab)
 Pantelic, MV, 1140(ab)
 Panyutin, IG, 1009(ab), 1405(ab)
 Papatheofanis, FJ, 750(ab), 1121(ab), 1256(ab), 1420
 Papay, FA, 236(ab)
 Papazian, V, 144(ab)
 Pappas, N, 439(ab), 1215(ab)
 Pappas, NR, 145(ab), 442(ab), 443(ab), 588(ab), 715, 1176(ab), 1217(ab), 1218(ab), 1285
 Papperl, G, 1048(ab)
 Paracchi, A, 1928
 Parbhoo, SP, 68(ab), 1038(ab)
 Pare, C, 1305(ab)
 Parellada, E, 123(ab)
 Parent, F, 173(ab)
 Park, CH, 756(ab), 1055(ab), 1094(ab)
 Park, CM, 549(ab)
 Park, JM, 49(ab), 380(ab), 751(ab), 851(ab), 884(ab), 1102(ab)
 Park, JY, 1086(ab)
 Park, KM, 214(ab)
 Park, KO, 549(ab)
 Park, KS, 452(ab), 476(ab), 505(ab), 1171(ab), 1198(ab), 1214(ab), 1221(ab)
 Park, KY, 10(ab)
 Park, MH, 586(ab)
 Park, SJ, 166(ab), 1359(ab)
 Park, SW, 166(ab), 1359(ab)
 Park, SY, 1128(ab)
 Park, YH, 376(ab)
 Park, YS, 205(ab)
 Parker, A, 574
 Parker, JA, 483(ab), 714(ab)
 Parker, MA, 509(ab)
 Parkhouse, HF, 643
 Parkman, HP, 366(ab), 854(ab)
 Parma, D, 357(ab)
 Parmeshwar, P, 1191(ab)
 Parry-Jones, DR, 249(ab), 1093(ab)
 Parsey, RV, 114(ab), 117(ab), 1162(ab), 1210(ab)
 Pasqualini, R, 883
 Pasque, MK, 4(ab)
 Pasquier, F, 956
 Passchier, J, 116(ab), 1167(ab)
 Passeri, A, 1310(ab)
 Pastan, I, 1381
 Patel, M, 625, 2107
 Patel, S, 1392
 Patel, SJ, 971(ab), 1454(ab)
 Patelas, G, 660
 Patt, BE, 599(ab)
 Patterson, J, 747
 Patton, DD, 18N(4), 24N(7), 25N(11)
 Patton, JA, 110, 432, 1295(ab)
 Pattyn, P, 783
 Paul, AK, 805(ab), 1693
 Pauli, S, 1157(ab)
 Pauls, S, 422(ab)
 Paulus, W, 1064(ab)
 Paulusma-Annema, A, 2073
 Pauwels, E, 180(ab)
 Pauwels, EKJ, 740(ab), 2073
 Pauwels, S, 253(ab), 1013(ab), 1109(ab)
 Pavel, DG, 1268(ab)
 Pavia, J, 123(ab)
 Pavlinkova, G, 1536
 Pavlinovic, Z, 531(ab), 937(ab)
 Pay, L, 768(ab)
 Payne, JK, 449(ab)
 Paz, A, 376
 Pearson, DA, 321(ab), 417(ab), 887(ab), 950(ab)
 Pecking, AP, 546(ab)
 Pedarsani, M, 1164
 Peeters, M, 1451
 Pegoix, M, 901(ab), 905(ab)
 Peker, C, 893(ab)
 Peker, MC, 369(ab), 1602
 Pelegrenelli, LR, 848(ab)
 Pelikan, H, 180(ab)
 Pelizzetti, CA, 347
 Pellegrini, M, 196(ab)
 Peller, M, 290(ab)
 Peller, PJ, 1126(ab), 1233
 Pellot-Barakat, CJ, 1264(ab)
 Peng, NJ, 60, 367(ab), 1050(ab)
 Pennell, DJ, 343(ab), 344(ab)
 Penney, BC, 456, 1334(ab)
 Pentlow, KS, 328(ab), 1238(ab)
 Penuelas, I, 845(ab), 1096(ab), 1145(ab), 1401(ab)
 Pereira, PL, 956(ab)
 Perek, B, 19(ab)
 Perentesis, P, 268
 Perera, A, 768
 Peressini, A, 1123(ab)
 Pérez, R, 768
 Pérez, V, 1212(ab)
 Perkins, AC, 365(ab), 399(ab)
 Perlman, SB, 1180(ab)
 Permanetter, B, 188(ab)
 Perrine, K, 1184(ab)
 Perrot, JL, 80(ab)
 Peschl, S, 340(ab), 591(ab), 1308(ab)
 Peter, J, 1260(ab)
 Peterdy, AE, 422
 Peters, GN, 237(ab)
 Peterson, LM, 614, 1074(ab)
 Pethig, K, 719(ab)
 Petit-Taboué, M-C, 25
 Petretta, M, 194(ab), 1683
 Petric, A, 284(ab)
 Petrov, A, 838(ab)
 Petterson, G, 290
 Pettigrew, RI, 650, 753(ab)
 Pezzoli, G, 271(ab)
 Pham, HL, 1080(ab), 1363(ab)
 Phelps, ME, 20(ab), 184(ab), 186(ab), 189(ab), 225(ab), 226(ab), 227(ab), 281(ab), 283(ab), 284(ab), 285(ab), 295(ab), 323(ab), 332(ab), 408(ab), 826(ab), 1045, 1083(ab), 1468(ab), 1164
 Philip, PA, 1079(ab)
 Phillips, KE, 329(ab)
 Phillips, PC, 520(ab)
 Pi, B, 1225(ab)
 Picardi, V, 556(ab)
 Piccolo, S, 66(ab), 1142(ab)
 Pichler, BJ, 1234(ab)
 Pidcock, J, 1162(ab), 1242(ab)
 Piel, M, 1222(ab)
 Piepsz, A, 52, 210(ab), 972
 Pierantoni, M, 1716
 Piers, DA, 70(ab), 393(ab), 398(ab), 1119(ab), 1146(ab)
 Pieterman, RM, 116(ab), 351(ab), 561(ab)
 Piffanelli, A, 167(ab), 302(ab), 778(ab), 1168(ab), 1382(ab), 1556
 Pikul, R, 1182(ab)
 Pillai, M, 1015(ab), 1402(ab)
 Pimentel, G, 768
 Pinchera, A, 1716
 Pinheiro, VR, 958(ab)
 Pinkert, J, 268(ab)
 Pinot, L, 602(ab)
 Pinson, CW, 1784
 Pio, BS, 1083(ab)
 Pippin, CG, 166
 Pirich, C, 1277, 1499
 Pitts, J, 455(ab)
 Piwnica-Worms, DR, 316(ab), 1024(ab)
 Pizzocaro, C, 375(ab)
 Plaat, BE, 381, 398(ab), 1146(ab)
 Plaizier, MA, 966(ab)
 Plascjak, PS, 329(ab), 472(ab)
 Plössl, K, 108(ab), 150, 152(ab), 583(ab), 660, 1200(ab), 1345(ab), 1812
 Plotkin, M, 1041(ab)
 Plouin, P, 786
 Pocock, N, 250(ab), 544(ab), 1153(ab)
 Podda, M, 1085(ab)
 Podoloff, DA, 160(ab), 404(ab), 955(ab), 1206(ab), 1366(ab), 1367(ab), 1467(ab)
 Pointon, BW, 1461(ab)
 Pointurier, I, 173(ab), 743(ab)
 Poirier, C, 821(ab)
 Polak, E, 311(ab)
 Polastri, L, 1053(ab)
 Poldermans, D, 1(ab), 1866
 Poldermans, D, 731(ab)
 Poletti, E, 843(ab)
 Pollak, A, 331(ab), 497(ab), 499(ab), 504(ab), 614(ab), 1346(ab)
 Pollock, CM, 497(ab), 499(ab)
 Polyakov, VR, 316(ab)
 Ponath, C, 988(ab)
 Pongratz, D, 853(ab)
 Pons-Llado, G, 3(ab)
 Ponto, JA, 613(ab)
 Ponto, R, 287(ab)
 Pontvianne, V, 513
 Popa, N, 1333(ab), 1978
 Popilskis, S, 117(ab)
 Popov, V, 468(ab), 600(ab)
 Porenta, G, 362(ab)
 Porrino, L, 1346(ab)
 Potaux, L, 412
- Potier, JC, 8(ab), 175(ab)
 Potter, R, 883(ab)
 Potts, N, 836(ab)
 Potts, NV, 824(ab), 842(ab)
 Pötzl, C, 1049(ab)
 Pouillart, F, 224, 917
 Pounds, TR, 255(ab)
 Pourdehnad, M, 387(ab), 453(ab), 888(ab)
 Powsner, RA, 1453(ab)
 Prakesh, K, 279(ab)
 Prat, T, 734(ab)
 Prato, FS, 1306(ab)
 Prats, E, 296
 Pratt, JP, 200(ab), 296(ab), 314(ab), 797(ab), 1165(ab)
 Predic, P, 1067(ab)
 Press, O, 75(ab)
 Pressler, H, 871(ab)
 Pretorius, PH, 456(ab), 590(ab)
 Prevost, R, 192
 Price, DC, 935(ab), 1248(ab)
 Price, JC, 1798, 2053
 Price, MR, 399(ab)
 Prieto, J, 845(ab), 1401(ab)
 Prigent, A, 743(ab)
 Prillwitz, A, 528(ab)
 Prince, S, 1245(ab)
 Printz, D, 121(ab)
 Provost, N, 1124(ab)
 Pruckmayer, M, 1477
 Prueter, I, 944(ab)
 Pruijm, J, 116(ab), 262, 561(ab), 1132(ab)
 Prunier-Levillon, C, 1393(ab)
 Pruzzo, R, 59(ab)
 Pryor, M, 983(ab)
 Pugliese, PV, 478(ab)
 Puig, M, 5(ab)
 Puigdemont, D, 1212(ab)
 Pullman, J, 484
 Pupi, A, 196(ab), 573(ab)
 Pyatt, B, 406(ab)
 Pyatt, BE, 438(ab)
 Pyzalski, RW, 1180(ab)
 Qaim, SM, 501(ab)
 Qi, J, 129(ab), 130(ab), 2043
 Qiao, J, 1386(ab)
 Qu, T, 900(ab), 1397(ab)
 Quach, T, 250(ab), 544(ab), 1153(ab)
 Quaife, RA, 169(ab), 177(ab)
 Quak, JJ, 263(ab)
 Quarantelli, M, 442
 Que, TH, 561(ab), 1132(ab)
 Quereshi, E, 171(ab), 176(ab), 181(ab)
 Quesada, R, 347(ab)
 Quinn, TP, 484(ab)
 Quint, LE, 1089(ab)
 Quintana, JC, 394(ab), 1268(ab), 1276(ab)
 Quirijnen, JM, 639
 R, 6(ab), 970(ab)
 Raab, D, 925(ab)
 Rabitti, C, 926(ab)
 Rabøl, A, 290
 Radau, P, 570(ab)
 Radauer, M, 1277
 Raderer, M, 395(ab), 1081(ab), 1082(ab)
 Raedler, TJ, 1348(ab)
 Rafecas, M, 1234(ab)
 Raffel, DM, 232, 323
 Raffelt, K, 973(ab)
 Rafique, I, 215(ab)
 Rai, A, 548(ab)
 Raja, S, 279(ab)
 Rajeevan, N, 124(ab), 143(ab), 1902
 Rajotte, D, 883
 Rakowski, H, 776(ab)
 Ramirez, C, 427(ab)

- Ramos, CD, 746(ab), 848(ab), 958(ab), 1148(ab)
 Ramos, D, 911(ab)
 Ramos-Suzarte, M, 768
 Ransley, PG, 643
 Ranzi, T, 1630
 Rao, DV, 978(ab)
 Rao, PS, 485(ab), 491(ab), 1398(ab)
 Raphael, M, 40, 960(ab)
 Rappoport, V, 1244(ab)
 Rasey, JS, 100(ab), 1072
 Raspe, J, 398(ab), 1146(ab)
 Rattan, S, 352
 Rau, F, 85(ab)
 Raubitschek, A, 260(ab), 268
 Raubitschek, AA, 323(ab), 325(ab), 1151
 Rauch, SL, 579(ab)
 Raue, F, 1029
 Rauth, AM, 331(ab), 1019(ab)
 Raval, U, 464
 Ravert, HT, 115(ab), 373(ab), 446(ab), 447(ab), 1014(ab), 1180, 1164(ab), 1207(ab)
 Raviv, U, 860(ab)
 Ravizzini, G, 26(ab)
 Raylman, RR, 468(ab), 600(ab)
 Razola, P, 296
 Reader, AJ, 1224(ab), 1232(ab)
 Recker, BE, 1089(ab), 1125
 Redvanly, RD, 92(ab)
 Reed, JH, 306(ab)
 Reed, MW, 1405(ab)
 Regan, D, 990(ab)
 Regan, DD, 77(ab), 989(ab)
 Reichart, B, 30(ab)
 Reidl, G, 397(ab)
 Reilly, RM, 1370(ab)
 Reiman, E, 717(ab), 1304(ab)
 Reimold, M, 460(ab), 1289(ab)
 Reinauer, H, 977
 Reinhard, P, 389(ab)
 Reinhardt, M, 247(ab), 977
 Reinhardt, MJ, 340(ab), 423(ab)
 Reischl, G, 933(ab)
 Reising, A, 981(ab)
 Reist, CJ, 631
 Remacle, M, 253(ab)
 Rempel, TD, 1245(ab)
 Reneman, L, 113(ab), 1216(ab)
 Renlund, M, 12
 Rentschler, M, 1623
 Reschini, E, 271(ab), 1928
 Reske, SN, 82(ab), 93(ab), 247(ab), 250, 262(ab), 341(ab), 368(ab), 422(ab), 571(ab), 945(ab), 1272(ab), 1388(ab), 1407, 1623, 1637
 Reubi, J-C, 2081
 Reuning, U, 1061
 Reutter, BW, 457(ab)
 Revel, D, 821(ab)
 Reyes, J, 850(ab)
 Reynolds, C, 1117(ab)
 Reynolds, JC, 268, 539
 Rhee, CH, 1066(ab)
 Rhodes, BA, 2107
 Rhodes, CG, 507, 834(ab)
 Ribic, CM, 497(ab)
 Ricard, M, 157(ab), 602(ab), 1517
 Ricaurte, GA, 115(ab)
 Riccabona, G, 74(ab)
 Rice, KC, 1348(ab)
 Richman, CM, 969(ab)
 Richter, E, 540(ab), 605(ab), 730(ab), 921(ab), 944(ab)
 Richter, JA, 424(ab), 555(ab), 845(ab), 1096(ab), 1145(ab), 1401(ab)
 Richter, T, 85(ab)
 Richter, WS, 195(ab), 795(ab), 840(ab)
 Riecke, J, 387
 Rickert, C, 1064(ab)
 Rickford, MS, 329(ab)
 Riddell, CA, 1297(ab)
 Riemann, B, 1017(ab), 1064(ab)
 Ries, V, 571(ab)
 Riggert, J, 992(ab)
 Righini, A, 271(ab)
 Rigo, P, 359(ab)
 Rijks, LJ, 1107(ab)
 Rijk-van Andel, JF, 272(ab)
 Rimoldi, O, 1848
 Ringelstein, EB, 1017(ab)
 Rini, J, 1044(ab)
 Rini, JN, 912(ab)
 Rinne, NA, 36(ab)
 Ripke, B, 268(ab)
 Risdon, RA, 643
 Risso, J, 974(ab), 988(ab)
 Ritter, EP, 752(ab)
 Roach, PJ, 924(ab)
 Roarke, MC, 525(ab)
 Robb, RA, 677, 1098
 Robbins, RJ, 1042(ab), 1044(ab)
 Roberts, AD, 437(ab), 503(ab)
 Roberts, DW, 278(ab)
 Robertson, A, 144(ab)
 Robidoux, A, 1124(ab)
 Robillard, P, 2029
 Robins, PD, 1259(ab)
 Robinson, BG, 924(ab)
 Rocchisani, J, 1305(ab)
 Rockey, DC, 502(ab)
 Roddy, R, 597(ab)
 Rodenheiser, J, 121(ab), 1210(ab)
 Rodriguez, S, 832(ab), 876
 Rodrigues, CJ, 870(ab)
 Rodriguez, G, 522
 Rodriguez, N, 768
 Rodriguez, T, 768
 Roe, DG, 497(ab), 499(ab), 1346(ab)
 Roelants, V, 219(ab), 766(ab), 792(ab)
 Rogers, JS, 548(ab)
 Rogers, WL, 133(ab)
 Rohmer, V, 1252
 Rojas, A, 59(ab)
 Rojter, S, 427(ab)
 Roland, PS, 449(ab)
 Romano, JE, 492(ab)
 Rombaut, E, 766(ab), 792(ab)
 Römer, W, 247(ab), 737
 Rommelfanger, SG, 76(ab), 77(ab), 989(ab), 991(ab)
 Roos, A, 180(ab)
 Roos, JC, 263(ab), 966(ab)
 Rosa, P, 577(ab)
 Rosai, J, 1042(ab)
 Rösch, F, 1222(ab)
 Rose, DM, 1784
 Rose, GE, 455(ab)
 Rose, P, 232
 Rosen, G, 84(ab)
 Rosen, SD, 507
 Rosenthal, DI, 1054(ab)
 Ross, SG, 459(ab)
 Rossettin, PF, 1832
 Rossini, PL, 172(ab), 178(ab), 375(ab)
 Rossleigh, MA, 54(ab), 55(ab), 1805
 Rossman, MD, 888(ab)
 Rosso, J, 223(ab)
 Rosso, L, 1085(ab)
 Rotenberg, G, 63(ab)
 Roth, D, 377(ab)
 Rothman, RB, 441(ab)
 Rotman, M, 268
 Roussakis, G, 343(ab), 344(ab)
 Rousseau, JA, 1728
 Rousseaux, M, 721
 Rouvier, E, 1002(ab)
 Rovai, D, 363
 Roveri, R, 1168(ab), 1556
 Roy, L, 16N(4)
 Royal, HD, 1236
 Royen, EA, 111(ab)
 Rozanski, A, 171(ab), 176(ab), 181(ab), 507(ab), 715(ab), 716(ab), 924
 Ruan, S, 156(ab)
 Rubenstein, W, 850(ab)
 Rubinov, R, 265(ab)
 Rubins, DJ, 1156(ab)
 Rückert, RI, 795(ab)
 Ruddy, TD, 732(ab)
 Rudolph, F, 528(ab), 558(ab)
 Ruechel, R, 907(ab)
 Ruhmann, J, 78(ab)
 Ruiz, M, 142, 821
 Runge, R, 1385(ab)
 Ruotsalainen, U, 12, 862, 1330(ab)
 Rupcic, V, 739(ab)
 Rusckowski, M, 484, 900(ab), 1397(ab)
 Rushman, RW, 536(ab)
 Rusic, AM, 739(ab)
 Russell, CD, 1122
 Russo, JE, 1089(ab)
 Rutecki, P, 1180(ab)
 Rutgeerts, P, 1451
 Rutgers, E, 70(ab)
 Rutgers, EJ, 1119(ab)
 Rüth, F, 1702
 Ruth, TJ, 283
 Rutkowski, JV, 321(ab), 417(ab), 887(ab), 950(ab), 954(ab)
 Rypins, EB, 62(ab)
 Ryu, JS, 214(ab), 534(ab), 547(ab), 568(ab), 1090(ab)
 Sabahi, R, 856(ab)
 Saboorian, H, 237(ab)
 Sabri, O, 450(ab)
 Sadato, N, 91(ab), 243(ab), 317, 1000(ab), 1034(ab), 1085, 1132, 1137(ab), 1174(ab), 1332(ab), 1441
 Sadek, A, 520(ab)
 Sadek, S, 84(ab)
 Sadler, LL, 1268(ab)
 Saeed, S, 1080(ab), 1363(ab)
 Saffer, J, 108(ab), 1812
 Saffer, JR, 660
 Safi, N, 1092(ab), 1127(ab)
 Saga, T, 191(ab), 512(ab), 685, 1003(ab), 1463
 Saha, GB, 279(ab)
 Sahin, M, 864(ab)
 Saidi, L, 173(ab), 411(ab), 743(ab)
 Sai-Maurel, C, 198
 Saito, K, 12(ab), 569(ab)
 Saito, M, 493(ab)
 Saito, Y, 895
 Saitta, B, 1053(ab)
 Sajii, H, 493(ab), 1371(ab), 1406(ab)
 Sakahara, H, 479, 685, 1003(ab), 1097(ab), 1371(ab), 1424, 1463
 Sakai, E, 426(ab), 1072(ab)
 Sakaki, T, 780(ab)
 Sakanoue, Y, 1492
 Sakata, K, 6
 Sako, K, 1173(ab)
 Sakomura, Y, 744(ab)
 Sakurai, M, 14(ab)
 Salako, Q, 302
 Salamon, E, 882(ab)
 Salditt, S, 1036(ab)
 Salegh-Mghir, A, 893(ab)
 Salem, S, 84(ab), 889(ab)
 Salensky, H, 716(ab)
 Salgam, M, 319(ab)
 Salgueiro, MJ, 1080
 Salib, A, 428(ab)
 Salisbury, SM, 613(ab)
 Saller, B, 923(ab)
 Saloum, A, 518(ab)
 Salvatore, M, 194(ab), 442
 Salzer-Muhar, U, 1477
 Samii, A, 283
 Sampalis, FS, 1103(ab)
 Sampalis, JS, 1103(ab)
 Samson, Y, 935
 Samuel, G, 1015(ab)
 San Pedro, EC, 1181(ab)
 Sanacora, G, 576(ab)
 Sanchez, JE, 799
 Sanchez, P, 768(ab)
 Sandberg, K, 373(ab)
 Sandell, J, 151(ab), 1343(ab)
- Sandhu, J, 1370(ab)
 Sandler, MP, 9N(1), 110, 1295(ab)
 Sando, Y, 878(ab)
 Sandrock, D, 795(ab), 920(ab), 936(ab), 948(ab)
 Sanger, JJ, 62(ab)
 Sansana, CR, 746(ab), 848(ab)
 Santambrogio, L, 1085(ab)
 Santana, CA, 315(ab), 508(ab), 511(ab), 787(ab), 1290(ab)
 Santens, P, 269(ab)
 Santiago, J, 84(ab)
 Santiago, JF, 889(ab)
 Santjohanser, C, 82(ab)
 Santoro, GM, 196(ab), 363
 Santos, AO, 746(ab), 848(ab), 958(ab)
 Saperstein, LA, 228(ab)
 Sapienza, MT, 916(ab)
 Saran, PA, 1089(ab), 1099(ab)
 Sarda, L, 701(ab), 794(ab), 809(ab), 893(ab), 903(ab)
 Sarkar, MR, 1637
 Sarkar, SD, 43(ab), 930(ab), 961(ab)
 Sarkis, M, 517(ab)
 Sarma, HD, 1015(ab), 1402(ab)
 Sartor, J, 974(ab)
 Sasaki, H, 70
 Sasaki, M, 1091(ab), 1111(ab), 1203(ab), 1595, 1778
 Sasaki, N, 858(ab), 1652
 Sasaki, T, 1056
 Sasaki, Y, 418, 1005(ab), 1116
 Sasayama, S, 7(ab), 471
 Sassaman, MB, 150(ab)
 Sassolas, G, 369(ab)
 Sasson, Y, 1213(ab)
 Sato, J, 211(ab), 212(ab), 747(ab), 855(ab), 1173(ab)
 Sato, K, 244, 317
 Sato, M, 244
 Sato, N, 479, 685, 1003(ab), 1463
 Sato, S, 1971
 Sato, T, 137
 Satoh, A, 371
 Satoh, H, 371
 Satomi, S, 1022(ab)
 Sattler, B, 570(ab)
 Satyamurthy, N, 102(ab), 142(ab), 332(ab), 585(ab), 587(ab)
 Satyamurthy, NM, 284(ab)
 Sau, J, 1676
 Saunders, C, 560(ab), 1116(ab)
 Sauret, V, 2094
 Sautter-Bihl, ML, 248(ab), 1059(ab)
 Savi, A, 1617
 Sawula, JA, 46(ab)
 Saxena, P, 1268(ab)
 Saxena, S, 283(ab)
 Sayman, HB, 429
 Sbrenna, S, 1168(ab), 1556
 Scardigno, R, 1329(ab)
 Schaar, M, 320(ab), 414(ab)
 Schäfer, J, 1272(ab)
 Schäfer, W, 830(ab)
 Schäfers, K, I, 185(ab), 834(ab)
 Schäfers, M, I
 Schäfers, MA, 185(ab), 834(ab)
 Schaffland, A, 1913
 Schaffrinski, M, 907(ab)
 Schaub, J, 47(ab)
 Scheff, AM, 1117(ab), 1143
 Scheffel, U, 115(ab), 318(ab), 1180
 Scheidhauer, K, 403(ab)
 Scheinberg, DA, 163(ab), 166, 431(ab), 1722, 1935
 Scheithauer, S, 1384(ab)
 Schelbert, HR, 20(ab), 32(ab), 184(ab), 186(ab), 189(ab), 295(ab), 826(ab), 1045
 Scherbaum, N, 1217(ab)
 Scherer, J, 126(ab)
 Scherrer-Crosbie, M, 193(ab)
 Scheurs, MW, 1028(ab)

- Schibli, R, 1913
 Schicha, H, 202(ab), 403(ab), 791(ab), 830(ab), 932(ab), 973(ab), 1036(ab), 1372(ab)
 Schiepers, C, 225(ab), 226(ab), 408(ab)
 Schillaci, O, 556(ab), 843(ab)
 Schima, W, 1082(ab)
 Schirmacher, A, 1017(ab)
 Schirmeister, H, 82(ab), 93(ab), 571(ab), 945(ab), 1623
 Schlemmer, M, 1477
 Schlosser, R, 125(ab)
 Schloter, B, 1041(ab)
 Schmaljohann, J, 1049(ab), 1347(ab)
 Schmand, M, 306(ab)
 Schmickler, H, 1372(ab)
 Schmidt, G, 904
 Schmidt, M, 320(ab), 2081
 Schmidt, MA, 993(ab), 996(ab), 997(ab)
 Schmidt, PG, 357(ab), 402(ab)
 Schneider, CA, 791(ab)
 Schneider, CM, 774(ab)
 Schneider, D, 121(ab), 122(ab)
 Schneider, JS, 1200(ab)
 Schneider, K, 254(ab)
 Schneider, ML, 437(ab)
 Schneider, P, 590(ab)
 Schneider, PW, 287(ab)
 Schneier, F, 581(ab)
 Schober, O, 1, 185(ab), 388(ab), 392(ab), 834(ab), 1017(ab), 1064(ab)
 Schröder, H, 32(ab), 186(ab), 189(ab)
 Schoenberger, JA, 1154(ab)
 Schoeneck, G, 974(ab)
 Schomaecker, K, 403(ab), 1036(ab), 1372(ab)
 Schomaecker, K, 830(ab)
 Schömöig, A, 24(ab), 34(ab)
 Schottler, T, 372(ab)
 Schoutens, A, 1978
 Schoutens, AC, 1333(ab)
 Schramm, M, 282(ab)
 Schreck, CE, 458(ab)
 Schreckenberger, M, 450(ab)
 Schretter, D, 441(ab)
 Schricke, U, 24(ab)
 Schrobabilgen, GJ, 604(ab)
 Schroeder, E, 766(ab)
 Schryvers, F, 766(ab), 792(ab)
 Schubiger, PA, 326(ab), 399(ab), 1913
 Schueller, MJ, 437(ab), 503(ab)
 Schuemichen, C, 528(ab), 558(ab)
 Schuetz, C, 448(ab)
 Schuhmacher, C, 433(ab)
 Schul, C, 1064(ab)
 Schulte, M, 1637
 Schulzer, M, 283
 Schurrer, ME, 1434
 Schweiger, M, 18(ab), 24(ab), 30(ab), 33(ab), 34(ab), 35(ab), 85(ab), 104(ab), 183(ab), 188(ab), 205, 247(ab), 291(ab), 397(ab), 433(ab), 448(ab), 451(ab), 550(ab), 593(ab), 828(ab), 904, 1061, 1234(ab), 1311(ab), 1367, 1499, 1771, 1824
 Schwameis, E, 1277
 Schwartz, A, 63(ab)
 Schwarz, J, 571(ab)
 Schwarz, M, 422(ab)
 Schwarz, UP, 329(ab)
 Schweizer, HP, 871(ab)
 Schwenzner, K, 1048(ab)
 Sciacca, R, 29(ab), 720(ab), 911(ab)
 Sciagrà, R, 196(ab), 363, 573(ab)
 Scioti, RM, 898(ab)
 Sciuk, J, 388(ab), 392(ab)
 Scitio, R, 46
 Scopinaro, F, 556(ab), 843(ab)
 Scopinaro, G, 926(ab)
 Scott, AM, 328(ab)
 Seabold, JE, 613(ab), 1226, 1434
 Seaton, D, 758(ab)
 Sébahoun, S, 910(ab)
 Sedagathian, MR, 861(ab)
 Sedelnikova, OA, 1009(ab)
 Sedvall, G, 120(ab), 1157(ab)
 Seemann, A, 374(ab)
 Segall, GM, 252(ab), 255(ab), 545(ab), 1358
 Seibyl, J, 480(ab), 730
 Seibyl, JP, 124(ab), 143(ab), 107(ab), 270(ab), 275(ab), 444(ab), 576(ab), 580(ab), 1199(ab), 1228(ab), 1270(ab), 1362(ab), 1902
 Seidel, J, 1321(ab)
 Seidenberg, M, 1180(ab)
 Seifert, B, 79(ab)
 Seike, Y, 1175(ab), 1190(ab), 1302(ab)
 Seitz, U, 262(ab), 1388(ab)
 Seki, H, 86(ab), 1095(ab)
 Seki, M, 137
 Sekimoto, T, 1590
 Seldin, DW, 590(ab)
 Seltzer, M, 226(ab)
 Seltzer, MA, 130(ab), 225(ab), 408(ab), 2043
 Selzer, E, 985(ab), 1376(ab)
 Semah, F, 903(ab), 935
 Semprebene, A, 46
 Sen Gupta, S, 897(ab), 952(ab)
 Senda, K, 847(ab)
 Senda, M, 317, 808(ab), 1056, 1269(ab), 205, 433(ab), 1061, 1367, 1702
 Sengupta, S, 282(ab)
 Senior, R, 464
 Senitko, M, 258(ab)
 Senma, J, 191(ab)
 Seo, IS, 844(ab)
 Seo, JD, 736(ab)
 Seo, JG, 1141(ab)
 Seregni, E, 1114(ab)
 Seret, A, 1978
 Seret, AE, 1333(ab)
 Serita, T, 371
 Serra-Grima, R, 734(ab), 786(ab)
 Serrano, J, 539
 Sestini, S, 196(ab), 363, 573(ab)
 Seto, H, 1138
 Seto, M, 371
 Severiche, FA, 958(ab)
 Sevigny, SA, 406
 Seymour, KM, 1400(ab)
 Sfakianakis, G, 574
 Sfakianakis, GN, 204(ab), 206(ab), 208(ab), 377(ab), 768(ab), 799
 Sgouros, G, 105(ab), 158(ab), 159(ab), 162(ab), 163(ab), 164(ab), 1380(ab), 1935, 2102
 Shaban, N, 956(ab)
 Shah, KS, 304(ab)
 Shahinian, A, 103(ab)
 Shahzad, K, 215(ab), 716(ab)
 Shai, E, 1295(ab)
 Shaker, R, 279(ab)
 Shalab-Rana, EI, 523(ab)
 Shankar, LK, 199(ab), 526(ab)
 Shanley, TJ, 69(ab)
 Shao, L, 481(ab)
 Shao, Y, 303(ab), 304(ab), 599(ab), 1164
 Shapiro, B, 554, 1292(ab), 1457(ab)
 Sharir, T, 6(ab), 25(ab), 28(ab)
 Sharkey, RM, 428(ab), 500(ab), 992(ab), 1002(ab), 1380(ab), 1609
 Sharma, A, 924
 Sharma, R, 287(ab)
 Sharma, SD, 485(ab)
 Sharp, PF, 552(ab)
 Sharp, TL, 824(ab), 836(ab), 842(ab)
 Shaw, L, 27(ab)
 Shaw, LJ, 347(ab), 710(ab), 722(ab)
 Shaw, LK, 26(ab)
 Sheerin, A, 603(ab)
 Sheerin, AA, 500(ab)
 Sheikh, A, 970(ab), 1044(ab)
 Sheikh, MA, 711(ab)
 Shelton, DK, 1264(ab)
 Shelton, SE, 437(ab), 1169(ab)
 Shen, C, 592(ab), 1985
 Shen, S, 159(ab), 302, 965(ab), 969(ab), 980(ab), 1317, 2014, 2102
 Shepherd, J, 231(ab)
 Shepherd, JE, 227(ab)
 Sher, L, 427(ab)
 Sherman, AL, 199(ab)
 Shevlak, G, 1303(ab)
 Shi, B, 1267(ab), 1338(ab)
 Shi, R, 491(ab)
 Shi, XB, 324(ab)
 Shi, Y, 485(ab)
 Shiba, E, 65(ab), 1003
 Shiba, T, 1057(ab)
 Shibasaki, T, 399
 Shibuya, H, 64
 Shields, AF, 101(ab), 245(ab), 335(ab), 614, 1079(ab)
 Shiga, T, 527(ab), 963, 1204(ab), 1247(ab)
 Shih, LB, 500(ab)
 Shim, YM, 1076(ab)
 Shim, YS, 1051(ab), 1151(ab)
 Shimada, I, 770(ab)
 Shimizu, H, 895
 Shimizu, M, 1138
 Shimizu, Y, 802(ab), 877(ab), 885(ab), 1188(ab)
 Shimono, T, 1273(ab)
 Shin, EK, 10(ab)
 Shin, JW, 166(ab), 214(ab)
 Shin, MJ, 534(ab)
 Shin, SA, 819(ab)
 Shin, SK, 166(ab)
 Shin, A, 114(ab)
 Shin, AK, 1242(ab)
 Shinohara, H, 1318(ab), 1328(ab), 1337(ab)
 Shinotsuka, T, 1131(ab)
 Shinozaki, T, 390(ab)
 Shio, H, 1992
 Shiomi, S, 858(ab), 1652
 Shiozaki, T, 1273(ab)
 Shirakawa, S, 1335(ab)
 Shirotani, M, 6
 Shiue, C, 118(ab), 333(ab)
 Shiue, CY, 401(ab)
 Shiue, GG, 118(ab), 333(ab), 401(ab)
 Shively, JE, 323(ab), 325(ab)
 Shnier, D, 61(ab), 868(ab)
 Shoghi-Jadid, K, 142(ab), 587(ab)
 Shohtsu, A, 563(ab), 1078(ab), 1131(ab), 1155(ab)
 Shoner, SC, 1237(ab)
 Short, MD, 1116(ab)
 Shouda, S, 2088
 Shoup, TM, 331
 Shreve, PD, 242(ab), 1139(ab)
 Shuke, N, 211(ab), 212(ab), 216(ab), 569(ab), 747(ab), 855(ab), 1138, 1173(ab), 1644
 Shukla, SK, 976(ab)
 Shulkin, BL, 519(ab)
 Shyr, Y, 1784
 Siciliano, M, 1345(ab)
 Siddiqui, F, 1281(ab)
 Sideni, M, 235(ab)
 Siebelink, HJ, 755(ab)
 Siebner, HR, 290(ab)
 Sieckman, GL, 419(ab)
 Sieff, C, 1031(ab)
 Siegel, AH, 278(ab)
 Siegel, AM, 278(ab)
 Siegel, BA, 525(ab)
 Siegel, JA, 990(ab)
 Siegel, MJ, 525(ab)
 Siessmeier, T, 291(ab)
 Siewert, JR, 550(ab)
 Silberstein, EB, 264(ab)
 Sillanpää, M, 12
 Sillar, R, 64(ab)
 Silva, AM, 1148(ab)
 Silverman, D, 225(ab), 1468(ab)
- Silverman, DH, 130(ab), 260(ab), 281(ab), 283(ab), 285(ab), 408(ab), 1083(ab), 2043
 Silverman, RW, 304(ab), 1164, 1223(ab)
 Simcic, V, 1245(ab)
 Simkin, PH, 590(ab)
 Simmons, J, 419(ab)
 Simms, MS, 399(ab)
 Simonneau, G, 173(ab)
 Simons, GT, 1197(ab)
 Simpson, N, 114(ab), 117(ab), 435(ab), 609(ab), 1162(ab), 1209(ab)
 Simpson, SD, 419(ab), 499(ab)
 Singer, FR, 203(ab)
 Singh, B, 360(ab)
 Singh, D, 1205(ab)
 Siniscalchi, A, 1556
 Sink, J, 339(ab)
 Sinusas, AJ, 21(ab), 339(ab), 353(ab)
 Sinzinger, H, 1277
 Sisini, F, 167(ab)
 Sisson, JC, 519(ab)
 Sitbon, O, 173(ab)
 Sitek, A, 128(ab), 816(ab), 829(ab)
 Siu, S, 776(ab)
 Sixl, M, 282(ab)
 Skiest, D, 896(ab)
 Skopek, J, 37(ab)
 Slama, M, 173(ab), 743(ab)
 Slates, RB, 131(ab), 303(ab)
 Slegers, G, 1354(ab)
 Slifstein, M, 114(ab), 141(ab), 435(ab), 474(ab), 1162(ab), 1211(ab), 1242(ab)
 Slizofski, WJ, 856(ab)
 Sloggett, C, 776(ab)
 Slomka, PJ, 110(ab), 448, 1091
 Sloof, G, 1107(ab)
 Sloof, GW, 190(ab), 192(ab), 731(ab), 765(ab), 827(ab), 831(ab), 1204, 1866
 Small, GW, 281(ab), 283(ab), 284(ab), 285(ab)
 Smekhov, M, 1213(ab)
 Smetana, S, 860(ab)
 Smit, EF, 564(ab)
 Smith, CJ, 419(ab)
 Smith, EO, 1228(ab)
 Smith, GT, 96(ab), 469(ab), 1283(ab)
 Smith, IC, 552(ab)
 Smith, KF, 844(ab)
 Smith, MF, 138(ab), 472(ab)
 Smith, RJ, 308(ab), 562(ab), 1054(ab), 1286(ab), 1239(ab), 1241, 1257
 Smith, T, 464, 625, 2107
 Smith, WJM, 26N(1), 16N(2), 26N(3), 24N(4), 23N(5)
 Smith-Jones, P, 74(ab), 395(ab), 1082(ab)
 Smith-Jones, PM, 1001(ab), 1008(ab)
 Smolarz, K, 202(ab), 932(ab), 973(ab)
 Snead, C, 1183(ab)
 Snell, GI, 381(ab)
 Snow, GB, 263(ab)
 Snowdon, GM, 924(ab)
 Snyder, LC, 1240(ab)
 So, EL, 677
 So, Y, 529(ab), 938(ab), 986, 1143(ab)
 Soares, EJ, 1011
 Soares, J, 1208(ab)
 Soares, JP, 21(ab)
 Sobnack, RK, 764(ab)
 Sochor, H, 362(ab)
 Socolsky, RC, 1104(ab)
 Sodee, DB, 1138(ab)
 Soeda, H, 1778
 Soejima, Y, 770(ab)
 Soekler, M, 946(ab), 956(ab), 957(ab)
 Sohn, HS, 376(ab)
 Sojkova, J, 278(ab)
 Sokranski, R, 422(ab)
 Solal, M, 602(ab)
 Solanki, KK, 60(ab), 904(ab)
 Soler, C, 80(ab), 733(ab)
 Solin, O, 12, 1163(ab)

- Solinas, ME**, 1105(ab)
Solinas, P, 1105(ab)
Sollitto, R, 574
Soloviev, D, 552(ab)
Som, P, 825(ab)
Soman, P, 345(ab)
Soman, Z, 771(ab)
Son, JW, 10(ab)
Son, M, 1350(ab)
Son, MS, 10(ab)
Sondak, V, 233(ab)
Song, HC, 286(ab), 549(ab), 1202(ab), 1378(ab)
Song, MH, 1083(ab)
Sönmezoglu, K, 429
Sonnemann, U, 1150(ab)
Soong, TC, 1052(ab)
Sorensen, B, 250(ab), 544(ab)
Sorenson, B, 1153(ab)
Soroa, V, 904(ab)
Soroa, VE, 60(ab)
Sossi, V, 481(ab)
Soucy, JP, 267(ab)
Soufer, R, 21(ab), 346(ab)
Soufer, RS, 1220(ab)
Souladaki, M, 1342
Soulen, RL, 1079(ab)
Soulez, G, 2029
Southwick, SM, 578(ab)
Soyka, M, 448(ab)
Soyne, D, 981(ab)
Spahn, G, 387
Spallarossa, P, 1832
Spanak, MV, 275(ab), 730
Spanu, A, 1105(ab)
Sparks, R, 261(ab)
Sparks, RB, 625, 1357(ab)
Spar, G, 224(ab)
Spaulding, M, 94(ab)
Speelman, JD, 753
Spencer, RP, 533(ab)
Spencer, SS, 275(ab), 730, 1199(ab), 1270(ab)
Spetsieres, P, 1264
Spetzger, U, 450(ab)
Spicer, KM, 971(ab), 1383(ab), 1390(ab), 1454(ab)
Spiegel, S, 290(ab), 593(ab)
Spies, S, 260(ab)
Spies, SM, 509(ab), 712(ab), 1278(ab), 1327(ab)
Spill, EJ, 1224(ab)
Spiller, RC, 365(ab)
Spillert, AM, 729(ab)
Spinelli, L, 194(ab), 338(ab), 777(ab), 1683
Spirnak, P, 1138(ab)
Spitz, FR, 1143
Spitzer, S, 1165(ab)
Spivack, D, 363(ab)
Spottswood, SE, 1455(ab)
Springer, CS, 1301(ab)
Srinivasan, A, 317(ab), 320(ab), 322(ab), 415(ab), 418(ab), 993(ab), 996(ab), 997(ab), 2081
Srivastava, SC, 264(ab), 302, 489(ab), 490(ab), 978(ab)
Stabin, M, 331, 1524
Stabin, MG, 165(ab), 260(ab), 1355(ab), 1357(ab), 1364(ab), 1375(ab), 1380(ab)
Stadalmik, RC, 137, 1149
Stagg, B, 76(ab)
Stahl, F, 337(ab)
Stahl, TJ, 232(ab)
Staib, L, 93(ab), 250
Staib, LH, 578(ab), 1220(ab)
Staley, CA, 92(ab)
Staley, JK, 576(ab), 1208(ab)
Stallings, L, 1383(ab)
Stallings, LE, 1390(ab)
Standke, R, 1152(ab)
Stauch, S, 1251(ab)
Staudenherz, A, 1376(ab)
Stauraka, A, 976(ab)
Stav, I, 1037(ab)
Stavropoulos, SW, 406
Stayanoff, JC, 101(ab)
Stearns, CW, 466(ab), 1236(ab)
Steen, K, 78(ab)
Steffens, MG, 829
Stegemann, G, 78(ab)
Stehr, B, 427(ab)
Stein, R, 968(ab), 1392
Steinbach, J, 293(ab), 584(ab)
Steinberg, T, 51(ab)
Steinert, HC, 79(ab)
Steinke, R, 754(ab)
Steinling, M, 721, 956
Steinmetz, AP, 51(ab), 522(ab), 880(ab)
Stekhova, S, 494(ab)
Stephane, M, 441(ab), 1164(ab)
Stephens, AW, 357(ab)
Stephenson, R, 1224(ab)
Sterman, D, 1241
Stern, R, 825(ab)
Steuer, J, 9N(2)
Stevens, SC, 873(ab)
Stevenson, A, 152(ab)
Steventon, RS, 1292(ab)
Stewart, R, 723(ab)
Stiévenart, JL, 786
Stix, G, 362(ab)
Stokkel, MP, 259(ab), 574, 1056(ab)
Stokking, R, 311, 1199(ab), 1270(ab)
Stollfuss, JC, 1824
Stone, CD, 139(ab)
Stone, CK, 187(ab), 354(ab), 723(ab)
Stone, DM, 75(ab)
Stooft, JC, 106(ab), 111(ab)
Stoot, JM, 38(ab)
Storey, G, 218(ab)
Storm, G, 58(ab), 192, 2066
Stout, DB, 142(ab), 585(ab), 587(ab)
Straehler-Pohl, HJ, 988(ab)
Strand, S-E, 1524
Stratton, K, 769(ab)
Strauss, HW, 38(ab), 60, 184, 252(ab), 559(ab), 814(ab), 846(ab), 1122(ab), 1832
Strauss, J, 204(ab)
Strauss, LG, 1061(ab), 1288(ab), 1323(ab)
Strijckmans, V, 935
Stroehlein, K, 902(ab)
Strom, S, 850(ab)
Stroobants, S, 98(ab), 899(ab)
Stroobants, SG, 564(ab)
Stroszczynski, C, 387
Stubbs, JB, 625
Studholme, C, 278(ab), 1199(ab), 1270(ab)
Styblo, T, 238(ab)
Su, MS, 1186(ab)
Su, ZF, 331(ab)
Sugawara, Y, 554(ab), 1089(ab), 1099(ab), 1125, 1130(ab), 1456
Sugihara, H, 514(ab), 2007
Sugimoto, K, 243(ab), 704(ab), 1441
Sugimura, K, 426(ab), 1072(ab)
Sugio, K, 1778
Sugioka, J, 13(ab), 745(ab)
Sugiura, M, 317
Sugiura, S, 1116
Suh, JH, 1055(ab)
Suh, JS, 1023(ab)
Suh, YS, 1394(ab)
Suhara, T, 1342(ab), 1351(ab)
Suhonen-Polvi, H, 12
Sullivan, A, 25N(10), 26N(11), 16N(12)
Sullivan, CL, 67(ab)
Sullivan, T, 572(ab)
Sumiya, H, 535(ab), 1818
Sun, AJ, 97(ab)
Sun, B-F, 1381
Sun, QY, 97(ab)
Sunderland, T, 119(ab)
Sundram, FX, 904(ab)
Sung, C, 1547
Sunohara, N, 1583
Surya Prakash, GK, 1368(ab)
Sutinen, E, 1330(ab)
Suzuki, H, 1018(ab)
Suzuki, K, 207(ab), 527(ab), 847(ab), 1342(ab), 1351(ab)
Suzuki, T, 217, 867(ab), 1021(ab)
Suzuki, Y, 1137(ab)
Swahn, C, 120(ab), 151(ab)
Swahn, CG, 436(ab)
Swaney, CM, 574
Swanson, D, 850(ab)
Sweet, MP, 489(ab)
Sy, WM, 844(ab)
Sychra, JJ, 394(ab), 1276(ab)
Symes, JF, 760(ab)
Symonds-Taylor, JR, 1232(ab)
Syrota, A, 31(ab), 224, 411(ab), 917, 1147(ab)
Szabo, K, 115(ab), 373(ab)
Szabo, Z, 115(ab), 373(ab), 594(ab), 940(ab), 1014(ab), 1180
Szajek, LP, 472(ab)
Sze, P, 844(ab)
Szecsi, J, 737
Szeimies, U, 1048(ab)
Szilard, M, 822(ab)
Taat, CW, 1107(ab)
Tabrizi, MH, 1329(ab)
Tadamura, E, 7(ab), 782(ab), 1840
Taddei, G, 522
Taddei, GZ, 926(ab)
Taegtmeyer, H, 1186
Tagaya, Y, 1027(ab)
Tagesson, M, 1524
Tagil, K, 224(ab)
Taguchi, M, 1332(ab)
Tahmassian, AZ, 935(ab)
Tai, Y, 130(ab)
Taillefer, R, 40(ab), 41(ab), 345(ab), 359(ab), 1103(ab), 1124(ab), 1233, 1244(ab), 2029
Tait, JF, 38(ab), 184, 846(ab)
Takagi, S, 1155(ab)
Takagi, Y, 1792
Takahashi, K, 780(ab), 875(ab), 1999
Takahashi, M, 1318(ab), 1328(ab), 1331(ab), 1337(ab)
Takahashi, N, 207(ab), 243(ab), 704(ab), 1332(ab), 1441
Takahashi, T, 137, 802(ab), 877(ab), 885(ab), 1188(ab)
Takahashi, W, 563(ab), 1155(ab)
Takahashi, Y, 64
Takamiya, M, 796(ab), 1187(ab)
Takano, A, 1204(ab)
Takao, N, 779(ab)
Takahima, H, 371
Takatoku, K, 289(ab)
Takatsu, H, 2036
Takayama, T, 1300(ab)
Takebayashi, S, 1792
Takeda, K, 12(ab), 895, 1172(ab), 1300(ab)
Takeda, Y, 394, 1971
Takei, K, 915(ab)
Takei, T, 527(ab)
Takeishi, Y, 1999
Takekoshi, N, 512(ab), 812(ab)
Takeshita, K, 728(ab)
Takeuchi, A, 847(ab), 1172(ab)
Takeuchi, K, 1492
Takezawa, H, 728(ab)
Taki, J, 191(ab), 216(ab), 512(ab), 535(ab), 727(ab), 761(ab), 915(ab), 1644, 1874
Taki, S, 865(ab)
Takizawa, N, 1818
- Talbot, JN**, 1077(ab)
Tamagnan, G, 154(ab), 607(ab)
Tamaki, N, 14(ab), 207(ab), 471, 527(ab), 748(ab), 782(ab), 798(ab), 807(ab), 963, 1097(ab), 1204(ab), 1247(ab), 1319(ab), 1424, 1840
Tamaki, T, 770(ab)
Tamamura, H, 1095(ab)
Tamgac, F, 1092(ab)
Tamura, S, 1047(ab), 1057(ab)
Tamura, Y, 312(ab), 841(ab)
Tan, P, 148(ab), 1208(ab)
Tanabe, M, 198(ab), 875(ab)
Tanada, S, 1005(ab)
Tanaka, F, 530, 1183(ab)
Tanaka, H, 1078(ab)
Tanaka, K, 1463
Tanaka, R, 713(ab)
Tanaka, T, 1173(ab)
Tang, CY, 355(ab)
Tang, HR, 458(ab), 596(ab), 820(ab), 1248(ab), 1249(ab)
Taniguchi, K, 217
Taniguchi, M, 915(ab), 1095(ab)
Tanimura, K, 1138
Tannahill, L, 1913
Tansey, LW, 1467(ab)
Tapia-Palacios, M, 377(ab)
Tapscott, E, 13N(10)
Tarlati, M, 1080
Tarii, L, 434(ab)
Tarolo, GL, 77
Tashiro, M, 70
Tateishi, J, 780(ab)
Tateno, M, 939(ab)
Tatsch, K, 110(ab), 112(ab), 389(ab), 737, 853(ab), 1048(ab)
Tatsch, KR, 126(ab)
Tatschida, T, 273(ab)
Tatsumi, M, 65(ab), 384(ab), 566, 854, 1003
Tatum, JL, 1455(ab)
Tatumi, N, 942(ab)
Taylor, A, 209(ab), 1403(ab)
Taylor, I, 560(ab), 1116(ab)
Taylor, MD, 187(ab)
Tazi, A, 962(ab)
Tedeschi, E, 442
Teerlink, T, 827(ab), 1204
Tega, H, 430(ab), 1020(ab)
Teixeira, AB, 1148(ab)
Tellmann, L, 501(ab)
Tembli, A, 3(ab), 5(ab), 734(ab), 786(ab)
ten Broek, FW, 1056(ab)
Tenney, CR, 138(ab)
Tepe, G, 837(ab)
Teratani, T, 1190(ab), 1302(ab)
Terauchi, T, 1465(ab)
Terhaard, CH, 259(ab)
Terno, G, 1114(ab)
Terui, S, 1465(ab)
Terzi, AA, 172(ab), 178(ab)
Tesar, R, 10N(3)
Teshima, H, 942(ab)
Tesoro Tess, JD, 251(ab)
Testori, A, 1125(ab)
Tetrault, T, 52(ab), 56(ab)
Teule, GJ, 407(ab), 667, 953(ab)
Tewson, TJ, 494(ab), 1072, 1400(ab)
Teyssier, F, 80(ab)
Thakrar, DS, 68(ab), 536(ab)
Thakur, ML, 62(ab), 352, 485(ab), 491(ab), 625, 1080(ab), 1363(ab), 1398(ab), 2107
Thanos, PK, 1217(ab)
Thérez, P, 198, 1216
Thelen, MH, 871(ab), 933(ab)
Thérasse, E, 2029
Thie, JA, 96(ab), 469(ab), 1283(ab)
Thierens, H, 1354(ab)
Thigpen, KA, 169(ab)
Thirion, P, 1147(ab)
Thödtmann, R, 1771
Thomas, C, 917(ab)

- Thomas, PA, 579
 Thomas, R, 66(ab)
 Thompson, CJ, 542(ab)
 Thompson, TD, 27(ab), 710(ab), 722(ab)
 Thorberg, S, 151(ab)
 Thornback, J, 504(ab)
 Thornback, JR, 331(ab), 419(ab), 497(ab), 499(ab), 614(ab), 872(ab), 995(ab), 1346(ab)
 Tidmarsh, G, 76(ab), 989(ab), 991(ab)
 Tiepoli, C, 543(ab)
 Tietje, N, 1246
 Tiffany-Jones, L, 166
 Tiffet, O, 80(ab)
 Tikofsky, RS, 1197(ab), 1205(ab)
 Tiling, R, 1048(ab)
 Timothy, AR, 425(ab), 1135(ab)
 Ting, G, 1170(ab)
 Tissingh, G, 106(ab)
 Tjuvajev, JG, 105(ab), 1012(ab)
 Toba, M, 796(ab), 799(ab), 800(ab), 801(ab)
 Tobey, EA, 449(ab)
 Tocharoenchai, C, 461(ab)
 Todd-Pokropek, A, 16(ab), 140(ab), 471(ab), 595(ab), 1314(ab)
 Todd-Pokropek, AE, 1294(ab)
 Tofani, A, 46
 Togami, I, 394
 Togasaki, D, 587(ab)
 Tojo, T, 1999
 Tokita, N, 708(ab), 803(ab), 804(ab), 805(ab), 806(ab), 1693
 Tokunaga, M, 390(ab)
 Tölle, TR, 291(ab)
 Tolmachev, V, 982(ab)
 Tolvanen, T, 1330(ab)
 Tomaru, Y, 878(ab), 1018(ab)
 Tomas, MB, 43(ab), 57(ab), 201(ab), 478(ab)
 Tomczak, R, 571(ab)
 Tomiguchi, S, 1331(ab)
 Tomita, I, 371
 Tomiyama, N, 566
 Tomiyama, Y, 239
 Tomiyoshi, K, 336(ab), 399, 878(ab), 1018(ab)
 Tomoike, H, 1999
 Tompkins, EA, 895(ab)
 Tompkins, RG, 370(ab), 391(ab)
 Ton, A, 1281(ab)
 Tonakie, A, 233(ab)
 Tonami, H, 1095(ab)
 Tonami, N, 191(ab), 216(ab), 430(ab), 535(ab), 727(ab), 761(ab), 855(ab), 915(ab), 1020(ab), 1138, 1644, 1818, 1874
 Tondeur, M, 52, 972
 Tondini, C, 251(ab)
 Top, LE, 268
 Topuzovic, NB, 739(ab)
 Torizuka, T, 1088(ab), 1424
 Tornai, MP, 138(ab), 1260(ab), 1176
 Toro, J, 929(ab)
 Torp, B, 907(ab)
 Torres, L, 768
 Torres, O, 768
 Tosch, M, 575(ab)
 Toth, B, 342(ab)
 Touber, ME, 411(ab)
 Toubi, A, 45(ab)
 Tourwé, D, 1913
 Towbin, RB, 850(ab)
 Townsend, DW, 597(ab), 1134(ab)
 Toyama, H, 705(ab), 808(ab), 847(ab), 1172(ab), 1269(ab)
 Toyama, K, 574(ab), 835(ab)
 Toyama, T, 217
 Toyoda, H, 1188(ab), 1273(ab)
 Toyokuni, T, 102(ab), 332(ab)
 Toyokuni, TT, 323(ab)
 Traeger, H, 82(ab), 93(ab), 945(ab)
 Träger, H, 1623
 Tran, HD, 1457(ab)
 Trattning, S, 1277
 Traub, T, 395(ab), 1081(ab)
 Travaini, L, 1617
 Travin, MI, 350(ab), 810(ab)
 Trenkwalder, C, 112(ab)
 Treves, ST, 51(ab), 52(ab), 56(ab), 908(ab), 1896
 Triantafyllou, N, 976(ab)
 Trifiro, G, 1125(ab)
 Trigaux, JP, 219(ab)
 Trojan, H, 1016(ab), 1032(ab)
 Tronco, G, 43(ab)
 Tronco, GG, 201(ab)
 Troychak, MJ, 1138(ab)
 Trujillo, N, 797(ab)
 Trujillo, NP, 200(ab)
 Tsai, S, 323(ab), 325(ab), 1052(ab)
 Tsai, S-C, 1106
 Tsay, D-G, 60
 Tsay, DW, 367(ab), 1050(ab)
 Tschmelitsch, J, 1764
 Tsuboi, N, 728(ab)
 Tsuchida, T, 704(ab), 1085, 1201(ab), 1441
 Tsuchimochi, S, 222(ab), 726(ab)
 Tsuchiya, H, 535(ab)
 Tsuda, T, 1071(ab)
 Tsugawa, H, 812(ab)
 Tsui, B, 134(ab), 461(ab), 470(ab), 1252(ab)
 Tsui, BM, 1011
 Tsuji, S, 1818
 Tsujihata, M, 371
 Tsujimura, E, 805(ab)
 Tsukakoshi, M, 878(ab)
 Tsukamoto, E, 14(ab), 207(ab), 527(ab), 748(ab), 798(ab), 807(ab), 963, 1204(ab), 1247(ab), 1319(ab)
 Tsukamoto, T, 493(ab)
 Tsukune, Y, 867(ab)
 Tuchida, T, 1183(ab)
 Tuji, S, 761(ab)
 Tull, CR, 599(ab)
 Tung, CH, 137(ab)
 Turetskiy, V, 1144(ab)
 Turgut, B, 1046(ab)
 Turi-Nagy, E, 1158(ab)
 Turkington, TG, 136(ab), 432, 477(ab), 1176, 1241(ab)
 Turner, JH, 873(ab)
 Turpin, S, 1124(ab), 2029
 Turzo, A, 298(ab), 473(ab)
 Twieg, D, 1181(ab)
 Tzakis, AG, 208(ab)
 Tzen, K, 1299(ab)
 Tzen, KY, 109(ab)
 Uccelli, L, 167(ab), 302(ab), 778(ab), 1168(ab), 1382(ab), 1556
 Uchiyama, M, 874(ab)
 Udelman, R, 940(ab)
 Udelson, JE, 345(ab)
 Ueberfuhr, P, 30(ab)
 Ueda, S, 1590
 Ueda, T, 289(ab)
 Ueda, Y, 86(ab), 1095(ab)
 Uehara, T, 239, 1884
 Uemura, K, 841(ab)
 Ueno, M, 1273(ab), 1992
 Ueti, OM, 746(ab)
 Uffelman, W, 25N(10), 26N(11), 16N(12)
 Ugwoke, M, 610(ab)
 Ulanski, JS, 1031(ab)
 Umehara, I, 64
 Underwood, SR, 343(ab), 344(ab)
 Ungerer, M, 188(ab)
 Unni, PR, 1015(ab)
 Uno, H, 1169(ab)
 Uno, M, 1192(ab)
 Unterberg, R, 34(ab)
 Unterreiner, R, 821(ab)
 Unterweger, MP, 1508
 Urbain, JL, 497, 498, 854(ab), 1236
 Urbannek, V, 932(ab)
 Urbina, RA, 1348(ab)
 Uribe, J, 307(ab), 598(ab), 1233(ab)
 Uslu, İ, 429
 Usui, K, 211(ab), 212(ab), 747(ab), 855(ab), 1173(ab)
 Usui, Y, 779(ab)
 Utsunomiya, K, 1201(ab)
 Vaalburg, W, 116(ab), 262, 292(ab), 300(ab), 351(ab), 381, 496(ab), 507, 561(ab), 890(ab), 1132(ab), 1159(ab), 1167(ab), 1177(ab), 1270
 Vaca, A, 1104(ab)
 Vainionpää, L, 12
 Vaitkevicius, VK, 1079(ab)
 Valdavia, AY, 363(ab)
 Valdés Olmos, RA, 70(ab), 1119(ab), 1414
 Vale, PR, 760(ab)
 Valentín, L, 602(ab)
 Valette, H, 1374
 Valeyre, D, 962(ab), 1092(ab)
 Valk, PE, 255(ab)
 Valkema, R, 416(ab), 2081
 Vallabhanjosula, S, 1001(ab), 1008(ab), 1303(ab)
 Vallis, K, 1370(ab)
 van Aswegen, A, 1532
 van Balen, S, 1313(ab)
 Van Cutsem, E, 98(ab)
 Van de Wiele, C, 783
 Van den Eeckhaut, AC, 783
 Van den Heuvel, PA, 706(ab), 1468
 van den Hoff, J, 719(ab), 1272(ab)
 van der Ent, FW, 1118(ab)
 Van der Graaf, WT, 1146(ab), 1159(ab)
 van der Linden, C, 269(ab)
 van der Mark, TW, 1270
 van der Meer, JW, 192
 van der Meer, JWM, 2066
 van der Pol, HA, 1118(ab)
 van der Vusse, GJ, 1204
 van der Wall, EE, 180(ab), 740(ab)
 Van der Wall, H, 85, 218(ab), 869(ab)
 van der Wouden, E, 496(ab)
 van Dijk, A, 639
 Van Dongen, GA, 263(ab)
 van Dyck, CH, 1208(ab)
 van Eijkeren, M, 491
 Van Every, B, 381(ab)
 van Gammeren, A, 320(ab)
 van Ginkel, RJ, 262
 Van Heertum, R, 114(ab), 121(ab), 122(ab), 435(ab), 1211(ab)
 Van Heertum, RL, 90(ab), 228(ab), 412(ab), 611(ab), 1197(ab), 1205(ab)
 van het Schip, AD, 639
 van Isselt, JW, 311
 van Kaick, G, 372(ab), 1061(ab)
 Van Laere, K, 210(ab)
 Van Laere, KJ, 269(ab), 277(ab), 1250(ab)
 van Lier, JE, 832(ab), 876, 1728
 van Lingen, A, 190(ab), 192(ab), 263(ab), 407(ab), 1235(ab), 1257(ab), 1313(ab), 1866
 van Loon, M, 1235(ab), 1313(ab)
 Van Raemdonck, D, 98(ab)
 van Rijk, PP, 259(ab), 311, 639, 1056(ab)
 van Royen, EA, 753, 1091
 van Staden, JA, 1532
 van Tienhoven, G, 1107(ab)
 van Waerde, A, 116(ab), 292(ab), 351(ab), 496(ab), 890(ab), 1167(ab), 1177(ab), 1270
 Vanbiloen, HP, 610(ab)
 VanBrocklin, H, 352(ab)
 Vandekerckhove, T, 277(ab)
 Vandenberghe, S, 1250(ab)
 Vander Borght, T, 219(ab), 766(ab), 792(ab), 882(ab)
 Vanderheyden, J, 1389(ab)
 vanderMeer, JW, 58(ab)

- Vonck, K, 277(ab)
 Vosberg, H, 575(ab), 977
 Votaw, D, 331
 Votaw, J, 331, 1344(ab)
 Voth, E, 202(ab), 791(ab), 830(ab), 932(ab)
 Voth, M, 952(ab), 1227(ab)
 Vriens, P, 38(ab)
 Vu, C, 159
 Vural, G, 524(ab), 919(ab), 1046(ab)
 Wackers, F, 817(ab)
 Wackers, FJTh, 1310
 Waddington, WA, 560(ab), 1113(ab), 1116(ab)
 Wagner, C, 291(ab)
 Wagner, HN, 318(ab)
 Wagner, HN, Jr., 13N(8), 30N(10), 574, 1009
 Wahl, LM, 1666
 Wahl, RL, 76(ab), 77(ab), 87(ab), 88(ab), 89(ab), 155(ab), 233(ab), 405(ab), 554(ab), 556, 612(ab), 989(ab), 990(ab), 991(ab), 1089(ab), 1099(ab), 1110(ab), 1125, 1130(ab), 1139(ab), 1456, 2025
 Waibel, R, 1913
 Waikar, S, 552(ab)
 Wainer, N, 136(ab)
 Wakabayashi, Y, 2088
 Wakasugi, S, 942(ab), 943(ab)
 Wakasugi, T, 191(ab)
 Waki, A, 91(ab), 243(ab), 330(ab), 704(ab), 1000(ab), 1034(ab), 1085, 1174(ab), 1332(ab), 1441
 Wald, JJ, 554(ab)
 Wald, M, 1111
 Waldman, TA, 329(ab)
 Waldmann, TA, 268, 327(ab), 837, 1006(ab), 1027(ab), 1381
 Walicka, MA, 1377(ab)
 Walker, B, 1745
 Wallace, AM, 1149
 Wallace, WE, 379(ab)
 Wallhaus, TR, 187(ab), 723(ab)
 Wallis, JW, 510(ab)
 Walter, R, 595(ab)
 Wand, G, 446(ab)
 Wang, FW, 1745
 Wang, G, 145(ab), 588(ab), 1217(ab)
 Wang, GJ, 442(ab), 443(ab), 715, 1154, 1176(ab), 1215(ab), 1218(ab), 1285
 Wang, HE, 1365(ab)
 Wang, J, 307(ab), 598(ab), 997(ab), 1233(ab), 1370(ab)
 Wang, JC, 1087(ab)
 Wang, JK, 1452(ab)
 Wang, MF, 97(ab)
 Wang, S, 354(ab), 502(ab)
 Wang, S-J, 1106
 Wang, TS, 90(ab), 611(ab)
 Wang, W, 301(ab), 1042(ab), 1044(ab)
 Wang, WT, 470(ab)
 Wang, X, 86(ab)
 Wang, Y, 1397(ab)
 Wängberg, B, 2094
 Wanivenhaus, A, 1277
 Ward, HB, 1304(ab)
 Warnet, A, 1252
 Warren, J, 1383(ab)
 Warren, S, 402(ab)
 Warren, W, 813(ab)
 Warren, WK, 815(ab)
 Wassmann, H, 1064(ab)
 Wastie, ML, 399(ab)
 Watabe, H, 464(ab)
 Watanabe, A, 1138, 1175(ab)
 Watanabe, H, 390(ab)
 Watanabe, KA, 334(ab), 1368(ab)
 Watanabe, M, 943(ab)
 Watanabe, N, 1005(ab), 1138
 Watanabe, S, 718(ab), 767(ab)
 Watanabe, T, 781(ab)
 Watanabe, W, 802(ab), 885(ab)
 Watanabe, Y, 566, 1166(ab)
 Watanuki, S, 70
 Waters, DD, 518(ab), 702(ab), 711(ab)
 Watson, CC, 305(ab)
 Watson, DD, 142, 821
 Waxman, A, 280(ab)
 Waxman, AD, 246(ab), 378(ab), 883(ab), 959(ab), 1182(ab)
 Waxman, AS, 9(ab)
 Wearne, MJ, 455(ab)
 Weaver, JP, 604
 Weber, B, 1158(ab)
 Weber, DA, 1264(ab)
 Weber, P, 319(ab)
 Weber, PB, 1399(ab)
 Weber, W, 85(ab), 205, 574, 737
 Weber, WA, 397(ab), 550(ab), 593(ab), 1311(ab), 1771
 Weckesser, M, 566(ab), 1017(ab), 1064(ab)
 Wegener, WA, 67(ab)
 Wegman, T, 1177(ab)
 Wehrmann, E, 1375(ab)
 Weidel, J, 44(ab)
 Weiden, PL, 75(ab)
 Weijss, L, 717(ab)
 Weilke, F, 451(ab)
 Weinberger, DR, 445(ab), 1348(ab)
 Weinberger, J, 611(ab)
 Weiner, RE, 533(ab)
 Weinmann, P, 962(ab)
 Weiping, W, 912(ab)
 Weir, GJ, 574
 Weisenberger, D, 468(ab)
 Weiss, R, 121(ab), 1210(ab), 1242(ab)
 Weissman, IA, 1334(ab)
 Weisz, G, 741(ab), 811(ab)
 Welch, A, 552(ab)
 Welch, MJ, 177, 704(ab)
 Weller, R, 1272(ab)
 Welling, MM, 2073
 Wells, C, 1108(ab)
 Wells, P, 41(ab)
 Wells, RG, 590(ab)
 Welt, S, 970(ab), 1764
 Wendt, RE, 160(ab)
 Wenger, M, 74(ab)
 Werner, JA, 257(ab), 776, 1150(ab)
 Werner, M, 1637
 Werner, T, 151(ab)
 Wessell, DE, 134(ab)
 Wessells, B, 971(ab)
 West, JH, 371(ab)
 Wester, HJ, 205, 448(ab), 1061, 1367
 Westlin, JE, 982(ab)
 Wetter, T, 112(ab)
 Wevers, RA, 272(ab)
 Wey, SP, 1170(ab)
 Whang, SC, 1094(ab)
 Whatley, M, 385(ab), 565(ab), 1029(ab)
 White, CA, 260(ab)
 White, CM, 518(ab)
 White, JD, 268
 White, LL, 1232(ab)
 White, MP, 517(ab), 702(ab), 711(ab)
 Whiting, JS, 356(ab), 1508
 Wichter, T, 1, 834(ab)
 Widstrom, C, 982(ab)
 Wieland, DM, 232, 323, 519(ab)
 Wienhard, K, 306(ab)
 Wiens, L, 494(ab), 1400(ab)
 Wiggers, H, 1292
 Wijns, W, 1893
 Wilcut, E, 303(ab)
 Wilderman, SJ, 133(ab)
 Wilding, P, 2107
 Wilhelm, AJ, 263(ab)
 Wilhelm, RR, 993(ab), 996(ab)
 Wilk, M, 1295(ab)
 Willemart, B, 882(ab)
 Willemsen, A, 717(ab)
 Willemsen, AT, 116(ab), 300(ab), 351(ab), 507, 561(ab), 755(ab), 1159(ab)
 Willemsen, ATM, 1270
 Williams, C, 1182(ab)
 Williams, CM, 378(ab), 959(ab)
 Williams, JE, 16N(1), 9N(6), 12N(12)
 Williams, KA, 774(ab)
 Williams, KV, 1798
 Williams, LE, 323(ab), 325(ab), 1151
 Williams, NE, 1241(ab)
 Williams, S, 1207(ab)
 Williams, W, 1219(ab)
 Williamson, PD, 278(ab)
 Willoch, F, 290(ab), 291(ab), 448(ab)
 Wilson, CG, 365(ab)
 Wilson, DA, 234(ab)
 Wilson, M, 1230(ab)
 Winkle, W, 846
 Winkler, B, 570(ab)
 Winkler, P, 737
 Winnard, P, Jr, 484
 Winogrodzka, A, 106(ab), 111(ab)
 Winsor, D, 427(ab)
 Wirquin, V, 37(ab)
 Wiseman, GA, 260(ab)
 Witzel, C, 195(ab)
 Witzel, M, 195(ab)
 Witzig, TA, 260(ab)
 Witzling, M, 860(ab)
 Wodarski, C, 1061(ab)
 Wohrle, J, 341(ab)
 Wojcik, R, 468(ab), 600(ab)
 Wolek, R, 73(ab)
 Wolf, F, 537(ab)
 Wölfel, R, 1342
 Wolloch, Y, 376
 Wolpers, HG, 719(ab)
 Wolter, A, 897(ab), 952(ab)
 Wolters, EC, 106(ab), 111(ab)
 Wong, C, 83(ab), 287(ab)
 Wong, CO, 993
 Wong, CT, 145(ab), 442(ab), 443(ab), 588(ab), 715, 1217(ab), 1285
 Wong, DC, 54(ab), 55(ab), 1805
 Wong, DF, 125(ab), 441(ab), 1164(ab)
 Wong, E, 504(ab)
 Wong, FC, 955(ab), 1206(ab)
 Wong, J, 323(ab), 325(ab)
 Wong, JY, 1151
 Wong, KH, 596(ab), 820(ab)
 Wong, W, 307(ab), 598(ab)
 Wong, WH, 1233(ab)
 Woo, JI, 1198(ab)
 Woo, KS, 1358(ab)
 Woo, SL, 1012(ab)
 Woodard, AR, 1180(ab)
 Woolfenden, JM, 601(ab)
 Wörmann, B, 992(ab)
 Worthley, SG, 355(ab)
 Wright, GA, 364(ab)
 Wright, JK, 1784
 Wu, AM, 323(ab), 325(ab)
 Wu, C, 166
 Wu, HM, 146(ab), 147(ab), 283(ab)
 Wu, HR, 1106(ab)
 Wu, JC, 1106(ab)
 Wu, L, 102(ab)
 Wu, LC, 1307(ab), 1452(ab), 1460(ab)
 Wu, MC, 596(ab), 820(ab), 1249(ab)
 Wu, S, 947(ab)
 Wu, SY, 922(ab)
 Wu, XF, 1004(ab)
 Wun, T, 965(ab)
 Wunderlich, G, 1385(ab)
 Wurthman, S, 319(ab)
 Wuttke, B, 397(ab)
 Xanthopoulos, E, 1211(ab)
 Xia, W, 456
 Xie, Y, 1294(ab)
 Xiong, CY, 324(ab)
 Xiuli, M, 805(ab), 1693
 Xu, L, 86(ab)
 Xu, M, 1304(ab)
 Xu, Y, 1352(ab)
 Yaakob, W, 1454(ab)
 Yafai, S, 1083(ab)
 Yahanda, A, 233(ab)
- Yamac, K, 39(ab)
 Yamada, I, 64
 Yamada, K, 567(ab)
 Yamada, N, 1116
 Yamada, T, 1179(ab)
 Yamagishi, H, 1492
 Yamaguchi, H, 803(ab), 804(ab), 805(ab), 806(ab), 708(ab), 1693, 1884
 Yamaguchi, K, 567(ab)
 Yamaguchi, T, 1284(ab)
 Yamaji, S, 1185(ab)
 Yamamoto, H, 1190(ab), 1302(ab)
 Yamamoto, I, 86(ab), 1095(ab)
 Yamamoto, K, 243(ab), 1441
 Yamamoto, S, 191(ab)
 Yamamoto, T, 1318(ab), 1328(ab), 1337(ab)
 Yamamoto, W, 211(ab), 212(ab), 747(ab), 855(ab), 1173(ab)
 Yamamoto, Y, 198(ab), 875(ab)
 Yamamura, N, 1406(ab)
 Yamaoka, M, 1999
 Yamasaki, K, 426(ab), 1072(ab)
 Yamashina, A, 779(ab)
 Yamashita, S, 239
 Yamauchi, DM, 1151
 Yamauchi, H, 1992
 Yamazaki, S, 418
 Yanada, S, 874(ab)
 Yanch, JC, 1280(ab)
 Yanez, M, 594(ab)
 Yang, DJ, 404(ab), 1366(ab), 1367(ab), 1467(ab)
 Yang, H, 863(ab), 866(ab)
 Yang, HI, 852(ab)
 Yang, JH, 1102(ab)
 Yang, JY, 821
 Yang, KR, 217(ab)
 Yang, L, 721(ab), 771(ab)
 Yang, S, 1370(ab)
 Yang, SD, 1394(ab)
 Yang, WD, 1004(ab)
 Yang, WH, 485(ab)
 Yang, WI, 1043(ab), 1051(ab), 1058(ab), 1066(ab), 1073(ab), 1075(ab), 1151(ab)
 Yang, YW, 1252(ab)
 Yang, Z, 1087(ab)
 Yanovskaya, L, 1458(ab)
 Yao, R, 1321(ab)
 Yao, S, 171(ab), 176(ab), 181(ab), 507(ab), 716(ab)
 Yao, SS, 715(ab), 924
 Yao, T, 1006(ab)
 Yao, WJ, 1307(ab)
 Yao, Z, 479, 685, 1371(ab)
 Yap, JT, 1848
 Yapar, AF, 429
 Yarnitsky, D, 265(ab)
 Yasuda, S, 563(ab), 1078(ab), 1131(ab), 1155(ab)
 Yasuda, T, 193(ab), 729(ab), 783(ab)
 Yasuhara, Y, 1287(ab)
 Yasumura, Y, 799(ab)
 Yaw, M, 1144(ab)
 Yazaki, PJ, 323(ab), 325(ab)
 Yazaki, Y, 939(ab), 1116
 Yee, RE, 142(ab), 585(ab), 587(ab)
 Yeh, EL, 142(ab)
 Yeh, S, 912(ab)
 Yeh, SD, 1042(ab)
 Yeh, SH, 244(ab), 909(ab), 1062(ab), 1065(ab), 1186(ab), 1452(ab)
 Yeldell, D, 972(ab)
 Yen, LK, 1052(ab)
 Yen, SH, 244(ab), 1050(ab), 1062(ab)
 Yen, TC, 109(ab)
 Yeo, JS, 789(ab), 1195(ab)
 Yerlioglu, EM, 821(ab)
 Yester, MV, 479(ab)
 Yetman, RJ, 236(ab)
 Yeung, D, 750(ab)
 Yeung, H, 1044(ab)

- Yeung, HW, 95(ab), 1039(ab)
 Yeung, RS, 557(ab), 1074(ab)
 Yiu, JH, 1186(ab)
 Yokoi, F, 441(ab), 1164(ab)
 Yokoi, T, 859(ab), 1318(ab), 1328(ab), 1337(ab), 1737
 Yokota, M, 728(ab)
 Yokoyama, A, 704(ab), 1000(ab), 1034(ab)
 Yokoyama, I, 762(ab), 793, 841(ab), 862(ab), 867(ab), 939(ab), 1116
 Yokoyama, K, 430(ab), 1020(ab), 1138
 Yomoda, I, 289(ab)
 Yonekura, K, 939(ab), 1116
 Yonekura, Y, 91(ab), 243(ab), 317, 330(ab), 704(ab), 1000(ab), 1034(ab), 1085, 1132, 1137(ab), 1174(ab), 1332(ab), 1441
 Yonemura, T, 7(ab)
 Yoneyama, T, 761(ab)
 Yoo, TM, 1381
 Yoon, CH, 205(ab)
 Yoon, J, 715(ab)
 Yoon, JK, 386(ab), 751(ab), 851(ab), 884(ab), 1102(ab)
 Yoon, SN, 756(ab)
 Yordanov, AT, 329(ab)
 Yoriyaz, H, 1364(ab), 1524
 Yoshibayashi, M, 7(ab)
 Yoshida, D, 1035(ab)
 Yoshida, H, 6
 Yoshida, M, 1085, 1132
 Yoshida, S, 1035(ab), 1084(ab), 1101(ab), 1189(ab)
 Yoshida, T, 1091(ab), 1111(ab), 1203(ab), 1595, 1778
 Yoshikawa, E, 1282(ab)
 Yoshikawa, J, 1492
 Yoshikawa, K, 418, 793, 862(ab), 867(ab)
- Yoshimoto, M, 91(ab), 1000(ab), 1034(ab), 1174(ab)
 Yoshiro, Y, 512(ab)
 Yoshioka, J, 708(ab), 803(ab), 804(ab), 805(ab), 806(ab), 1693
 Yoshioka, S, 244
 Yoshizumi, T, 239
 You, DL, 1052(ab)
 You, J, 1277(ab), 1317(ab), 1325(ab)
 Youn, YK, 529(ab), 986
 Young, C, 574
 Young, IH, 382(ab)
 Young, JC, 977(ab)
 Young, JW, 306(ab)
 Young, MC, 343(ab), 344(ab)
 Younsi, N, 1077(ab)
 Yu, CL, 1452(ab)
 Yu, D, 404(ab)
 Yu, DF, 1367(ab)
 Yu, EH, 776(ab)
 Yu, F, 539
 Yu, JN, 525(ab)
 Yu, KH, 1394(ab)
 Yu, SM, 909(ab), 1186(ab)
 Yu, X, 465(ab)
 Yu, YM, 391(ab)
 Yuan, A, 965(ab), 969(ab), 2014
 Yuan, Z, 1018(ab)
 Yudd, AP, 232(ab)
 Yum, HY, 1045(ab)
 Yumoto, K, 770(ab)
 Yuri, H, 426(ab), 1072(ab)
 Yutani, K, 65(ab), 384(ab), 566, 854, 1003, 1166(ab)
 Zabrodina, Y, 772(ab)
 Zabrodina, YV, 889
 Zacherl, S, 1477
 Zagar, I, 933(ab)
 Zahedi, A, 882(ab)
 Zalupska, MM, 1079(ab)
- Zalutsky, MR, 631, 1197
 Zamarripa, F, 942
 Zamora, PO, 825(ab)
 Zamperini, P, 922(ab)
 Zantron-Przybysz, I, 966(ab)
 Zanzi, I, 264(ab)
 Zanzonic, PB, 1007(ab), 1024
 Zardi, L, 434(ab)
 Zareneyrizi, F, 160(ab), 404(ab), 1366(ab), 1367(ab)
 Zaret, BL, 346(ab)
 Zasadny, KR, 76(ab), 77(ab), 87(ab), 155(ab), 556, 989(ab), 991(ab), 1099(ab), 1110(ab), 1456
 Zavattini, G, 302(ab)
 Zea-Ponce, Y, 121(ab), 122(ab), 581(ab), 606(ab), 1210(ab)
 Zecchinelli, A, 271(ab)
 Zee, A, 1132(ab)
 Zeggel, T, 450(ab)
 Zellweger, MJ, 25(ab)
 Zeng, GL, 137(ab), 462(ab), 1254(ab), 1255(ab), 1296(ab)
 Zervos, GD, 729(ab)
 Zettinig, G, 881(ab)
 Zhang, CG, 863(ab), 866(ab)
 Zhang, C-H, 1609
 Zhang, M, 479, 685, 1342(ab), 1351(ab), 1371(ab)
 Zhang, N, 307(ab), 598(ab), 1233(ab)
 Zhang, T, 866(ab)
 Zhang, X, 331(ab)
 Zhang, ZY, 355(ab)
 Zhao, DS, 863(ab), 866(ab)
 Zhao, J, 97(ab)
 Zhao, JH, 866(ab)
 Zhao, S, 479
 Zhao, XD, 461(ab)
 Zhao, X-G, 631
 Zheng, L, 1400(ab)
- Zheng, QH, 495(ab)
 Zhong, YG, 498(ab)
 Zhou, Y, 146(ab), 147(ab)
 Zhu, CM, 1004(ab)
 Zhuang, HM, 61(ab), 868(ab), 888(ab)
 Ziegler, S, 30(ab), 33(ab), 34(ab), 1243(ab), 1824
 Ziegler, SI, 397(ab), 593(ab), 1234(ab), 1311(ab), 1771
 Ziessman, HA, 1236, 2038
 Zietkiewicz, M, 19(ab)
 Ziffer, JA, 347(ab), 508(ab), 511(ab), 787(ab)
 Zijlstra, JM, 953(ab)
 Zilleruelo, G, 204(ab)
 Zimmer, L, 1393(ab)
 Zimmerman, BE, 1508
 Zimmerman, RE, 482(ab), 483(ab), 1896
 Zimmermann, K, 326(ab)
 Zimny, M, 450(ab)
 Zinn, KR, 994(ab)
 Zipes, DP, 846
 Zito, F, 271(ab), 914(ab)
 Zoboli, S, 72(ab)
 Zoghbi, S, 73(ab), 576(ab), 578(ab)
 Zoghbi, SS, 124(ab), 143(ab), 154(ab), 270(ab), 607(ab), 1902
 Zohar, J, 1213(ab)
 Zona, T, 153(ab)
 Zonnenberg, BA, 639
 Zornoza, G, 555(ab)
 Zubal, IG, 275(ab), 480(ab), 730, 1199(ab), 1270(ab)
 Zubillaga, MB, 1080
 Zuna, I, 372(ab)
 Zurkowski, D, 52(ab), 56(ab)
 Zwas, ST, 63(ab), 1213(ab)

A

Absorbed dose estimation system, radioimmunotherapy. 1151

Absorptiometry, effect on increasing tissue. 929(ab)

Academy of Radiology Research (ARR), advocate for change. 9N(6)

Acceptance testing, gamma camera. 12N(12)

Acetate, precursor for lipid synthesis. 1034(ab)

Acetazolamide challenge

time-dependency of, 1203(ab)

vascular factor affecting pathophysiology of, 1221(ab)
^{99m}Tc ECD SPECT as predictor for carotid stunning, 568(ab)

Acetylcholinesterase

AChE activity imaging agent for SPECT, 289(ab)

Brain, [11C]CP-126,998 as a radioligand for, 1207(ab)

[¹¹C] neostigmine, potential PET cardiac marker, 495(ab)

Acquired immune deficiency syndrome (AIDS)

brain SPECT to differentiate cerebral infections from lymphoma, 258(ab)

mental status correlation, 1191(ab)

[⁶⁷Ga citrate, 889(ab)

[²⁰¹Tl] SPECT diagnosis of central nervous system lymphoma and toxoplasma, 896(ab)

Acquisition, CdZnTe with multimode digital electronics. 127(ab)

Activation study

brain, [¹⁵O]-water, 1302(ab)

brain SPECT, 277(ab)

cluster analysis, 1276(ab)

cochlear implant users, 1160(ab)

localization of working and episodic memory by, 1171(ab)

macro square wave jerks in torticollis spasmodicus, 268(ab)

pain and itch processing, 451(ab)

palidal electrostimulation in Parkinson's disease, 269(ab)

PET imaging of, 1175(ab)

presurgical PET assessment of eloquent brain areas, 450(ab)

SPECT, rCBF studies of speech perception, 449(ab)

subliminal perception, 1158(ab)

subthreshold high-frequency repetitive transcranial magnetic stimulation, 290(ab)

three-dimensional PET, 1190(ab)

Xe SPECT and functional MRI, 1181(ab)

Addiction, opioid receptor binding changes in alcohol dependency. 448(ab)

Adelstein, S. James, de Hevesy Award. 12N(6)

Adenocarcinoma, antibody imaging of. 969(ab)

Adenosine

heart, comparison of ATP with, 515(ab)

myocardial perfusion imaging protocol using, 513(ab)

quantification of myocardial blood flow in N-13 ammonia cardiac studies, 717(ab)

short infusion does not increase defect size, 517(ab)

Adenosine triphosphate, mitochondrial glycolysis. 1035(ab)

Adrenergic receptor

beta, myocardial density, parametric polar map of, 507
lipophilic [¹⁸F] labeled adrenergic receptor ligands, 1400(ab)

pulmonary adrenoreceptor density, 834(ab)

synthesis and evaluation of lipophilic ligand, 494(ab)

Advanced Nuclear Medicine Initiative, medicare modernization. 25N(10)

Aebersold Award. 30N(8)

SNM members, 12N(6)

Aerosol

distribution mapping, lung morphometry for, 383(ab)

PET lung imaging, comparison of, 886(ab)

Xe ventilation in diagnosis of pulmonary embolism, 883(ab)

Aging

changes related to, ^{99m}Tc ECD cerebral distribution, 1818

decreased myocardial mechanical function, 4(ab)

dopamine transporters and, healthy humans, 1812

effect on dopamine transporters, 108(ab)

Mu opioid receptor, brain changes in, 447(ab)

PET studies with 6-FMT and 6-DOPO, 1169(ab)

Agonist

lung, C-11 procaterol as a radioligand for, 496(ab)
[¹¹C] ZYY-339, 1338(ab)

Alavi/Mandell Fund, Education & Research Foundation. 32N(8)

Alcohol

addiction in humans, 446(ab)
effects on regional brain glucose, 1217(ab)
moderate dose during pregnancy, 437(ab)
^{99m}Tc DTPA, index of intestinal permeability ingestion of, 370(ab)

Alcoholism, regional cerebral blood flow changes. naltrexone and, SPECT, 19

Alpha-emitting radionuclides

Bi-213, role in lymphoma therapy, 431(ab)
mutated E-cadherin, binding characteristics of radionuclides to, 433(ab)

pharmacokinetic modeling, 164(ab)

Alpha-fetoprotein antibody imaging, of hepatocellular carcinoma. 427(ab)

Alpha-particle emitters

pharmacokinetics and dosimetry of, leukemia patients, 1935

therapeutic efficacy of, in radioimmunotherapy, 1375(ab)

Alpha particles, ²¹³Bi, preparation of constructs for clinical use. 1722

Alzheimer's disease

apolipoprotein E type, glucose metabolism of, 1198(ab)

brain, [¹¹C] VC-004 as a radioligand for, 1177(ab)

cerebral blood flow, ^{99m}Tc HMPAO SPECT in, 244

limbic system, 1193(ab)

longitudinal evaluation of Alzheimer-type dementia, 1192(ab)

quantitative analysis of, 1221(ab)

^{99m}Tc HMPAO cerebral blood flow, qEEG and, 522

^{99m}Tc N252 visualization of, 288(ab)

Ambulatory patient classification (APC), prospective payment system for outpatient departments. 24N(4)

American Medical Accreditation Program (AMAP), SNM Physical Evaluation Program. 26N(1)

American Medical Association, Clinical Practice Guideline Recognition Program. 23N(5)

American Society of Radiologic Technologists, news from the Technologist Section. 16N(4)

Amino acids

blood-brain transport, 584(ab)

kinetic analysis of transport, 1016(ab)

1-amino-3-fluorocyclobutane-carboxylic acid, brain tumor imaging, 331

¹⁸F-labeled, transport mechanism and uptake kinetics, 1367

5-Aminosalicylic acid, absorption, ileorectal anastomosis patients. 1630

Ampphetamines, neurotoxicity. 113(ab)

Amyloidosis

evaluation of proximal tubular function, 864(ab)

scintigraphic diagnosis, 898(ab)

Amytal, distribution, regional cerebral perfusion and, Wada test. 747

Anatomical standardization, ¹¹C WAY-100635 PET, localization of serotonin receptors, brain. 102

Androgen receptor, PET ligands for prostate cancer. 1136(ab)

Angina, unstable, ²⁰¹Tl detection of culprit lesion. 779(ab)

Angiography, pulmonary perfusion scintigraphy to evaluate pulmonary embolism. 222(ab)

Angioplasty

assessing perfusion function after PTCA, 702(ab)

cost-effectiveness of ^{99m}Tc sestamibi SPECT, 172(ab)

detection of functional myocardial recovery, 505(ab)

percutaneous transluminal coronary, myocardial salvage after, 363

Angiotensin-converting enzyme (ACE) inhibitor

effect on regulation of AT1 receptors, 373(ab)

therapy, ¹²³I-MIBG myocardial imaging, 217

Animal studies

evaluation of infection imaging, 893(ab)

high-resolution lutetium oxyorthosilicate PET scanner, 1164

myocardial perfusion imaging. 20(ab)

PET research. 1176(ed)

pinhole SPECT system, 1249(ab)

radioprotection of salivary glands, 1033(ab)

^{99m}Tc alpha-fetoprotein, scintigraphy with, 1030(ab)

Annexin

anti-annexin V antibody imaging, 818(ab)

evaluation of transplant rejection, 38(ab)

Antibodies

antibody localization to tumors, 1007(ab)

stability of, 1381(ab)

[⁹⁰Y], pharmacokinetics and dosimetry of, 980(ab)

Antibody conjugates, blood clearance, hepatocyte-directed. 1392

Antibody fragments

improved tumor targeting, 1006(ab)

PET tumor tracers, ⁶⁴Cu-labeled genetically altered, 323(ab)

radioimmunotherapy with ^{99m}Tc-labeled IMMU-LL2, 949(ab)

targeting of tumor angiogenesis, 434(ab)

triglycine linker improves ⁶⁷Cu antibody uptake, 326(ab)

Antibody labeling

[¹¹I]-labeled antibody, in vivo stability of, 329(ab)

crosslinking potential of glycolaldehyde, 1404(ab)

stability of, 1387(ab)

^{99m}Tc humanized antibody imaging of lymphatic metastases, 1108(ab)

Antibody pharmacokinetics

compartment modeling, 1007(ab)

pharmacokinetic-based treatment planning, 1364.5(ab)

Anticarcinembryonic antigen, monoclonal antibodies.

[¹³¹I]-labeled, after radioimmunotherapy, 1609

Anti-CEA antibodies, antibody fragments, genetically engineered anti-CEA antibody. 325(ab)

Antiphospholipid antibody syndrome, regional cerebral blood flow in, ^{99m}Tc HMPAO evaluation. 1446

Antisense imaging, nuclear medicine and. 693

Aorta, aortic aneurysm, surgical repair of. 744(ab)

Aortic valve, myocardial sympathetic innervation. 34(ab)

Apoptosis

imaging with ^{99m}Tc annexin V, 184

quantification of caspase, for in vivo imaging of, 316(ab)

Appendicitis, ^{99m}Tc anti-CD 15 monoclonal antibody scan. 62(ab)

Arrhythmias, influence on gated SPECT. 924

Arterial input function, plasma FDG concentration. 1282(ab)

Arthroplasty, FDG PET infection imaging. 868(ab)

Artificial intelligence

artificial neural networks, 224(ab)

brain PET, discrimination of temporal lobe epilepsy, 476(ab)

computer-based decision support system, physician benefit from, 96

Asialoglycoprotein receptor

GSA, function of, 216(ab)

hepatic, ^{99m}Tc GSA, liver after resection, 137

method for estimating, 855(ab)

scintigraphy, auxiliary partial orthotopic liver transplant, 1463

Aspiration

fine-needle, ²⁰¹Tl scintigraphy and, thyroid nodules, 1971

radionuclide salivagram, milk scan, 51(ab)

Astatine-211, preparation and in vivo stability testing of linkers. 329(ab)

Atherosclerosis

macrophage burden, detection and quantification of, 355(ab)

migration of monocyte in detection of, 814(ab)

Attention deficit hyperactivity disorder

methylphenidate, 113(ab)

rCBF recovery after methylphenidate treatment, 1214(ab)

Attenuation correction

additive diagnostic efficacy, myocardial SPECT, 358(ab)

analytical methods for, 1337(ab)

bone SPECT, spine, 604

cardiac imaging, PET and SPECT transmission images, 135(ab)

Subject Index • 1999

211

- cardiac SPECT, 359(ab), 456(ab), 1310(ed), 1335(ab)
comparison of filtered backprojection and OS-EM methods, 1252(ab)
dual detector coincidence imaging, 1303(ab)
effect of transmission scan duration and smoothing, 1313(ab)
error estimation, 1308(ab)
esophageal cancer, FDG PET assessment, 594(ab)
false-positive myocardial ischemic study, 788(ab)
FDG coincidence imaging in oncology studies, 1311(ab)
FDG lung studies, 461(ab)
FDG PET, 562(ab)
 lesion detectability in breast cancer, 2021, 2025(ed)
geometrical models, 298(ab)
image processing, 1309(ab)
improves infarct size assessment on ^{201}Tl SPECT images, 749(ab)
initial clinical validation profile, 361(ab)
iodinated contrast, accounting for the presence of, 458(ab)
iterative calculated body contour-based vs scan-based, 730(ab)
iterative reconstruction, 1323(ab)
iterative reconstruction methods, 1326(ab)
line array source for, 1331(ab)
maximum-likelihood transmission gradient algorithm, 1312(ab)
MRP reconstruction in whole-body PET studies, 1330(ab)
multiple line source array, 15(ab)
nonuniform scatter in brain SPECT without transmission imaging, 1306(ab)
PET brain studies, 1315(ab)
processing techniques for, clinical evaluation of, 1257
reducing urinary bladder artifacts in SPECT studies, 1334(ab)
registration problems, 1296(ab)
scatter window measurements, 1277(ab)
segmented, 460(ab), 1304(ab)
simultaneous emission/transmission tomography, visual assessment of ^{201}TL perfusion images, 1303
specificity improves ^{201}Tl SPECT images, 363(ab)
three-dimensional myocardial SPECT, quantification of defect size, 817(ab)
transmission-emission myocardial gated SPECT, 752(ab)
transmission scans in cardiac SPECT, 1262(ab)
transmission SPECT cardiac images, 701(ab)
watershed segmentation algorithm, 1297(ab)
 ^{99m}Tc SPECT, brain imaging, 456
 ^{153}Gd scanning line source for noncardiac, 1327(ab)
- Auger electrons**
DNA cleavage, 1405(ab)
gene radiotherapy, 1009(ab)
therapeutic efficacy of, 1374(ab)
 ^{125}I , decrease in induction and toxicity from decay of, 1377(ab)
 ^{125}I in vivo therapy of neoplastic meningitis, 986(ab)
- Autonomic nervous system**, idiopathic dilated cardiomyopathy, prognostic value of ^{123}I MIBG in, 917
- Autosynthetic device**, multipurpose apparatus for radiopharmaceutical production, 1467(ab)
- Avascular necrosis**
bone SPECT vs MRI in detection of, 534(ab)
changes in blood flow and bone metabolism, 870(ab)
- Avidin**, modification, glycosylation and isoelectric point, 479
- Avidin-biotin system**, clearance of antigen, preinjection of intact antibody, 1381
- Avidin chase**, reduction of bone marrow toxicity, 1003(ab)
- B**
- Back pain**, bone SPECT, attenuation correction, 604
- Bacterial infection**
in granulocytopenia, scintigraphic imaging, 2066
 ^{99m}Tc HNP, imaging, 2073
- Barium**, history of, 24(N7)
- Basal ganglia**
disorders, diagnosis, optimized and automated, 110(ab)
SPECT imaging of Crigler-Najjar syndrome, 914(ab)
- Bench to Bedside program**, NIH imaging research opportunities, 9N(4)
- Benzamides**, sigma receptor scintigraphy with, 488(ab)
- Benzodiazepine receptor**
decreased frontal cortical receptors, 578(ab)
detection of viable cortical neurons, 1166(ab)
neocortical epileptic foci, ^{11}C FMZ PET, 1985
neuroprotective agent, FK506, 1172(ab)
in vivo imaging of activated microglia, 571(ab)
 ^{18}F fluoroethylflumazenil imaging of, 1222(ab)
- Benzodiazepines**, regional brain metabolic responses, reproducibility of, 715
- Beta-adrenergic receptor**
cardiac imaging, 351(ab)
perfusion defects reversed by glucagon, 518(ab)
synthesis and evaluation of, 496(ab)
- Beta-methyl-p-iodophenyl-pentadecanoic acid (BMIPP)**
dual label studies, rat tissues, 1918
sestamibi scintigraphy and, myocardial viability, 1468
- Beta-Ray emitters**, pure, Bremsstrahlung radiation exposure from, 1024
- Biliary dyskinesia**, radionuclide prediction of clinical outcome, 856(ab)
- Biliary tract stasis**, scintigraphic assessment of obstruction after hepatic resection, 214(ab)
- Biodistribution studies**
animal experiments, ^{123}I -DES for, 403(ab)
compartmental models, 830(ab)
PET radioligands, 1167(ab)
receptor scintigraphy with substituted benzamides, 488(ab)
 ^{99m}Tc complexes and ^{201}Tl , tumor/background ratios, 1036(ab)
 ^{111}In -labeled dendritic cells, 1028(ab)
 ^{123}I -PK 11195, 1354(ab)
 ^{188}Re , elimination study, 356(ab)
- Biotin**, ^{111}In -labeled, streptavidin and, pretargeting of bacterial endocarditis, 484
- Bismuth-213**, antibody labeled with, preparation of constructs for clinical use, 1722
- Bismuth-213 HUM195**, alpha-particle emitter labeled antibody, leukemia patients, 1935
- Bisphosphonates**, radiohalogenated, stability and bone accumulation, 1197
- Bladder tumor**, staging and therapy of, 399(ab)
- Blood flow**
assessment of relative flow to detect viable myocardium, 184(ab)
bronchial artery, perfusion scintigraphy, after lung transplant, 290
cerebral
 acetazolamide challenge test, 1173(ab)
 diagnosis of brain death, 1459(ab)
 diagnosis of brain death with ^{99m}Tc ECD, 1464(ab)
 distribution of ^{99m}Tc ECD, changes related to age, 1818
 dose response of remifentanil, 291(ab)
 epilepsy, SPECT image registration for, 1098
 gender differences, 1220(ab)
 naltrexone effects in alcoholics, SPECT, 19
 noninvasive determination of, 1272(ab)
 primary antiphospholipid antibody syndrome, ^{99m}Tc HMPAO evaluation of, 1446
 quantification and SPECT to detect vasospasm, 1188(ab)
 quantification using ^{99m}Tc ECD and SPECT, 1737
 remote regional consequences of focused infarcts, 721
 SPECT evaluation of acute cerebral infarction, 569(ab)
 statistical parametric matching, Parkinson's disease, 1583
 without blood sampling, 1273(ab)
 ^{99m}Tc compounds to measure brain perfusion index, 1271(ab)
- muscle, PET assessment of, 391(ab)
- myocardial
 absolute quantification with ^{201}Tl , 312(ab)
 baseline and hyperemic, ^{15}O -labeled water and PET, 1848
 intersubject variability in baseline studies, 763(ab)
 iterative reconstruction, PET, 862
 monitoring therapeutic response, 732(ab)
 oxidative metabolism abnormalities, PET, 846
 parametric imaging of, 295(ab)
 quantification by gated SPECT in normal subjects, 748(ab)
 simultaneous measurement of brain and MBF, 841(ab)
- Bone ammonia and PET**, 1045
- ^{125}I iodorotenone and ^{99m}Tc sestamibi in ischemic and infarcted myocardium**, 352(ab)
- PET measurement of skeletal muscle, 391(ab)
tumor, PET and MRI to measure, 1029(ab)
tumoral, measurement with O-15 water, 464(ab)
- Blood-pool imaging**
determination of left ventricular ejection fraction, 776(ab)
evaluation of left ventricular ejection fraction, 178(ab) gated
 bull's-eye polar map display, 794(ab)
 quantification of abnormal ventricular function, 712(ab)
three-dimensional analysis program for, 1278(ab)
- ^{99m}Tc , dose estimates, 1532
- Blood sampling**
programmable sampling device, 1235(ab)
 ^{18}F FDG as radiolabel for cells, 951(ab)
- BMIPP 15-(*p*-iodophenyl)-3-(R,S)-methyl pentad**
early detection of doxorubicin cardiotoxicity, 12(ab)
early detection of myocardial damage with, 796(ab)
myocardial viability assessment, 804(ab)
- Bombesin**
accumulation and retention of, 419(ab)
design and synthesis of, 318(ab)
gastrin-releasing peptide receptor, 317(ab), 418(ab)
- Bone**
anti-NCA granulocyte to image bone infection, 897(ab)
leukocyte imaging of painful joint replacements, 43(ab)
SPECT, OSEM vs filtered backprojection in, 1333(ab)
- Bone densitometry**
calcaneal ultrasound of postmenopausal osteoporosis, 538(ab)
differential bone loss in femoral neck, 533(ab)
effect of increasing tissue, 929(ab)
third-generation fan-beam bone densitometer, 1230(ab)
- Bone marrow**
FDG PET in acute leukemia, 956(ab)
local irradiation, effect on, 88(ab)
sparing effects of Sn-117m-DTPA for pain palliation, 978(ab)
 ^{99m}Tc anti-NCA 90 granulocyte imaging of, 952(ab)
 ^{99m}Tc MIBI, high accumulation of, 943(ab)
- Bone metastases**
distribution in lung cancer, 1144(ab)
FDG PET detection of, whole-body, 386(ab)
gastroenteropancreatic tumor, somatostatin receptor imaging, 1602
- high-dose Ho-166-DOTMP therapy, 160(ab)
planar bone scintigraphy, vs ^{18}F PET, 1623
receiver operating curve as SUV, 387(ab)
same-day sequential FDG studies, 83(ab)
- ^{18}F sodium fluoride PET detection of breast cancer, 82(ab)
 ^{99m}Tc methylene diphosphonate, detection of bone tumors, 1146(ab)
- Bone neoplasm**, malignant lymphoma, bone, ^{67}Ga scintigraphy and MRI comparison, 387
- Bone pain**
metastatic, management with systemic radionuclide therapy, 1420
palliation
 breast cancer metastasis, ^{186}Re etidronate in, 639
 clinical data analysis, 264(ab)
 with Re-186, 1015(ab)
 Re-186 HEDP, 265(ab)
 Re-188, kinetics and therapeutic effect, 975(ab)
 ^{85}Sr therapy, 585
radiohalogenated bisphosphonates, 1197
- Bone resorption**
proximal femoral component remodeling, 533(ab)
usefulness of NTx in, 874(ab)
- Bone scan**
detection of breast cancer metastases, 82(ab)
FDG PET detection of osseous metastasis, 81(ab)
patterns in multiple stress injuries, 876(ab)
SPECT vs MRI in nasopharyngeal carcinoma, 1052(ab)
- Bone scanning**, radionuclide, osseous lesions, 1623
- Bone scintigraphy**
bone metastasis, 413(ab)
diagnostic value in prostate cancer, 874(ab)
FDG PET replacement of, primary staging of malignant lymphoma, 1407
infection imaging, 905(ab)

- orthopedic infections, 901(ab)
 pelvic fractures, 873(ab)
 somatostatin receptor comparison, gastroenteropancreatic tumors, 1602
 SPECT evaluation of back pain, 536(ab)
 subtrochanteric and innominate osteotomies, 870(ab)
 three-phase imaging of musculoskeletal lesions, 875(ab) vs ultrasonography in plantar fascitis, 45(ab)
^{99m}Tc MDP in diagnosis of leukemia, 523(ab)
²⁰¹TL scintigraphy comparison, multiple myeloma, 1138
- Bone therapy**, radiohalogenated bisphosphonates, 1197
- Bone tumor**
 FDG uptake in giant-cell tumors, 390(ab)
 FDG uptake patterns in, 1141(ab)
 pediatric chemotherapeutic response of osseous sarcomas, 1148(ab)
 therapy with new Sn-117m formulations, 490(ab)
- Brain**
 adjuvant radioimmunotherapy in glioma, 266(ab)
 age-related defects in dopamine D2 receptors, 1218(ab)
 development of novel DAT radioligands, 1340(ab)
 dopamine mediates reinforcing of psychostimulants, 442(ab)
 effect of methamphetamine on dopamine transporters, 443(ab)
 frequency encoding, simultaneous display using, 442
 glutathione localization, ^{99m}Tc HMPAO, 1056
 integrated visualization of data, validation, 311
 maturation, distribution of ^{99m}Tc ECD, age-related changes, 1818
 metabolism, ^{99m}Tc HMPAO, in nervous tissue, 1556
 neoplasms, FDG PET and coincidence detection with a gamma camera, 110
 quantification of P-glycoprotein, transport in blood-brain barrier, 1159(ab)
 quantification of ^{11C} FLB 457 binding to extrastriatal dopamine receptors, 436(ab)
 serotonin receptors in, localization with ^{1C} WAY-100635 PET, 102
 spatial normalization methods, PET, validation of, 317
 SPECT, statistical parametric mapping in dementia, 1205(ab)
 SPECT to differentiate cerebral infections from lymphoma, 258(ab)
^{99m}Tc SPECT, attenuation correction in, 456
- Brain imaging**
 acetylcholinesterase, inhibitor of, 1207(ab)
 brain activation to normal and degraded speech, 449(ab)
 diagnosis of brain death, 1459(ab)
 diagnosis of brain death with ^{99m}Tc ECD, 1464(ab)
 emission-based attenuation correction, 1315(ab)
 itch, central processing of, 451(ab)
 neuropsychiatric disorders, 1240(ab)
 radioligand transport across blood-brain barrier, in vitro testing, 1348(ab)
 restless legs syndrome, 112(ab)
 SPECT and TCT, using asymmetric fanbeam collimator, 1252(ab)
 statistical parametric mapping, 1268(ab)
 statistical parametric mapping analysis, 1187(ab)
 synthesis and structure-affinity studies of piperidine-based analogs, 1341(ab)
^{11C} as a radioligand for, 1351(ab)
^{11C} raclopride to measure endogenous dopamine release, 1209(ab)
- Brain neoplasm**
 diagnostic test comparison, 1067(ab)
 edema, 453(ab)
 neurofibromatosis Type 1, 520(ab)
 PET activation study, 450(ab)
 role of FDG PET in clinical management of, 521(ab)
¹²³I-methyl tyrosine and ²⁰¹Tl in differential diagnosis of, 1064(ab)
- Brain perfusion**
 human immunodeficiency virus, 1191(ab)
 serial SPECT pre-post liver transplantation, 914(ab)
 subcortical aphasia, 1194(ab)
- Brain stem**, focused infarcts, remote regional blood flow responses, 721
- Brain tumor**
 enhanced ^{11C} TPMP uptake, PET, 1180
 FDG PET imaging applications, 591
- imaging**
^{18F} FABCC PET, 331
^{18F} FET PET, 205
 malignant, ¹³¹I-labeled 81C6 monoclonal antibody, 631
^{18F} FMT PET, 399
- Breast**
 correlation of mammogram and scintimammogram, 66(ab)
 influence of volume and injection site, 237(ab)
 lymphoscintigraphy in breast neoplasm, 557(ab)
 monoclonal antibody imaging of breast lesions, 1108(ab)
 normal FDG uptake, 1099(ab)
 radiopharmaceuticals excreted in breast milk, 1355(ab)
 tumor imaging with PET, 307(ab)
- Breast biopsy**
 stereotactic, positron emission mammography-guided, 468(ab)
 stereotactic real-time image-guided, 1256(ab)
- Breast cancer**
 axillary lymph node metastasis and, FDG PET and dual-head coincidence imaging comparison, 1003
 diagnostic protocol, ^{99m}Tc-MIBI mammography in, 296
 double phase ^{99m}Tc sestamibi scintimammography, T-scan and, 376
 early, sentinel node localization in, 1403(ie)
 lesion detectability, attenuation correction in FDG PET, 2021, 2025(ed)
 metastatic bone pain with, ¹⁸⁶Re etidronate in, 639
 new look, 1009(ed)
¹²³I iodovinylestradiol imaging, estrogen receptors, 1728
- Breast neoplasm**
 antibody imaging, 67(ab)
 breast cancer xenografts, comparative study of ima, 1030(ab)
 comparison of scintigram and immunohistochemical, 65(ab)
 FDG as predictor of pathological response of chemotherapy, 552(ab)
 FDG coincidence imaging, 540(ab)
 FDG PET assessment of, 554(ab)
 FDG PET detection of axillary metastases, 555(ab)
 FDG PET detection of recurrent breast cancer, 1109(ab)
 four-view scintimammography with pinhole collimator, 1104(ab)
 fusion proteins for targeting of, 1370(ab)
 intratumoral uptake of sestamibi and C-14-deoxyglucose, 1022(ab)
 lymphoscintigraphy
 role in sentinel node biopsy, 1119(ab)
 role in sentinel node detection, 70(ab)
 lymphoscintigraphy to detect sentinel node, 1122(ab)
 lymphoscintigraphy vs Gamma Probe, 558(ab)
 multidrug resistance, 1101(ab)
 PET imaging to predict therapeutic response, 1110(ab)
 pinhole SPECT detection of axillary lymph node metastasis, 1105(ab)
 planar and MIBI SPECT detection of axillary lymph node, 556(ab)
 positioning to improve lymphoscintigraphy results, 1112(ab)
 quantitative studies of metabolic images for detection, 542(ab)
 scintigraphic assessment of therapeutic response, 553(ab)
 scintimammography of, 1106(ab)
 sentinel node mapping in, 1123(ab)
 sestamibi imaging to detect preinvasive lesions, 64(ab)
 single- or double-method lymph node biopsy, 1114(ab)
 Z-MIVE scintigraphy, predictor of tamoxifen efficacy, 1107(ab)
¹⁸F FES assessment of estrogen receptors, 1111(ab)
^{99m}Tc P1410 targets breast cancer xenografts, 417(ab)
- Breast scintigraphy**
 dual slant-angle collimation in, 1256(ab)
 four-view scintimammography with pinhole collimator, 1104(ab)
 improved identification of axillary sentinel nodes, 1112(ab)
 procedure guidelines, 1233
 sentinel node, lymphatic mapping of, 559(ab)
 therapeutic response assessment, 553(ab)
^{99m}Tc sestamibi, effect on breast biopsies, 1103(ab)
- Bremsstrahlung**, radiation exposure, pure beta-ray emitters, 1024
- Briner, Capt. William H.**, nuclear medicine in the military, 10N(1)
- Bronchial artery**, revascularization, perfusion scintigraphy, after lung transplant, 290
- [⁷⁶Br]4-bromodexetimide**, PET, imaging of temporal lobe epilepsy, 935
- C**
- Camera systems**, sensitivity of Pem-1, 542(ab)
- Cancer**. *see also* specific type and site
 metastatic bone pain, management with systemic radionuclide therapy, 1420
 postsurgical radioiodine therapy of differentiated thyroid cancer, 987(ab)
¹¹¹In-octreotide therapy, 73(ab)
- Cancer imaging**
 advantage of small solid-state gamma camera, 1121(ab)
 aptamer against tenascin-C, 402(ab)
 delayed FDG PET breast images, 566(ab)
 farnesyl transferase distribution, 400(ab)
 FDG and FLT, 245(ab)
 FDG PET, 408(ab), 1040(ab)
 FDG PET imaging of solitary pulmonary nodules, 225(ab)
 FDG PET staging of malignant lymphoma, 247(ab)
 PET detection of metastatic tumors, 1131(ab)
 PET radiotracer, kinetic modeling of farnesyl transferase, 1014(ab)
 PET tumor agents, ^{18F} FHBG for gene expression, 103(ab)
 PET with ^{18F} FLT, 101(ab)
 potential of ^{18F} RO41-0960, 406(ab)
 restaging of indeterminate colorectal cancer lesions, 93(ab)
 synthesis of ^{18F} FMAU, 334(ab)
 tumor localization with FDG SPECT and CT, 1281(ab)
 whole-body FDG-PET detection of colon cancer metastases, 565(ab)
¹⁸ arabinonucleosides, synthesis of, 1368(ab)
- Cancer staging**
 FDG PET and MRI in abdominal lymph node staging, 423(ab)
 FDG PET assessment of cervical cancer, 1129(ab)
 whole-body FDG PET, 226(ab)
- Captopril**
 cardiac MIBG kinetics and, failing heart, 224
 hypotensive response to, scintigraphic assessment of renal artery stenosis, 406
 renal scintigraphy, hypertensive patients with renal failure, 412
- Captopril renography**
 criteria for baseline studies, 375(ab)
 differential diagnosis of transplant complications, 376(ab)
- Carbon-11**, activity, after injection of methyl-^{11C} thymidine, 491
- Carbon-11 acetate**
 dual-isotope PET study to determine beta oxidation in malignant neoplasm, 1062(ab)
 prostate cancer, PET imaging of, 242(ab)
 renal cell carcinoma, PET imaging with, 1139(ab)
- Carbon-11 DTBZ**, reproducibility studies, healthy human subjects, 283
- Carbon-11 epinephrine**, PET imaging of neuroblastoma, 519(ab)
- Carbon-11 FMZ**, PET, neocortical epileptic foci, 1985
- Carbon-11 hydroxyephedrine**, PET assessment of aortic stenosis, 34(ab)
- Carbon-11 MET**
 correlation of MIB-1 positive rate in brain tumors, 1065(ab)
 PET, FDG PET and, thymic tumors, 1595
- Carbon-11 PHEN**
 monoamine oxidase activity, vesicular storage and, isolated heart, 323
 sensitivity to monoamine oxidase activity, heart, 232
- Carbon-11 raclopride**, endogenous dopamine competition with, brain response to methylphenidate, 1285
- Carbon-11 thymidine**, PET, validation studies, 614
- Carbon-11 TPMP**, enhanced uptake, brain tumor, PET, 1180

- Carbon-11 tyrosine**, cervical cancer, detection of, 1132(ab)
- Carbon-13 breath test**, orocecal transit time, 1451
- Carbon-14 deoxyglucose**, 99m Tc HL91 comparison, detection of tumor hypoxia, 854
- Carcinoembryonic antigen (CEA)**
medullary thyroid cancer producing-, radioimmunotherapy, 198
in vivo tumor targeting of, 1004(ab)
- Carcinoid tumor**
uptake of I-123- α -MT detection of, 393(ab)
 111 In-octreotide therapy for, 73(ab)
- Carcinoma cells**, 99m Tc sestamibi and 3 H daunomycin, 672
- Cardiac function**
age effects on, 4(ab)
exercise-induced abnormalities of, 782(ab)
gated SPECT reconstruction of strain and stress tensors, 816(ab)
improved accuracy of gated SPECT assessment of, 740(ab)
LV volume and ejection fraction, 805(ab)
reduction of partial volume errors, 797(ab)
 123 I MIBG sympathetic reinnervation of allografts, 911
- Cardiac imaging**
attenuation correction, 769(ab)
cardiac SPECT and angiography, 315(ab)
dipyridamole perfusion imaging, use in renal transplant, 707(ab)
dual-isotope imaging, prognostic value of, 22(ab), 170(ab)
gated SPECT reconstruction of strain and stress tensors, 816(ab)
Ga-67 in rheumatic carditis, 11(ab)
list mode PET, 457(ab)
metabolism and function, 832(ab)
multiple line source array TCT/ECT system, 15(ab)
quantitation of SPECT images, 16(ab)
reversible perfusion defects, outcomes for, 27(ab)
scatter correction, 462(ab)
simultaneous assessment of ventricular function, 915(ab)
SPECT leukocyte imaging in occult infective endocarditis, 9(ab)
SPECT with rotating chair and solid-state gamma camera, 750(ab)
three-dimensional alignment in PET assessment of, 18(ab)
transmyocardial laser revascularization, 764(ab)
viability and endpoint markers, 738(ab)
 99m Tc sestamibi, 348(ab)
- Cardiac output**, forward, measurements, 99m Tc-labeled agents for myocardial perfusion imaging, 1874, 1882(ed)
- Cardiac sympathetic function**, 123 I-MIBG myocardial imaging, after β -blocker or ACE therapy, 217
- Cardiac sympathetic innervation**
adriamycin-induced cardiac toxicity, 833(ab)
cardiac transplantation, 10(ab)
PET study after orthoptic heart transplantation, 30(ab)
relationship with function and metabolism, 188(ab)
sinus bradycardia, 786(ab)
- Cardiac sympathetic nerve function**, MIBG scintigraphy of, 727(ab)
- Cardiac sympathetic reinnervation**, 123 I MIBG, cardiac allografts, 911
- Cardiac volume**
bias from reconstructed filters, 1319(ab)
prognostic value of, 6(ab)
- Cardiomyopathy**
alterations in myocardial sympathetic innervation, 188(ab)
dilated, 123 I-MIBG myocardial imaging in, 217, 224
gated SPECT differentiation of ventricular dysfunction, 711(ab)
hypertrophic, impairment of BMIPP accumulation, ventricular junction, 2007
idiopathic dilated, prognostic value of 123 I MIBG in, 917
low cardiac MIBG uptake a predictor of, 175(ab)
potential alterations in oxygen, glucose and fatty acid metabolism, 808(ab)
quantitative SPECT to differentiate ischemic and nonischemic, 507(ab)
steal phenomenon in, 7(ab)
viability and endpoint markers, 738(ab)
 18 F FTHA PET studies of, 187(ab)
 123 I-BMIPP imaging of, 799(ab)
- Carotid artery diseases**, carotid shunt during carotid endarterectomy, 568(ab)
- Catechol-O-methyltransferase (COMT) inhibition**, PET imaging of estrogen metabolism, 406(ab)
- CBF SPECT**
evaluation of Alzheimer-type dementia with, 1192(ab)
high-field MRI in basal ganglia and, 271(ab)
- CD36 deficiency**, enhanced myocardial glucose use in, 239
- Cellular dosimetry**, S-factors, alpha particle-emitting radionuclides, 162(ab)
- Central Nervous System (CNS)**, lymphoma vs toxoplasma, diagnostic utility of 201 Tl SPECT, 896(ab)
- Cerebellum**, focused infarcts, remote regional cerebral blood flow consequences, 721
- Cerebral cortex**, 99m Tc HMPAO retention, nervous tissue, 1556
- Cerebral glucose metabolism**
adverse effects of edema on, 453(ab)
FDG PET assessment of changes in, 454(ab)
radiolabeled glucose and acetate to measure, 1165(ab)
- Cerebral infarction**
focused, remote regional blood flow responses, 721
prognostic value of 99m Tc ECD, 1202(ab)
- Cerebral ischemia**
phosphoinositide turnover, evaluation with PET, 1590
 99m Tc HMPAO metabolism, nervous tissue, 1556
- Cerebral metabolism**, increased brain glucose use, Salla disease, 12
- Cerebral oxygen metabolism**, radiolabeled glucose and acetate to measure, 1165(ab)
- Cerebral perfusion reserve**, alterations in chronic traumatic brain injuries, 286(ab)
- Cerebral perfusion SPECT**
contralateral thalamic uptake, 1189(ab)
reproducibility of serial ictal/postictal images, 1199(ab)
- Cerebrovascular disease**, five-year prognosis, increased oxygen extraction fraction in, 1992
- Cervical cancer**, FDG PET in, 1125
- Cesium-137**, history corner, 18N(4)
- 10 CFR 35**, rewrite of, 22N(1)
- Chelate**, rhenium-labeled chelators, 504(ab)
- Chelating agents**, combinatorial libraries, 499(ab)
- Chemoradiotherapy**, evaluated by FDG PET, 1132
- Chemotactic peptides**
effects of neutrophil depletion and immunosuppression, 895(ab)
high-throughput screening, 497(ab)
infection and sterile inflammation imaging, 894(ab)
- Chemotherapy**, chemotherapy-induced neurotoxicity, 99m Tc ECD SPECT assessment of, 522(ab)
- Chemotherapy response**
breast cancer assessed by 99m Tc MIBI, 1038(ab)
changes in tumor blood flow and metabolism as predictor of, 551(ab)
- Chest pain**
significance of reduced BMIPP uptake in evaluation of, 14(ab)
women, myocardial perfusion imaging or dobutamine stress echocardiography, 1222(ie)
- Cholangiocarcinoma**, hilar, 99m Tc-GSA accumulation, 394
- Cholecystitis**, acalculous, cholecystokinin cholescintigraphy in, 2038
- Cholecystokinin**
acute cholecystitis, diagnosis of, 215(ab)
biliary dyskinesia, 856(ab)
radiolabeled, targeting cholecystokinin-B/gastrin receptor-expressing tumors, 1029
- Cholecystokinin receptor ligands**, medullary thyroid cancer, staging of, 396(ab)
- Cholecystokinin receptors**, radiolabeled CCK analogs, evaluation of, 2081
- Cholescintigraphy**, cholecystokinin, 2038
- Choline**
cervical cancer, PET studies of, 1132(ab)
lymph node staging with FDG PET in lung cancer, 240(ab)
PET imaging of prostate cancer, 241(ab)
vs FDG lymph node staging in esophageal cancer, 239(ab)
- Cholinergic neurons**, high-affinity choline uptake, 1353(ab)
- Circulation**. see Blood flow; Collateral circulation
- Cirrhosis**
liver, prognosis with 99m Tc GSA scintigraphy, 1652
umbilico-portal collaterals, 844(ab)
- Cisplatin**, 116 Re HEDP and, prostate cancer cells, 667
- Clearance**
camera-computer quantitation of bladder activity, 208(ab)
effect of time interval/blood sampling on Cr-51 EDTA, 210(ab)
- Clinical outcome**
acute pulmonary embolism, 220(ab)
aging, effect on predictive value of SPECT, 722(ab)
myocardial perfusion SPECT on angina pectoris, stress test in angina pectoris, clinical outcome, 710(ab)
online data tracking and reporting, 1468(ab)
solitary pulmonary nodules, 231(ab)
 131 I-labeled anti-B1 antibody, 76(ab)
- Clinical practice**, nuclear medicine in the military, 10N(1)
- Clinical Practice Guideline Recognition Program**, AMA, 23N(5)
- Cocaine**, reduction of dopamine release, 444(ab)
- Cocaine analogs**, *in vitro* and *in vivo* evaluation of, 1343(ab)
- Cochlear implant**, pre-surgical prediction of, 452(ab)
- Coding and Reimbursement**, questions and answers, 16N(2)
- Cognitive dysfunction**, FDG PET detection of metabolic abnormalities in, 1184(ab)
- Coincidence detection camera**
attenuation correction for, 136(ab)
comparison with FDG PET, 1187(ab)
dual-detector, 1303(ab)
effects of uncollimated crystal exposure, 478(ab)
FDG imaging modalities, 1154(ab)
FDG lung studies, 461(ab)
FDG uptake in myocardial viability assessment, 708(ab)
oncology studies, low-activity camera vs conventional PET camera, 1152(ab)
optimization of crystal thickness, 1229(ab)
performance characteristics, high-contrast clinical images with gamma camera, 1245(ab)
performance characteristics of, 1243(ab)
performance evaluation, 482(ab)
singles rate optimization in, 479(ab)
- Coincidence imaging**
acquisition methods and detector performance for, 1298(ab)
cross-talk correction algorithm, 480(ab)
dual-detector, 18 F FDG, solitary pulmonary lesions, 574
dual-head
FDG PET comparison, breast cancer, 1003
vs ring PET, tumor patients, 1617
dual-head FDG detection cameras, 9N(3)
dual-head scintillation camera, 432
effects of uncollimated crystal exposure, 478(ab)
FDG, 1243(ab)
diagnostic accuracy in thyroid cancer, 543(ab)
FDG in oncology studies, 540(ab)
FDG PET detection of pulmonary lesions, 1094(ab)
FDG tumor imaging, 1153(ab)
gamma camera, FDG, lung cancer, 566
head and neck cancer, 1055(ab)
high-resolution with acceptable acquisition times, 1245(ab)
iterative reconstruction algorithm, 1295(ab)
lesion detectability with coincidence capability, 545(ab)
myocardial studies, 132(ab)
oncology studies, 546(ab), 1040(ab)
performance of SPECT camera with PET option, 1244(ab)
phantom studies, 479(ab)
pileup prevention, 598(ab)
simultaneous acquisition of FDG and Tc agents, 1247(ab)
staging of tumors of the mouth and tongue, 1048(ab)
task-based instrument evaluation, 483(ab)
three-dimensional acquisition, 1332(ab)
 18 F FDG, 944(ab)
- Collateral circulation**, dynamic radionuclide angiography, 844(ab)
- Collimation, Collimators**
dual-planar circular-orbit cone-beam SPECT, 1253(ab)
effect and correction of detector sag in SPECT systems, 1260(ab)

- effect on lesion detection in breast imaging, 140(ab)
fan-beam evaluation and calibration of, 1259(ab)
hole array pattern of, 1310(ab)
mapping of hole angulation errors, 1257(ab)
NEMA system plane sensitivity, penetrating photons, 1261(ab)
predicted lesion detection performance, 133(ab)
small gamma camera, 1226(ab)
ultra-high resolution uranium pinhole, 138(ab)
- Colon cancer**
FDG PET whole-body imaging, 93(ab)
liver metastasis from, radiolabeled antibody distribution and radioimmunotherapy, 685
transplanted to nude mice, ¹⁸F FDG uptake in, 339
xenograft
fractionated external beam radiotherapy and radioimmunotherapy, 1764
MAb CC49 constructs, 1536
- Colonic transit**
Psyllium suspension in, 848(ab)
⁶⁷Ga labeling of activated charcoal capsules, 1383(ab)
⁶⁷G citrate transport, in constipation, 277
- Colorectal cancer**
biodistribution of ^{99m}Tc P1666 vasoactive peptide, 1081(ab)
correlation of PET studies with CEA levels in, 1070(ab)
diagnosis with PET, 412(ab)
FDG PET assessment of recurrence, 1074(ab)
improved FDG PET abdominopelvic evaluation, 1083(ab)
multimodality imaging, 92(ab)
potentially resectable lesions, 1068(ab)
radioimmunotherapy of small-volume disease, 428(ab)
therapeutic efficacy of combined radioimmunotherapy, 429(ab)
^{99m}Tc-labeled VIP receptor agonist, functional studies, 352
- Community hospitals**, FDG PET scanning in, 11N(11)
- Compartmental models**
accurate parameter estimates for dynamic ²⁰¹Tl SPECT, 313(ab)
FDG distribution, 1358
muscarinic cholinergic ligand, 119(ab)
- Compton camera**, predicted lesion detection performance, 133(ab)
- Computed tomography (CT)**
combined CT/SPECT, 596(ab)
radionuclide transmission, attenuation maps, multimodality registration, 448
tumor imaging, 1134(ab)
vs SPECT in evaluation of cerebral hypoperfusion, 572(ab)
- Computer-assisted diagnosis**
database tracking on the Internet, 1468(ab)
decision support system, physician benefit from, 96
D2 receptors, semi-quantitation of, 110(ab)
education, 1455(ab), 1456(ab)
interpretation of myocardial perfusion tomograms, 508(ab)
MIRDose 4, 1357(ab)
myocardial perfusion imaging, 1457(ab)
myocardial perfusion SPECT databases, 1290(ab)
voice recognition dictation system, 1292(ab)
- Computer simulation**
computer-based tutorials, 1461(ab)
Monte Carlo estimate of Cr-51-EDTA clearance, 210(ab)
- Congestive heart failure**
cardiac sympathetic function, 736(ab)
clues to prognosis, 1699(ed)
left ventricular dilatation as predictor of, 181(ab)
- Constipation**, ⁶⁷G citrate, segmental colonic transit after, 277
- Continuing Medical Education (CME)**, earning credit electronically, 9N(2)
- Convex hull**, global spatial normalization, brain, 942
- Copper-62 ATSM**, comparative analysis reduction of, 330(ab)
- Copper-62 PTSM**, vs ^{99m}Tc sestamibi SPECT in detection of coronary artery disease, 723(ab)
- Copper-64 ATSM**, evaluation, hypoxic tumor model, 177
- Copper-67 2IT-BAT-Lym-1**, radioimmunotherapy, non-Hodgkin's lymphoma, 2014
- Coronary artery bypass surgery**
effects on brain perfusion, 1225(le)
- gated myocardial SPECT to assess improved perfusion and function, 742(ab)
ischemic heart disease, assess regional function a, 761(ab)
myocardial perfusion SPECT, prognostic value of, 22(ab)
risk of cardiac death, 25(ab)
sternal vascularity of, 539(ab)
- Coronary artery disease (CAD)**
cardiac events, prediction with dipyridamole perfusion, 707(ab)
changes in myocardial tetrofosmin uptake indicate, 514(ab)
dobutamine assessment of regional myocardial blood flow, 791(ab)
improved diagnostic yield with ²⁰¹Tl, 360(ab)
improved myocardial perfusion after rhVEGF therapy, 342(ab)
Monte Carlo simulation, 165(ab)
multimodality detection of, 723(ab)
multivessel CAD, 733(ab)
myocardial perfusion SPECT, prognostic value of, 170(ab)
myocardial perfusion SPECT, simultaneous ^{99m}Tc sestamibi and ²⁰¹Tl dual isotope, 895
percutaneous laser revascularization, therapeutic effect of, 337(ab)
PET, serial evaluation with, 732(ab)
prognostic value of weightier quantitative analysis, 169(ab)
rest and exercise dual-isotope SPECT, 774(ab)
rest-exercise stress and rest-ATP stress, ^{99m}Tc sestamibi scintigraphy, 512(ab)
simultaneous emission/transmission tomography, attenuation correction in, 1303
SPECT myocardial perfusion imaging, 347(ab)
stress testing, 516(ab)
⁶²Cu-ATSM vs FDG in detecting ischemic myocardium, 704(ab)
^{99m}Tc sestamibi SPECT, right ventricular uptake, 889
²⁰¹Tl lung uptake as discriminant indicator of, 809(ab)
- Coronary flow**, acute estrogen administration and coronary vasomotion, 32(ab)
- Coronary flow reserve**
differences in response to mental stress, 346(ab)
prominent in noninsulin-dependent diabetes, 762(ab)
steal phenomenon in pediatric hypertrophic cardiomyopathy, 7(ab)
validation of, ¹⁵O-water PET studies, 31(ab)
- Coronary intervention**
reversible perfusion defects on ²⁰¹Tl SPECT, 741(ab)
²⁰¹Tl SPECT, perfusion defects after angioplasty, 811(ab)
- Coronary syndrome**, acute, fatty acid imaging, ¹²³I-9-MPA, 1999
- Cortical bone**, absorbed fractions of energy within, three-dimensional transport model, 2115
- Cost-effectiveness**
age basis for captopril baseline studies, 375(ab)
decision analysis in nuclear medicine, 1570
dipyridamole myocardial perfusion SPECT, 171(ab)
exercise ²⁰¹Tl SPECT, 718(ab)
FDG PET in lung cancer, 227(ab)
sentinel node biopsy in breast cancer management, 560(ab)
somatostatin analog, ^{99m}Tc depreotide, assessment of solitary pulmonary nodules, 231(ab)
- Cross-talk correction**
accurate estimation of myocardial perfusion on FDG and tetrofosmin images, 801(ab)
modeling Pb X-ray contamination in dual-isotope SPECT, 470(ab)
simultaneous ^{99m}Tc / ²⁰¹Tl imaging, 839(ab)
- Cyclopentadienyl technetium**, brain uptake and dopamine transporter binding of, 154(ab)
- Cystography**, radionuclide, direct and indirect, dosimetry in children, 2127(le)
- Cytomegalovirus**, ¹⁸F FHPG PET in, 890(ab)
- D**
- Data analysis**
database management system, 1291(ab)
functional PET, 300(ab)
- kinetic analysis of PET time-activity curves, 310(ab)
Monte Carlo probabilities of cluster formation, 1276(ab)
quantification with I-123-epidepride SPECT, 143(ab)
quantitation of condensed image, 859(ab)
tracking of left ventricular motion, 829(ab)
- Database**
normal confidence interval, 1466(ab)
relational management system, 1291(ab)
- Decision modeling**
nuclear medicine, 1570
ROC analysis, 475(ab)
- Deconvolution**, comparison, Patlak-Rutland plot in renography, 1503
- Deep venous thrombosis**
contrast-enhanced venography, ^{99m}Tc apcitide scintigraphy and, 2029, 2036(ed)
technetium-labeled peptide detection of, 613(ab)
^{99m}Tc anti-fibrin peptide detection of, 491(ab)
^{99m}Tc P424, evaluation of receptor binding agent, 887(ab)
- de Hevesy Award**, 12N(6), 30N(8)
- Dementia**
early Alzheimer detection, 283(ab)
effect of apolipoprotein E on regional brain metabolism, 281(ab)
FDG PET and SPECT, differential diagnosis with, 282(ab)
with Lewy bodies, ^{99m}Tc HMPAO SPECT study, 956
neurofibrillary tangles, 284(ab)
PET, clinical outcome with, 285(ab)
statistical parametric mapping to evaluate, 1205(ab)
- Deoxyribonucleic acid**, antisense and nuclear medicine, 693
- Department of Energy (DOE)**
ACNP/SNM Government Relations Activities, 1998 year end report, 25N(2)
isotope conference, 22N(1)
Medical Isotopes Conference, 13N(5)
- Depression**
activation study of, 1212(ab)
amphetamine-induced dopamine release in, 1210(ab)
cortical metabolic deficits in, 1211(ab)
low serotonin synthesis in temporal lobe, 577(ab)
SPECT imaging of, 576(ab)
5HT2 receptors, 575(ab)
- Detector defects**, clinical relevance of, PET quality assurance, 1657
- Diabetes**, exercise-induced abnormalities of cardiac function in, 782(ab)
- Diabetic foot**
osteomyelitis in, 871(ab)
^{99m}Tc HMPAO four-phase imaging, 902(ab)
- Diagnosis**
aesthesioneuroblastoma with SRS, 1059(ab)
FDG PET assessment of malignant lesions, 1097(ab)
myocardial infarction with ^{99m}Tc tetrofosmin SPECT, 781(ab)
- Diagnostic test comparisons**, lacrimal scintigraphy and dacrocystography, 455(ab)
- Diagnostic tests**, HCFA ruling on, 25N(7)
- DICOM** Image display, WEB picture archiving system, 1460(ab)
- Differentiated thyroid cancer**, reduces subsequent ablation in DTC, 531(ab)
- Dimercaptosuccinic acid (DMSA)**
diagnostic and therapeutic effects on head and neck cancer, 988(ab)
evaluation of urinary tract infection in children, 916(ab)
Re-188, in vitro and in vivo evaluation, 1384(ab)
SPECT imaging of renal scars, 865(ab)
- Dipyridamole**, myocardial perfusion SPECT, cost-effectiveness of in myocardial infarction, 171(ab)
- Distinguished service awards**, 30N(8)
- Dobutamine**
changes in left ventricular function, 709(ab)
estimation of ejection fraction, after His bundle ablation, 754(ab)
gated myocardial SPECT, 790(ab)
induced changes in left ventricular function, 703(ab)
predictor of improved LVEF post-revascularization, 1(ab)
stress testing with ^{99m}Tc sestamibi SPECT, 518(ab)
- Donner Laboratory**, history of nuclear medicine, 16N(1)
- Dopamine**
dopamine transporter occupancy and behavior, 440(ab)

- effect of exercise on striatal dopamine release**, 588(ab)
endogenous, ^{11}C raclopride competition with, brain response to methylphenidate, 1285
IBZM SPECT measure of reduced dopamine release, 444(ab)
PET measurement of receptor availability, 1176(ab)
schizophrenic psychopathology and presynaptic, 125(ab)
SPECT imaging of dopaminergic system in bipolar disorder, 580(ab)
SPECT measurement of amphetamine-induced release, 1210(ab)
 ^{18}F fallypride and F-18 FMT, system characterization of, 437(ab)
- Dopamine D2 receptors**
 autosomal recessive Dopa-responsive dystonia, 272(ab)
 binding potential associated with social phobia, 581(ab)
 brain imaging, ^{123}I IBZM SPECT, neonatal period, 2125(le)
 elevation in schizophrenia, 121(ab)
 endogenous release in thalamus, 1209(ab)
 intrasynaptic dopamine level, 124(ab)
 quantification, ^{123}I epidepride SPECT, 1902
 raclopride, 586(ab)
 regioselective and efficient synthetic method, 607(ab)
 relative distribution in postmortem brain, 1157(ab)
 simplified analysis to metabolite corrected distribution, 143(ab)
 ^{11}C CPHT, 1338(ab)
 ^{18}F fallypride, parametric imaging of striatal and nonstriatal binding, 1267(ab)
- Dopamine neurons**
 FMT and FDOPA uptake in PET studies of aging, 1169(ab)
 MPTP, effects on striatal transport and decarboxylation of, 587(ab)
 striatal metabolism of $6\text{-}^{18}\text{F}$ fluoro-L-dopa, 1163(ab)
- Dopamine receptors**
 D1 receptors, quantitative analysis of, 435(ab)
 serotonergic and dopaminergic PET binding studies, 579(ab)
 simultaneous SPECT studies, baboons, 660
 synthesis and evaluation of ^{11}C YM-50001, as a PET radioligand, 1342(ab)
- Dopamine transporters**
 age effects, healthy humans, 1812
 autosomal recessive Dopa-responsive dystonia, 272(ab)
 changes in cocaine users, 441(ab)
 characterization of highly selective DAT ligand for SPECT, 153(ab)
 detection presymptomatic phase of Parkinson's disease with I-123-FP CIT SPECT, 106(ab)
 functional lateralization in basal ganglia in Parkinson's disease, 267(ab)
 IPT SPECT assessment of decrease of, 126(ab)
 nigrostriatal dopaminergic pathway, Parkinson's disease, 753
 pharmacokinetics of ^{18}F FPCT, 1339(ab)
 simultaneous SPECT studies, baboons, 660
 SPECT, Parkinson's disease, 530
 SPECT imaging with ^{99m}Tc TRODAT-1, 583(ab)
 striatal quantitation with microPET, 1156(ab)
 synthesis and structure-affinity studies of piperidine-based analogs, 1341(ab)
 in vitro evaluation of acyclic amine-amide analogs, 1340(ab)
 ^{99m}Tc labeled ligand and SPECT imaging of, 1161(ab)
 ^{99m}Tc TRODAT SPECT imaging of Parkinson's disease, 109(ab)
 ^{99m}Tc TRODAT-1 imaging agent, kinetic modeling of, 150
 ^{123}I FPCIT, reproducibility of SPECT images, 1201(ab)
 ^{123}I labeling, brain uptake and binding, 154(ab)
 ^{123}I labeling to monitor progression of Parkinson's disease, 111(ab)
- Dose calibrator**
 errors related to radiopharmaceutical administration, 616(ab)
 setting for ^{188}Re , 1508
- Dose estimation**
 therapy with ^{111}In -octreotide, 982(ab)
 ^{99m}Tc lipiodol after brachytherapy, 167(ab)
 ^{99m}Tc vasoactive peptides, 1363(ab)
- Dosimetry**
 applications, new rectal model for, 1524
- autonomous thyroid nodule, radioiodine therapy candidates, 1928
 biodistribution of ^{18}F FCWAY, 168(ab)
 biological, radiation adaptive response, 1378(ab)
brain
 pediatric head and brain models, 1327
 revised model, radionuclide S values in, 62S
 clearance fitting, in thyroid cancer, 131
 direct and indirect radionuclide cystography, children, 2127(le)
 effective dose determination of ^{18}F FBT, 1356(ab)
 error estimation, 158(ab)
 influence of stents, 165(ab)
 internal radiation, mouse models for, 1969(le)
 internal radionuclide, EGS4 Monte Carlo code-based software for, 1517
 intraperitoneal radioimmunotherapy, 979(ab)
 marrow, radioactivity concentration in blood and body, 2102
MIRDose 4, 1357(ab)
 Monte Carlo calculation of dose conversion factors, 1364(ab)
 nonuniform, implications for radioimmunotherapy, 1337
 nonuniform activity distributions, radionuclide S values at voxel level, 11S
 normal organ estimates of I-131-NM-404, 155(ab)
 patient morphology, MIRD models of, 157(ab)
radiation
 biodistribution and, ^{111}In antimyosin, 464
 FDG distribution, 1358
 marrow dosimetry based on radioactivity concentration, 159(ab)
 non-Hodgkin's lymphoma and chronic lymphocytic leukemia, 1317
 testes, after ^{131}I therapy for thyroid cancer, 1716
 urinary bladder model for, MIRD, 102S
 ^{18}F fluorouracil, effect of $5\text{-}^{18}\text{F}$ EU on, 1361(ab)
 ^{67}Cu -21T-BAT-Lym-1, tumor regression in lymphoma, 302
 ^{99m}Tc DMP-HSA serum albumin, 1532
 ^{99m}Tc -labeled IgM antibody to CD15 antigens, granulocytes, 625
 radiation absorbed dose and response to I-131-Anti-B1 therapy, 77(ab)
 radiopharmaceuticals excreted in breast milk, 1355(ab)
 red marrow, prediction with ^{131}I -labeled anti-CEA MAbs, 1609
 therapeutic radionuclide, 596(ab)
 three-dimensional transport model
 absorbed fractions of energy, cortical bone, 2115
 absorbed fractions of energy within trabecular bone, 1947
 two-step targeting and, small cell lung cancer, 1216
 ^{86}Y , PET imaging with, 1237(ab)
 ^{90}Y -m170 and ^{111}In -m170, 969(ab)
 ^{123}I -Pk 11195, 1354(ab)
 ^{131}I -labeled 81C6 monoclonal antibody, malignant brain tumors, 631
 ^{131}I MIBG radionuclide therapy, errors in, 983(ab)
 ^{188}Re endovascular irradiation, 1359(ab)
- Drug development**
 research, PET and, 1154
 Society of Nuclear Medicine Imaging in Drug Development (SNIDD), 22N(7)
- Drug-tracer interaction**
 biological activity of brain cannabinoid CB1 receptors, 438(ab)
 PET assessment of, 440(ab)
- DTPA**, alpha-emitting bismuth cyclohexylbenzyl, anti-CD33 antibodies, 166
- Dual-isotope imaging**
 accurate assessment of myocardial perfusion, ^{99m}Tc tetrofosmin and FDG SPECT, 801(ab)
 assessing renal function in essential hypertension, 863(ab)
 cross-talk correction, 470(ab)
 dopamine transporter, 1170(ab)
 false-negative studies, 733(ab)
 left ventricular ejection fraction measurements, 724(ab)
 prostate cancer, 394(ab)
 SPECT, in vivo prediction of radioresistance and multidrug resistance, 1084(ab)
 spectral factor analysis in, 471(ab)
- Dynamic SPECT**
 accurate parameter estimates, 313(ab)
 acquisition protocol design for, 589(ab)
 detection of doxorubicin cardiotoxicity with I-123-BMIP, 12(ab)
 physiological parameter estimation, kinetic modeling, 312(ab)
 quantification of dopamine transporter, 144(ab)
 simultaneous emission/transmission, 382(ab)
- D2-like dopamine receptor density**, reproducibility, 270(ab)
- D2 receptors**, SPECT study of schizophrenia, 123(ab)

E

- Echocardiography (ECG)**
 acute chest pain, 174(ab)
 dobutamine, ^{99m}Tc sestamibi comparison, 1683
 gated SPECT
 automatic ejection fraction determination, 797(ab)
 left ventricular function and volumes, 1857
 myocardial contrast, salvage after primary PTCA, 363
 vs gated SPECT in determining left ventricular volume and ejection fraction, 778(ab)
- Echocardiography (ECG)**
 dobutamine stress, myocardial perfusion imaging or, chest pain in women, 1222(le)
- Ecstasy**, upregulation of 5HT2A receptors in occipital cortex, 1216(ab)
- Education & Research Foundation, Society of Nuclear Medicine**, 32N(8)
- Ejection fraction**
 automated gated SPECT calculations, 314(ab)
 calculation with gated SPECT, 364(ab)
 ECG-gated SPECT evaluation of, 747(ab)
 gated PET determination of, 755(ab)
 gated SPECT measure, 768(ab)
 supernormal automated LVEF, 714(ab)
- Electroencephalography, quantitative**, ^{99m}Tc HMPAO SPECT and, Alzheimer's disease, 522
- Embryonic antigen-1**, anti-stage-specific, infection imaging, granulocyte membranes, 2107
- Embryonic antigen-1 antibody**, anti-stage specific, radiation dosimetry, granulocytes, 625
- Emission computed tomography**
 limited memory quasi-Newton reconstruction, 301(ab)
 segmentation-based reconstruction vs gamma-regularized Bayesian reconstruction, 299(ab)
- Emphysema**, diffuse lung disease, scintigraphy, 85
- EMT6 cells**, hypoxic tumor model, $^{64}\text{ATSM}$ evaluation of, 177
- Endocarditis**, bacterial, pretargeting with streptavidin and ^{111}In -labeled biotin, 484
- Endothelial cells**, labeling with ^{99m}Tc HMPAO, cell-biomaterial interactions, 1756
- Enrico Fermi Award**, Presidential award given for PET research, 10N(4)
- Enzyme inhibitors**, hypoxic accumulation and metabolism of BRU59-21, 1019(ab)
- Epidermal growth factor receptor antibody**, ^{99m}Tc -labeled antihuman, tumors of epithelial origin, 768
- Epilepsy**
 artificial neural network classifier for, 476(ab)
 brain perfusion, 277(ab)
 extratemporal and temporal, ^{18}F FDG PET studies, 737
 FDG PET as predictor of surgical outcome, 1195(ab)
 foci localization with FDG PET, 274(ab)
 fractionated ECD kits in epileptogenic zone detection, 1393(ab)
 ictal SPECT predictor of epileptogenic region, 280(ab)
 image registration and subtraction in ictal brain SPECT, 278(ab)
 influence of anti-epileptic drugs on cerebellar glucose metabolism, 1186(ab)
 localization of seizure foci, ictal SPECT in children, 786
 neocortical foci, ^{11}C FMZ PET, 1985
 normalization of ictal and interictal SPECT, 279(ab)
 partial, dual-isotope ^{99m}Tc and ^{123}I SPECT in, 677
 postictal SPECT images of prolonged hyperperfusion, 275(ab)
 postoperative neuropsychological changes, PET, 1180(ab)

reproducibility of serial ictal/postictal SPECT images, 1199(ab)
 SPECT image registration in, quantitative and clinical analysis, 1098
 SPECT in, quantitative differences, 730
 temporal lobe, imaging with new PET tracer ^{76}Br , 935
 thalamic asymmetry on interictal SPECT, 1204(ab)
 ^{15}O -water PET, 1196(ab)
Epithelial tumors, ^{99m}Tc -labeled AntiEGF-R, scintigraphy, 768
Erythrocytes
 FDG radiolabeling of, 951(ab)
 mass, obesity and, 422
 nonprimate, glucose permeability in, 2125(ie)
E-selectin, binding peptide, infection imaging with, 1399(ab)
Esophageal cancer
 dynamic FDG PET studies, 1075(ab)
 FDG coincidence imaging of, 1077(ab)
 FDG PET evaluation of, 95(ab)
 FDG PET in clinical staging of, 97(ab)
 FDG PET quantification, 550(ab)
 FDG PET staging, 98(ab)
 FDG PET staging of, 96(ab)
 immunohistochemistry, 1076(ab)
 lymph node staging with ^{11}C choline and FDG PET, 239(ab)
Esophageal scintigraphy
 esophageal transit time after endoscopic injection, 859(ab)
 pharmaceutical dosage forms in, 365(ab)
 treated and untreated body myositis, 853(ab)
Esophagus, scintigraphy, with semisolid meal, systemic sclerosis and Raynaud's phenomenon, 77
Estrogen receptor ligand
 mamma-carcinoma, estrogen-analog with high specificity, 403(ab)
 pharmacokinetics of I-123 and I-125-DES, 1372(ab)
 ^{18}F FES uptake in breast neoplasm, 1111(ab)
Estrogen receptors, ^{123}I iodovinylestradiol imaging, breast cancer, 1728
Exercise
 heart, perfusion defect of, 735(ab)
 running, muscle activity, FDG PET imaging of, 70
Exercise capacity, value of myocardial perfusion imaging in women, 348(ab)

F

Fab fragment, antiTac, glycolated, 837
Factor analysis
 coronary reserve measurements, 31(ab)
 dynamic myocardial PET, 309(ab)
 dynamic structures, cardiac gated studies, 1676
Factor analysis of dynamic structure (FADS), somatostatin receptor imaging, neuroendocrine tumors, 33
Factors, noise reduction in functional PET images, 300(ab)
Fatty acid imaging
 BMIPP detection of viable myocardium, 765(ab)
 differentiation of ischemic and idiopathic cardiomyopathy, 799(ab)
 dysfunctional but viable myocardium, 13(ab)
 noninvasive assessment of myocardial beta oxidation, 354(ab)
 relation with dobutamine echocardiogram, 745(ab)
 ^{18}F FTF in PET liver studies, 502(ab)
Fatty acids
 DMIPP, kinetics of, 827(ab)
 extraction in isolated hearts, 840(ab)
 free, myocardial utilization, gated SPECT, 1840
 long-chain, deficiency, enhanced myocardial glucose use in, 239
 metabolism
 accumulation at ventricular junction, impairment, hypertrophic cardiomyopathy, 2007
 animals and humans, 1484
 hibernating myocardium during potassium channel opener therapy, 767(ab)
 imaging with ^{123}I 9-MPA, acute coronary syndrome, 1999
 significance of reduced uptake in evaluation of acute chest pain, 14(ab)

wall motion recovery precedes normalization of, 195(ab)
 prognosis, quantitative SPECT evaluation, 770(ab)
 radioiodinated, metabolism, rat tissues, 1918
 radioiodinated analogs, ischemic and hypoxic canine myocardium, 1204
 ^{123}I IPPA, low flow or after acute infarction and reperfusion, myocardium, 821
Fermi Award, 12N(6)
Fever, whole-body FDG PET, diagnostic role of, 899(ab)
Field uniformity, acceptance testing, 1264(ab)
Filtering, significant bias in left ventricular cavity, 1319(ab)
First-pass radionuclide angiogram, velocity gradient imaging, 806(ab)
Flouro-dopa, 6-fluoro-dopa, 6-fluoro-L-dopa, in vivo microdialysis of, 1163(ab)
Flow cytometry, ^{201}TL uptake, nuclear DNA content, and clinical behavior relations, metastatic thyroid cancer, 963
Fluorine-18
 electrophilic fluorination, 604(ab)
 fatty acid imaging in hepatic studies, 502(ab)
 PET tracer to detect pulmonary fibrosis, 379(ab)
 serotonin receptors, 149(ab)
 transferrin receptors, targeting in tumors, 1547
 tropanes, 1344(ab)
 vs trans-4-fluorocyclohexane derivatives, 150(ab)
Fluorine-18 altanserin, quantification of 5HT2a, 1208(ab)
Fluorine-18 FACBC, synthesis and evaluation, brain tumor imaging, 331
Fluorine-18 FDG
 biodistribution in glycerol-treated mice, 90(ab)
 cardiac study after transcoronary ablation of septal hypertrophy, 185(ab)
 chemotherapy response in bone tumors, 388(ab)
 coincidence detection with a gamma camera, brain disorders, 110, 250(ab), 544(ab)
 coincidence imaging in lung cancer, 384(ab)
 coincidence imaging of esophageal cancer, 1077(ab)
 coincidence imaging in oncology studies, 546(ab)
 comparison of restoration filters in myocardial SPECT image, 1324(ab)
 correlation of PET studies with CEA levels in recurrent colon cancer, 1070(ab)
 cross-talk algorithm in simultaneous coincidence and ^{99m}Tc SPECT, 480(ab)
 detection of metastatic cervical lymph nodes with PET, 1044(ab)
 detection of recurrent breast cancer with PET, 1109(ab)
 dual-head coincidence PET vs ring PET, tumor patients, 1617
 ECAT vs ECAM, 1154(ab)
 functional viability, dual-isotope assessment of, 193(ab)
 head and neck tumors, 1055(ab)
 immunohistochemical markers, 1076(ab)
 incremental value over CT in esophageal cancer, 95(ab)
 irradiation of bone marrow, 88(ab)
 I-123-labeled iododeoxyuridine monophosphate, 1066(ab)
 lumped constant for, skeletal muscle, 1798
 lymph node uptake of, 85(ab)
 myocardial glucose use, CD36 deficiency, 239
 oncology studies, low-activity camera vs conventional PET camera, 1152(ab)
 orbitofrontal glucose utilization, 1219(ab)
 pancreatic tumor staging, 422(ab)
PET
 ^{11}C MET and, thymic tumors, 1595
 extratemporal and temporal epilepsy, 737
 pancreatic cancer, liver metastases from, 250
 planar bone scintigraphy vs, osseous lesions, 1623
 primary staging of malignant lymphoma, 1407
 physiological uptake in gastrointestinal tracts, 89(ab)
 positron imaging, solitary pulmonary lesions, 574
 quantitative MIBI/FDG SPECT, 1322(ab)
 radiation-induced lung injury, 1039(ab)
 radionuclide studies of neuroblastoma, 912(ab)
 regional left ventricular function, after revascularization, 1866
 SPECT imaging of left ventricular dysfunction, 192(ab)
 staging of primary bone tumors, 392(ab)

therapy monitoring, 550(ab)
 uptake mechanisms, colon cancer transplanted to nude mice, 339
 uptake patterns in bone tumors, 1141(ab)
 uptake pattern in pulmonary tuberculosis, 380(ab)
 in vitro uptake of, 888(ab)
 vs I-123-BMIPP and ^{201}TI SPECT to assess myocardial viability, 804(ab)
 vs ^{18}F FMT whole-body imaging, 1018(ab)
 vs ^{99m}Tc tetrofosmin to assess myocardial viability, 803(ab)
Fluorine-18 FDOPA
 constraints on distribution volume, 142(ab)
 effects of MPTP on, 587(ab)
 MRI-aided spatial normalization, 1179(ab)
Fluorine-18 FETA
 characterization of, detecting tumor hypoxia, 1072
 tumor imaging, brain tumor, 205
Fluorine-18 FHGP, improved synthesis of, 333(ab)
Fluorine-18 FLT
 cancer imaging, 245(ab)
 PET tumor tracer, 335(ab)
 pharmacokinetics of, 101(ab)
 S-phase fraction vs FLT cell uptake, 100(ab)
Fluorine-18 fluorocarazolol, studies in isolated rat heart, 1400(ab)
Fluorine-18 fluoro-L-dopa, amino acid effects on distribution volume of FDOPA, 585(ab)
Fluorine-18 fluorouracil
 modulation by ethynyluracil, 1361(ab)
 uptake in tumors, 1032(ab)
Fluorine-18 FMISO
 biological characterization of, 1365(ab)
 limitations in evaluating hypoxia in nasopharyngeal carcinoma, 244(ab)
 modified synthesis of, 605(ab)
 simultaneous study with ^{11}C acetate, 1062(ab)
Fluorine-18 FMT, PET, brain tumor patients, 399
Fluorine-18 FPCT, basal ganglia, detection of, 1339(ab)
Fluorine-18 FTIA
 noninvasive assessment of myocardial oxidation, 354(ab)
 PET studies of dilated cardiomyopathy, 187(ab)
Fluorine-18 setoperone, serotonin receptor distribution with, neocortex, parametric PET imaging of, 25
Fluorodeoxyglucose (FDG)
 bioreductive antitumor agent, 91(ab)
 cerebral glucose metabolism, brain responses to lorazepam, 715
 diagnostic and therapeutic value, 407(ab)
 differential uptake with various oncogenes, 1000(ab)
 distribution, mathematical model for, 1358
 dual-head coincidence detection cameras, 9N(3)
 dual-head gamma camera coincidence imaging, lung cancer, 566
 extent of viable tissue determines improved LVEF postrevascularization, 190(ab)
 heart and skeletal muscle uptake, insulin action on, hypertriglyceridemia patients, 1116
PET
 brain, predictive value for cochlear implantation, 452(ab)
 brain tumors, colorectal cancer lymphoma, and melanoma, 591
 cervical cancer patients, 1125
 chemoradiotherapy evaluated by, 1132
 differentiation, from osteradionecrosis, 1049(ab)
 drug research and development, 1154
 hematocrit correction, 1282(ab)
 in lung cancer, 814
 for management of lesions failing biopsy, 409(ab)
 metabolic measurements of malignant tumors, 1771
 metastatic thyroid cancer, 993(ed)
 optimal interpretation, pancreatic cancer, 1784
 papillary thyroid carcinoma, 986
 preoperative investigation with FDG and a hybrid PET camera system, 541(ab)
 prognostic value in malignant pleural mesothelioma, 1241
 skeletal muscle, glucose transport and phosphorylation, 977
 SPECT or gamma coincidence imaging, myocardial viability, 1893(ed)

- therapy control, 941(ab)
tumor response after photodynamic therapy, 876
- PET**, oncologic imaging applications, 1706
- PET imaging**, muscle activity in runners, 70
- phantom for system evaluation and design, 1241(ab)
- splenic uptake, granulocyte colony-stimulating factor therapy, PET imaging, 1456
- tyrosine imaging and, soft tissue tumors, 381
- uptake, glucose transporters and, non-small cell lung cancer, 536
- urinary excretion, optimization during PET, 1352
- Fluoro-m-tyrosine**, oxygen difluoride, 604(ab)
- Fontan procedure**, congenital heart disease, scintigraphic evaluation of whole-body blood flow patterns, 1477
- Food and Drug Administration (FDA)**, ACNP/SNM Government Relations Activities, 1998 year end report, 25N(2)
- Fourier space method**, PET quality assurance, clinical relevance of detector defects, 1657
- Fractal dimension**, quantification of radioisotope distribution, 1287(ab)
- Fractional cold kits**, cost-effectiveness of, 1393(ab)
- Fractionation**
metabolic studies of ¹⁸F alpha-methyl tyrosine, 336(ab)
nonuniform tumor doses, radioimmunotherapy and, 1337
- Frequency encoding**, simultaneous display using, brain, 442
- Fungal infection**, in granulocytopenia, scintigraphic imaging, 2066
- Eurosemide**
diuresis renography, infants and children, 1805
optimal timing of diuretic administration, 204(ab)
- Fused image tomography**
integrative force, 13N(8)
where do we go from here?, 30N(10)
- Fv fragment**, adverse effect of circulating antigen, 1381
- G**
- Gallbladder**, cholecystokinin cholescintigraphy, 2038
- Gallium**, tumor cell uptake, photodegraded nifedipine and, 2129(ab)
- Gallium scintigraphy**
gynecologic lymphoma with SPECT and CT, 955(ab)
predictor of residual tumor viability in NHL, 251(ab)
renal uptake of Ga-67, 1140(ab)
rheumatic carditis, 11(ab)
- Gallium-67**
scintigraphy
MRI comparison, bone neoplasms, 387
non-Hodgkin's lymphoma, 40
transferrin-independent uptake, nifedipine promotion of, tumor cells, 159
transferrin receptors CD71, 960(ab)
- Gallium-67 citrate**
oral, segmental colonic transit after, in constipation, 277
solid colonic transit study, 1383(ab)
SPECT imaging of pretreated vertebral osteomyelitis, 48(ab)
- Gallium-67 Cu-21T-BAT-Lym-1**, pharmacokinetics, tumor regression in lymphoma, 302
- Gamma camera**
coincidence imaging, FDG, lung cancer, 566
diverging collimator, 1226(ab)
FDG-PET, quantification of uptake, 1246(ab)
measured attenuation correction fo FDG imaging, 1311(ab)
performance characteristics of quantitized camera, 1225(ab)
solid-state photodetector, 599(ab)
^{99m}Tc MAG3, evaluation of renal function, 793
- Gamma detectors**, intraoperative detection of tumors, ¹¹¹In-labeled radiopharmaceuticals, 2094
- Gastric banding**, laparoscopic adjustable silicone, ^{99m}Tc pertechnetate scintigraphy, 783
- Gastric cancer**
FDG PET staging of, 94(ab)
whole-body FDG PET, 1073(ab)
- Gastric emptying**
four-hour vs two-hour studies, 854(ab)
in hypothyroid patients undergoing radioiodine treatment, 527(ab)
motility and, procedure guidelines, 1236
quantitation and interpretation of liquid emptying studies, effect of, 52(ab)
rate assessment, intra-abdominal radioactivity in the stomach, 1106
- Gastrin**, radiolabeled, targeting cholecystokinin-B/gastrin receptor-expressing tumors, 1029
- Gastritis**, FDG uptake in gastric wall, 851(ab)
- Gastroenteropancreatic tumors**, somatostatin receptor scintigraphy in, 539
- Gastroenteropancreatic tumor**, bone metastases from, somatostatin receptor imaging, 1602
- Gastroesophageal reflux**
gastric emptying rate, relationship between, 849(ab)
upper GI series, barium swallow, 51(ab)
- Gastrointestinal bleeding**
detection with intra-arterial scintigraphy, 852(ab)
Meckel's diverticulum and, procedure guidelines, 1226
- Gastrointestinal tract**
bowel preparation for FDG uptake, 89(ab)
clinical utility of whole gut transit scintigraphy, 366(ab)
FDG uptake in, 563(ab)
four-hour vs two-hour gastric emptying studies, 854(ab)
salivary secretory function in Sjogren's syndrome, 857(ab)
- Gender differences**
radionuclide angiography, 26(ab)
voice recognition dictation system, 1292(ab)
- Gene expression**
adenoviral-mediated, 1012(ab)
genetic constitution of serotonin transporter, 445(ab)
probe assay for herpes simplex virus Type 1, 102(ab)
¹²³I FIAU imaging of, 104(ab)
- Gene therapy**
development of, PET imaging in, 995
PET with ¹⁸F FHPG, 333(ab)
quantitative evaluation, in myocardial angiogenesis, 760(ab)
viral transfer of nucleoside transporter, 1011(ab)
5-FU pretreatment with HSV thymidine kinase, 1010(ab)
¹⁸F FHBG, PET imaging agent of gene expression, 103(ab)
¹³¹I FIAU, 105(ab)
- Glioblastoma**, malignant glioma brachytherapy, 971(ab)
- Glioma**
enhanced ¹¹C TPMP uptake, PET, 1180
prognostic assessment with ²⁰¹Tl SPECT, 1063(ab)
SPECT delineation of, 397(ab)
- Glomerular filtration rate**
count based camera method, to measure, 207(ab)
estimation, renography, 1968(ie)
- Glucose**
cerebral metabolic rate of, FDG PET noninvasive measurement, 1441
metabolism
blood-brain transport ¹¹C methyl-D-glucose measure of metabolic rate of glucose, 293(ab)
brain tumors, after stereotactic radiosurgery, 1085
cerebral, regional brain metabolic responses to lorazepam, 715
cerebral cortex, statistical mapping of, 294(ab)
dynamic changes in, 1174(ab)
FDG uptake in human inflammatory cells, 888(ab)
FDG uptake of prazosin, 828(ab)
heart and skeletal muscle, insulin action effects on FDG uptake, 1116
myocardial PET imaging of, lump constant variability, 824(ab)
myocardial uptake, ischemic cardiomyopathy patients, FDG PET, 1292
permeability, nonprimate erythrocytes, 2125(ie)
tumor localization, 1369(ab)
underestimation of MGU with C-11, 842(ab)
uptake, myocardial, FDG PET measurement, 1186
¹¹C vs ¹⁸F FDG to measure MGU, 836(ab)
- Glucose metabolic rates**, cortical metabolic deficits in depression, 1211(ab)
- Glucose transport**, phosphorylation and, FDG PET, 977
- Glucose transporter**
FDG uptake and, untreated primary non-small cell carcinoma, 536
putative hypoxic tracer, detection of tumor hypoxia, 854
¹¹C O-methyl-D-glucose, 293(ab)
- Glutathione**
kit preparation of, 1395(ab)
localization, brain, ^{99m}Tc HMPAO, 1056
- GLUT-1 (glucose transporter)**
expression in bronchioloalveolar lung carcinoma, 86(ab)
Ki-67 score, 998(ab)
mitochondrial hexokinase, 999(ab)
- Glycolate**, conjugation, biodistribution of humanized antitac Fab fragment, 837
- Glycosylation**, isoelectric point relations, tumor accumulation of avidin, 479
- Government Relations Update**, 1998 year end report, 25N(2)
- Granulocyte colony-stimulating factor therapy**, splenic FDG uptake, PET evaluation of, 1456
- Granulocytopenia**, bacterial and fungal infection, scintigraphic imaging, 2066
- Graves' disease**
anti-thyroid drugs, 932(ab)
dose calculation, 528(ab)
retreatment with radioiodine, 215(ie)
somatostatin receptor scintigraphy of, 925(ab)
- H**
- HCFA reimbursement**, PET, Town Hall Meeting, 10N(3)
- HCPCS codes**, 1999, 26N(3)
- Head and neck cancer**
chemoradiotherapy, evaluated by FDG PET, 1132
cost-effectiveness of FDG PET imaging, 255(ab)
diagnosis of with FDG PET, 253(ab)
diagnostic and therapeutic assessment with DMSA, 988(ab)
differentiation of tumor recurrence and post-treatment effects, 259(ab)
dual-tracer lymphoscintigraphy, 257(ab)
FDG PET assessment, 1051(ab)
nuclear medicine in, 91
primary staging and recurrence, 254(ab)
prognostic value of ²⁰¹Tl -chloride, 1057(ab)
staging primary tumors with dual-head PET camera, 1056(ab)
¹⁸⁶Re-labeled monoclonal antibody, radiimmunotherapy with, 263(ab)
- Head and neck tumors**
cervical lymph node metastases, 1150(ab)
diagnosis of recurrent tumor with IMT SPECT, 256(ab)
dual-time point FDG PET imaging of, 1054(ab)
FDG PET imaging of, 1053(ab)
lymphoscintigraphy, double tracer technique, 776
sestamibi scintigraphy, prediction of radiotherapeutic response, 985(ab)
SUV, 1049(ab)
- Head injury**, PET vs CT/MRI in closed-head injury, 287(ab)
- Health Care Financing Administration (HCFA)**
hospital outpatient prospective payment system (HOPPS), 24N(4), 16N(12)
Medicare coverage of PET, 23N(5)
ruling on diagnostic tests, 25N(7)
Y2K, 16N(12)
- Health Professions Network**, news from the Technologist Section, 16N(4)
- Heart**
chronic heart failure, PET measures of, 19(ab)
congenital anomalies, surgical intervention, scintigraphic assessment, 1477
failing, cardiac MIBG kinetics and metoprolol, 224
gated images, using factor analysis of dynamic structures, 1676
hibernating myocardium, 822(ab)
sensitivity of ¹¹C PHEN kinetics, monoamine oxidase activity and, 232
- Heart disease, ischemic**
computer-assisted decision support system use in, 96
¹²³I BMIPP myocardial metabolism in, 471
- Heart rate**, variability, ¹²³I MIBG kinetics after myocardial infarction and reperfusion, 904

- Heart transplantation**
 allograft rejection, 5(ab)
 reinnervation, effect on myocardial metabolism, 30(ab)
 sympathetic reinnervation, by ^{123}I MIBG, 911
 ^{13}N ammonia PET study with angiography in allograft vasculopathy, 719(ab)
- Helicobacter pylori**, oral flora, a false-positive factor of, 367(ab)
- Hemodialysis**, left ventricular function and volume in patients on, 739(ab)
- Hepatic cancer**, radiotherapy with Ho-166-chitosan, 1360(ab)
- Hepatobiliary scan**
 cholescintigraphy, 215(ab)
 differential diagnosis of extrahepatic metastases, 1071(ab)
 $^{99\text{m}}\text{Tc}$ DISIDA, assessment of biliary obstruction after hepatic resection, 214(ab)
- Hepatocellular cancer**
 alpha-fetoprotein antibody imaging, 427(ab)
 class differentiation with $^{99\text{m}}\text{Tc}$ sestamibi, 1072(ab)
 detection of extrahepatic tumors with $^{99\text{m}}\text{Tc}$ PMT, 1071(ab)
- Hepatocytes**, ^{111}In labeled, biodistribution of, 850(ab)
- Hepatoma**, combination gene therapy enhanced by 5-FU, 1010(ab)
- Herpes simplex virus thymidine kinase**
 gene imaging, 1012(ab)
 genetic targeting of radiation therapy, 105(ab)
 ^{11}C FMAU imaging of, 890(ab)
- Hexamethyl propyleneamine oxime (HMPAO)**, stereo-selective synthesis of, 1350(ab)
- Hibernating myocardium**, blood flow/metabolism mismatch pattern, 186(ab)
- Histidine**, $^{99\text{m}}\text{Tc}$ -labeled, unprecedented high specific activity, 1913
- History corner**
 barium enigma, 24N(7)
 The Heritage Project, 21N(11)
- Hodgkin's disease**
 comparison with CT and ESR, 941(ab)
 FDG PET and ^{67}Ga in staging and follow-up of patients, 252(ab)
 primary staging and therapy control, 248(ab)
- Holmium-166**
 feasibility study using micro-TLD chips, 1358(ab)
 pharmacokinetics, 160(ab)
 radiotherapy for hepatic cancer, 1360(ab)
- Human immunodeficiency virus (HIV)**, myocardial damage, 3(ab)
- Hydrazinonicotinamide**, annexin V coupled with, imaging of apoptosis, 184
- Hydrazino nicotinyl**, liposomes labeled, $^{99\text{m}}\text{Tc}$, 192
- Hydronephrosis**, Extra-renal pelvis, 860(ab)
- Hydroxyurea**, assessment of therapeutic effects on splenic function with, 958(ab)
- Hypercholesterolemia**, detection of early silent ischemia in hypercholesterolemia, 737(ab)
- Hyperglycemia**, effect on improved myocardial flow reserve, 762(ab)
- Hyperparathyroidism**
 following total thyroidectomy, 936(ab)
 oxyphil cell content, $^{99\text{m}}\text{Tc}$ sestamibi relations, 1402(le)
 parathyroid adenomas, 202(ab)
- Hypertension**
 essential, in cardiac sympathetic nervous system, ^{123}I MIBG imaging, 6
 gated SPECT measure of myocardial cavity and mass volumes, 807(ab)
 hypertrophic heart, 796(ab)
 hypotensive response to captopril, renal artery stenosis assessment and, 406
 renal failure and, captopril renal scintigraphy in, 412
 resting glomerular filtration rate variability, 372(ab)
- Hyperthyroidism**, randomized control trial, 934(ab)
- Hypertriglyceridemia**, FDG uptake, heart and skeletal muscle, insulin action on, 1116
- Hypofunctional thyroid nodules**, variable scintigraphic patterns of chronic thyroiditis, 1458(ab)
- Hypothyrodisism**, congenital, pertechnetate scintigraphy in, 799
- Hypoxia**
 bioreductive characteristics of Tc-ATSM2, 493(ab)
 clinical PET study, 605(ab)
- cytochrome P450 reductase, 1019(ab)
 FDG vs blood flow as an indicator of, 1110(ab)
 isolated perfused rat heart, 823(ab)
 neurotoxicity result of free radicals, 1174(ab)
 noninvasive assessment of, 401(ab)
 noninvasive assessment with $^{99\text{m}}\text{Tc}$ metronidazole, 1366(ab)
 oxygenation status in tumor xenografts, 1021(ab)
 radiation necrosis, limitations of F-19-FMISO PET, 244(ab)
 tumor model, ^{64}Cu ATSM evaluation of, 177
 ^{64}Cu ATSM, as hypoxic tissue tracer in myocardial ischemia, 704(ab)
 $^{99\text{m}}\text{Tc}$ labeled HL-91, kinetic analysis of, 353(ab)
 $^{99\text{m}}\text{Tc}$ nitroimidazole, effect of lipophilicity, 331(ab)
- I**
- Ileorectal anastomosis**, 5-aminosalicylic acid absorption, radioisotope imaging, 1630
- Image analysis**
 attenuation correction, PET and SPECT myocardial perfusion imaging, 362(ab)
 automated lesion volume estimation, 466(ab)
 automated ROI generation, 1279(ab)
 computer-based tutorials, 1461(ab)
 covariance of three-dimensional Bayesian reconstructions, 129(ab)
 effect on noise propagation in SPECT, 1317(ab)
 pixel-to-pixel regression analysis, 279(ab)
 SPECT and PET brain studies, 1289(ab)
 tumor detection, improved by ROC analysis, 1314(ab)
- Image coregistration**, wavelet-based image registration, 467(ab)
- Image fusion**
 oncology, anatomical and functional image fusion, 597(ab)
 three-dimensional datasets, 1454(ab)
- Image orientation**, scintigraphic assessment of the elbow, 869(ab)
- Image processing**
 denoising technique for PET, 1307(ab)
 network, TCP/IP, 1460(ab)
 Poisson impulse field analysis, 1317(ab)
 portable image processing package, 1294(ab)
 resolution recovery, 1327(ab)
 wavelet-based image registration, 467(ab)
- Image reconstruction**
 EM algorithm, 297(ab)
 kinetic modeling, 311(ab)
 modeling dynamic data during, 589(ab)
 optimization of, 1320(ab)
 ordered subsets expectation maximization (OSEM), 593(ab)
 quantitation of spatially varying fanbeam collimation, 1325(ab)
 sampling pattern compensation, 1234(ab)
 spiral PET, implementation of, 1232(ab)
 three-dimensional, evaluation of, 1255(ab)
- Image registration**
 automated, 3-D multimodality registration maps using, 448
 need for in multicoincidence SPECT, 1281(ab)
 prior to interactive subtraction, 200(ab)
 SPECT, epilepsy studies, 1098
- Image smoothing**, denoising technique for PET, 1307(ab)
- Imaging figure of merit**
 detection of lesions in vessels, 1280(ab)
 dual-head PET, performance of, 481(ab)
 quantification of performance, 482(ab)
- Immunoassays**
 Compound W in maternal serum and urine, 922(ab)
 third generation TSH assay, 923(ab)
- Immunohistochemistry**, GLUT-1 expression in breast and lung cancer, 87(ab)
- Immunoscopy**
 new management algorithm, 67(ab)
 $^{99\text{m}}\text{Tc}$ HIG in postoperative spinal infection, 63(ab)
 $^{99\text{m}}\text{Tc}$ labeled antibody fragments for osteomyelitis, 47(ab)
- Indium-111**
 antibody fragment labeled with, 327(ab)
 antimyosin, cardiac imaging, 3(ab)
- intraoperative detection of tumors, gamma detectors for, 2094
 pharmacokinetics of CDTA-Di-XASP dyes, 1396(ab)
 ^{90}Y -labeled anti-Tac monoclonal antibody distribution, differences, 268
- Indium-111 antimyosin**
 biodistribution and radiation dosimetry, idiopathic inflammatory myopathies, 464
 hereditary muscular dystrophy, 1222(le)
- Indium-111 diethylenetriamine pentaacetic acid**, antibody conjugates, blood clearance, 1392
- Indium-111 DOTATOC**, 111-In-DTPAOC comparison, tumor uptake, 762
- Indium-111 DTPAOC**, 111-In-DOTATOC comparison, tumor uptake, 762
- Indium-111 octreotide**
 imaging in Grave's ophthalmopathy, 925(ab)
 somatostatin receptor imaging
 meningioma, 1246
 pituitary adenoma, 1252
- Indium-111 oxine**, tumor vaccination with, 1028(ab)
- Indium-111 pentetreotide**
 Langerhans cell histiocytosis, 962(ab)
 radiolabeling with Fe-59-ferric chloride, 1389(ab)
 somatostatin receptor imaging, FADS in, neuroendocrine tumors, 33
- Infection imaging**
 bacterial detection in orthopedic patients with $^{99\text{m}}\text{Tc}$ ciprofloxacin, 60(ab)
 bone/gallium study of painful joint replacements, 43(ab)
 bone scintigraphy of diabetic foot, 871(ab)
 fungal infections, 907(ab)
 in granulocytopenia, 2066
 labeled leukocyte scintigraphy, 905(ab)
 labeled leukocytes in orthopedic infections, 901(ab)
 leukocyte vs ciprofloxacin imaging, 59(ab)
 tuberculosis, 380(ab)
 $^{99\text{m}}\text{Tc}$ chemotactic peptide, 1398(ab)
 $^{99\text{m}}\text{Tc}$ ciprofloxacin, 904(ab)
 $^{99\text{m}}\text{Tc}$ ciprofloxacin in prosthetic joint infection, 893(ab) with $^{99\text{m}}\text{Tc}$ glutathione kit, 1395(ab)
 $^{99\text{m}}\text{Tc}$ HNP, bacterial infections, 2066
 $^{99\text{m}}\text{Tc}$ -labeled murine immunoglobulin M antibody, granulocyte membranes, 2107
 $^{99\text{m}}\text{Tc}$ labeled Peg liposomes, 58(ab)
 $^{99\text{m}}\text{Tc}$ labeled receptor antagonist, 892(ab)
 $^{99\text{m}}\text{Tc}$ P483H, uptake in *E. coli*, 954(ab)
 $^{99\text{m}}\text{Tc}$ P483H binding to monocytes and leukocytes, 950(ab)
 ^{125}I labeled Blankophor for fungal infection imaging, 907(ab)
- Inflammation**
 accumulation of $^{99\text{m}}\text{Tc}$ labeled chemotactic peptide, 895(ab)
 cartilage alterations by I-123-Alp, 537(ab)
 detection of plantar fascitis, 45(ab)
 esophageal function in treated and untreated body myositis, 853(ab)
 FDG-labeled WBC and FDG PET evaluation of colorectal cancer, 1083(ab)
- Inflammation/infection imaging**
 E-selectin binding peptide, in vivo studies of, 1399(ab)
 FDG PET differentiation of prostheses loosening, 389(ab)
 membrane probe, with ^{111}In -CDTA-Di-XASP, 1396(ab)
 radiolabeled antibodies in diagnosis of equivocal appendicitis, 62(ab)
 SPECT leukocyte imaging in occult infective endocarditis, 9(ab)
 $^{99\text{m}}\text{Tc}$ labeled N-formylpeptide antagonist analog, 497(ab)
 $^{99\text{m}}\text{Tc}$ labeled Peg liposomes, 58(ab)
 $^{99\text{m}}\text{Tc}$ labeled peptide, 900(ab)
 $^{99\text{m}}\text{Tc}$ P483H peptide imaging, 57(ab)
- Inflammatory bowel disease**, $^{99\text{m}}\text{Tc}$ white blood cell imaging in, 50(ab)
- Inhalation scintigraphy**, distribution quantification, validation of, 886(ab)
- In memoriam**
 Glenn T. Seaborg, 31N(5)
 Joseph F. Ross, 28N(5)
- Input function**
 derivation from brain O-15-water PET images, 146(ab)
 image-derived, PET studies, 463(ab)
 quantitative PET, venous ROI, 1666

Institute of Medicine, 24N(12)**Instrumentation**

- breast cancer imaging system, 1223(ab)
- compact quantitized gamma camera, 1225(ab)
- detectors
 - avalanche photodiode array, 304(ab)
 - high resolution gamma ray, 303(ab)
- micro-PET, lutetium oxyorthosilicate scanner for, 1164
- penetration, determination of, 1261(ab)
- PET, high resolution camera, 1233(ab)
- PET scanner for neuropsychiatric disorders, 1240(ab)
- scintigraphic findings of HIS-RIS interface, 1465(ab)
- segmentation algorithms, effect of acquisition time on, 459(ab)
- solid-state photodetector, 599(ab)

Insulin, hepatic targeting property, 498(ab)**Insulin-resistance syndrome, effect on FDG uptake, 939(ab)****Integrin antagonists, radiolabeled, tracers for tumor targeting, 1061****Interleukin-2, pharmacokinetic differences of, 1027(ab)****Intralesional therapy, P-32 radiotherapy for unresectable pancreatic cancer, 984(ab)****Intraoperative detection, gamma detectors for, ^{111}In -labeled radiopharmaceuticals, 2094****Intraperitoneal tumor (IPT)**

- enhanced accumulation of albumin in, 1371(ab)
- pharmacokinetics of Lu-66-CC49, 967(ab)

Iodine-123

- AChE activity imaging, 289(ab)
- comparison with I-131 scintigraphy, 526(ab)
- dual-isotope SPECT, partial epilepsy, 677
- Flau, gene expression, 104(ab)
- scatter correction, downscattered component compensation method, 1300(ab)
- synthesis and radiolabeling of serotonin transporter ligand, 1346(ab)
- Iodine-123 α -methyl tyrosine**
 - recurrent head and neck tumors, 256(ab)
 - role in radiotherapy of glioma, 397(ab)
 - uptake in carcinoid tumors, comparison with ^{111}In , 393(ab)
 - uptake in soft-tissue tumors, proliferation rate, 398(ab)

Iodine-123 β CIT,

- dopamine transporters, 107(ab)
- SPECT data, Parkinson's disease, 530

Iodine-123 BMIPP

- accumulation at ventricular junction, impairment, hypertrophic cardiomyopathy, 2007
- metabolic marker of ventricular pressure overload, 800(ab)
- myocardial metabolism, ischemia model, 471
- $^{99\text{m}}\text{Tc}$ MIBI and, myocardial viability studies, 707
- Iodine-123 epidepride**
 - outcome measures, 270(ab)
 - SPECT, quantification of dopamine D₂ receptors, 1902

Iodine-123 FPCIT

- defects of functional dopaminergic system, automatic algorithm, 1091
- SPECT, nigrostriatal dopaminergic pathway in Parkinson's disease, 753

Iodine-123 IBZM

- dopamine D₂-receptors, 122(ab)
- efficient synthesis, 607(ab)
- reliable synthesis for clinical studies, 606(ab)
- SPECT study for schizophrenia, 123(ab)
- synthesis for routine clinical studies, 606(ab)
- Iodine-123 IMP**
 - interictal SPECT imaging of frontal lobe epilepsy, 1204(ab)
 - radioiodinated amphetamine, simplified chemical synthesis, 1391(ab)
 - SPECT estimation of regional cerebral blood flow, 1273(ab)
 - SPECT rCBF study to differentiate dementia, 1185(ab)

Iodine-123 IMT, pharmacokinetics in glioma cells, 1017(ab)**Iodine-123 IMZ, ischemia-reperfusion injury, 1172(ab)****Iodine-123 iomazenil, SPECT assessment of post-traumatic stress disorder, 578(ab)****Iodine-123 MBG**

- Behcet's disease, 39(ab)
- cardiac allografts evaluated with, sympathetic reinnervation of, 911

- cardiac sympathetic denervation detection, 744(ab)
- cardiac uptake, idiopathic ventricular tachycardia and fibrillation, 1
- cardiomyopathy, 736(ab)
- early essential hypertension, cardiac sympathetic nervous system in, 6
- effect of exercise on, 734(ab)
- kinetics

- after myocardial infarction and reperfusion, 904
- elevated plasma norepinephrine effects, 2088
- myocardial imaging, cardiac sympathetic activity, 217
- myocardial sympathetic innervation in sinus bradycardia, 786(ab)
- prognostic value, idiopathic dilated cardiomyopathy, 917
- sympathetic nerve alterations assessed with, failing heart, 224
- vs ^{201}Tl and $^{99\text{m}}\text{Tc}$ MIBI gated SPECT in sympathetic cardiac innervation, 10(ab)

Iodine-123 9 MPA, fatty acid imaging with, acute coronary syndrome, 1999**Iodine-125, radiobiologic effects, 1377(ab)****Iodine-125 BMIPP, gated SPECT, myocardial free fatty acid utilization and left ventricular function, 1840****Iodine-125 DTPA, camera-computer quantitation of bladder activity, 208(ab)****Iodine-125-labeled antitac ds Fv, biodistribution of, adverse effect of circulating antigen, 1381****Iodine-131**

- Graves' disease retreatment with, 215(le)
- radiation dosimetry, non-Hodgkin's lymphoma and chronic lymphocytic leukemia, 1317
- stunning radiosensitivity of, 931(ab)
- therapy

- nontoxic multinodular goiter, 1313
- vocal cord paralysis after, 505(le)

Iodine-131 BMIPP, pharmacokinetics and metabolism, animals and humans, 1484**Iodine-131 MIBG, uptake, heart, effects of Parkinson's disease, 371****Iodine-131 orthoiodohippurate, single-sample clearance, renal, reproducibility of, 1122****Iodine-131 sodium iodide**

- rapid automated blood volume analyzer, 961(ab)
- uptake measurement in thyroid remnants, 930(ab)

Iodine-131 sodium therapy, stunning, well-differentiated thyroid carcinoma, 1046(ab)**Iodine-131 whole-body scan**

- comparison of measurement techniques, 989(ab)
- diagnostic and post-therapeutic imaging, 1046(ab)

Ischemia

- effects on glucose utilization, 828(ab)
- three-dimensional location, size and intensity of ischemia, 729(ab)

Ischemic heart disease

- effect of exercise on myocardial perfusion, 734(ab)
- prognostic value of dual SPECT studies of, 13(ab)

Ischemic left ventricular dysfunction, ^{201}Tl , fixed defects on stress-reinjection SPECT, 731(ab)**Ischemic penumbra, detection of viable cortical neurons, 1166(ab)****Iterative reconstruction**

- coded aperture imaging, 1305(ab)
- comparison of two methods with nonuniform attenuation correction, 1326(ab)
- heart study, PET, 862
- limited-memory quasi-Newton, 301(ab)
- maximum likelihood, bone SPECT, 1978
- mixed continuity image, 1299(ab)
- OSEM vs standard filtered backprojection in brain studies, 592(ab)
- reconstruction methods for PET detection of small lesions, 591(ab)
- segmentation-based reconstruction vs gamma-regularized Bayesian reconstruction, 299(ab)
- SPECT, 202(ab)
- time-dependent compensation methods for, 1298(ab)

J**Journal of Nuclear Medicine (JNM)**

- outstanding article, 15N(9)
- Sandler, Martin P., Editor, Directions, 9N(1)
- single-case study, 2130(le)

K**Kawasaki disease, reverse mismatch of myocardial perfusion and metabolism, 909(ab)****Kidney**

- failure, hypertensive patients, captopril renal scintigraphy in, 412
- function
 - automated technique to assess, 862(ab)
 - radionuclide therapy with ^{111}In -DTPA-octreotide, 416(ab)
 - renal depth as predictor of, 867(ab)
 - hypotensive response to captopril, renal artery stenosis assessment and, 406
 - plasma flow, $^{99\text{m}}\text{Tc}$ EC clearance, radionuclide renography, 429
 - reconstruction of inconsistent SPECT data, 128(ab)
 - reproducibility of $^{99\text{m}}\text{Tc}$ DMSA, 56(ab)
 - scarring, $^{99\text{m}}\text{Tc}$ DMSA use in, 60
 - tumor enucleation, function after, $^{99\text{m}}\text{Tc}$ DMSA SPECT assessment of, 968
 - ureteropelvic junction obstruction, SPECT of $^{99\text{m}}\text{Tc}$ DMSA uptake, infant, 1111
 - $^{99\text{m}}\text{Tc}$ MAG3 uptake, reproducibility and accuracy, 972

Kidney function

- $^{99\text{m}}\text{Tc}$ DMSA quantitative SPECT uptake, children, 56
- $^{99\text{m}}\text{Tc}$ EC clearance, radionuclide renography, 429
- $^{99\text{m}}\text{Tc}$ MAG3 clearance, reproducibility of, 1122

Kidney transplantation, captopril renal scintigraphy of complications, 376(ab)**Kinetic analysis**

- neuroreceptor modulation, 1265(ab)
- quantitation of dynamic FDG PET oncology images, 465(ab)

Kinetic modeling

- reproductibility studies of ^{11}C carbonyl-WAY 100635, 1162(ab)
- PET dopamine D₁ receptors, 435(ab)
- serotonin transporters, 114(ab)
- simplified modeling protocol, 583(ab)
- ^{11}C carbonyl-WAY-100635 and endogenous serotonin, 117(ab)

Kinetics

- radionuclide distribution, 163(ab)
- reconstruction of inconsistent SPECT data, 128(ab)

L**Labia, biopsy, salivary gland scintigraphy in Sjögren's syndrome, 64****Latin America, nuclear medicine in, 9N(9)****Lawrence, John, Donner Laboratory, 16N(1)****Left bundle branch block**

- fatty acids added in, myocardial viability and, 213(le)
- pattern of myocardial perfusion abnormality, 783(ab)

Left ventricular dysfunction

- after acute MI, prediction of recovery, 1683
- chronic, BMIPP imaging, 1468
- severe, $^{99\text{m}}\text{Tc}$ tetrofosmin SPECT for prediction of, 1824

Left ventricular ejection fraction

- automatic, echocardiographic-gated $^{99\text{m}}\text{Tc}$ tetrofosmin SPECT, 1693
- blood-pool imaging of, 776(ab)
- gated SPECT techniques to assess left ventricular function, 753(ab)
- gated SPECT vs radionuclide ventriculography in assessment, 757(ab)
- gated thallium SPECT in, major myocardial infarction patients, 513
- large perfusion defects and, gated SPECT, 805
- perfusion and, gated SPECT, 650
- radionuclide, sympathetic nerve alterations, failing heart, 224
- simultaneous dual-isotope gated SPECT study for, 724(ab)
- viability in chronic infarction, BMIPP imaging, 1468

Left ventricular function

- free fatty acid utilization and, ^{123}I BMIPP gated SPECT assessment of, 1840
- gated myocardial perfusion SPECT assessment of, 705(ab)
- improvement in, after pulmonary thromboendarterectomy, 173(ab)
- prediction by BMIPP in chronic infarction, 706(ab)

- quantitative assessment with FDG PET, 35(ab)
volume and, gated SPECT and echocardiography, 1857
- Left ventricular mass**, cardiac sympathetic nervous system and, ^{123}I MIBG imaging, 6
- Left ventricular volume**
gated sestamibi SPECT measure of, as predictor of CHF, 181(ab)
myocardial viability with rest ^{201}Tl , 743(ab)
- Leptomeningeal metastases**, cerebrospinal fluid study of, 1206(ab)
- Leukemia**
anti-CD33 in, pharmacokinetics and dosimetry, 1935
chronic lymphocytic, non-Hodgkin's lymphoma and, radiation dosimetry, 1317
early and delayed whole-body scan to detect, 523(ab)
minimal residual disease, 942(ab)
 ^{188}Re labeled antibodies to treat leukemia, 262(ab)
- Leukocytes**, utility of delayed HMPAO in diabetic foot, 903(ab)
- Lewy body disease**, discrimination from Alzheimer's-type dementia, 1185(ab)
- Limp perfusion**, hyperthermic isolated, soft-tissue sarcoma and skin cancer, 262
- Liposomes**, ^{99m}Tc labeled, hydrazino nicotinyl derivative, 192
- Liver**
hemodynamic change and uptake ratio of, 217(ab)
hilar cholangiocarcinoma, ^{99m}Tc GSA accumulation, 394
ischemia-reperfusion injury, FK506, 847(ab)
lesion detection, scattered subtraction in SPECT, 1011
metastasis, radiolabeled antibody distribution and radioimmunotherapy, 685
partial resection of, 212(ab)
portal hemodynamics, 858(ab)
resection
residual functional reserve, ^{99m}Tc GSA SPECT, 1644
 ^{99m}Tc GSA, recovery of asialoglycoprotein receptors, 137
transferrin receptors, ^{18}F targeting in tumors, 1547
 ^{99m}Tc annexin assessment of transplant rejection, 846(ab)
- Liver clearance**, comparison between Tc-99-Sn colloid and ^{99m}Tc GSA, 211(ab)
- Liver disease**
chronic, functional calculation with liver-spleen scan, 1745
pathophysiology of biliary secretion, 845(ab)
- Liver function**
liver, quantitative evaluation of, 213(ab)
segmental estimation of, 216(ab)
Tc-labeled fatty acid analog to assess, 1406(ab)
- Liver malignancies**, SPECT assessment of PGP expression, 426(ab)
- Liver metastases**, pancreatic cancer, FDG PET, 250
- Liver-spleen scan**, functional spleen volume calculation, 1745
- Liver transplantation**, auxiliary partial orthotopic, asialoglycoprotein receptor scintigraphy in, 1463
- Loevinger-Berman Award**, 15N(9)
- Low flow**, fatty acid imaging of ischemia, 840(ab)
- Lung**
aerosol scintigraphy, ^{99m}Tc -labeled exogenous natural surfactant in, 1080
detection of pulmonary lesions with coincidence imaging, CT and MRI, 1094(ab)
FDG uptake, errors in, 385(ab)
fibrosis in, 379(ab)
muscarinic receptors, PET detection of, 1270
pulmonary adrenoreceptor density, 834(ab)
scintigraphy, pulmonary segmented reference charts in, 1402(1e)
- Lung cancer**
chemosensitivity of, reproducibility by ^{99m}Tc MIBI SPECT, 1778
diagnosis, staging and management of, 544(ab)
diagnosis with FDG PET, 230(ab)
differential diagnosis with Met PET and FDG PET, 1091(ab)
distribution of bone metastases in, 1144(ab)
dynamic 30-minute PET imaging of, 1088(ab)
FDG detection of pulmonary lesions, 1092(ab)
FDG detection of skeletal metastases, FDG, 1145(ab)
FDG gamma camera coincidence imaging in, 566
FDG PET diagnosis of, 228(ab)
- FDG PET evaluation of chemotherapeutic effect**, 1090(ab)
FDG PET staging, 229(ab), 547(ab), 561(ab)
FDG PET tumor detection, 1039(ab)
FDG uptake as prognostic marker, 548(ab)
lesion detection, FDG PET, ROC analyses, 2043
lymph node staging with ^{11}C choline and FDG PET, 240(ab)
multidrug resistance, and radioresistance, 1084(ab)
non-small cell
glucose transporters and FDG uptake in, 536
 P-glycoprotein and ^{99m}Tc tetrofosmin uptake in, 1223(1e)
non-small-cell
chemotherapeutic effect of, 1086(ab)
response monitoring, 564(ab)
staging of, with coincidence imaging, 1093(ab)
PET imaging, patterns and pitfalls of, 1462(ab)
PET in, 814
preoperative assessment of mediastinal lymph nodes, 1085(ab)
pulmonary nodules, evaluation of, 36(ab)
small cell
targeting cholecystokinin-B/gastrin receptor-expressing tumors, 1029
two-step targeting and dosimetry, 1216
- SPECT ^{99m}Tc MIBI imaging of**, 1087(ab)
uptake of FDG in, 1089(ab)
validation of three-dimensional PET imaging, 1096(ab)
 ^{111}In -DOTA-lanreotide scintigraphy, 395(ab)
- Lung disease**, diffuse, threshold of detection, 85
- Lung perfusion**
prognostic value of, 880(ab)
quantification of regional pulmonary artery flow, 877(ab)
- Lung scintigraphy**
detection bronchiolitis obliterans syndrome after lung transplantation, 525(ab)
helical computed tomography, 881(ab)
partial ventilation/perfusion mismatch, 221(ab)
whole-body blood flow patterns, congenital heart anomalies, 1477
- Lutetium oxyorthosilicate PET scanner**, high-resolution, animal imaging, 1164
- Lyme neuroborreliosis**, reduced cerebral perfusion, 1197(ab)
- Lymphadenopathy**, FDG PET vs CT in assessment of metastasis, 69(ab)
- Lymphedema**, prediction of infection risk, 49(ab)
- Lymph nodes**
axillary, metastasis, breast cancer, FDG PET and dual-head coincidence imaging comparison, 1003
axillary lymph node detection with planar and ^{99m}Tc MIBI SPECT, 556(ab)
sentinel
localization, early breast cancer, 1403(1e)
 ^{99m}Tc serum albumin identification of, in melanoma, 1143
- Lymphoma**
brain SPECT, lesion size determinant of scan accuracy, 891(ab)
clinical behavior of CB-CC variant, 957(ab)
colorectal cancer, FDG PET imaging applications, 591
FDG coincidence imaging of, 249(ab)
FDG PET staging of, 247(ab)
high-dose chemotherapy, 946(ab)
malignant
bone, ^{67}Ga scintigraphy and MRI comparison, 387
primary staging, FDG PET replacement of bone scintigraphy in, 1407
- non-Hodgkin's**
B-cell, ^{67}GA scintigraphy in, 40
chronic lymphocytic leukemia and, radiation dosimetry, 1317
conventional treatments, 1967(1e)
 ^{67}Cu 21T-BAT-Lym-1 radioimmunotherapy, 2014
low-dose radioimmunotherapy, compared to high-dose, 992(ab)
radiomunotherapy with Y-90 and IDEC = Y2B8, 260(ab)
response monitoring with FDG PET, 953(ab)
radionuclide imaging and MRI of, 251(ab)
staging and follow-up with FDG, 944(ab)
tumor regression in, ^{67}Cu -11T-BAT-LYM-1 pharmacokinetics in, 302
- tumor staging with FDG coincidence imaging**, 250(ab)
 ^{99m}Tc imaging of, 965(ab)
 ^{67}Ga SPECT assessment of primary gynecologic, 955(ab)
 ^{67}Ga uptake, *in vivo* and *in vitro* studies, 960(ab)
- Lymphoscintigraphy**
clinical significance of intercalated lymph nodes, 233(ab)
complete groin dissection in vulvar cancer, 235(ab)
detection of lower extremity lymphedema, 49(ab)
diagnosis of breast cancer, 559(ab)
double tracer technique, head and neck tumors, 776
dual-tracer imaging of head and neck tumors, 257(ab)
influence of volume and injection site in breast cancer, 237(ab)
internal mammary drainage, 557(ab)
nodal drainage patterns of, 1120(ab)
primary melanoma of the trunk management of, 1125(ab)
reproducibility of sentinel lymph node detection, 234(ab)
vs subdermal and peritoneal injections, 238(ab)
 ^{99m}Tc sulfur colloid sentinel node detection, 236(ab)

M

Magnetic resonance imaging (MRI)

- chronic synovitis, radiation synovectomy effects, 1277
combination of Fourier space with 1H20 MR image, 1301(ab)
correlation to SPECT in acute cerebral infarction, 569(ab)
dopamine receptor sensitivity, 582(ab)
frequency encoding, simultaneous display using, brain, 442
gated, severe left ventricular dysfunction, recovery from, 1824
partial volume correction schemes based on, PET, 2053
tumor membrane metabolism, 973(ab)
use with SPECT, to quantify pulmonary arterial flow, 877(ab)
vs gated SPECT assessment of left ventricular volume and LVEF, 180(ab)
 ^{67}Ga scintigraphy comparison, bone neoplasms, 387
 ^{201}TL SPECT and, neck metastases, 1414

Malignant disease, FDG-PET in lung lesions without tissue, diagnosis, 409(ab)

Mammography, scintimammography and, suspected breast cancer, 296

Managed care, 9N(12)

Marrow imaging, FDG PET of multiple myeloma, 945(ab)
Mass spectrometry, BMIPP pharmacokinetics and metabolism, animals and humans, 1484

Mathematical modeling

- analytic formula, 1310(ab)
blood flow, 1269(ab)
McIntyre, Patricia A., 20N(6)
MDS Nordin, MAPLE reactors, 20N(6)
Meckel's diverticulum, gastrointestinal bleeding and, procedure guidelines, 1226

Medical Internal Radiation Dose (MIRD) method

- dosimetry, 166(ab)
dynamic urinary bladder model, 102S
internal dosimetry, pediatric head and brain models for, 1327
radionuclide S values, revised dosimetric model and, adult brain, 62S

techniques for radiation dose methods, 37S
 ^{99m}Tc DMP-HSA serum albumin, dose estimates, 1532

Medical Isotopes Conference, nuclear physicians and the political process, 13N(5)

Medical specialty integration, nuclear medicine in the 21st Century, 13N(7)

Medulla, focused infarcts, remote regional cerebral blood flow consequences, 721

Melanoma

- affinity for ^{99m}Tc complexes, 487(ab)
FDG PET imaging, 78(ab), 591
FDG PET vs scintigraphy in outcome analysis, 79(ab)
lymphoscintigraphy, 234(ab)
lymphoscintigraphy in management of, 1125(ab)
lymphoscintigraphy in sentinel node biopsy, 1124(ab)
sentinel lymph nodes in, ^{99m}Tc serum albumin identification of, 1143
TNF perfusion, TYR PET in, 262
tumor targeting of ^{99m}Tc cyclic melanotropin peptide, 484(ab)
 ^{99m}Tc sulfur colloid filtration effects, 236(ab)

- Melanoma scintigraphy**
 dynamic lymphoscintigraphy, 232(ab)
 prognostic value of 99m Tc sestamibi, 80(ab)
 radioguided surgery, 1124(ab)
 99m Tc peptide 829, detection of melanoma, 1126(ab)
- Melrose, Margaret**, history corner, 18N(4)
- Meningioma**, somatostatin receptor imaging, 1246
- Mental performance**, neurotoxic deficit after Pfeisteria exposure, 454(ab)
- Mesothelioma**, malignant pleural, value of FDG PET, 1241
- Metaiodobenzylguanidine (MIBG)**
 evaluation of cardiac adrenergic nerve, 833(ab)
 low cardiac uptake as predictor of cardiomyopathy, 175(ab)
 plasma cortisol levels on myocardial uptake of, 726(ab)
 scintigraphy in dilated cardiomyopathy, 8(ab)
 sympathetic effects, comparison with tyramine, 1342
 uptake, heart, effects of Parkinson's disease, 371
- Metastasis**
 carcinoma of unknown primary (CUP), 1149(ab)
 optimize treatment, 164(ab)
- Metastatic carcinoma**, unknown primary sites, 1151(ab)
- Methionine**, lymph node uptake of, 85(ab)
- 11 β -Methoxy-(17 α ,20E/Z)- 123 I iodovinylestradiol**, imaging of estrogen receptors, breast cancer, 1728
- Methylphenidate**, brain response to, repeated measures of dopamine release, 1285
- Metoprolol**, cardiac MIBG kinetics and, failing heart, 224
- MicroPET I**
 myocardial blood flow, dynamic acquisition of, 20(ab)
 myocardial imaging on, 826(ab)
- Military medicine**, 10N(1)
- Modeling**
 kinetic, dopamine transporter imaging agent, 99m Tc TRODAT-1, 150
 myocardial glucose utilization measurements, blood activity corrected/uncorrected for metabolites, 842(ab)
 quantification of FHT2, 1266(ab)
- Modeling software, SPECT**, improved detectability of perfusion defects, 218(ab)
- Molecular imaging**, topics, 497
- Molecular probes**, oncogenes, cancer, and imaging, 498
- Monoamine oxidase**, activity, sensitivity of 13 C PHEN kinetics, heart, 232
- Monoamine oxidase B**, effect of cigarette on, 1215(ab)
- Monoclonal antibodies (MAB)**
 anticarcinoembryonic antigen, 131 I-labeled, after radioimmunotherapy, 1609
 anti-CD33, alpha-emitting bismuth cyclohexylbenzyl DTPA, 166
 anti-colon cancer xenografts with deoxyglucose, 430(ab)
 anti-mucin antibody, to stage bladder cancer, 399(ab)
 biodistribution of 90 Y- and 111 In-labeled 90 Y, 328(ab)
 CC49, constructs, colon carcinoma xenografts, 1536
 mutation specificity of 6H8, 433(ab)
 red marrow, dosimetry of, 972(ab)
 therapy, biodistribution and dosimetry of I-131-TNT antibody, 971(ab)
 vs MIBI in breast tumor imaging, 1106(ab)
 90 Y, dosimetry of, 261(ab)
 213 Bi labeled, preparation of constructs for clinical use, 1722
- Monomine transporter 2**, vesicular, reproducibility studies with, 283
- Monte Carlo simulation**
 absorbed fractions of energy, within cortical bone, 2115
 accurate modeling of photon interactions, 473(ab)
 code-based software for, EG54, internal radionuclide dosimetry, 1517
 effect and correction of detector sag in SPECT systems, 1260(ab)
 effects of cardiac chamber size determined by, 314(ab)
 mathematical anthropomorphic phantoms, 157(ab)
 rectal model, dosimetry applications, 1524
 three-dimensional transport model, absorbed fractions of energy within trabecular bone, 1947
- Motion artifacts**
 head immobilization device for PET, 1242(ab)
 myocardial SPECT studies, 510(ab)
- Motion correction**
 diverging circle algorithm for, 1329(ab)
- head immobilization device for PET, 1242(ab)
 respiratory compensation in cardiac PET, 457(ab)
- Motor activation**, PET quantitation of, 1178(ab)
- Movement disorders**, 99m Tc ECD SPECT study of, torticollis spasmoides, 268(ab)
- Moyamoya disease**
 cerebral hemodynamics in, 1203(ab)
 pregnancy and, 214(le)
- Multidrug resistance (MDR)**
 breast neoplasm, 1102(ab)
 overexpression of MDR1 P-glycoprotein, 1024(ab)
 prediction of chemosensitivity by MIBI, lung cancer, 1778
 radionuclide imaging of, 1025(ab)
 99m Tc MIBI, as a substrate for P-glycoprotein, 1086(ab)
 99m Tc MIBI as a tracer, carcinoma cells, 672
- Multidrug resistance (MDR) reversing agents**
 tumor, effect of, 1023(ab)
 99m Tc sestamibi in evaluation of, 1026(ab)
- Multimodality display**
 epilepsy, 1270(ab)
 three-dimensional datasets, 1454(ab)
- Multimodality imaging**
 FDG PET, contractile function using MRI, 821(ab)
 perfusion, 315(ab)
 X-ray CT and radionuclide imaging, 127(ab)
- Multinodular goiter**, nontoxic, radioiodine treatment for, 1313
- Multiple myeloma**, 246(ab)
 evaluation, 201 Tl scintigraphy, 1138
 FDG PET imaging, 945(ab)
 whole-body 99m Tc MIBI imaging of, 959(ab)
- Multivessel disease**, acute myocardial infarction, reverse flow-metabolism mismatch pattern on PET, 1492, 1499(ed)
- Mu opioid receptor**
 alcohol, brain changes due to, 446(ab)
 neuroreceptors, sex differences in, 447(ab)
 regional cerebral blood flow study, 291(ab)
- Muscarinic acetylcholine receptor**, distribution PET studies of, 1177(ab)
- Muscarinic cholinergic ligand**, compartmental models, 119(ab)
- Muscarinic receptors**
 imaging of, temporal lobe epilepsy, 935
 PET detection of, lung, 1270
- Muscle**
 metabolism, runners, FDG PET imaging, 70
 skeletal
 glucose transport and phosphorylation, FDG PET, 977
 involvement in malignant lymphoma, primary staging, FDG PET replacement of bone scintigraphy in, 1407
 18 F FDG, lumped constant for, 1798
- Muscular dystrophy, hereditary**, 111 In-labeled antimyosin scintigraphy for, 1222(le)
- Musculoskeletal sarcoma**
 FDG vs 99m Tc MDP evaluation of chemotherapy, 388(ab)
 staging with FDG PET vs conventional methods, 392(ab)
 201 Tl, evaluation of therapeutic effect, 535(ab)
- Myelotoxicity**
 preclinical therapy with antioxidant vitamins, 981(ab)
 radiation-induced, factors influencing, 1380(ab)
- Myocardial fatty acid metabolism**, heterogeneity, 831(ab)
- Myocardial flow reserve**, cardiac allograft vascularity, 719(ab)
- Myocardial gated SPECT**, improved myocardial perfusion and function, assessment of, 742(ab)
- Myocardial imaging agents**
 beta-adrenergic receptors, 351(ab)
 comparison of thallium and technetium, 344(ab)
 myocardial biokinetics, 830(ab)
 Tc-labeled agents perfusion imaging, with and without fatty meal, 343(ab)
 tetrofosmin scintigraphy, 725(ab)
 113 C neostigmine, 495(ab)
 99m Tc glucarate detection of myocardial necrosis, 815(ab)
- Myocardial infarction**
 acute
 assessment of myocardial viability with 201 Tl, 505(ab)
 detecting salvage after, 363
 detection, 99m Tc glucarate, 1832
 fusion imaging to diagnose, 746(ab)
- glycemic state, effect on 99m Tc glucarate uptake ratios, 838(ab)
- left ventricular dysfunction after, prediction of recovery, 1683
- prediction of recovery wall motion, 745(ab)
- prognostic value of scintigraphically assessed myocardial salvage, 24(ab)
- reverse flow-metabolism mismatch pattern on PET, 1492, 1499(ed)
- reverse redistribution of 99m Tc sestamibi and risk area after PTCA, 713(ab)
- 99m Tc tetrofosmin SPECT after reperfusion, 781(ab)
- clinical variables or time-interval as predictor of tissue viability, 773(ab)
- gated SPECT, 789(ab)
- major, gated thallium SPECT in, 513
- recovery of left ventricular dysfunction, 194(ab)
- size determination with 201 Tl SPECT, 749(ab)
- 123 I IPPA low flow, acute infarction and reperfusion, 821
- 123 I MIBG kinetics after, 904
- Myocardial ischemia**
 abnormal images of peripheral vascular disease, 795(ab)
 differences in BMIPP uptake, 831(ab)
 ischemic memory imaging with I-123-DTPA, 818(ab)
 laser revascularization, 340(ab)
 myocardial perfusion imaging, 347(ab)
 radioiodinated fatty acid analogs, 1204
 stress perfusion imaging in octogenarians, 350(ab)
- Myocardial metabolism**, 827(ab)
 effect of alterations in hypertrophic cardiomyopathy, 808(ab)
- Myocardial perfusion imaging**
 acute chest pain patients, detection of acute MI in, 1832
 adjunctive value of left lateral planar view, 810(ab)
 automated LVEF, as predictor of normal study, 714(ab)
 detection of silent ischemia in hypercholesterolemia, 737(ab)
 dobutamine stress echocardiography or, chest pain in women, 1222(le)
 expert system of interpretation of myocardial perfusion tomograms, 508(ab)
 gated
 left ventricular function and volumes, echocardiography vs, 1857
 left ventricular modeling assessment, 702(ab)
 utility of stress only 99m Tc sestamibi, 759(ab)
- gated SPECT
 accuracy and reproducibility of, 810(ed)
 arrhythmia effects, 924
- gated SPECT to assess CAD, 787(ab)
- large SPECT databases improve diagnostic decision making, 1290(ab)
- left ventricular ejection fraction, perfusion and, 650
- left ventricular function, 777(ab)
- polar map analysis of PET and SPECT images, 362(ab)
- sestamibi, echocardiography vs, salvage after primary PTCA, 363
- simultaneous 99m Tc sestamibi and 201 Tl dual isotope, coronary artery disease, 895
- stress imaging in octogenarians, 350(ab)
- 99m Tc-labeled agents, forward cardiac output measurements, 1874, 1882(ed)
- 99m Tc sestamibi, right ventricular uptake, in coronary artery disease, 889
- 99m Tc tetrofosmin, left ventricular volumes and ejection fraction, 1693
- 201 Tl, simultaneous emission/transmission tomography, 1303
- 201 Tl rest redistribution, prognostic indicator, 28(ab)
- Myocardial redistribution**, 201 Tl SPECT vs stress-rest abnormalities, 28(ab)
- Myocardial scintigraphy**, 201 Tl, attenuation correction and resolution recovery, 701(ab)
- Myocardial uptake**
 myocardial functional characterization, 1466(ab)
 plasma cortisol levels on MIBG, 726(ab)
- Myocardial viability**, 721(ab)
 after coronary revascularization, SPECT prediction of improvement, 1866
 assessment of relative myocardial blood flow in detection of, 184(ab)
 assessment, FDG PET, SPECT or gamma coincidence imaging, 1893(ed)
 automatic assessment of, 821(ab)

BMIPP detection of, 765(ab)
cardiac PET management of congestive heart failure, 189(ab)
clinical variables or time-interval as predictor of, 773(ab)
comparison of I-125-lodorothenone and ^{99m}Tc sestamibi in detecting, 352(ab)
determinant of improved LVEF postrevascularization, 190(ab)
dobutamine echocardiography, 777(ab)
dual-isotope assessment of, 193(ab)
effect of filtering on MIBI/FDG SPECT, 1322(ab)
fatty acid imaging, ¹²³I 9-MPA, acute coronary syndrome, 1999
fatty acids added in left bundle branch block, 213(ie)
FDG PET study of, 708(ab)
gated FDG vs static NH₃ in assessment of, FDG, 183(ab)
gated SPECT and dobutamine echo assessment of, 338(ab)
gated ^{99m}Tc sestamibi imaging, segmental thickening by, 177(ab)
ischemic left ventricular dysfunction, BMIPP imaging, 1468
¹⁻¹²³BMIPP and ^{99m}Tc MIBI, mismatching, 707
¹⁻¹²³IPPA, low flow or after acute infarction and reperfusion, 821
left ventricular dysfunction, 725(ab)
LVEF, postrevascularization improvement of, 196(ab)
PET, spatial coregistration techniques, 18(ab)
post-stress ECG-gated SPECT assessment of, 798(ab)
recovery of left ventricular dysfunction, 194(ab)
recovery post-revascularization, 706(ab)
wall thickening or wall motion, 790(ab)
^{99m}Tc MIBI vs ²⁰¹Tl SPECT, 2(ab)
^{99m}Tc sestamibi defect severity, poor prognostic indicator of function, 716(ab)
^{99m}Tc tetrofosmin assessment, models of coronary occlusion and reperfusion, 142
²⁰¹Tl reverse redistribution to assess, 756(ab)
²⁰¹Tl SPECT imaging of, 191(ab)

Myocardium

glucose uptake, FDG PET measurement of, 1186
glucose use, in CD36 deficiency, 239
influx and efflux of ^{99m}Tc MIBI, 835(ab)
ischemic, ^{99m}Tc-MIBI and ¹²³I-BMIPP studies, 707
ischemic and hypoxic, radioiodinated fatty acid analogs, 1204
oxidative metabolism abnormalities, PET, 846
reperfusion therapy, 770(ab)
¹²³I MIBG kinetics, elevated plasma norepinephrine effects, 2088
²⁰¹Tl SPECT, distribution of image amplitude, 730(ab)

Myopathies, inflammatory, biodistribution and radiation dosimetry of ¹¹¹In antimyosin in, 464

N

Naltrexone, regional cerebral blood flow changes, alcoholics, SPECT, 19
Nasopharyngeal carcinoma
PET study of malignant tumor, 1050(ab)
SPECT imaging of skull base involvement, 1052(ab)
National Cancer Institute, prostate cancer, 33(n)(10)
National Institute of Biomedical Imaging, Academy of Radiology Research (ARR), 9N(6)
National Institutes of Health (NIH), imaging research opportunities, 9N(4)
National licensure
public affairs update, 25N(10)
rewrite of 10 CFR 35, 22N(1)
Neck, metastases, ²⁰¹Tl SPECT and MRI, 1414
NEMA, acceptance testing, 12N(12)
NEMA protocol, signal-to-noise ratio, evaluation of, 481(ab)
Nephron-sparing surgery, ^{99m}Tc MDP renal retention after, 418
Neural networks
PET activation study of cochlear implant users, 1160(ab)
PET studies of sound processing and memory process, 1175(ab)
Neuroblastoma
image analysis, 912(ab)
somatostatin receptor scintigraphy and FDG PET, 1059(ab)
¹¹C epinephrine PET imaging of, 519(ab)

Neuroendocrine tumors

somatostatin receptor imaging, factor analysis of dynamic series in, 33
somatostatin receptor scintigraphy in, 539
^{99m}Tc P829 vs ¹¹¹In-Pentetotide in detection, 369(ab)
Neuroimaging
CBF with flow-sensitive alternating inversion recovery, 574(ab)
database for image analysis and documentation, 1289(ab)
revised dosimetric model, adult head and brain, 62S
Neurophysiology, functional neuroanatomy, 1190(ab)
Neurotensin, ^{99m}Tc-labeled, unprecedented high specific activity, 1913
Nicotinic acetylcholine receptors
kinetic modeling of, 1164(ab)
occupancy by nicotine doses, 439(ab)
PET imaging with, 1349(ab)
Nicotinic receptors, acetylcholine, with [¹⁸F]fluoro-A-85380, 1374

Nifedipine, photodegraded
promotion of gallium uptake in tumor cells, 159
tumor cell uptake of gallium and, 2129(ie)
Nitrogen-13 ammonia, PET, myocardial blood flow, 1045
NMDA (N-methyl-D-aspartate) receptor, glycine site of, 1351(ab)
Noise, removal, using factor analysis of dynamic structures, 1676
Norepinephrine, plasma, extrinsically elevated, myocardial MIBG kinetics and, 2088
Norepinephrine transporter, vesicular storage and monoamine oxidase activity, isolated heart, 323
Normal uptake, myocardial perfusion baseline studies, inter- and intrasubject variability, 763(ab)
Nuclear medicine

advances, fused image tomography, 13N(8)
clinical practice, 10N(1)
decision analysis in, 1570
history of, Donner Laboratory, 16N(1)
Latin America, 9N(9)
lines from the president, 21N(9), 38N(8)
in managed care, 9N(12)
in the military, 10N(1)
U. S. Congress, 20N(3)

Nuclear Medicine Archives, The Heritage Project, 21N(11)

Nuclear Medicine Pioneer Series

McAfee, John G., 15N(11)
Wagner, Henry N., 13N(10)

Nuclear Regulatory Commission (NRC)

ACNP/SNM Government Relations Activities, 1998 year end report, 25N(2)
DOE isotope conference, 22N(1)
instructions to patients following radioiodine therapy, 990(ab)
10 CFR Part 35, Sustained Growth Rate System, 25N(11)

O

Obesity

laparoscopic adjustable silicone gastric banding, ^{99m}Tc pertechnetate scintigraphy in, 783
red cell mast and, 422

Octreotide

evaluation of experimental radiation pneumonitis, 37(ab)
peptide receptor radionuclide therapy, 415(ab)
radiolabeled, thymic concentration of, 1967(ie)

Oligodeoxynucleotide

DNA cleavage conjugated to, 1405(ab)
MDR1 gene, 1009(ab)
synthesis of ¹⁸F labeled, 332(ab)

Oligonucleotide

radiotherapy, problems with, 1582(ie)

Oncogenes

cancer and imaging, 498

Oncologic imaging

FDG PET, 1706

Oncology

head and neck, nuclear medicine in, 91

Ordered subsets expectation maximization (OSEM)

cardiac, rotating slant-hole, 134(ab)
COSEM iterative algorithm, 1295(ab)

Fourier rebinning technique, 1302(ab)

scatter and attenuation correction of, 1318(ab)

whole-body PET, 1316(ab)

Orocecal transit

¹³C breath test, scintigraphy, 1451

Osteitis

diagnosis of in diabetic foot disease, 903(ab)

Osteogenic sarcoma

FDG PET evaluation of chemotherapy in, 1143(ab)
multidrug resistance, 919(ab)
neoadjuvant therapy response, FDG PET, 1637
tumor necrosis, 524(ab)

Osteomyelitis

assessment and efficacy of imaging vertebral osteomyelitis, 906(ab)
bacterial detection with ^{99m}Tc ciprofloxacin, 60(ab)
FDG PET exclusion of, 61(ab)
pediatric imaging of, 47(ab)
^{99m}Tc HMPAO four-phase imaging, 902(ab)

Osteosarcoma, radiotherapy with high-dose Sm-153-EDTMP, 977(ab)

Ovarian cancer

experimental ovarian carcinoma, effect of radioimmunotherapy, 432(ab)
ovarian cancer, using a hybrid PET scanner, 541(ab)
recurrence, detection of with whole-body FDG PET, 424(ab)
¹³¹I-labeled chimeric monoclonal antibody, 966(ab)

Oxygen extraction fraction, increased, prognosis in cerebrovascular diseases, 1992

Oxygen metabolism, myocardial, iterative reconstruction, PET heart studies, 862

Oxygen-15 water

calculated input function in relative rCBF study, 1272(ab)
derivation of input function on PET brain images, 146(ab)
echocardiography, 791(ab)
multiplane factor analysis in PET images, 309(ab)
PET and, baseline and hyperemic myocardial blood flow measurement, 1848
O-(2-[¹⁸F]fluoroethyl)-L-tyrosine, transport mechanism, uptake kinetics and, 1367

P

Pancreatic cancer

FDG PET, optimal interpretation of, 1784
FDG PET assessment of treatment response, 1079(ab)
FDG PET vs CT in management of, 421(ab)
liver metastases from, ¹⁸F FDG PET, 250
preoperative FDG uptake, correlation with Ki-67 immunostaining, 368(ab)
unresectable, intraoperative radiation therapy, FDG PET evaluation of, 1424

Pancreatic tumor, PET preoperative diagnosis of, 422(ab)

Pancreatitis, Ga infection imaging, 371(ab)

Parametric imaging

cluster analysis, 1269(ab)
myocardial beta-adrenoceptor density, 507
myocardial perfusion study, 295(ab)
representation in image format, 163(ab)
ridge regression, 147(ab)
striatal and nonstriatal binding, 1267(ab)

Parathyroid

hyperfunctional, ^{99m}Tc MIBI correlated with histology, 1792
rapid scintigraphy with ^{99m}Tc tetrofosmin, 920(ab)
scanning accuracies, 361(ie)

Parathyroid adenoma

SPECT, diagnostic utility and cost-effectiveness of, 940(ab)
^{99m}Tc MIBI correlated with histology, 1792
^{99m}Tc sestamibi, pre- and postoperative localization of, 197(ab)
¹²³I subtraction and delayed ^{99m}Tc MIBI imaging, 199(ab)

Parathyroid imaging

effect of cell type of sestamibi sensitivity, 201(ab)
sequential pertechnetate-sestamibi imaging, 200(ab)

Parathyroid scintigraphy

perchlorate in, 1769(ie)
radioguided surgery, comparison of, 203(ab)

Parkinson's disease

cardiac sympathetic dysfunction in, 727(ab)
dementia with Lewy bodies, 1179(ab)
differential diagnosis vs multiple system atrophy, 271(ab)
disease progression, 107(ab)
dopamine degeneration in, 111(ab)
dopamine D2 receptors, 273(ab)
dopamine SPECT in, 530

- dopamine transporter and D2/D3 receptors, 1170(ab)
 lipophilicity of glucose analogs in, 1352(ab)
 loss of ^{131}I MIBG uptake, heart, 371
 movement disorders, 1178(ab)
 nigrostriatal dopaminergic pathway in, ^{123}I -FPCIT SPECT, 753
 pallidal electrostimulation, 269(ab)
 parietal abnormalities in, 1184(ab)
 presymptomatic phase detection with I-123-FP-CIT SPECT, 106(ab)
 regional metabolic covariance patterns, FDG PET, 1264
 specificity of dopamine transporter imaging agents, 152(ab)
 SPECT image analysis, statistical parametric matching, 1583
 ^{99m}Tc HMPAO SPECT study, 956
 ^{99m}Tc sestamibi vs N-13-ammonia detection of, 21(ab)
 ^{99m}Tc TRODAT-1 and motor activation, 1200(ab)
 ^{123}I -bTCIT SPECT imaging of, 267(ab)
- Partial-volume correction**, for PET, based on MR, 2053
- Partial volume effect**
 averaging of noisy PET data, 474(ab)
 mixed continuity image, 1299(ab)
 small spheroids, radioactivity concentration of, 118
- Partition coefficient**, peptidic chelator, 331(ab)
- Patient privacy**, HHS regulations for, 25N(11)
- Patlak-Rutland plot**, deconvolution comparison, renographic analysis, 1503
- Pediatric patients**
 applications of pinhole magnification imaging, 1896
 direct and indirect radionuclie cystography, dosimetry in, 2127(l)e
 diuresis renography in, 1805
 dosimetry, head and brain models for use in, 1327
 PET evaluation of noncentral nervous system tumors, 908(ab)
 quantitative gravity-assisted drainage, diuretic renography, 55(ab)
 seizure foci, subtraction ictal SPECT, 786
 thyroid cancer, UICC/AJCC classification in, 2125(l)e
 urinary tract infection, ^{99m}Tc DMSA clearance and, 52
 validation of F+O diuretic renography, 54(ab)
 ^{99m}Tc DMSA quantitative SPECT uptake, kidney, 56
 ^{99m}Tc white blood cell imaging of inflammatory bowel disease, 50(ab)
 ^{123}I IBZM SPECT, dopamine receptor brain imaging, neonatal period, 2125(l)e
- Peptide receptor imaging**
 angiogenesis, intravascular agent for detection of, 319(ab)
 calcitonin receptor imaging, 417(ab)
 cholecystokinin-B/gastrin receptor ligands, preclinical development of, 420(ab)
 GPIIb/IIIa, 887(ab)
 melanoma, 485(ab)
 metastatic medullary thyroid cancer, staging of, 396(ab)
 ^{99m}Tc labeled leukotriene-B4 receptor antagonist, 892(ab)
 ^{99m}Tc vasoactive intestinal peptide, 1081(ab)
 ^{111}In -labeled analogs, 320(ab)
- Peptide-receptor radiotherapy**
 for lymphoma with Interleukin-15, 1027(ab)
 medullary thyroid cancer, 420(ab)
 somatostatin analog radionuclide therapy, 414(ab)
 ^{111}In -DTPA-octreotide, nonimpairment of renal function, 416(ab)
- Peptides**
 epidermal growth factor receptor targeting of breast cancer, 1370(ab)
 infection imaging multicenter trial results, 57(ab)
 pharmacokinetics and biodistribution of ^{111}In -DTPA-G-CSF, 1031(ab)
 uptake and pharmacokinetics in *E. coli*, 954(ab)
 in vivo and *in vitro* properties of ^{99m}Tc labeled, 1397(ab)
 ^{99m}Tc labeled infection imaging, 950(ab)
- Peptide chelator**
 single isomer, 504(ab)
 tumor uptake of Cu-67-labeled antibody fragments, 326(ab)
- Perchlorate**, attribution of use, parathyroid scintigraphy, 1769(l)e
- Percutaneous transluminal coronary angioplasty**
 defect severity, prognostic indicator of function, 716(ab)
 postrevascularization recovery, 767(ab)
- Perfusion agents**
 BMIPP, metabolism in rat tissues, 1918
 for measurement of forward cardiac output, 1874, 1882(ed)
- Perfusion imaging**
 aging, 349(ab)
 ECG-gated ^{201}Tl SPECT imaging, 771(ab)
 exercise and adenosine, effect on defect size, 517(ab)
 quantitated prognosis of coronary artery disease, 169(ab)
 rest and exercise dual-isotope SPECT, 774(ab)
 SPECT depiction of improved blood flow after treatment with rhVEGF, 342(ab)
 variability in SPECT studies, 509(ab)
 ^{99m}Tc sestamibi, regional quantification of, 506(ab)
 ^{99m}Tc sestamibi cardiac study, 361(ab)
- Perfusion lung scan**
 lung volume reduction surgery, 381(ab)
 sequential SPECT study, 882(ab)
 SPECT acquisition of, 219(ab)
- P-glycoprotein**, quantification of, facilitates transport in blood-brain barrier, 1159(ab)
- Phage display**, peptide libraries, identification of receptor ligands with, 883
- Pharmacokinetics**
 biomodulation of 5-FU, 1032(ab)
 characteristics of I-131-anti-B1 (anti-CD20) antibody, 991(ab)
 compartmental analysis, heterogeneous tissue model of ^{11}C acetyl aminoisobutyric acid, 1016(ab)
 design of oral pharmaceutical dosage forms, 365(ab)
 drug formulation evaluation, 610(ab)
 ^{111}In antimyosin, idiopathic inflammatory myopathies, 464
- Pharmacologic stress test**, imaging protocol for, 513(ab)
- Pharmatokinetic studies**
 dosimetry of ^{99m}Tc vasoactive peptides, 1363(ab)
 PET data processing, 1288(ab)
- Phelps, Michael**, Fermi Award, 12N(6)
- Phelps, Michael E.**, Presidential award given for PET research, 10N(4)
- Phosphoinositide**, turnover, ischemic brain, PET, 1590
- Phosphorus-32**
 palliation in skeletal metastases, 256
 radiocolloid treatment of joint hemorrhage, 44(ab)
- Photodynamic therapy**, tumor response after, high-resolution PET, 876
- Physical Evaluation Program (PEP)**, earning CME credit electronically, 9N(2)
- Physician fee schedule**
 CHCPP news, 26N(3)
 SNM Physical Evaluation Program, 26N(1)
- Pinhole magnification imaging**, pediatric applications of, 1896
- Pituitary adenoma**, octreotide in, somatostatin receptor scintigraphy, 1252
- Platelet imaging**, kinetic measurements with probes, 948(ab)
- Polycythemia**, red cell mass, obesity effects, 422
- Pons**, focused infarcts, remote regional cerebral blood flow consequences, 721
- Positron camera**
 comparison to SPECT camera with PET option, 1244(ab)
 dynamic PET imaging, Yappet scanner for, 302(ab)
 large-area positron camera (PETRRA), 1224(ab)
 small animal imaging device, 1258(ab)
- Positron emission tomography (PET)**
 activation study, 1171(ab)
 age-related defects in dopamine D2 receptors, 1218(ab)
 akinetic wall motion depicted on gated scans, 183(ab)
 animal model of dysfunctional viable myocardium, 822(ab)
 assessment of abnormal CEA levels in recurrent colorectal cancer, 412(ab)
 attenuation correction, 1308(ab), 1309(ab)
 automated synthesis system for ^{11}C bicarbonate, 1401(ab)
 autoradiographic-based activity distributions, 131(ab)
 biliary bicarbonate secretion, 845(ab)
 brain activation study, 290(ab)
 camera performance measurements, 308(ab)
 cerebral blood flow study, 1220(ab)
 clinical performance of CPET camera, 1239(ab)
 closed-head injury, 287(ab)
 coincidence imaging of non-small-cell lung cancer, 1093(ab)
- combination of Fourier space with 1H2O MR image, 1301(ab)
- computer-aided education, 1457(ab)
- correlation with bone scan in detection of bone tumors, 1145(ab)
- correlation with per rectal portal scintigraphy, 858(ab)
- Cu-62-ETS myocardial perfusion imaging, 775(ab)
- dedicated system for breast cancer imaging, 1223(ab)
- delineation of serotonin receptors with ^{18}F MPPF, 116(ab)
- detection of muscarinic receptors, lung, 1270
- detectors compact high resolution gamma ray, 304(ab)
- diagnostic capability of FDG in pediatric tumors, 908(ab)
- differential diagnosis of lung tumors, 1091(ab)
- dopamine receptor density measurement, 145(ab)
- dopamine receptor mediation, 442(ab)
- dopamine receptor sensitivity, 582(ab)
- dopamine transporter changes in cocaine users, 441(ab)
- dopamine transporter damage due to methamphetamine, 443(ab)
- drug research and development, 1154
- dual-head camera, detection of head and neck cancer with, 259(ab)
- dual-head coincidence, vs ring PET, tumor patients, 1617
- early detection of small breast lesions, 307(ab)
- effect of apolipoprotein E on regional brain metabolism, 281(ab)
- enhanced ^{11}C TPMP uptake, brain tumor, 1180
- estrogen administration and coronary vasomotion, 32(ab)
- evaluation of phosphoinositide turnover, cerebral ischemia, 1590
- FDG**, 1058(ab)
 acute effects of anti-insulin resistance on uptake of, 939(ab)
- angiography of brain and carotid arteries, 1274(ab)
- APOE-4 genetic risk, 283(ab)
- assessment of hepatic metastases, 92(ab)
- assessment of mediastinal lymph node metastasis, 69(ab)
- assessment of oral ethanol on regional brain glucose, 1217(ab)
- assessment of radiotherapy for nasopharyngeal cancer, 1050(ab)
- attenuation correction of whole-body images, 561(ab)
- brachial plexopathy, evaluation of, 554(ab)
- brain glucose use in Salla disease, 12
- brain responses to lorazepam, 715
- brain tumors, colorectal cancer lymphoma, and melanoma, 591
- cancer of unknown primary, 1150(ab)
- cardiac study after transcoronary ablation of septal hypertrophy, 185(ab)
- cerebellar hypometabolism, 1186(ab)
- cervical cancer patients, 1125
- characterization of solitary pulmonary nodules, 225(ab)
- chemoradiotherapy evaluated by, 1132
- clinical management of pediatric brain tumors, 521(ab)
- clinical staging and follow-up of, 97(ab)
- coincidence detection with a gamma camera, 110
- coincidence imaging comparison, breast cancer, 1003
- coincidence imaging of lymphoma, 249(ab)
- colorectal cancer, assessment of recurrence, 1074(ab)
- correlation of clinical outcome in neurofibromatosis, 520(ab)
- cost-effectiveness in lung carcinoma, 227(ab)
- delayed imaging of malignant lesions, 1097(ab)
- detection of breast neoplasm, 566(ab)
- detection of carcinoma of unknown primary, 1149(ab)
- detection of recurrence in gynecology, 1131(ab)
- detection whole-body early detection of recurrent ovarian cancer, 424(ab)
- diagnosis of head and neck cancer, 253(ab)
- diagnosis of head and neck neoplasms, 1053(ab)
- diagnosis of mouth and tongue tumors, 1048(ab)
- diagnostic role in fever unknown origin, 899(ab)
- differentiation of prostheses loosening and infection, 389(ab)
- differentiation of tumor and inflammatory sites, 1054(ab)
- efficacy in recurrent testicular carcinoma, 425(ab)
- evaluation of cervical cancer pre and post-radiation therapy, 1130(ab)
- evaluation of chemotherapeutic effect, 1090(ab)

evaluation of endocrine therapy in prostate cancer, 1137(ab)
 evaluation of global left ventricular function, 35(ab)
 evaluation of intraoperative radiotherapy in pancreatic cancer, 1424
 exclusion of chronic osteomyelitis, 61(ab)
 flow-metabolism mismatch, 1196(ab)
 gated, LVEF determination with, 755(ab)
 germ-cell tumor staging, 1133(ab)
 head and neck cancer, 91
 heart and skeletal muscle uptake, insulin action on, 1116
 hematopoietic bone marrow, 956(ab)
 histopathological correlation with aortic uptake, 355(ab)
 human cancer cell lines, 999(ab)
 infection imaging of hip prosthesis, 868(ab)
 lesion detectability, attenuation correction on, breast cancer, 2021, 2025(ed)
 lesion detection, ROC analyses, 2043
 liver metastases from pancreatic cancer, 250
 lumped constant for, skeletal muscle, 1798
 in lung cancer, 814
 lung cancer staging, 229(ab)
 malignant melanoma, diagnosis of, 78(ab)
 management costs in head and neck cancer, 255(ab)
 management of solitary pulmonary nodules, 228(ab)
 metabolic measurements of malignant tumors, 1771
 metabolic response to treatment, 946(ab)
 metabolism in low-grade lymphoma, 957(ab)
 metaplastic gastritis, 851(ab)
 metastatic thyroid cancer, 993(ed)
 muscle activity in runners, 70
 myocardial glucose uptake, 1186
 myocardial glucose uptake in ischemic cardiomyopathy patients, 1292
 neoadjuvant chemotherapy, evaluation of, 1143(ab)
 neoadjuvant therapy response of osteosarcoma, 1637
 noninvasive measurement of cerebral metabolic glucose, 1441
 normal breast uptake of FDG, 1099(ab)
 occult malignancy, identification with, 410(ab)
 oncological applications, 1706
 optimal interpretation, pancreatic cancer, 1784
 papillary thyroid carcinoma, 986
 Patlak analysis, 1075(ab)
 postsurgery an post-irradiation imaging of head and neck cancer, 1051(ab)
 predictive value in soft-tissue sarcoma, 1147(ab)
 predictor of pathological response to chemotherapy in breast cancer, 552(ab)
 predictor of prognosis in lung cancer, 1095(ab)
 preoperative lymph node staging of esophageal cancer, 98(ab)
 preoperative uptake in breast cancer, 555(ab)
 presurgical evaluation of recurrence in cervical lymph nodes, 529(ab)
 primary staging and detection of recurrent head and neck cancer, 254(ab)
 primary staging of malignant lymphoma, 1407
 prognostic value in malignant pleural mesothelioma, 1241
 proliferation index, 998(ab)
 quantitation, correlation with histopathologic tumor contro, 547(ab)
 regional metabolic covariance patterns, 1264
 role in oncology management, 408(ab)
 routine follow-up procedure with thyroid carcinoma, 1043(ab)
 same-day sequential studies, 83(ab)
 sequential studies in AIDS patients, 889(ab)
 skeletal muscle, glucose transport and phosphorylation, 977
 splenic uptake, granulocyte colony-stimulating factor therapy, 1456
 staging of gastric cancer, 94(ab)
 staging of primary head and neck cancer, dual-head camera, 1056(ab)
 staging of testicular carcinoma, 1135(ab)
 temporal lobe hypometabolism, 276(ab)
 thyroglobulin elevation in differentiated thyroid cancer, 1041(ab)
 tumor volume assessment in cervical cancer, 1129(ab)

uptake as prognostic marker to therapeutic response, 548(ab)
 uptake in giant cell-rich primary bone tumors, 390(ab)
 uptake in intestine, skeleton and myocardium, 563(ab)
 uptake in non-small-cell lung cancer, 1089(ab)
 uptake of bronchioloalveolar lung carcinoma, 86(ab)
 urinary excretion during, 1352
 value of 30-minute scan in lung cancer, 1088(ab)
 vs coincidence imaging in lesion detection, 545(ab)
 vs coincidence imaging of thyroid cancer, 543(ab)
 vs Ga-67 in Hodgkin's disease, 252(ab)
 vs MRI in abdominal lymph node staging in cervical cancer, 423(ab)
 vs whole-body ¹⁸F FMT to detect malignancies, 1018(ab)
 vs ^{99m}Tc chemotactic peptide in infection/inflammation imaging, 894(ab)
 whole-body imaging, follow-up of thyroid cancer, 1042(ab)
 whole-body imaging in Hodgkin's disease, 248(ab)
 whole-body imaging of potentially resectable colorectal cancer lesions, 1068(ab)
 whole-body scanning of gastric cancer, 1073(ab)
 whole-body scanning of metastatic cervical lymph node, 1151(ab)
 whole-body tumor imaging, 1134(ab)
 FDG and tyrosine imaging, soft tissue tumors, 381
 FDG imaging vs ^{99m}Tc bone scan bony metastasis, 386(ab)
 FDG management of differentiated thyroid cancer, 411(ab)
 FDG PET diagnosis of primary or secondary lung cancer, 81(ab)
 FDG quantification, 564(ab), 953(ab)
 FDG vs CT in management of pancreatic cancer, 421(ab)
 flow/metabolism imaging, 19(ab)
 frequency encoding, simultaneous display using, brain, 442
 frontotemporal metabolism in Alzheimer's disease, 1198(ab)
 glucose metabolism, brain tumors, after stereotactic radiosurgery, 1085
 hepatic, scatter subtraction effects, 1011
 high-resolution, tumor response after photodynamic therapy, 876
 high-resolution cardiac study, 832(ab)
 image analysis, 1279(ab)
 Impressions on the HCFA Town Hall Meeting, 10N(3)
 increased oxygen extraction fraction, cerebrovascular diseases, 1992
 integrated visualization, anatomic brain data, 311
 iterative reconstruction, heart study, 862
 LSO-based camera, Lu-176 radiation effects on, 305(ab)
 lump constant variability during MGU measurement, 824(ab)
 mammography-guided stereotactic breast biopsy, 468(ab)
 MAP reconstruction, 129(ab)
 measurement of dopamine receptor availability, 1176(ab)
 Medicare coverage of, HCFA expansion of, 23N(5)
 melanoma staging, 79(ab)
 methyl-¹¹C thymidine, ¹¹C activity after, 491
 micro, performance evaluation, 1164
 microgravity, 1451(ab)
 missing data effect on image quality, 1234(ab)
 monoamine oxidase B, 1215(ab)
 myocardial beta-adrenoceptor density, 507
 myocardial blood flow, quantitative assessment of, 29(ab)
 myocardial fatty acid metabolism, 911(ab)
 myocardial hibernation, 186(ab)
 myocardial oxidative metabolism, 33(ab)
 myocardial perfusion imaging in CAD, 346(ab)
 new high-resolution research tomograph, 306(ab)
 new tracer, imaging of temporal lobe epilepsy, 935
 nicotinic acetylcholine receptors, 439(ab)
 nicotinic acetylcholine receptor studies, 1164(ab)
 noise suppression in image reconstruction of, 297(ab)
 nonhuman primate
 human vs nonhuman primate, comparison of, 294(ab)
 nicotinic acetylcholine receptors, 1349(ab)
 noninvasive assessment of hypoxia, 401(ab)
 nuclear medicine, clinical, 11N(11)
 N-13-ammonia detection of ischemia, 21(ab)
 O-methyl-¹⁸F L-DOPA, blood-brain transport, 584(ab)

oxidative metabolism abnormalities, sympathetically denervated myocardium, 846
 parametric, 5HT₂ receptor distribution, neocortex, 25
 partial volume averaging of noisy data, 474(ab)
 partial volume correction schemes, MR-based, 2053
 patterns and pitfalls in lung cancer imaging, 1462(ab)
 PET, bone and soft-tissue sarcoma, 84(ab)
 potential applications of, developing novel cancer therapies, 995
 preoperative FDG evaluation of Liver metastases, 1069(ab)
 probe for imaging gene expression, 332(ab)
 prognostic value of regional brain metabolism in assessment of dementia, 285(ab)
 prostate cancer detection with ¹¹C acetate, 243(ab)
 quality assurance, clinical relevance of detector defects, 1657
 quantification of myocardial glucose utilization, 836(ab)
 quantitation
 analytic scatter correction, 1236(ab)
 automated lesion volume estimation, 466(ab)
 brain studies with reversible ligands, 1265(ab)
 cascade gamma rays, effects on, 1238(ab)
 chemotherapy response in esophageal cancer, 594(ab)
 comparison of SUV, visual grading and ROC, 565(ab)
 conditions of physics and reconstruction methods, 591(ab)
 CO₂ quantitation in brain and myocardium, 841(ab)
 dopamine D1 receptor binding, 120(ab)
 equilibrium modeling, 5HT2a, 1208(ab)
 errors in FDG lung uptake, 385(ab)
 FDG and ¹¹C aminoisobutyric acid in tumors, 1061(ab)
 hottest pixel analysis, 1286(ab)
 image-derived input function, 463(ab)
 image evaluation on personal computers, 1288(ab)
 lung, deposition studies of, 383(ab)
 myocardial blood flow by N-13 ammonia PET, 1304(ab)
 OSEM vs standard filtered back projection in brain studies, 592(ab)
 phantom testing of I-120, 501(ab)
 post-adenosine data, 717(ab)
 reconstruction of small animal images, 1321(ab)
 response to therapy, 1246(ab)
 serotonergic innervation with ¹¹C McNS652 PET, 115(ab)
 standardized uptake value, time corrections, 469(ab)
 standardized uptake value distribution features, 1283(ab)
 statistical bias in Logan graphical method, 141(ab)
 striatal dopamine transporter, 1156(ab)
 ¹¹C FLB457, 436(ab)
 ¹⁵O water and ⁶⁸Ga EDTA, 147(ab)
 ⁶⁸Y, quantitative accuracy, 1237(ab)
 quantitative, venous sinuses as input functions for, 1666
 reciever operating curve as SUV in bone marrow tumor, 387(ab)
 registration, vascular structure for, pelvis, 347
 reverse flow-metabolism mismatch pattern, acute myocardial infarction, 1492, 1499(ed)
 reverse mismatch of myocardial perfusion and metabolism, 909(ab)
 role in management of congestive heart failure, 189(ab)
 R-82, wavelet-base noise reduction, 720(ab)
 segmentation algorithms for transmission scanning, 459(ab)
 senile plaques, 284(ab)
 short-segmented transmission scans, effect on lesion detection and image quality, 1320(ab)
 small-animal
 dedicated PET camera for, 303(ab)
 imaging device, 1258(ab)
 new era in research, 1176(ed)
 small spheroids, radioactivity concentration of, 118
 Society of Nuclear Medicine Imaging in Drug Development (SNIDD), 22N(7)
 spatial normalization methods, anatomic validation of, 317
 table-based standardized uptake value, 1284(ab)
 tumor tracers
 assessment of presurgical chemotherapy with, 551(ab)
 correlation of tumor blood flow, 1029(ab)
 FDG and FMT uptake in sarcoidosis, 878(ab)
 FDG and ¹¹C aminoisobutyric acid, 1061(ab)

- FDG** assessment of pancreatic cancer, 1079(ab)
 FLT vs DG uptake, 100(ab)
 kinetic analysis of farnesyl transferase, 1014(ab)
¹⁸F arabinonucleosides, 1368(ab)
¹⁸F FMAU, 334(ab)
two-dimension and three-dimension acquisition modes, 477(ab)
 TYR, soft-tissue sarcoma and skin cancer, 262
 unconscious perception and retrieval, 1158(ab)
 in vivo validation of reporter gene/reporter probe assay
 for imaging herpes simplex virus Type 1, 102(ab)
 vs NMR in seizure focus localization, 274(ab)
whole-body
 attenuation correction with MRP reconstruction, 1330(ab)
 attenuation correction with watershed segmentation algorithm, 1297(ab)
 attenuation correction with ¹³⁷Cs in, 1257
 CPET camera, 1239(ab)
 diagnosis and staging of pleural lung lesions with FDG, 230(ab)
 FDG cancer screening, 1155(ab)
 FDG evaluation of esophageal cancer, 1078(ab)
 FDG scanning in multiple myeloma, 246(ab)
 FDG staging of lung cancer, 226(ab)
 image reconstruction methods on FDG studies, 593(ab)
 parameters, optimization of, 1232(ab)
 simultaneous emission and transmission scanning, 1231(ab)
 transmission scans, 460(ab)
whole-body imaging, tumor detection with FDG, 567(ab)
¹¹C Nad-299 receptor imaging, 151(ab)
¹¹C raclopride, repeated measures of dopamine release, 1285
¹¹C WAY-100635, localization of serotonin receptors, brain, 102
¹³N ammonia and, myocardial blood flow, 1045
¹⁵O-labeled water and, baseline and hyperemic myocardial blood flow measurement, 1848
¹⁸F and ¹¹C, 1353(ab)
¹⁸F FET, tumor imaging, 205
¹⁸F fluorine, central nicotinic acetylcholine receptors, 1374
¹⁸F FMT, brain tumor patients, 399
¹⁸F-labeled amino acids, transport mechanism and uptake kinetics, 1367
¹⁸F labeled ligands for prostate cancer, 1136(ab)
¹⁸F 5-fluoro-2'-deoxyuridin, 1388(ab)
⁹⁴Tc, radioisotope mixture and decay correction for, 472(ab)
Positron imaging
 biodistribution of FDG uptake, 1241(ab)
 combined PET/CT scanner, design and operation, 597(ab)
 space, 1451(ab)
Positron volume imaging
 large-area positron camera (PETRRA), 1224(ab)
 new high-resolution research tomograph, 306(ab)
 small animal imaging, 302(ab)
Practice expense, CHCPP news, 26N(3)
Pregnancy, moyamoya disease and, 214(le)
Pretargeting
 bispecific antibody studies with ^{99m}Tc/Re-188-labeled peptides, 1002(ab)
 bispecific tumor-targeting radiotherapeutics, 324(ab)
 lymphoma, 75(ab)
Probe
 coincidence detection, using ¹¹¹In, 601(ab)
 sentinel node detection, 1228(ab)
Probe system
 beta-sensitive probe, 600(ab)
 intraoperative detection, development of a compact, 602(ab)
 sentinel node detection, 1228(ab)
Procedure guidelines
 breast scintigraphy, 1233
 gastric emptying and motility, 1236
 Meckel's diverticulum, gastrointestinal bleeding and, 1226
Prognosis
 dipyridamole stress myocardial SPECT, 23(ab)
 FDG PET as predictor of surgical outcome, 1195(ab)
- FDG SPECT in ischemic left ventricular dysfunction**, 192(ab)
 gender differences in ischemic heart disease, 722(ab)
 reversible perfusion defects, 27(ab)
 SPECT perfusion and functional studies to predict cardiovascular death, 26(ab)
 value of FDG in non-small-cell lung cancer, 1095(ab)
- Proliferation**
 correlation of FDG and MIBI uptake with, 65(ab)
 MIB-1 and ¹¹C methionine uptake in brain tumors, 1065(ab)
 preclinical validation of ¹¹C thymidine, 1013(ab)
 preoperative FDG uptake, correlation with Ki-67 immunostaining, 368(ab)
- Prospective payment systems**, HCFA, 24N(4)
- Prostate cancer**
 cisplatin and ¹⁸⁶Re HEDP in, 667
 CT-SPEC registration, pelvis, vascular structure for, 347
 dose-escalation study in osseous metastases from prostate cancer, 974(ab)
 dual-isotope staging, 394(ab)
 effect of ¹¹C Choline on hormonal therapy, 241(ab)
 FDG and carbon-11-acetate images of, 243(ab)
 FDG PET evaluation of endocrine therapy, 1137(ab)
 immunodetection of residual/recurrent lesions, 1138(ab)
 National Cancer Institute initiatives, 33n(10)
 radioimmunotherapy, 1008(ab)
 radioimmunotherapy with ¹¹¹In and Y-90, 963(ab)
 in vivo evaluation of I-131-labeled monoclonal antibodies, 1001(ab)
¹¹C acetate, PET imaging with, 242(ab)
^{99m}Tc labeled bombesin receptor binding analog in, 318(ab)
- PTCA**. *see* Angioplasty, percutaneous transluminal coronary
- Pulmonary embolism**
 automated interpretation, image processing algorithm, 224(ab)
 blood-pool subtracted SPECT imaging techniques, 42(ab)
 diagnosis with SPECT, 219(ab)
 helical computed tomography, role in ventilation-perfusion imaging, 881(ab)
 perfusion lung scintigraphy, ^{99m}Tc technegas, 579
 pulmonary perfusion scintigraphy, evaluation with, 222(ab)
 short-term prognosis, 220(ab)
 SPECT detection of, 218(ab)
 systematic lung scan depiction of, 223(ab)
 variations in ventilation/perfusion scan interpretation, 879(ab)
 Xe ventilation in diagnosis of pulmonary embolism, 883(ab)
^{99m}Tc bitistatin as a ligand for, 492(ab)
¹³³Xe imaging of ventilation/perfusion mismatch, 221(ab)
- Pulmonary hypertension**, ventricular pressure overload, 800(ab)
- Pulmonary lesions**, solitary, ¹⁸F FDG positron imaging, 574
- Pyelonephritis**
 acute, renal changes in acute phase and follow-up, 916(ab)
 declining diagnostic yield of ultrasound, 53(ab)
 experimental, ^{99m}Tc DMSA uptake in, 643
- Q**
- Quality assurance**, arrhythmia effects, gated SPECT, 924
- Quality control**
 attenuation correction of transmission scans in cardiac SPECT, 1262(ab)
 dose calibration and radiopharmaceutical administration, errors in, 616(ab)
 evaluation and calibration of fan-beam collimation, 1259(ab)
 generator, tungsten-188/Re-188, 1385(ab)
 PET camera performance measurements, 308(ab)
 polarographic technique, 1394(ab)
 portable image processing package, 1294(ab)
 SPECT validation program, 1263(ab)
 using collimated flood source, 1257(ab)
- Quantitative image analysis**
 kinetic analysis or brain perfusion SPECT studies, 1275(ab)
 table-based standardized uptake value, 1284(ab)
- Quantification**
 FDG PET and SPECT images of dementia, 282(ab)
 nonuniform transmission in brain SPECT, 1250(ab)
 photon energy recovery, 1336(ab)
¹¹⁰In PET and ¹¹¹In SPECT, 982(ab)
- Quantitation**
 activity estimation in coincidence imaging systems, 483(ab)
 nonlinear ML estimation at low SNR, 475(ab)
 tissue concentration of FDG, 826(ab)
- R**
- Radiation**
 Bremsstrahlung, exposure, pure beta-ray emitters, 1024
 protection, code-based software for Monte Carlo simulation, 1517
- Radiation pneumonitis**, ¹¹¹In-pentetetotide evaluation of, 37(ab)
- Radiation synovectomy**, MRI, chronic synovitis, 1277
- Radioactivity**, intra-abdominal, stomach, gastric emptying rate assessment based on, 1106
- Radioaserosol**, deposition and clearance quantification, 382(ab)
- Radiobiological effectiveness**
 biological effect, 1379(ab)
 radiation adaptive response in lymphocytes, 1378(ab)
- Radioenema imaging**, 5-aminosalicylic acid absorption, ileorectal anastomosis patients, 1630
- Radioimmunodetection**
 biodistribution of ¹²³I-labeled antiac dsFv, 1381
 glycolate conjugation, biodistribution of humanized antiac Fab fragment, 837
 lymphoma, antibody localization to tumor, 949(ab)
^{99m}Tc labeled monoclonal antibody G250, renal cell carcinoma, 829
¹¹¹In-DTPA-anti-CEA Mab to improve, 1005(ab)
- Radioimmuno diagnosis**, MAb CC49 constructs, colon cancer xenografts, 1536
- Radioimmuno PET**, microPET I, murine xenograft model, 323(ab)
- Radioimmunoscintigraphy**, ^{99m}Tc-labeled AntiEGF-R, tumors of epithelial origin, 768
- Radioimmunotherapy**
 alpha-particle dosimetry, leukemia patients, 1935
 antioxidant vitamins to reduce gastrointestinal and hematopoietic toxicity, 981(ab)
 beta emitters vs alpha-emitters, therapeutic efficacy of, 1375(ab)
 beta emitters vs Auger conversion-electrons, 1374(ab)
 brain, imaging and dosimetry of, 138(ab)
 characteristics of I-131-anti-B1 (anti-CD20) antibody, 991(ab)
 concentration in blood and body, patient-specific marrow dose using, 2102
 dosimetry of IDECOY2B8 in non-Hodgkins lymphoma, 260(ab)
 fractionated external beam radiotherapy and, human tumor xenograft, 1764
 gamma camera-based dosimetry-, 158(ab)
 hematologic toxicity after, prediction with ¹³¹I-labeled anti-CEA MAbs, 1609
 high-dose therapy, compared to low-dose in acute lymphatic leukemia, 992(ab)
 humanized MAbs, 968(ab)
 implications of nonuniform tumor doses for, 1337
 labeled antibodies for prostate cancer, 963(ab)
 liver metastasis, 1003(ab)
 marrow dosimetry based on radioactivity concentration, 159(ab)
 medullary thyroid cancer xenograft, 198
 non-Hodgkin's lymphoma, chronic lymphocytic leukemia, 1317
 optimization of combination therapy with radiolabeled antibodies, 156(ab)
 ovarian cancer, 966(ab)
 progeny radioisotopes, 162(ab)
 prostate cancer, 1001(ab)
 radiation protection after radioiodine therapy, 990(ab)

- radiolabeled antibody distribution and, liver metastases model**, 685
stability of monoclonal antibodies, 1381(ab)
synergic effects of, 430(ab)
treatment planning, dose estimation system and, 1151
vs chemotherapy in colorectal cancer, 428(ab)
5-fluorouracil/leucovorin as radiosensitizer, 429(ab)
 ^{67}Cu , pharmacokinetics and dosimetry of, 980(ab)
 ^{67}Cu -21T-BAT-LYMPH-1, lymphoma patients, 302
 ^{67}Cu 21T-BAT-Lym-1, non-Hodgkin's lymphoma, 2014
 ^{90}Y biotin therapy in glioma, 266(ab)
 ^{90}Y DOTA biotin, 75(ab)
 ^{90}Y DTPA-anti-CEA Mab to improve, 1005(ab)
 ^{90}Y HMFG1 in ovarian cancer, 432(ab)
 ^{111}In and ^{90}Y study of non-Hodgkin's lymphoma, 965(ab)
 ^{131}I anti-B1, comparison of treatment techniques, 989(ab)
 ^{131}I -anti B1 in lymphoma, 77(ab)
 ^{131}I -labeled chimeric antibodies, 970(ab)
 ^{131}I -labeled 81C6 monoclonal antibody, malignant brain tumors, 631
 ^{131}I -labeled anti-B1 antibody, 76(ab)
 ^{186}Re -labeled monoclonal antibody, 263(ab)
 ^{188}Re -labeled antibodies in leukemia, 262(ab)
 ^{212}Bi -labeled anti-CD19 antibody in lymphoma, 431(ab)
- Radioiodine therapy**
 adjuvant effect of lithium, 934(ab)
 autonomous thyroid nodule, dosimetry study in, 1928
 bone and lung metastasis, 530(ab)
 cost-effectiveness, 528(ab)
 dose to public, 935(ab)
 hemithyroidectomy, 927(ab)
 lesion uptake, thyroid cancer, 131
 patient education, 1453(ab)
 post-therapy scan, discrepancy of, 1045(ab)
 radioiodine reduces subsequent ablation, 531(ab)
 remnant thyroid dosimetry of I-131, 937(ab)
 retreatment, Graves' disease, 215(le)
 ^{131}I biokinetics, 932(ab)
- Radioisotopes, availability**, Medical Isotopes Conference, 13N(5)
- Radiolabeled antibodies**
 radioimmuno diagnosis, 1008(ab)
 ^{90}Y DOTA conjugates, 603(ab)
- Radiolabeled peptides**
 multiple dose regimen, effect on biodistribution, 997(ab)
 pretargeting studies with, 1002(ab)
- Radiolabeling, antisense**, 693
- Radiometals, Lut177**, facile labeling with, 968(ab)
- Radionuclide angiography**
 brain imaging with ^{18}F FDG, 1274(ab)
 estimation of brain perfusion index, 1271(ab)
 liver scintigraphy, 217(ab)
- Radionuclide cocktails, peripheral neuropathy in osseous metastases**, 976(ab)
- Radionuclide cystography, incidence of vesico-ureteral reflux/infection**, 860(ab)
- Radionuclide imaging**
 computer-assisted decision support system, ischemic heart disease, 96
 diagnosis of GER by radionuclide imaging, 849(ab)
 osteosarcoma, neoadjuvant therapy response, FDG PET, 1637
 ^{94m}Tc , radioisotope mixture with, 472(ab)
 ^{99m}Tc tetrofosmin, myocardial viability after coronary occlusion, 142
 ^{120}I , phantom study to test positron emitter, 501(ab)
 ^{123}I IPPA, low flow or after acute infarction and reperfusion, 821
- Radionuclides, S values at voxel level**, dosimetry of nonuniform activity distributions, 11S
- Radionuclide studies, frequency encoding, simultaneous display using, brain**, 442
- Radionuclide therapy**
 concentration in blood and body, patient-specific marrow dose using, 2102
 dose conversion factors, 1364(ab)
 dose to household members, 935(ab)
 efficacy of copper-64-TETA-Y3-octreotate, 997(ab)
 interstitial administration, dosimetry from, 161(ab)
 peripheral neuropathy following Re-186-HEDP/Sr-89-chloride therapy, 976(ab)
 radiolabeled CCK analogs, medullary thyroid cancer, 2081
- synovectomy in hemophiliac children, 44(ab)
 systemic, management of metastatic bone pain, 1420
 ^{47}Sc as a replacement for ^{67}Cu , 489(ab)
 ^{85}Sr , bone pain palliation, 585
 ^{117m}Sn citrate, 490(ab)
 ^{188}Re -labeled colloids, 1392(ab)
 ^{212}Bi -labeled octreotide, 415(ab)
- Radionuclide ventriculography**
 estimation of ejection fraction, after His bundle ablation, 754(ab)
 exercise capacity, 739(ab)
 vs gated SPECT in assessment of left ventricular ejection fraction, 757(ab)
- Radiopharmaceutical chemistry**
 multipurpose autosynthesis apparatus, 1467(ab)
 nuclear pharmacy, radioiodination method, 1391(ab)
 radiochemical studies with ^{99m}Tc , 1402(ab)
 radiolabeled antibody preparation, 1404(ab)
 reduction of Re-188 perrhenate, 1382(ab)
 stannous chloride, 1379(ab)
 ^{99m}Tc depreotide, characterization of, 321(ab)
 ^{111}In -pentetreotide labeled with Fe-59-ferric chloride, 1389(ab)
- Radiopharmaceutical development**
 biliary secretion studies, 1401(ab)
 dosimetry for two PET tracers, para- and meta- ^{18}F PFBG and MFBC, 1362(ab)
 FLT labeling substrate design, 335(ab)
 iodine-labeled estrogen receptor ligands, 1372(ab)
 peptide receptor radionuclide therapy, 322(ab)
 radioligand transport across blood-brain barrier, 1348(ab)
 Sep Pak purification, 608(ab)
 5-HT2 receptor, 1347(ab)
 ^{18}F labeled benzamides, 118(ab)
- Radiopharmaceuticals**
 generator-produced PET myocardial perfusion agents, 775(ab)
 medication utilization evaluation, 1390(ab)
 quantitative biodistribution, MIRD Pamphlet No. 16, 37S
 radiolabeled monocyte chemoattractant protein-1, 814(ab)
 Tc myocardial perfusion imaging with and without fatty meal, 343(ab)
 thallium vd technetium for MPI, 344(ab)
 tumor-locating, imperfect, 554 (ed)
 uptake ratio of ^{99m}Tc glucarate in acute myocardial infarction, 838(ab)
 ^{18}F YP501, analog of altanserin and MDL 10, 148(ab)
- Radioprotection, amifostine to reduce parenchymal damage from I-131**, 71(ab)
- Radiosurgery, stereotactic, glucose metabolism after, brain tumors, PET**, 1085
- Radiosynovectomy, efficacy in inflammatory joint disorders**, 46(ab)
- Radiotherapy**
 cervical cancer, 1130(ab)
 delivery efficacy of radiopharmaceuticals, local drug delivery device, 837(ab)
 efficacy of Lu-177-DOTA-Y3-octreotate, 993(ab)
 fractionated external beam, radioimmunotherapy and, human tumor xenograft, 1764
 intraoperative, unresectable pancreatic cancer, FDG PET evaluation of, 1424
 oligonucleotide, problems with, 1582(le)
 optimization of combination therapy with radiolabeled antibodies, 156(ab)
 pharmacokinetics and biodistribution of ^{111}In -DTPA-G-CSF, 1031(ab)
 registration, vascular structure for, pelvis, 347
 $\text{Sm}-153$ and Lu-177-DTPA, biodistribution of, 996(ab)
 three-dimensional assessment of pulmonary injury, 882(ab)
 unresectable pancreatic carcinoma, 984(ab)
 uptake of ^{99m}Tc sestamibi and ^{201}Tl , effect of irradiation on, 1376(ab)
- Raynaud's phenomenon, esophageal dysmotility, scintigraphy with semisolid meal to evaluate**, 77
- Receiver operating characteristic curve**
 PET brain imaging, 477(ab)
 three-dimensional moving match filter on simultaneous SPECT images, 1280(ab)
- Receptor-binding radiopharmaceutical**
 IQNP, rapid purification of, 608(ab)
 radiolabeling methods for, 322(ab)
- synthesis and preliminary evaluation of, 494(ab)
 ^{99m}Tc RP527, accumulation and retention of, 419(ab)
 ^{111}In -labeled, 317(ab)
 ^{111}In -labeled analogs, 418(ab)
- Receptor genes, Society of Nuclear Medicine Imaging in Drug Development (SNIDD)**, 22N(7)
- Receptor imaging**
 alcohol dependency, 448(ab)
 cannabinoid receptor radioligand, 438(ab)
 dopamine receptor radioligand, effects of amphetamines, 586(ab)
 Galactosyl-insulin, 498(ab)
 IPT/IBZM analysis of pre and postsynaptic dopaminergic system, 112(ab)
 P-gp modulation, 292(ab)
 predictor of therapeutic response, 1107(ab)
 synthesis, labeling and evaluation of ^{99m}Tc ECD-folate, 404(ab)
- Receptor ligands, identification, phage display peptide libraries**, 883
- Receptors, effective dose determination of ^{18}F FBT**, 1356(ab)
- Reconstruction**
 algorithms, impact on activity quantitation, 595(ab)
 effect of transmission scan duration and smoothing, 1313(ab)
 effects on ROC analysis lesion detection, 130(ab)
 iterative, 590(ab)
 matrix inversion for image, 296(ab)
 PET, normalization corrections, 1233(ab)
- Reflex sympathetic dystrophy, responsiveness to NSAID/steroid**, 1189(ab)
- Regional cerebral blood flow (rCBF), PET, activation studies with oxygen-14-CO2**, 503(ab)
- Regional metabolic covariance patterns**, FDG PET, 1264
- Regional myocardial blood flow, transmyocardial laser revascularization vs PMR**, 337(ab)
- Region of interest, hottest pixel analysis**, 1286(ab)
- Renal artery stenosis**
 PET imaging after treatment with lisinopril, 373(ab)
 scintigraphic assessment, hypotensive response to captopril, 406
- Renal cell carcinoma**
 fractionated radioimmunotherapy, 1364.5(ab)
 ^{11}C acetate, PET imaging with, 1139(ab)
 ^{99m}Tc labeled monoclonal antibody G250, characterization, 829
 ^{111}In -labeled chimeric antibodies, 970(ab)
- Renal cortical scintigraphy, pediatric applications of pinhole magnification imaging**, 1896
- Renal imaging**
 duplicated collecting systems, 913(ab)
 renal uptake of Ga-67, 1140(ab)
 stereoisomerism effects on structure and clearance, 1403(ab)
- Renal scintigraphy**
 ACE inhibition in diagnosis of RVH, 374(ab)
 assessment of cardiac function during, 378(ab)
 captopril vs captopril exercise to detect RVH, 866(ab)
 communicating bladders in conjoined twins, 861(ab)
 urologic management, 913(ab)
- Renography**
 diuretic
 evaluate paranchymal effects in renal transplant, 377(ab)
 infants and children, 1805
 optimal timing of diuretic administration, 204(ab)
 quantitative gravity-assisted drainage, 55(ab)
 stratification of acute renal colic, 206(ab)
 suprapubic tapping maneuver, 205(ab)
 validation of F+O in pediatric patients, 54(ab)
 dual-isotope assessment of renal function, 863(ab)
 glomerular filtration rate estimation from, 1968(le)
 Patlak-Rutland plot in, deconvolution comparison, 1503
 radionuclide, ^{99m}Tc EC clearance, single plasma sample, validation of, 429
 resistance vessel dysfunction, 372(ab)
 ^{99m}Tc MAG3, evaluation of renal function, 793
- Renovascular hypertension**
 captopril/exercise imaging to detect RVH, 866(ab)
 losartan vs captopril in depiction of, 374(ab)
- Reperfused, reversible trapping**, 813(ab)

- Reperfusion therapy**, myocardial infarction and, ¹²³I MIBG kinetics after, 904
- Reproducibility**
camera-based clearance measurements, 209(ab)
myocardial perfusion SPECT studies, 509(ab)
PET studies, malignant tumors, 1771
¹¹C DTZB, healthy human subjects, 283
¹²³I FPCIT SPECT imaging of dopamine transporters, 1201(ab)
- Research radionuclides**, thymidine as a cell proliferation marker, 1013(ab)
- Resolution improvement**, cardiac SPECT imaging, 359(ab)
- Resource-based practice expense**, SNM Physical Evaluation Program, 26N(1)
- Restenosis**
brachytherapy, 837(ab)
inhibition of, after angioplasty, 819(ab)
Re-188 prevention of, after PTCA, 341(ab)
- Revascularization**
adjunctive transmyocardial laser, 339(ab)
PET and transmyocardial laser, 340(ab)
- Reverse flow-metabolism mismatch**, PET, acute myocardial infarction, 1492, 1499(ed)
- Rhenium-186 etidronate**, breast cancer, with metastatic bone pain, 639
- Rhenium-186 HEDP**, cisplatin and, prostate cancer cells, 667
- Rhenium-188**
bidistribution and elimination, 356(ab)
comparison of radiation absorbed dose, 166(ab)
dose calibrator setting for, 1508
DTPA liquid-filled to inhibit restenosis, 819(ab)
labeled antibody, stability study, 1387(ab)
labeled colloids as radiotherapeutic agent, 1392(ab)
labeled agents, preparation of, 1382(ab)
on-demand labeling of metal stents, 825(ab)
palliative treatment of metastatic bone pain, 975(ab)
phosphonate ligands, 1015(ab)
prevention of restenosis after PTCA, 341(ab)
radiation dose measurements of, 1359(ab)
spectral analysis, 1385(ab)
in vitro stability to prevent restenosis, 611(ab)
in vivo and in vitro analysis of stereoisomers, 1384(ab)
¹⁸⁸Re HEDP, dose-escalation study, 974(ab)
- Rheumatoid arthritis**
experimental antigen-induced arthritis, 537(ab)
inflammation imaging of, 872(ab)
osteoarthritis and inflammatory joint disorders, 46(ab)
- Right lateral**, ^{99m}Tc MIBI SPECT, diagnostic accuracy, 785(ab)
- Right ventricular function**
gated SPECT to measure, 758(ab)
improvement in, after pulmonary thromboendarterectomy, 173(ab)
^{99m}Tc sestamibi SPECT, in coronary artery disease, 889
- ROC curve**, whole-body PET lesion detection with, 130(ab)
- S**
- Salivary gland**, scintigraphy, in Sjögren's syndrome, 64
- Salivary glands**
impaired function after radioiodine therapy, 1033(ab)
protection from parenchymal damage by amifostine, 71(ab)
quantitative scintigraphic indices, variability of, 2129(le)
- Sallis disease**, brain glucose use in, FDG PET, 12
- Samarium-89**, palliation, in skeletal metastases, 256
- Samarium-153 EDTMP**
structure-activity-relationships of, 1386(ab)
treatment of bone sarcomas, 977(ab)
- Sandler, Martin P.**, JNM Editor, Directions, 9N(1)
- Sarcoidosis**, uptake of ¹⁸F FMT and FDG in, 878(ab)
- Sarcomatoid carcinoma**, predictive value of FDG PET in progressive disease, 1147(ab)
- Scandium-47**, replacement for Cu-67, 489(ab)
- Scatter correction**
analytic methodology for, 1236(ab)
cardiac SPECT, 456(ab)
cross-talk correction in dual-isotope imaging, 471(ab)
detection and quantitation with, hepatic SPECT, 1011
- high-energy photon compensation, 1300(ab)
ROC curve in myocardial SPECT, 358(ab)
spectral deconvolution, 1336(ab)
TEW method for, 1331(ab)
- SCFV fragments**, radioimmunotherapy, 324(ab)
- Schizophrenia**
dopamine D1 receptor binding in, 120(ab)
IPT SPECT of decrease dopamine transporter binding, 126(ab)
receptor ligand imaging of, 609(ab)
SPECT imaging of amphetamine-induced striatal dopamine, 122(ab)
SPECT imaging of endogenous dopamine, 121(ab)
¹⁸F FDOPA assessment of, 125(ab)
- Scintigraphy**. *see also* specific type
esophageal, with semisolid meal, systemic sclerosis and Raynaud's phenomenon, 77
lung, threshold of detection of diffuse disease, 85
perfusion, bronchial artery revascularization, after lung transplant, 290
whole-body, congenital vascular malformation, 751(ab)
- Scintillation camera**
dual-head, coincidence imaging with, 432
gas detector, detection of electrons emitted by ^{99m}Tc, 868
optimization of crystal thickness, 1229(ab)
- Scintimammography**
assessment of chemotherapy response, 1038(ab)
breast cancer, scintimammography in recurrent, 68(ab)
breast neoplasm, 1100(ab)
cone-beam, 1254(ab)
correlation of scan patterns with ^{99m}Tc MDP, 66(ab)
effect of lesion size on ^{99m}Tc sestamibi, 64(ab)
lesion detection with, 140(ab)
patterns in radionuclide uptake, 1463(ab)
reduction in breast biopsies, 1103(ab)
ROC analysis to improve tumor detection in, 1314(ab)
sestamibi SPECT vs planar imaging, 1098(ab)
^{99m}Tc MIBI
dedicated nuclear mammography use in, 46
suspected breast cancer, 296
^{99m}Tc sestamibi, T-scan and, breast cancer diagnosis, 376
^{99m}Tc tetrofosmin, 1102(ab)
- Sclerosis**, systemic, esophageal dysmotility, scintigraphy with semisolid meal to evaluate, 77
- Scrotal scintigraphy**, pediatric applications of pinhole magnification imaging, 1896
- Seizures**
postoperative neuropsychological changes, PET, 1180(ab)
temporal lobe hypometabolism, 276(ab)
- Sentinel nodes**
active uptake of macromolecule tracers, 1117(ab)
biopsy, role of lymphoscintigraphy in breast cancer, 1119(ab)
biopsy, cost-effectiveness in breast cancer management, 560(ab)
detection with lymphoscintigraphy, 70(ab)
dynamic lymphoscintigraphy, 232(ab)
filtered or unfiltered Tc-sulfur colloid for lymphoscintigraphy, 612(ab)
- imaging**
advantage of small solid-state gamma camera, 1121(ab)
melanoma and breast cancer staging, detection of, 602(ab)
nonvisualization in patients with breast neop, 1122(ab)
single- or double-method lymph node biopsy, 1114(ab)
imprint cytology, 1115(ab)
localization, early breast cancer, 1403(le)
lymphoscintigraphic imaging, 233(ab)
lymphoscintigraphy in breast cancer, 238(ab)
mapping
 ^{99m}Tc serum albumin detection, 1149(ed)
 ^{99m}Tc serum albumin identification of, in melanoma, 1143
needle free tracer injection, 1113(ab)
preoperative management of, counting properties of gamma probes used in, 1227(ab)
radiation safety of lymphoscintigraphy, 1116(ab)
sensitivity of gamma probe in localization of, 558(ab)
sentinel node biopsy, 1118(ab)
- Serotonin**
low synthesis in temporal lobe indicator of major depression, 577(ab)
- receptor distribution, neocortex, parametric PET imaging of, 25
turnover rate and orbitofrontal glucose utilization, 1219(ab)
- Serotonin receptors**
binding studies of depression pre- and post-treatment, 579(ab)
biodistribution and dose estimates for ¹⁸F FCWAY, 168(ab)
competition between ¹¹C carbonyl-WAY 100635 and endogenous serotonin, 117(ab)
hereditary depression, 575(ab)
localization with ¹¹C WAY-100635, brain, PET, 102
PET brain studies, 150(ab)
PET imaging of, 151(ab)
P-glycoprotein modulation, 1167(ab)
preparation of 5HT1A antagonist C-11 WAY100635, 609(ab)
quantification of 5HT2, 1266(ab)
regional distribution in human brain, 116(ab)
reproductivity studies of ¹¹C carbonyl-WAY 100635, 1162(ab)
visualization with I-123-R91150 SPECT in Ecstasy users, 1216(ab)
¹¹C PET, 1347(ab)
¹⁸F-labeled, 149(ab)
¹⁸F YPS01, PET radiotracer for 5-HT2A, 148(ab)
- Serotonin transporters**
effect on alcohol neurotoxicity, 445(ab)
kinetic modeling of ¹¹C Mcn5652, 114(ab)
kinetic model in nonhuman primates, 115(ab)
radiolabeled FEINT for mapping serotonin, 1344(ab)
in vitro activity of, 1346(ab)
in vitro and in vivo evaluation of, 1343(ab)
¹²³I B-CIT, follow-up SPECT study, 576(ab)
¹²³I DAM SPECT imaging of, 1345(ab)
- Sestamibi**
assessment of regional myocardial blood flow, 1100(ab)
breast cancer, in suspected recurrent, 68(ab)
delayed imaging to detect adenoma, 940(ab)
early and delayed ECG-gated SPECT, 812(ab)
femoral marrow imaging of minimal residual disease in acute leukemia, 942(ab)
high accumulation in bone marrow, 943(ab)
imaging of multiple myeloma, 959(ab)
quantitative SPECT method to identify cardiomyopathy, 507(ab)
reverse redistribution of, in acute myocardial infarction after direct PTCA, 713(ab)
stress testing, comparison of rest-exercise and rest-ATP stress, 512(ab)
uptake patterns in benign and malignant disease, 1463(ab)
uptake ratio indicator of multidrug resistance, 919(ab)
vs furiosmin and tetrofosmin in depicting tumor multidrug resistance, 1025(ab)
vs tetrofosmin in detection of mild-to-moderate coronary artery disease, 345(ab)
- Sickle cell anemia**
perfusion imaging in children with, 910(ab)
sulfur colloid assessment of hydroxyurea therapy on splenic function, 958(ab)
- Sigma receptors**
pharmacological targeting, 1127(ab)
¹⁸F labeled benzamides as, 118(ab)
¹²⁵I imaging in breast cancer, 405(ab)
¹²⁵I PMS tumor imaging agent, 486(ab)
- Simulations**, small animal PET system, 131(ab)
- Simultaneous dual-isotope imaging**
myocardial SPECT, validation of photon-energy recovery, 839(ab)
SPECT coincidence system, 1247(ab)
- Single photon emission computed tomography (SPECT)**
accurate determination of head boundary, 1277(ab)
alcoholics, naltrexone effects on cerebral blood flow, 19
attenuation and point response correction, 1254(ab)
attenuation correction, 137(ab)
 application in TI-201, 363(ab)
attenuation correction for, 1251(ab)
bone
 maximum likelihood reconstruction and ordered subsets in, 1978
spine, attenuation correction techniques, 604

brain
 bipolar disorder, depiction of, 580(ab)
 cerebral cortical blood flow in children, 917(ab)
 compared with DDST II in cerebral palsy, 918(ab)
 coregistration study, 1193(ab)
 differential diagnosis of brain tumors, 1064(ab)
 evaluation of intracranial malignancy, 1182(ab)
 frequency distance relation, 1328(ab)
 ictal scan predictor of epileptogenic region, 280(ab)
 nonuniform scatter without transmission image, 1306(ab)
 normal patterns, age-related changes, 1183(ab)
 obsessive compulsive disorders, 1213(ab)
 reduced cerebral blood flow to white matter in Lyme disease, 1197(ab)
 rotating parallel-hole collimator, 139(ab)
 statistical parametric mapping, 1268(ab), 1583
 stroke studies, automatic analysis of, 570(ab)
 three-dimensional volume visualization, 1270(ab)
 vs Xe CT in evaluation of cerebral hypoperfusion, 572(ab)

brain, distribution of ^{99m}Tc ECD, age-related changes, 1818

camera performance, 1264(ab)

cardiac imaging, quantitative image reconstruction, 1325(ab)

cerebral perfusion
 chemotherapy-induced neurotoxicity in children, 522(ab)
 image registration, 278(ab)
 quantitation, graphical method and rectified algorithm, 1275(ab)
 similarity of MRI in, 574(ab)

coincidence detection camera, 598(ab)

comparison of restoration filters in F-18 collimated SPECT image, 1324(ab)

coronary revascularization, prediction of improvement after, 1866

cost-effectiveness of ^{99m}Tc sestamibi, 172(ab)

dopamine, Parkinson's disease, 530

dopamine transporters, 273(ab)

dual-isotope imaging, retention index, 1101(ab)

dynamic myocardial scan, 311(ab)

epilepsy, quantitative differences, 730

evaluation of back pain, 536(ab)

FDG, uterine cervical carcinoma, 1128(ab)

F-18 FDG, extratemporal and temporal epilepsy, 737

gated
 assessment of ventricular function recovery, 338(ab)
 automatic quantitation of left ventricular function, 728(ab)
 blood-pool imaging of infarcted myocardium, 712(ab)
 blood-pool study of left ventricular volume, vs contrast ventriculography, 805(ab)
 cardiac ejection fraction measurements, 758(ab)
 comparative studies of different zoom factors, 768(ab)
 correlation of functional data with right ventriculography, 772(ab)
 differences in stress and rest ejection fraction images, 182(ab)
 differentiation of left ventricular dysfunction, 711(ab)

dobutamine-induced changes in left ventricular function in myocardial perfusion studies, 709(ab)

dobutamine-induced ventricular function changes, 703(ab)

effect on nonuniform attenuation correction on simultaneous emission-transmission images, 752(ab)

evaluation of left ventricular ejection fraction in CAD, 178(ab)

Fourier analysis, 794(ab)

heterogeneity in myocardial perfusion, 748(ab)

hospital cost considerations for ^{99m}Tc sestamibi, 176(ab)

identification of ischemic viable myocardium, 798(ab)

influence of arrhythmias on, 924

large perfusion defects and left ventricular dysfunction, 805

left ventricular ejection fraction and perfusion, 650

left ventricular function and volumes, 1857

left ventricular volume and LVEF assessment, 180(ab)

LVEF and end-diastolic volume from sestamibi and TI-201 studies, 784(ab)

measurement of myocardial cavity and mass volumes, 807(ab)

myocardial free fatty acid utilization and left ventricular function, 1840

myocardial infarction, 789(ab)

myocardial perfusion imaging in CAD, 787(ab)

myocardial viability assessment, 2(ab)

myocardial viability assessment with ^{99m}Tc tetrofosmin, 803(ab)

new method of cardiac function analysis, 705(ab)

overestimation of left ventricular ejection fraction, 17(ab)

overestimation of left ventricular volumes, 179(ab)

pinhole collimator, 1249(ab)

post-dobutamine left ventricular function, 766(ab)

poststress ventricular volume, 6(ab)

prognostic and diagnostic value of ^{99m}Tc sestamibi, 759(ab)

QGS program, early and delayed ^{99m}Tc sestamibi, 812(ab)

quantitation of myocardial perfusion studies, 364(ab)

quantitative assessment of regional wall thickening, 792(ab)

quantitative evaluation of gene therapy in myocardial angiogenesis, 760(ab)

reconstruction TI-201 images with end-diastolic frames, 771(ab)

regional wall motion, quantitative measure of, 802(ab)

scatter and attenuation correction, 78(ab)

severe left ventricular dysfunction, recovery from, 1824

small hearts, 915(ab)

Tc^{99m} -MIBI, regional function assessed by, 761(ab)

TI-201, reversible perfusion defects, 741(ab)

two techniques to assess left ventricular function, 753(ab)

vs echocardiography in determining left ventricular volume and ejection fraction, 778(ab)

^{99m}Tc tetrofosmin, left ventricular volumes and ejection fraction, 1693

^{201}Tl LVEF measurements, 743(ab)

gated myocardial perfusion, accuracy and reproducibility of, 810(ed)

HMPAO, amyloid and cerebral perfusion, Wada test, 747

image analysis, statistical parametric matching, Parkinson's disease, 1583

image reconstruction with matrix inversion, 296(ab)

image registration, epilepsy studies, 1098

integrated visualization, anatomic brain data, 311

iterative reconstruction, 462(ab)

motion correction in ^{201}Tl imaging, diverging circle algorithm for, 1329(ab)

myocardial
 absolute quantitation of myocardial activity, 820(ab)
 brain natriuretic peptides after, 735(ab)
 coincidence imaging, 132(ab)
 diagnostic accuracy of quantitative right lateral ^{99m}Tc MIBI, 785(ab)
 motion artifacts of, 510(ab)
 prognosis of, 23(ab)
 three-dimensional color modulated display, 511(ab)

myocardial perfusion
 adjunctive transmyocardial laser revascularization, 339(ab)
 adjunctive value of left lateral planar view, 810(ab)
 detection of culprit lesion, 779(ab)
 evaluation of acute chest pain, 174(ab)
 OSEM algorithm for attenuation correction, 1318(ab)
 quantification of ^{99m}Tc sestamibi defect size, 817(ab)
 rest ^{201}Tl activity enhanced by constant infusion, 721(ab)
 risk of cardiac death in patients early and late CABG, 25(ab)
 risk stratification, 349(ab)

myocardial perfusion imaging, ^{201}Tl studies in children with sickle cell disease, 910(ab)

neurological, partial epilepsy, 677

postictal images of prolonged hyperperfusion, 275(ab)

principal component analysis, 1296(ab)

quality control validation program, 1263(ab)

quantitation in cardiac imaging, 595(ab)

quantitative
 attenuation correction, 1335(ab)
 correlated X-ray CT images, use of, 1248(ab)
 correlation of visual assessment and automated computer analysis, 729(ab)

dipyridamole and exercise stress, 516(ab)

evaluation of left ventricular function, 728(ab)

normal databases, clinical validation of, 506(ab)

partial volume correction, 820(ab)

prediction of palliative response, 265(ab)

^{201}Tl , CEqual map in, 515(ab)

radioiodinated derivatives, 1352(ab)

reducing urinary bladder artifacts, 1334(ab)

registration, vascular structure for, pelvis, 347

rotating chair and solid-state gamma camera, 750(ab)

scatter, attenuation, collimator response correction, 16(ab)

serotonin transporter imaging, 1345(ab)

simultaneous studies, baboons, 660

stress myocardial perfusion SPECT in angina pectoris, 710(ab)

subtraction ictal, seizure foci in children, 786

thallium-gated, major myocardial infarction patients, 513

thoracolumbar spine, 413(ab)

three-dimensional image reconstruction, 134(ab), 1255(ab)

transcranial magnetic stimulation, 1212(ab)

truncation effects, 1253(ab)

weighted ordered subsets expectation maximization, 1316(ab)

^{99m}Tc , attenuation correction in, brain imaging, 456

^{99m}Tc DMSA
 quantitative uptake, kidney, children, 56

renal scarring, 60

renal tumor enucleation, 968

uptake, kidneys with ureteropelvic junction obstruction, infant, 1111

^{99m}Tc ECD, quantification of cerebral blood flow, 1737

^{99m}Tc ECD measurement of rCBF, 1173(ab)

^{99m}Tc HMPAO
 Alzheimer's disease, 522

cerebral blood flow, Alzheimer's disease, 244

dementia with Lewy bodies, 956

^{99m}Tc MDP or MRI in detection avascular necrosis, 534(ab)

^{99m}Tc TRODAT-1 derivatives, 152(ab)

^{123}I BMIPP, ischemic heart disease, 471

^{123}I epidepride, quantification of dopamine D₂ receptors, 1902

^{123}I FPCIT, defects of functional dopaminergic system, 1091

^{123}I FPCIT, Parkinson's disease, 753

^{123}I IBZM, dopamine receptor brain imaging, neonatal period, 2125(le)

^{123}I IBZM imaging of dopamine D₂ receptor binding, 581(ab)

^{123}I iodovinyloestradiol imaging, breast cancer, 1728

^{123}I to image farnesy transferase distribution, 400(ab)

^{201}TL , MRI and, neck metastases, 1414

^{201}TL , perfusion defects after angioplasty, 811(ab)

^{201}TL myocardial imaging, 1(ab)

Sjögren's syndrome, salivary gland scintigraphy in, 64

Skeletal metastases, ^{89}Sr and ^{32}P palliation of, 256

Skeletal scintigraphy, pediatric applications of pinhole magnification imaging, 1896

Sn-117m DTPA
 clinical data, long-term analysis, 264(ab)

marrow sparing effects in mice, 978(ab)

Society of Nuclear Medicine Imaging in Drug Development (SNIDD), 22N(7)

Society of Nuclear Medicine (SNM)
 annual meeting preview, 16N(5)

Education & Research Foundation, 32N(8)

fused image tomography, 13N(8)

lines from the president, 15N(4)

Medical Internal Radiation Dose (MIRD) Committee, 1S, 3S

Pamphlet #17, 11S

web site, earning CME credit electronically, 9N(2)

Soft-tissue sarcoma, limb perfusion with TNF, TYR PET in, 262

Soft-tissue tumor
 bone scan in staging of soft-tissue sarcomas, 1146(ab)

imaging, FDG and tyrosine, 381

uptake of I-123- α -methyl-tyrosine, 398(ab)

Somatostatin
 MAURITIUS therapy, 74(ab)

receptor-mediated tumor imaging, 72(ab)

- Somatostatin receptor imaging**
 bone metastasis, gastroenteropancreatic tumors, 1602
 factor analysis of dynamic series in, neuroendocrine tumors, 33
 melanoma metastases, 1126(ab)
 predictor of allograft rejection, 5(ab)
 ^{99m}Tc P829, tumor binding agent, 321(ab)
- Somatostatin receptors**
 comparison of In-labeled analogs, 320(ab)
 dose-dependent tumor suppression of, 994(ab)
 radionuclide therapy, 414(ab)
 radiotherapy studies of, 996(ab)
 scintigraphy, gastrinoma patients, 539
- Somatostatin receptor scintigraphy**
 four-hour ^{111}In -pentetreotide SPECT imaging, 843(ab)
 lung metastases, 1082(ab)
 pituitary adenomas, efficacy octreotide, 1252
 primary and metastatic soft-tissue sarcomas, 1142(ab)
 pulmonary nodules, scintigraphic detection of, 36(ab)
 24-hour delayed imaging, meningioma, 1246
 ^{111}In -Mauritius imaging of lung tumors, 395(ab)
- Spatial normalization**
 global, using convex hulls, brain, 942
 PET, anatomic validation of, brain, 317
- Spine, bone SPECT, attenuation correction, 604**
- Spleen**
 FDG uptake, granulocyte colony-stimulating factor therapy, PET evaluation, 1456
 volume, functional calculation with liver-spleen scan, 1745
- Spondylosisitis, ^{67}Ga citrate activity in, 48(ab)**
- Sports nuclear medicine**
 bone scan patterns, multiple stress injuries, 876(ab)
 scintigraphic assessment of the elbow, 869(ab)
- Squamous cell carcinoma**
 head and neck, FDG PET, 91
 neck metastases, ^{201}TL SPECT and MRI, 1414
- Staging, monitoring tumor response with FDG PET, 96(ab)**
- Standardized input function, noninvasive measurement, cerebral metabolic rate of glucose, 1441**
- Standardized uptake value**
 lognormal distribution and diagnosis implications, 1283(ab)
 time corrections from an empirical model, 469(ab)
- Steady state technique, gray matter perfusion imaging, 503(ab)**
- Stents**
 intracoronary stenting, 780(ab)
 on-demand labeling of metal stents in treating restenosis, 825(ab)
- Stevens, Sen. Ted, nuclear medicine and, 20N(3)**
- Strategic plan, SNM, lines from the president, 15N(4)**
- Streptavidin**
 specific activity of, 614(ab)
 ^{111}In -labeled biotin and, pretargeting of bacterial endocarditis, 484
- Stress testing, pattern of myocardial perfusion abnormality, 783(ab)**
- Stroke**
 activation in regions of diaschisis, 1181(ab)
 PET in vivo imaging of activated microglia, 571(ab)
 ^{99m}Tc ECD, 1194(ab)
- Strontrium-85, therapy, bone pain palliation, 585**
- Strontrium-89, radionuclide therapy, management of metastatic bone pain, 1420**
- Student fellowships, JNM honor research, 15N(9)**
- Stunned myocardium, disturbances in fatty acid metabolism, 195(ab)**
- Stunning**
 changes in urinary iodine excretion, 921(ab)
 gated sestamibi perfusion SPECT, 766(ab)
- Subarachnoid hemorrhage, detection of with ^{99m}Tc ECD, 1188(ab)**
- Substance abuse, NIH imaging research opportunities, 9N(4)**
- Sulfur colloid, liver-spleen scan, functional of spleen volume, 1745**
- Surfactant, exogenous natural, in aerosol lung scintigraphy, 1080**
- Surgery**
 endoscopy, miniature beta-sensitive probe for, 600(ab)
 utility of myocardial scintigraphy before vascular, 795(ab)
- Sympathetic denervation, myocardial, oxidative metabolism abnormalities, PET, 846**
- Sympathetic nervous system, cardiac**
 overactivity in hypertension, ^{123}I MIBG imaging, 6
 Parkinson's disease, 371
- Sympathetic nervous system, vesicular storage and monoamine oxidase activity, isolated heart, 323**
- Sympathomimetic actions, MIBG, tyramind comparison, 1342**
- Synovitis, chronic, effects of radiation synovectomy, MRI, 1277**
- T**
- Tachycardia, idiopathic ventricular, ^{123}I MIBG uptake in, 1 [snx1] *Talairach Atlas*, global spatial normalization, brain, 942**
- Technegas**
 three-dimensional fractal analysis, 1287(ab)
 ventilation scan, 884(ab)
 ^{99m}Tc , pulmonary embolus, 579
- Technetium-99m**
 acute ischemic injury, 1369(ab)
 aptamers, 357(ab)
 chrysamine G, 288(ab), 898(ab)
 combinatorially designed radiopharmaceuticals, 499(ab)
 dual-isotope SPECT, partial epilepsy, 677
 ECD, synthesis of, 1367(ab)
 electrons emitted by, scintillation gas detector used to localize, 868
- IgM antibody labeled with, granulocytes, 625**
infection imaging with ciprofloxacin, 904(ab)
labeling of highly selective DAT ligand for SPECT, 153(ab)
liposomes labeled with, hydrazino nicotinyl derivative, 192
melanoma scintigraphy, 485(ab)
metabolization of fatty acid analogs, 1406(ab)
metal binding ligands, 500(ab)
murine immunoglobulin M antibody labeled with, granulocyte membranes and, 2107
noninvasive assessment of hypoxia with metronidazole, 1366(ab)
SPECT imaging of dopamine transporter sites, 1161(ab)
stereoisomerism effects on structure and clearance, 1403(ab)
synthesis, labeling and evaluation of ECD-folate, 404(ab)
tumor targeting with labeled cyclic melanotropin peptide, 484(ab)
VIP receptor agonist labeled with, colorectal tumors, 352
in vitro and in vivo properties of labeled peptides, 1397(ab)
 ^{13}C breath test, orocecal transit, 1451
- Technetium-99m annexin V, imaging of apoptosis with, 184**
- Technetium-99m antibody labeling**
 MAG3-chelator for, 327(ab)
 mercaptoacetyltriglycine chelator for, 1006(ab)
 monoclonal antibody Fab' fragment in infection of, 897(ab)
- Technetium-99m apcitide, early and delayed scintigraphy, acute deep vein thrombosis, 2029, 2036(ed)**
- Technetium-99m Aquilon, peptide label, unprecedented high specific activity, 1913**
- Technetium-99m benzamides, affinity in melanoma, 487(ab)**
- Technetium-99m biotin, solid-phase labelling, 614(ab)**
- Technetium-99m colloid, double tracer technique, head and neck tumors, 776**
- Technetium-99m colloidal albumin, mucoadhesive drug formulation, 610(ab)**
- Technetium-99m complexes**
 formulation of NADH-sensitive Tc ligands, 493(ab)
 infection/inflammation imaging, 59(ab)
 synthesis of cysteine-oxime ligands, 1402(ab)
- Technetium-99m DMP-HSA, serum albumin, biodistribution and absorbed radiation dose estimates, 1532**
- Technetium-99m DMP 444, detection of deep venous thrombosis, 613(ab)**
- Technetium-99m DMSA, 52(ab)**
 clearance, overall and single-kidney, urinary tract infection and, children, 52
 renal SPECT, in renal scar, 60
- SPECT, renal measurements with, 56(ab)**
SPECT, renal tumor enucleation, 968
uptake
 experimental pyelonephritis, 643
 SPECT, ureteropelvic junction obstruction, 1111
- Technetium-99m DTPA**
 camera-based method to evaluate renal function, 867(ab)
 estimation of renal clearance, 207(ab)
 increase urinary excretion of, 370(ab)
 metronidazole complex for imaging hypoxia, 1373(ab)
- Technetium-99m ECD**
 brain death determination, 1390(ab)
 cerebral distribution, changes related to age, 1818
 clearance, single plasma sample, validation of, 429
 prognostic value in acute cerebral infarction, 1202(ab)
 quantitative analysis, regional cerebral blood flow studies, 1183(ab)
- Technetium-99m ECT, SPECT and, quantification of cerebral blood flow, 1737**
- Technetium-99m ENS, different freeze-dried formulations, in aerosol lung scintigraphy, 1080**
- Technetium-99m ethylenedicycysteine, nonuniform attenuation correction of, 1328(ab)**
- Technetium-99m glucarate**
 acute chest pain patients, detection of acute MI in, 1832
 myocardial viability assessment, 815(ab)
- Technetium-99m GSA**
 accumulation, hilar cholangiocarcinoma, 394
 asialoglycoprotein receptors, 847(ab)
 dynamic SPECT to predict postoperative liver function, 212(ab)
 evaluation of chronic liver disease with, 211(ab)
 hepatic asialoglycoprotein receptors, recovery after hepatic resection, 137
 liver, biodistribution study of, 213(ab)
 radioligand for asialo-glycoprotein receptor, 855(ab)
 SPECT
 prognosis, cirrhosis of the liver, 1652
 residual hepatic functional reserve, 1644
- Technetium-99m HIL91**
 applicability, detection of tumor hypoxia, 854
 hypoxic tissue metabolism of, 330(ab)
 kinetic study in isolated perfused rat hearts, 353(ab)
 oxygenation status in tumor xenografts pre- and post-radiotherapy, 1021(ab)
 perfuse oxygen level, 823(ab)
 trapping in hypoxic myocardium during low-flow ischemia, 813(ab)
- Technetium-99m HMPAO**
 acetazolamide challenge, 573(ab)
 assessment of alterations in chronic traumatic brain injuries, 286(ab)
 biodistribution of enantiomeric, 1350(ab)
 cerebral blood flow, qEEG and, Alzheimer's disease, 522
 dementia, Lewy bodies, Alzheimer's disease and Parkinson's disease, 956
 endothelial cell labeling, cell-biomaterial interactions, 1756
 glutathione localization with, brain, 1056
 regional cerebral blood flow, primary antiphospholipid antibody syndrome, 1446
 retention, nervous tissue, cerebral cortex slices, 1556
 semiquantitative analysis in cerebral palsy, 918(ab)
 SPECT
 cerebral blood flow deficits in Alzheimer's disease, 244
 epilepsy, quantitative differences, 730
- Technetium-99m HNP, imaging, bacterial infections, 2073**
- Technetium-99m human serum albumin, active uptake of macromolecule tracers, 1117(ab)**
- Technetium-99m HYNIC-folate, targeted radiopharmaceutical, tumor imaging, 1563**
- Technetium-99m labeled red blood cells**
 acute gastrointestinal bleeding, detection of, 852(ab)
 congenital vascular malformation, 751(ab)
 plasma volume determinations, 961(ab)
- Technetium-99m MAG3**
 assessment of cardiac function during renal imagin, 378(ab)
 camera-based MAG3 and creatinine clearance measure, 209(ab)
 clearance estimation by semi-automated ROI, 862(ab)

diuresis renography, infants and children, 1805
MAG3 to differentiate nephrotoxicity in transplant, 377(ab)
 renal uptake, 972
 renography, evaluation of renal function, 793
 single-sample clearance, renal, reproducibility of, 1122
 ureteropelvic junction obstruction in neonate, 205(ab)
 ^{99m}Tc MAG3 clearance to measure tubular function, 864(ab)
 ^{99m}Tc MAG3 for triage in acute renal colic, 206(ab)
Technetium-99m MDP, after nephron-sparing surgery, 418
Technetium-99m MIBI
 cardiac perfusion, diagnosis of, 1251(ab)
 deoxyglucose in intratumoral accumulation, 1022(ab)
 detectability of metastatic lesions, 1047(ab)
 detection of residual thyroid cancer, after ^{131}I therapy, 1434
 evaluation of chemotherapeutic response, 1087(ab)
 hyperfunctional parathyroid glands, correlated with histology, 1792
 influx and efflux in myocardial cells, 835(ab)
 $^{113}\text{BMIPP}$ and, myocardial viability studies, 707
 ^{113}I subtraction imaging of adenomas, 199(ab)
 MDR tracer, carcinoma cells, 672
 multidrug resistance reversing agents, evaluation of, 1026(ab)
 scintimammography
 dedicated nuclear mammography use in, 46
 suspected breast cancer, 296
 SPECT, chemosensitivity of lung cancer, 1778
 use in differentiated thyroid cancer, 1769(ie)
 vs CT in mediastinal lymph node involvement, 1085(ab)

Technetium-99m monoclonal antibody, G250
 preparations, characterization, 829

Technetium-99m-peptide conjugates
 abscess imaging, 1398(ab)
 brain tumor imaging with, 1080(ab)
 detection of deep venous thrombosis, 491(ab)
 inflammation imaging agent, 872(ab)
 inflammation/infection imaging, 900(ab)
 metal binding ligands, 500(ab)
 potential for imaging cytosolic targets, 316(ab)

Technetium-99m pertechnetate
 double tracer technique, head and neck tumors, 776
 scintigraphy, laparoscopic adjustable silicone gastric banding, 783

Technetium-99m P829
 colorectal adenocarcinomas, 1082(ab)
 diagnostic value of in neuroendocrine tumors, 369(ab)

Technetium-99m serum albumin
 blue dye and, sentinel node detection, 1149(ed)
 identification of sentinel lymph nodes, melanoma, 1143

Technetium-99m sestamibi
 baseline-nitrate SPECT, 196(ab)
 cardiac tomography, dobutamine echocardiography
 comparison, after acute MI, 1683
 chemotherapy response of osseous sarcomas, 1148(ab)
 double-phase scintimammography, T-scan and, breast cancer diagnosis, 376
 effect of revascularization on hospital costs, 176(ab)
 enhanced uptake in malignant cell lines, 1037(ab)
 fusion images, 746(ab)
 KR-30035, tumor uptake of, 1023(ab)
 localization of parathyroid adenomas, 197(ab)
 lymph node imaging, 80(ab)
 metastases of colorectal cancer, 426(ab)
 multidrug resistance, 549(ab)
 oxyphil cell content relations, hyperparathyroidism, 1402(ie)
 reperfusion success, 24(ab)
 sensitivity by cell type in adenomas, 201(ab)
 simultaneous ^{201}Tl dual-isotope SPECT, coronary artery disease, 895
 SPECT, right ventricular uptake, in coronary artery disease, 889
 uptake and characterization in HCC, 1072(ab)
 vs planar breast imaging, 1098(ab)
 whole-body imaging in thyroid cancer, 532(ab)

Technetium-99m sulfur colloid
 colonic reservoir, evaluation of, 848(ab)
 sentinel node detection with, 612(ab)

Technetium-99m technegas, perfusion lung scintigraphy, pulmonary embolus, 579

Technetium-99m tetrofosmin
 comparison with FDG PET in lung cancer, 384(ab)
 detection of axillary lymph node metastasis, 1105(ab)
 detection of differentiated thyroid cancer, 198(ab)
 functional imaging of FgP transport activity, 1024(ab)
 gated SPECT, left ventricular volumes and ejection fraction, 1693
 gated SPECT myocardial perfusion imaging, 740(ab)
 measurement, forward cardiac output, 1874, 1882(ed)
 myocardial uptake, indicator of severe coronary artery disease, 514(ab)
 myocardial viability, models of coronary occlusion and reperfusion, 142
 SPECT, functional recovery in severe left ventricular dysfunction, 1824
 stability of labelling, 615(ab)
 uptake, P-glycoprotein and, non-small cell lung cancer, 1223(ie)
 velocity gradient imaging, 806(ab)

Technetium-99m TRODAT-1
 age effects on dopamine transporters, 108(ab)
 assessment of motor function in Parkinson's disease, 1200(ab)
 dopamine transporter imaging agent, kinetic modeling of, 150
 dopamine transporter imaging in Parkinson's disease, 109(ab)
 dopamine transporters, age effects, 1812
 dopamine transporters, age effects, 1812

Telemedicine, low-cost, variable-resolution teleradiology system, 1293(ab)

Temporal lobe, dysphoric mood, 124(ab)

Testes, radiation dose, after ^{131}I therapy for differentiated thyroid cancer, 1716

Testicular neoplasms
 FDG PET in recurrent testicular neoplasm, 425(ab)
 multicenter trial, necessary standardization, 1133(ab)
 staging of, 1135(ab)

Tetrofosmin scintigraphy
 dipyridamole and SPECT vs ^{99m}Tc sestamibi in detection of coronary artery disease, 345(ab)
 left ventricular ejection fraction, evaluation with, 747(ab)

Thallium, gated SPECT
 large perfusion defects and left ventricular dysfunction, 805
 major myocardial infarction patients, 513

Thallium reinjection imaging
 acute myocardial infarction, detection of, 756(ab)
 correlation of gated SPECT with right ventriculography, 772(ab)
 fixed defects on, 731(ab)

Thallium-201
 AIDS, intracranial lesions in patients with, 891(ab)
 bone scans to evaluate chemotherapeutic response, 524(ab)
 evaluation, multiple myeloma, bone scintigraphy comparison, 1138
 gated SPECT studies of LVEF and end-diastolic volume, 784(ab)
 overestimation of left ventricular volumes, relation to infarct size, 179(ab)
 planar scintigraphy, fine-needle aspiration and, thyroid nodules, 1971
 rest-redistribution vs reinjection as predictor of functional recovery, 191(ab)
 scintigraphy, detection of residual thyroid cancer after ^{131}I therapy, 1434
 simultaneous ^{99m}Tc sestamibi dual-isotope SPECT, coronary artery disease, 895
 SPECT
 attenuation correction to diagnose CAD, 360(ab)
 cost-effectiveness analysis, 718(ab)
 lung uptake, discriminant indicator of coronary artery disease, 809(ab)
 survival analysis of cerebral glioma, 1063(ab)
 uptake, nuclear DNA content relations, metastatic thyroid carcinoma, 963
 uptake and retention of, 1035(ab)
 vs early and delayed scintigraphy in predicting chemotherapeutic response, 535(ab)

Thallium-201 chloride
 quantitative analysis of metal impurities, 1394(ab)
 radiotherapy in head and neck cancer, 1057(ab)
 SPECT and MRI, neck metastases, 1414
 three-phase imaging of musculoskeletal lesions, 875(ab)

Therapy
 effect of carvedilol therapy with $^{123}\text{MIBG}$, 8(ab)
 intrathoracic tumors, 986(ab)
 myelotoxicity, factor influencing, 1380(ab)
 PET quantitation, 933(ab)
 $^{113}\text{Re-labeled P829}$, dose-dependent tumor suppression, 994(ab)

Three-dimensional imaging
 color modulated display, 511(ab)
 validation and practical strategies for PET, 1096(ab)
 whole-body PET, interactive data integration display system, 1452(ab)

Three-dimensional volume imaging
 ordered subset expectation maximization, 1321(ab)
 relative distribution of D2 dopamine receptors, 1157(ab)

Thrombocytopenia, cardiopulmonary bypass, 947(ab)

Thrombolytic therapy, bleeding reversal with platelet transfusion, 947(ab)

Thrombosis imaging
 P-selectin, 357(ab)
 ^{99m}Tc apcitide sensitivity and specificity of, 40(ab)
 ^{99m}Tc FBD to detect acute deep vein thrombosis, 41(ab)
 ^{99m}Tc itistatin, 492(ab)
 $^{111}\text{In-labeled platelets}$ in, 780(ab)

Thrombus
 identification of biological markers, 40(ab)
 peptide-based imaging of, 41(ab)

Thymic cancer, differential diagnosis, ^{113}C MET PET and FDG PET, 1595

Thymidine
 methyl- ^{113}C , ^{113}C activity after, 491
 radiolabeled, evaluation of tumor response and recurrence, 1702
 ^{2-11}C PET, validation studies, 614

Thymoma, differential diagnosis, ^{113}C MET PET and FDG PET, 1595

Thymus, radiolabeled octreotide concentrations, 1967(ie)

Thyroglobulin, chromatography, 938(ab)

Thyroid
 congenital anomalies in infants with congenital hypothyroidism, 928(ab)
 congenital hypothyroidism, pertechnetate scintigraphy, 799
 dosimetry, 933(ab)
 postsurgical radioiodine therapy of differentiated carcinoma, 987(ab)
 variable scintigraphic patterns of chronic thyroiditis, 1458(ab)

Thyroid cancer
 brain metastasis of, 530(ab)
 childhood, UICCA/AJCC classification in, 2125(ie)
 comparative studies of I-131 ^{99m}Tc ^{201}Tl , 1047(ab)
 detection of recurrence, 938(ab)
 diagnosis and treatment with lanreotide, 74(ab)
 differentiated
 postsurgical remnants, ^{131}I therapy for, radiation dose to testes and, 1716
 ^{99m}Tc MIBI use in, 1769(ie)
 dosimetry, using clearance fitting, 131
 effect of irradiation on ^{99m}Tc sestamibi and ^{201}Tl uptake, 1376(ab)
 FDG PET detection of, 1044(ab)
 FDG PET follow-up studies, 1043(ab)
 FDG PET scans in follow-up of, 411(ab)
 FDG PET when radioiodine scan negative, 1041(ab)
 lobar ablation, 927(ab)
 management with recombinant human thyrotropin, 926(ab)
 medullary
 CEA-producing, radioimmunotherapy in, 198
 radiolabeled CCK analogs, evaluation of, 2081
 Re-188-DMSA diagnosis of, 924(ab)
 targeting cholecystokinin-B/gastrin receptor-expressing tumors, 1029
 metastatic
 FDG PET role in, 993(ed)
 ^{201}TL uptake, nuclear DNA content, and clinical behavior relations, 963
 monitoring TSH-suppressive therapy, 923(ab)
 papillary, FDG PET in, 986
 post-therapy scan, stunning of, 1045(ab)
 presurgical evaluation of recurrence in cervical lymph nodes, 529(ab)
 radionuclide imaging of, 973(ab)

- radiotherapy, 198(ab)
remnant thyroid dosimetry of, 937(ab)
residual, after ^{131}I therapy, 1434
stunning due to changes in urinary iodine excretion, 921(ab)
uptake measurements in thyroid remnants, 930(ab)
whole-body FDG PET in follow-up of, 1042(ab)
 $^{99\text{m}}\text{Tc}$ sestamibi whole-body imaging of, 532(ab)
 ^{123}I scintigraphy in management of, 526(ab)
- Thyroid disease**
fetal hypothyroidism diagnosis and management, 922(ab)
radioiodine therapy, 1453(ab)
stunning parameter in, 931(ab)
thyroid visualization on lung scan, 884(ab)
- Thyroid hormones**
cardiac effects, 33(ab)
gastric emptying in hypothyroidism, 527(ab)
- Thyroid nodule**
autonomous, dosimetry study in, 1928
fine-needle aspiration, ^{20}Tl scintigraphy and, 1971
- TLD, intraperitoneal dose measurement**, 1358(ab)
- Tomography**
blurring tomography and positron coincidence detection, 1332(ab)
FBP or OSEM reconstruction, 1333(ab)
four-hour ^{111}In -pentetreotide SPECT imaging, 843(ab)
gating errors in, 715(ab)
ML-EM iterative reconstruction, 1305(ab)
- Trabecular bone**, absorbed fractions of energy within, three-dimensional transport model, 1947
- Tracer kinetic modeling**
effects of metabolic alterations on brain retention of perfusion tracers, 1168(ab)
FDOPA distribution volume, 142(ab)
SPECT, dopamine transporter, 144(ab)
statistical bias in Logan graphical method, 141(ab)
 ^{18}F FDOPA, striatum and cerebellar distribution volumes, 585(ab)
- Trainee Awards, Education & Research Foundation, SNM**, 32N(8)
- Transferrin, ^{18}F** , targeting in tumors, 1547
- Transferrin receptor, expression**, ^{67}GA scintigraphy in non-Hodgkin's lymphoma, 40
- Transmission computed tomography**
cardiac imaging, 135(ab)
cone-beam collimation, 137(ab)
 Cs-137 fanbeam collimation, 136(ab)
geometrical models, 298(ab)
ordered subsets, 1323(ab)
scatter correction in emission/transmission SPECT, 1312(ab)
simultaneous emission and transmission whole-body imaging, 1231(ab)
static line sources in brain SPECT, 1250(ab)
- Transplantation. *see also* specific type**
biodistribution of ^{111}In -hepatocytes via portal vein infusion, 850(ab)
diagnostic accuracy of ventilation-perfusion scan, 525(ab)
lung, bronchial artery revascularization after, 290
prognostic value of lung scan, 880(ab)
 $^{99\text{m}}\text{Tc}$ annexin assessment of rejection, 846(ab)
 $^{99\text{m}}\text{Tc}$ annexin V to evaluate lung transplant rejection, 38(ab)
- Transport model, three-dimensional**, absorbed fractions of energy within cortical bone, 2115
- Trapping mechanism**, effects of metabolic alterations on brain retention of perfusion tracers, 1168(ab)
- Triphenylphosphonium**, enhanced uptake in malignant cell lines, 1037(ab)
- Triple-energy window scatter correction**, optimization of, 1337(ab)
- Tumor. *see also* specific type and site**
blood flow, noninvasive estimation of input function, 464(ab)
breast, FDG biodistribution in, 90(ab)
cultured cells, nifedipine promotion of gallium uptake in, 159
differential uptake of FDG in cultured cells, 1000(ab)
proliferation, 1034(ab)
radiotherapy structure-activity-relationships, 1386(ab)
- Tumor detection**
abdominal tumors, 562(ab)
FDG PET, 1128(ab)
FDG PET oncology studies, 465(ab)
FDG PET study of esophageal cancer, 1078(ab)
intracellular distribution in tumor cells, 1036(ab)
intraocular tumor, 1058(ab)
linear discriminant, use for tumor detection, 601(ab)
localization ROC, 590(ab)
whole-body FDG PET, 1155(ab)
- Tumor grading**, IdUMP SPECT vs FDG PET, 1066(ab)
- Tumor hypoxia**
detection of, $^{99\text{m}}\text{Tc}$ HL91 and ^{14}C -deoxyglucose comparison, 854
PET agents for evaluation of, 1365(ab)
synthesis of DTPA-metronidazole, 1373(ab)
 ^{18}F FETA detection of, 1072
 $^{99\text{m}}\text{Tc}$ labeled-HL91 imaging of vs ^{201}Tl , 1020(ab)
- Tumor imaging**
automated radiochemical synthesis, 1388(ab)
diagnostic potential of human antibody fragment E8, 434(ab)
evaluation of anti-angiogenic effect with $^{99\text{m}}\text{Tc}$ ECD, 1367(ab)
FDG coincidence imaging, 1153(ab)
sestamibi uptake as predictor chemotherapeutic response in lung cancer, 549(ab)
tumor-to-normal tissue ratios, 567(ab)
 $^{99\text{m}}\text{Tc}$ HYNIC folate, targeted radiopharmaceutical, 1563
 $^{99\text{m}}\text{Tc}$ VIP imaging of brain tumors, 1080(ab)
 ^{201}Tl brain SPECT, 1182(ab)
- Tumor localization**, imperfect radiopharmaceuticals, 554 (ed)
- Tumor markers**
abnormalities, scan yields with, 410(ab)
FDG detection of pulmonary lesions, 1092(ab)
- Tumor necrosis factor**, limb perfusion with, TYR PET in, 262
- Tumor recurrence**, tracer for, radiolabeled thymidine, 1702
- Tumor response**
DNA precursors, kinetics, 99(ab)
lactate production with bioreductive antitumor agent, 91(ab)
sestamibi imaging as predictor of, 985(ab)
tracer for, radiolabeled thymidine, 1702
- Tumor-seeking agents**
mannosylated albumin, 1371(ab)
tissue uptake of ^{18}F alpha-methyl tyrosine, 336(ab)
 $^{99\text{m}}\text{Tc}$ labeled HL91 vs ^{201}Tl , 1020(ab)
- Tumor-suppressor genes, oncogenes, cancer, and imaging**, 498
- Tumor targeting**
angiogenesis, 995(ab)
biodistribution of radioiodinated vs radiometal anti-CEA antibody fragments, 325(ab)
dosimetry and, small cell lung cancer, 1216
integrin antagonist, tumor detection using, 319(ab)
phospholipid ether agent for, 155(ab)
radiolabeled integrin antagonists for, 1061
- Tumor-to-normal tissue ratio**, aptamer tumor targeting, 402(ab)
- Tyramine, sympathomimetic effects**, MIBG comparison, 1342
- U**
- U. S. Congress**, nuclear medicine and, 20N(3)
- Ulcerative colitis**, 5-aminosalicylic acid absorption, radioenema imaging, 1630
- Ultrasound**
declining diagnostic value in urinary tract infection, 53(ab)
detection of postmenopausal osteoporosis, 538(ab)
- University of California Los Angeles (UCLA)**, nuclear medicine in the 21st Century, 13N(7)
- Urea breath test**, clinical significance of oropharyngeal urease, 367(ab)
- Ureteropelvic junction**, obstruction, SPECT of $^{99\text{m}}\text{Tc}$ DMSA uptake, infant, 1111
- Urinary bladder**
diagnosis of dual communicating bladder system, 861(ab)
radiation absorbed dose, dynamic model, MIRD, 102S
- Urinary tract infection**, $^{99\text{m}}\text{Tc}$ DMSA clearance and, children, 52

V

- Validation, brain data**
integrated visualization, 311
spatial normalization methods, PET, 317
- Vascular endothelial growth factor receptors**, peptide uptake and in vitro profile, 995(ab)
- Vascular graft**, cell-biomaterial interactions, labeling with $^{99\text{m}}\text{Tc}$ HMPAO, 1756
- Vasculitis**
diascisis, 573(ab)
pulmonary uptake of I-123-MIBG, 39(ab)
- Vasoactive intestinal peptide**, receptor agonist, $^{99\text{m}}\text{Tc}$ -labeled, 352
- Venography**, contrast-enhanced, $^{99\text{m}}\text{Tc}$ apcitide scintigraphy and, deep venous thrombosis, 2029, 2036(ed)
- Venous sinuses**, as input function, quantitative PET, 1666
- Venous thrombosis**, silent pulmonary embolism in deep venous thrombosis, 223(ab)
- Ventilation/perfusion imaging**, CT and nonradioactive xenon inhalation, 885(ab)
- Ventilation perfusion scintigraphy**, variations in image interpretation, 879(ab)
- Ventilation scintigraphy**, Techegas vs CT ventilation map, 885(ab)
- Ventricular fibrillation, idiopathic**, ^{123}I MIBG uptake in, 1
- Ventriculography**
cerebrospinal fluid study, 1206(ab)
gated SPECT to assess wall motion defects, 1278(ab)
- Vertebral osteomyelitis**, efficacy of imaging, 906(ab)
- Vesico-ureteral reflux**, voiding cystourethrography, 865(ab)
- Visualization**, integrated, functional and anatomic brain data, validation, 311
- Vocal cords**, paralysis, after ^{131}I therapy, 505(1e)
- Volume visualization**, whole-body PET data integration display system, 1452(ab)
- Voxel S values**, radionuclides, nonuniform activity distributions, 11S

W

- Wada test**, amytal distribution, regional cerebral perfusion and, 747
- Wall thickening**
artificial changes in, 715(ab)
evaluation by ECG-gated SPECT, 802(ab)
gated SPECT assessment, 792(ab)
gated $^{99\text{m}}\text{Tc}$ sestamibi, 177(ab)
- Welch, Michael J.**, 24N(12)
- Wolf, Walter**, Aebersold Award, 12N(6)
- World Federation of Nuclear Medicine and Biology (WFNMB)**, Santiago Meeting 2002, 16N(6)

X

- Xenon-133**, mean absolute cerebral cortical blood flow, 917(ab)

Y

- Y2K**
HCFA, 16N(12)
Medicare payment updates, 20N(6)
- Yttrium-86**
PET imaging of antibodies, 328(ab)
quantitation of PET images, 1238(ab)
- Yttrium-90**
facile labeling of DOTA-MAb conjugates, 603(ab)
radiation dose calculation after brachytherapy, 167(ab)
- Yttrium-90-labeled antiTac**, ^{111}In differences, 268

Z

- Zollinger-Ellison syndrome**, somatostatin receptor scintigraphy in, 539

JNM

DIRECT RESPONSE

Advertisers for December 1999

Listed below are the companies that have advertised in this issue. Simply circle the numbers of those companies you are interested in, fill out the information below and mail or FAX this to the Society of Nuclear Medicine, Advertising Department, 1850 Samuel Morse Drive, Reston, VA 20190, Fax: 703-708-9018. We will forward this information to the advertiser(s).

Reader Svc.No.	Advertiser	Telephone No.	Page(s)
1	ADAC Laboratories www.adaclabs.com	800/538-8531	Cover 3
23	Capintec, Inc. www.capintec.com	201/825-9500	2A
31	Diatide, Inc. www.diatide.com	877/DIATIDE	17A-20A
62	GE Medical Systems www.ge.com/medical/nuclear	800/643-6439	Back Cover
86	IS2 Research, Inc.	613/228-8755	22A
108	Macrocyclics www.macrocyclics.com	972/897-0424	25A
110	Mallinckrodt Medical, Inc. www.mkg.com	314/895-2000	13A-14A
135	Nycomed Amersham	800/633-4123	7A-8A
181	Siemens Medical Systems www.sms.siemens.com/nmg	847/304-7700	Inside Front Cover and 1A
188	Sony Medical Systems www.sony.com/medical	800/892-SONY	21A

SNM Meetings

SNM Membership Information

SNM Book Order Information

YOUR NAME: _____ TITLE: _____

INSTITUTION: _____ DEPT: _____

ADDRESS: _____

CITY: _____ STATE: _____ ZIP: _____

PHONE: _____ FAX: _____

PRIMARY SPECIALTY: _____ SECONDARY SPECIALTY: _____

CHECK ONE ANSWER IN EACH CATEGORY

Employer

- Hospital
- 500 patients plus
- 300-499 patients
- 200-299 patients
- 100-199 patients

Employer

- Private Clinic
- R&D Commercial
- University
- Government
- Other _____

Purchase Authority

- Recommend
- Specify
- Purchase

Reason for Inquiry

- Immediate Purchase
- General Information
- Budgeting Information

SNM Member

- Yes
- No

JNM/JNMT Subscriber

- Yes
- No